2976 genotypes with 5094 annotations displayed
of selected term and subterms
|
Searched Term: increased organ/body region tumor incidence
|
A4gnttm1Jnaka/A4gnttm1Jnaka
(B6.129S6-A4gnttm1Jnaka)
|
increased gastric adenocarcinoma incidence
|
J:184485
|
Abcb4tm1Bor/Abcb4tm1Bor
(either: (involves: 129P2/OlaHsd) or (involves: 129P2/OlaHsd * FVB/N))
|
increased hepatocellular carcinoma incidence
|
J:21232
|
Abcb4tm1Bor/Abcb4tm1Bor
(FVB.129P2-Abcb4tm1Bor/J)
|
increased hepatocellular carcinoma incidence
|
J:217802
|
Abcb4tm1Bor/Abcb4tm1Bor
(CAnNCrl.12P2(FVB)-Abcb4tm1Bor)
|
increased hepatocellular carcinoma incidence
|
J:217802
|
Abraxas1tm1.1Bwng/Abraxas1+
(involves: 129S6/SvEvTac * C57BL/6NCrl * FVB/N)
|
increased histiocytic sarcoma incidence
|
J:269823
|
increased lung adenocarcinoma incidence
|
J:269823
|
increased lymphoma incidence
|
J:269823
|
Abraxas1tm1.1Bwng/Abraxas1tm1.1Bwng
(involves: 129S6/SvEvTac * C57BL/6NCrl * FVB/N)
|
increased lymphoma incidence
|
J:269823
|
Acot12em1Holi/Acot12em1Holi
(involves: C57BL/6J * C57BL/6N)
|
increased hepatocellular carcinoma incidence
|
J:335836
|
Acox1lampe1/Acox1lampe1
(involves: C57BL/6J)
|
increased hepatocellular carcinoma incidence
|
J:174942
|
Acox1tm1Jkr/Acox1tm1Jkr
(involves: 129P2/OlaHsd * C57BL/6J)
|
increased hepatocellular carcinoma incidence
|
J:35794
|
increased hepatoma incidence
|
J:48180
|
Acox2em1Jynz/Acox2em1Jynz
(involves: C57BL/6N)
|
increased liver tumor incidence
|
J:323193
|
Acp3tm1Pivi/Acp3tm1Pivi
(B6.Cg-Acp3tm1Pivi)
|
increased prostate gland adenocarcinoma incidence
|
J:207558
|
increased prostate intraepithelial neoplasia incidence
|
J:207558
|
Actbtm1(PyVT)Arge/Actb+
(involves: 129S1/Sv)
|
increased mammary adenocarcinoma incidence
|
J:87544
|
Actbtm1(PyVT)Arge/Actb+ Waptm1(cre)Arge/Wap+
(involves: 129S1/Sv)
|
increased mammary adenocarcinoma incidence
|
J:87544
|
Actbtm2(Tag)Arge/Actb+ Tg(Hsp70-1-cre)1Arge/0
(involves: 129S1/Sv * C57BL/6J * CBA)
|
increased leiomyosarcoma incidence
|
J:87544
|
Actn4tm1a(EUCOMM)Wtsi/Actn4tm1a(EUCOMM)Wtsi
(C57BL/6N-Actn4tm1a(EUCOMM)Wtsi/Wtsi)
|
increased trigeminal neuroma incidence
|
J:239583
|
Acvr1tm1Emsh/Acvr1+
(chimera involves: BALB/c * C57BL/6 * CD-1)
|
increased osteochondroma incidence
|
J:194134
|
Acvr1tm1Mak/Acvr1+ Gt(ROSA)26Sortm1(Pik3ca*H1047R)Egan/Gt(ROSA)26Sor+ H3c2tm1Mak/H3c2+ Olig2tm1.1(cre)Wdr/Olig2+
(involves: 129 * C57BL/6 * FVB/N)
|
increased brain tumor incidence
|
J:285841
|
increased glioma incidence
|
J:285841
|
Acvr1tm1Mak/Acvr1+ Gt(ROSA)26Sortm1(Pik3ca*H1047R)Egan/Gt(ROSA)26Sor+ Olig2tm1.1(cre)Wdr/Olig2+
(involves: 129 * C57BL/6 * FVB/N)
|
increased brain tumor incidence
|
J:285841
|
increased glioma incidence
|
J:285841
|
Adamts3tm1b(KOMP)Wtsi/Adamts3tm1b(KOMP)Wtsi
(C57BL/6N-Adamts3tm1b(KOMP)Wtsi/Wtsi)
|
increased trigeminal neuroma incidence
|
J:239583
|
Adipoqtm1Chan/Adipoq+ Tg(MMTV-PyVT)634Mul/0
(B6.Cg-Adipoqtm1Chan Tg(MMTV-PyVT)634Mul)
|
increased mammary gland tumor incidence
|
J:147458
|
Adipoqtm1Chan/Adipoq+ Tg(MMTV-PyVT)634Mul/0
(FVB.Cg-Adipoqtm1Chan Tg(MMTV-PyVT)634Mul)
|
increased mammary gland tumor incidence
|
J:147458
|
Ahrtm1Bra/Ahr+ Tg(TRAMP)8247Ng/0
(B6.Cg-Ahrtm1Bra Tg(TRAMP)8247Ng)
|
increased prostate gland tumor incidence
|
J:118152
|
Ahrtm1Bra/Ahrtm1Bra Tg(TRAMP)8247Ng/0
(B6.Cg-Ahrtm1Bra Tg(TRAMP)8247Ng)
|
increased prostate gland tumor incidence
|
J:118152
|
Ahrtm1Gonz/Ahrtm1Gonz
(involves: 129S4/SvJae * C57BL/6N)
|
increased hepatoma incidence
|
J:44690
|
increased liver adenoma incidence
|
J:44690
|
Ahrtm1Yfk/Ahrtm1Yfk
(involves: 129S/SvEv * C57BL/6J)
|
increased urinary bladder carcinoma incidence
|
J:179919
|
Aicdatm1(cre)Mnz/Aicda+ Gt(ROSA)26Sortm2(sb11)Njen/Gt(ROSA)26Sor+ TgTn(sb-T2/Onc2)6070Njen/0
(involves: 129 * 129P2/OlaHsd * C57BL/6 * C57BL/6J)
|
increased B cell derived lymphoma incidence
|
J:153656
|
increased follicular lymphoma incidence
|
J:153656
|
increased hemolymphoid system tumor incidence
|
J:153656
|
increased leukemia incidence
|
J:153656
|
increased medulloblastoma incidence
|
J:153656
|
increased skin squamous cell carcinoma incidence
|
J:153656
|
increased T cell derived lymphoma incidence
|
J:153656
|
AipGt(RRI002)Byg/Aip+
(involves: 129P2/OlaHsd * C57BL/6)
|
increased pituitary adenoma incidence
|
J:165349
|
increased prolactinoma incidence
|
J:165349
|
Airetm1Pltn/Airetm1Pltn
(B6.129S4-Airetm1Pltn)
|
increased B cell derived lymphoma incidence
|
J:115076
|
Akt1Gt1Pnt/Akt1Gt1Pnt Tg(MMTV-Erbb2)NK1Mul/Tg(MMTV-Erbb2)NK1Mul
(involves: 129 * C57BL/6 * FVB/N)
|
increased mammary adenocarcinoma incidence
|
J:117336
|
Akt1Gt1Pnt/Akt1Gt1Pnt Tg(MMTV-PyVT)634Mul/0
(involves: 129 * C57BL/6 * FVB/N)
|
increased mammary adenocarcinoma incidence
|
J:117336
|
Akt2tm1.1Mbb/Akt2tm1.1Mbb Tg(MMTV-Erbb2)NK1Mul/Tg(MMTV-Erbb2)NK1Mul
(involves: 129 * C57BL/6 * FVB/N)
|
increased mammary adenocarcinoma incidence
|
J:117336
|
Akt2tm1.1Mbb/Akt2tm1.1Mbb Tg(MMTV-PyVT)634Mul/0
(involves: 129 * C57BL/6 * FVB/N)
|
increased mammary adenocarcinoma incidence
|
J:117336
|
Akt3tm1Mbb/Akt3tm1Mbb Tg(MMTV-Erbb2)NK1Mul/Tg(MMTV-Erbb2)NK1Mul
(involves: 129 * C57BL/6 * FVB/N)
|
increased mammary adenocarcinoma incidence
|
J:117336
|
Akt3tm1Mbb/Akt3tm1Mbb Tg(MMTV-PyVT)634Mul/0
(involves: 129 * C57BL/6 * FVB/N)
|
increased mammary adenocarcinoma incidence
|
J:117336
|
Aktiptm1a(EUCOMM)Hmgu/Aktiptm1a(EUCOMM)Hmgu Trp53tm1Tyj/Trp53+
(involves: 129S2/SvPas * C57BL/6N)
|
increased lymphoma incidence
|
J:276210
|
Aktiptm1a(EUCOMM)Hmgu/Aktiptm1a(EUCOMM)Hmgu Trp53tm1Tyj/Trp53tm1Tyj
(involves: 129S2/SvPas * C57BL/6N)
|
increased lymphoma incidence
|
J:276210
|
Albtm1(cre/ERT2)Mtz/Alb+ Gt(ROSA)26Sortm1(Notch1)Dam/Gt(ROSA)26Sor+
(involves: 129S2/SvPas * 129S4/SvJaeSor * C57BL/6)
|
increased cholangiocarcinoma incidence
|
J:192740
|
Albtm1(cre/ERT2)Mtz/Alb+ Krastm4Tyj/Kras+ Ptentm2Mak/Ptentm2Mak
(involves: 129P2/OlaHsd * 129S2/SvPas * 129S4/SvJae)
|
increased cholangiocarcinoma incidence
|
J:254370
|
increased hepatocellular carcinoma incidence
|
J:254370
|
Aldh2tm1a(EUCOMM)Wtsi/Aldh2tm1a(EUCOMM)Wtsi Fancd2tm1Hou/Fancd2tm1Hou
(involves: 129S4/SvJae * C57BL/6J * C57BL/6N)
|
increased acute lymphoblastic leukemia incidence
|
J:193232
|
increased lymphoma incidence
|
J:193232
|
increased T cell derived lymphoma incidence
|
J:193232
|
Alktm1.1(ALK*F1174L)Heno/Alk+ Tg(Mpz-cre)94Imeg/0 Tg(Th-MYCN)41Waw/0
(involves: 129X1/SvJ * BALB/c * C57BL/6 * SJL)
|
increased neuroblastoma incidence
|
J:294092
|
Alktm1.1(ALK*F1174L)Heno/Alktm1.1(ALK*F1174L)Heno Tg(Mpz-cre)94Imeg/0 Tg(Th-MYCN)41Waw/0
(involves: 129X1/SvJ * BALB/c * C57BL/6 * SJL)
|
increased neuroblastoma incidence
|
J:294092
|
Alktm1.1Ics/? Tg(Th-MYCN)41Waw/0
(involves: 129S2/SvPas * 129X1/SvJ * BALB/c * C57BL/6 * C57BL/6J)
|
increased neuroblastoma incidence
|
J:261033,
J:228124
|
Alktm2.1Ics/? Tg(Th-MYCN)41Waw/0
(involves: 129S2/SvPas * 129X1/SvJ * BALB/c * C57BL/6 * C57BL/6J)
|
increased neuroblastoma incidence
|
J:261033,
J:228124
|
Alox15tm1Fun/Alox15tm1Fun
(B6.129S2-Alox15tm1Fun/J)
|
increased chronic myelocytic leukemia incidence
|
J:119405
|
Altretm1.1Hbgl/Altretm1.1Hbgl Foxp3tm4(YFP/icre)Ayr/Y
(involves: 129S1/Sv * 129X1/SvJ * C57BL/6J)
|
increased liver tumor incidence
|
J:342907
|
AmfrGt(IST12797A11)Tigm/AmfrGt(IST12797A11)Tigm
(C57BL/6-AmfrGt(IST12797A11)Tigm)
|
increased liver tumor incidence
|
J:221247
|
Amhtm1Bhr/Amh+ Amhr2tm1Bhr/Amhr2tm1Bhr
(involves: 129S7/SvEvBrd * C57BL/6)
|
increased testis tumor incidence
|
J:36027
|
Amhr2tm1Bhr/Amhr2tm1Bhr Inhatm1Bay/Inha+
(involves: 129S7/SvEvBrd * C57BL/6)
|
increased testis tumor incidence
|
J:36027
|
Amhr2tm1Bhr/Amhr2tm1Bhr Inhatm1Bay/Inhatm1Bay
(involves: 129S7/SvEvBrd)
|
increased granulosa cell tumor incidence
|
J:36027
|
increased Leydig cell tumor incidence
|
J:36027
|
increased testis tumor incidence
|
J:36027
|
Amhr2tm3(cre)Bhr/Amhr2+
(involves: 129S/SvEv * C57BL/6)
|
increased ovarian carcinoma incidence
|
J:128934
|
increased ovary tumor incidence
|
J:128934
|
increased testis tumor incidence
|
J:128934
|
Amhr2tm3(cre)Bhr/Amhr2+ Ctnnb1tm1Mmt/Ctnnb1+
(involves: 129S7/SvEvBrd * 129X1/SvJ * C57BL/6)
|
increased granulosa cell tumor incidence
|
J:186144
|
increased testis tumor incidence
|
J:186144
|
Amhr2tm3(cre)Bhr/Amhr2+ Ctnnb1tm1Mmt/Ctnnb1+ Ptentm1Hwu/Ptentm1Hwu
(involves: 129S4/SvJae * 129S7/SvEvBrd * 129X1/SvJ)
|
increased granulosa cell tumor incidence
|
J:149060
|
increased ovary tumor incidence
|
J:142150
|
increased testis tumor incidence
|
J:149060
|
Amhr2tm3(cre)Bhr/Amhr2+ Ctnnb1tm1Mmt/Ctnnb1+ Ptentm1Hwu/Ptentm1Hwu
(involves: 129S4/SvJae * 129S7/SvEvBrd * 129X1/SvJ * C57BL/6)
|
increased granulosa cell tumor incidence
|
J:186144
|
increased testis tumor incidence
|
J:186144
|
Amhr2tm3(cre)Bhr/Amhr2+ KitW-v/KitW-v Trp53tm1Brn/Trp53tm1Brn
(involves: 129P2/OlaHsd * 129S7/SvEvBrd * C57BL/6J * FVB/N)
|
increased granulosa cell tumor incidence
|
J:236161
|
increased ovary adenoma incidence
|
J:236161
|
increased ovary tumor incidence
|
J:236161
|
Amhr2tm3(cre)Bhr/Amhr2+ Smad1tm2Rob/Smad1tm2.1Rob Smad5tm1Huy/Smad5tm1Huy
(involves: 129P2/OlaHsd * 129S/SvEv * C57BL/6)
|
increased ovarian carcinoma incidence
|
J:128934
|
increased ovary tumor incidence
|
J:128934
|
increased testis tumor incidence
|
J:128934
|
Amhr2tm3(cre)Bhr/Amhr2+ Smad1tm2Rob/Smad1tm2.1Rob Smad5tm1Huy/Smad5tm1Huy
(involves: 129P2/OlaHsd * 129S/SvEv * C57BL/6J)
|
increased granulosa cell tumor incidence
|
J:157310
|
Amhr2tm3(cre)Bhr/Amhr2+ Smad1tm2Rob/Smad1tm2Rob Smad5tm1Huy/Smad5tm1Huy
(involves: 129P2/OlaHsd * 129S/SvEv * C57BL/6J)
|
increased granulosa cell tumor incidence
|
J:157310
|
Amhr2tm3(cre)Bhr/Amhr2+ Smad1tm2Rob/Smad1tm2Rob Smad5tm1Huy/Smad5tm1Zuk
(involves: 129P2/OlaHsd * 129S/SvEv * 129S7/SvEvBrd * C57BL/6)
|
increased ovarian carcinoma incidence
|
J:128934
|
increased ovary tumor incidence
|
J:128934
|
increased testis tumor incidence
|
J:128934
|
Amhr2tm3(cre)Bhr/Amhr2+ Smad1tm2Rob/Smad1tm2Rob Smad5tm1Huy/Smad5tm1Zuk
(involves: 129P2/OlaHsd * 129S/SvEv * C57BL/6J)
|
increased granulosa cell tumor incidence
|
J:157310
|
Amhr2tm3(cre)Bhr/Amhr2+ Smad1tm2Rob/Smad1tm2Rob Smad5tm1Huy/Smad5tm1Zuk Smad9tm1Jfm/Smad9tm1Jfm
(involves: 129S/SvEv * 129S4/SvJaeSor * C57BL/6)
|
increased ovarian carcinoma incidence
|
J:128934
|
increased ovary tumor incidence
|
J:128934
|
Anxa7tm1Pll/Anxa7+
(B6.Cg-Anxa7tm1Pll)
|
increased hepatocellular carcinoma incidence
|
J:93685
|
increased lymphoma incidence
|
J:93685
|
ApcGt(XA018)Byg/Apc+
(B6.129P2-ApcGt(XA018)Byg)
|
increased colon adenoma incidence
|
J:202877
|
increased intestinal adenoma incidence
|
J:202877
|
ApcM1Tno/Apc+
(involves: C57BL/6 * DBA/2JJcl)
|
increased mammary gland tumor incidence
|
J:218227
|
increased osteoma incidence
|
J:218227
|
increased skin tumor incidence
|
J:218227
|
ApcM1Tno/Apc+
(either: B6JJcl.B6(D2JJcl)-ApcM1Tno or (involves: C57BL/6 * C57BL/6JJcl * DBA/2JJcl))
|
increased mammary adenocarcinoma incidence
|
J:218227
|
increased mammary gland tumor incidence
|
J:218227
|
increased osteoma incidence
|
J:218227
|
increased osteosarcoma incidence
|
J:218227
|
increased pilomatricoma incidence
|
J:218227
|
increased skin tumor incidence
|
J:218227
|
increased trichoepithelioma incidence
|
J:218227
|
ApcMin/Apc+
(involves: AKR/J * C57BL/6J)
|
increased intestinal adenocarcinoma incidence
|
J:10209
|
increased intestinal adenoma incidence
|
J:10209
|
ApcMin/Apc+
(C57BL/6J-ApcMin)
|
increased colon adenoma incidence
|
J:158733,
J:160399
|
increased intestinal adenoma incidence
|
J:158733,
J:241611,
J:1879,
J:85142
|
ApcMin/Apc+
(involves: C57BL/6J)
|
increased intestinal adenoma incidence
|
J:299895,
J:75393,
J:94108
|
increased mammary adenocarcinoma incidence
|
J:94108
|
ApcMin/Apc+
(B6.Cg-Brca2tm1Mbn ApcMin)
|
increased mammary gland tumor incidence
|
J:67445
|
ApcMin/Apc+
(involves: 129P2/OlaHsd * C57BL/6)
|
increased intestinal adenoma incidence
|
J:95893
|
ApcMin/Apc+
(B6(AKR)-ApcMin)
|
increased intestinal adenocarcinoma incidence
|
J:10209
|
increased intestinal adenoma incidence
|
J:10209
|
increased mammary gland tumor incidence
|
J:15101
|
ApcMin/Apc+
((AKR/J x C57BL/6J-ApcMin)F1)
|
increased intestinal adenocarcinoma incidence
|
J:21369
|
ApcMin/Apc+
(C57BL/6J-ApcMin/J)
|
increased colon adenoma incidence
|
J:331404
|
increased intestinal adenoma incidence
|
J:331404
|
ApcMin/Apc+ Bcl2l14tm1.1Boui/Bcl2l14tm1.1Boui
(involves: C57BL/6 * C57BL/6J)
|
increased colon tumor incidence
|
J:296081
|
ApcMin/Apc+ Blmtm1Grdn/Blm+
(involves: 129P2/OlaHsd * 129S/SvEv * Black Swiss * C57BL/6J)
|
increased colon adenoma incidence
|
J:79058
|
increased gastrointestinal tumor incidence
|
J:79058
|
increased intestinal adenoma incidence
|
J:79058
|
ApcMin/Apc+ Brca2tm1Mbn/Brca2+
(B6.Cg-Brca2tm1Mbn ApcMin)
|
increased mammary gland tumor incidence
|
J:67445
|
ApcMin/Apc+ Ccdc80tm1.1Ftk/Ccdc80tm1.1Ftk
(involves: 129P2/OlaHsd * BALB/cJ * C57BL/6 * C57BL/6J * C57BL/6N)
|
increased colon adenocarcinoma incidence
|
J:216704
|
increased colon adenoma incidence
|
J:216704
|
increased colon tumor incidence
|
J:216704
|
increased gastrointestinal tumor incidence
|
J:216704
|
ApcMin/Apc+ Ccnd1tm1Dsn/Ccnd1tm1Dsn
(involves: C57BL/6J)
|
increased intestinal adenoma incidence
|
J:78500
|
ApcMin/Apc+ Cd44tm1Stpa/Cd44tm1Stpa
(involves: C57BL/6J * C57BL/6JIco)
|
increased intestinal adenoma incidence
|
J:204874
|
ApcMin/Apc+ Cd44tm1Stpa/Cd44tm2Stpa
(involves: C57BL/6J)
|
increased intestinal adenoma incidence
|
J:204874
|
ApcMin/Apc+ Col1a1tm1(CAG-Sirt1)Dsin/Col1a1+
(involves: 129S4/SvJae * C57BL/6 * C57BL/6J)
|
increased gastrointestinal tumor incidence
|
J:134301
|
ApcMin/Apc+ Col1a1tm9(tetO-Dnmt3b_i1)Jae/Col1a1+ Gt(ROSA)26Sortm1(rtTA*M2)Jae/Gt(ROSA)26Sor+
(involves: 129S4/SvJae * C57BL/6 * C57BL/6J)
|
increased intestinal adenoma incidence
|
J:127808
|
ApcMin/Apc+ Col1a1tm11(tetO-Nup88)Jvd/Col1a1+
(involves: 129S4/SvJae * C57BL/6 * C57BL/6J)
|
increased colon tumor incidence
|
J:231166
|
ApcMin/Apc+ Dcctm1Wbg/Dcc+
(involves: C57BL/6J)
|
increased intestinal adenoma incidence
|
J:39765
|
ApcMin/Apc+ Dnd1Ter/Dnd1+
(involves: 129P3/J * C57BL/6J)
|
increased intestinal adenoma incidence
|
J:221231
|
ApcMin/Apc+ Eregtm1Dwt/Eregtm1Dwt
(involves: 129S6/SvEvTac * C57BL/6J)
|
increased intestinal adenoma incidence
|
J:93327
|
ApcMin/Apc+ Esr1tm1.1Mma/Esr1+
(involves: 129S2/SvPas * C57BL/6J)
|
increased colon adenoma incidence
|
J:118600
|
increased gastrointestinal tumor incidence
|
J:118600
|
ApcMin/Apc+ Esr2tm1Mma/Esr2+
(involves: 129S2/SvPas * C57BL/6J)
|
increased gastrointestinal tumor incidence
|
J:118600
|
ApcMin/Apc+ Esr2tm1Mma/Esr2tm1Mma
(involves: 129S2/SvPas * C57BL/6J)
|
increased colon adenoma incidence
|
J:118600
|
increased gastrointestinal tumor incidence
|
J:118600
|
ApcMin/Apc+ Foxl1tm1Khk/Foxl1tm1Khk
(involves: 129P2/OlaHsd * C57BL/6)
|
increased colon adenoma incidence
|
J:95893
|
ApcMin/Apc+ Fxyd5em1Namje/Fxyd5em1Namje
(C57BL/6J-Fxyd5em1Namje Apcmin)
|
increased gastrointestinal tumor incidence
|
J:325989
|
ApcMin/Apc+ Glp2rtm1Ddr/Glp2r+
(involves: C57BL/6J)
|
increased intestinal adenoma incidence
|
J:141821
|
ApcMin/Apc+ Glp2rtm1Ddr/Glp2rtm1Ddr
(involves: C57BL/6J)
|
increased intestinal adenoma incidence
|
J:141821
|
ApcMin/Apc+ Gpa33tm1(GNAS)Wtsi/Gpa33+ Hprt1tm1(CMV-cre)Brd/?
(involves: 129S7/SvEvBrd * C57BL/6J)
|
increased intestinal adenoma incidence
|
J:168378
|
ApcMin/Apc+ Gt(ROSA)26Sortm2(Rnf187)Jhai/Gt(ROSA)26Sor+ Tg(Vil1-cre)20Syr/0
(involves: 129S6/SvEvTac * C57BL/6 * DBA/2)
|
increased gastrointestinal tumor incidence
|
J:173145
|
ApcMin/Apc+ Hdac2Gt(W035F03)Joe/Hdac2Gt(W035F03)Joe
(involves: 129S2/SvPas * C57BL/6J)
|
increased small intestine adenocarcinoma incidence
|
J:152134
|
ApcMin/Apc+ Hptm1Skl/Hptm1Skl
(involves: 129P2/OlaHsd * C57BL/6J)
|
increased gastrointestinal tumor incidence
|
J:75249
|
ApcMin/Apc+ Hpgdstm1Urad/Hpgds+
(involves: 129 * C57BL/6J)
|
increased intestinal adenoma incidence
|
J:118232
|
ApcMin/Apc+ Hpgdstm1Urad/Hpgdstm1Urad
(involves: 129 * C57BL/6J)
|
increased intestinal adenoma incidence
|
J:118232
|
ApcMin/Apc+ Hsd11b2tm1.1Mzz/Hsd11b2tm1.1Mzz Tg(Vil1-cre)997Gum/0
(involves: 129 * C57BL/6 * C57BL/6J)
|
increased intestinal adenoma incidence
|
J:205456
|
ApcMin/Apc+ Il22ra2tm2Vlcg/Il22ra2tm2Vlcg
(involves: 129S6/SvEvTac * C57BL/6J * C57BL/6NTac)
|
increased intestinal adenoma incidence
|
J:189217
|
ApcMin/Apc+ Map9tm1.2Bcgen/Map9+
(involves: 129S4/SvJaeSor * BALB/cJ * C57BL/6 * C57BL/6J)
|
increased colon tumor incidence
|
J:299895
|
ApcMin/Apc+ Map9tm1.2Bcgen/Map9tm1.2Bcgen
(involves: 129S4/SvJaeSor * BALB/cJ * C57BL/6 * C57BL/6J)
|
increased colon tumor incidence
|
J:299895
|
ApcMin/Apc+ Mapkapk2tm1.2Gkl/Mapkapk2tm1.2Gkl
(involves: BALB/cJ * C57BL/6J)
|
increased intestinal adenoma incidence
|
J:262876
|
ApcMin/Apc+ Mbd4tm1Bird/Mbd4tm1Bird
(involves: 129P2/OlaHsd * C57BL/6J)
|
increased intestinal adenoma incidence
|
J:77896
|
ApcMin/Apc+ Mir10atm1.1Ahl/Mir10atm1.1Ahl
(B6.Cg-Mir10atm1.1Ahl Apcmin)
|
increased gastrointestinal tumor incidence
|
J:205135
|
increased intestinal adenoma incidence
|
J:205135
|
ApcMin/Apc+ Mir708tm1Wtsi/Mir708tm1Wtsi
(involves: C57BL/6J * C57BL/6N)
|
increased colon adenoma incidence
|
J:317482
|
ApcMin/Apc+ Mom5C57BL/6J/Mom5C57BL/6J
(involves: C57BL/6J)
|
increased intestinal adenoma incidence
|
J:152194
|
ApcMin/Apc+ Msh2tm1Htr/Msh2tm1Htr
(involves: 129P2/OlaHsd * BALB/c * C57BL/6J)
|
increased gastrointestinal tumor incidence
|
J:45433
|
ApcMin/Apc+ Msh2tm1Mak/Msh2tm1Mak
(involves: 129P2/OlaHsd * C57BL/6J)
|
increased intestinal adenoma incidence
|
J:75393
|
ApcMin/Apc+ Pms2tm1Lisk/Pms2tm1Lisk
(involves: 129S2/SvPas * C57BL/6J)
|
increased intestinal adenoma incidence
|
J:46419
|
ApcMin/Apc+ Ppardtm1Jps/Ppardtm1Jps
(involves: 129/Sv * AKR/J * C57BL/6 * C57BL/6J)
|
increased intestinal adenocarcinoma incidence
|
J:90337
|
ApcMin/Apc+ Ptentm1Hwu/Ptentm1Hwu Tg(Vil1-cre)997Gum/0
(involves: 129S4/SvJae * BALB/c * C57BL/6J * SJL)
|
increased intestinal adenoma incidence
|
J:150553
|
ApcMin/Apc+ Ptgdstm1Ohy/Ptgdstm1Ohy
(involves: 129P2/OlaHsd * C57BL/6J)
|
increased intestinal adenoma incidence
|
J:118232
|
ApcMin/Apc+ Rab11atm1.1Ngao/Rab11atm1.1Ngao Tg(Vil1-cre)997Gum/0
(involves: 129S4/SvJae * C57BL/6J * SJL/J)
|
increased intestinal adenoma incidence
|
J:278932
|
ApcMin/Apc+ Rab25tm1Jrgo/Rab25+
(B6.Cg-Rab25tm1Jrgo ApcMin)
|
increased intestinal adenoma incidence
|
J:158733
|
ApcMin/Apc+ Rab25tm1Jrgo/Rab25tm1Jrgo
(B6.Cg-Rab25tm1Jrgo ApcMin)
|
increased colon adenoma incidence
|
J:158733
|
increased intestinal adenoma incidence
|
J:158733
|
ApcMin/Apc+ Recql4tm1Glu/Recql4tm1Glu
(involves: 129S7/SvEvBrd * C57BL/6J)
|
increased colon adenoma incidence
|
J:97101
|
ApcMin/Apc+ Slc5a8tm1.1Boet/Slc5a8tm1.1Boet
(involves: C57BL/6 * C57BL/6J)
|
increased colon adenoma incidence
|
J:139883
|
ApcMin/Apc+ Spata18tm1.2Hifa/Spata18+
(involves: C57BL/6J)
|
increased colon adenocarcinoma incidence
|
J:254117
|
increased colon adenoma incidence
|
J:254117
|
increased intestinal adenocarcinoma incidence
|
J:254117
|
increased intestinal adenoma incidence
|
J:254117
|
increased small intestine adenocarcinoma incidence
|
J:254117
|
ApcMin/Apc+ Spata18tm1.2Hifa/Spata18tm1.2Hifa
(involves: C57BL/6J)
|
increased colon adenocarcinoma incidence
|
J:254117
|
increased colon adenoma incidence
|
J:254117
|
increased intestinal adenocarcinoma incidence
|
J:254117
|
increased intestinal adenoma incidence
|
J:254117
|
increased small intestine adenocarcinoma incidence
|
J:254117
|
ApcMin/Apc+ Tcf7tm1Cle/Tcf7tm1Cle
(involves: 129P2/OlaHsd * C57BL/6J)
|
increased intestinal adenoma incidence
|
J:57721
|
increased mammary adenoacanthoma incidence
|
J:57721
|
increased salivary gland tumor incidence
|
J:57721
|
ApcMin/Apc+ Tcf7l2tm1.1(EGFP/cre)Mrc/Tcf7l2+
(involves: 129S1/Sv * 129X1/SvJ * C57BL/6J)
|
increased intestinal adenoma incidence
|
J:170088
|
ApcMin/Apc+ Tcf7l2tm2.2Mrc/Tcf7l2+
(involves: C57BL/6J)
|
increased intestinal adenoma incidence
|
J:170088
|
ApcMin/Apc+ Tg(CAG-PGDS)S-55Hjl/0
(involves: C57BL/6J * FVB/N)
|
increased intestinal adenoma incidence
|
J:118232
|
ApcMin/Apc+ Tgfbr1tm1Bopa/Tgfbr1+
(involves: 129S1/SvImJ * C57BL/6J)
|
increased gastrointestinal tumor incidence
|
J:143706
|
increased intestinal adenocarcinoma incidence
|
J:143706
|
ApcMin/Apc+ Tgfbr1tm1Bopa/Tgfbr1+
(B6.Cg-Tgfbr1tm1Bopa ApcMin)
|
increased gastrointestinal tumor incidence
|
J:143706
|
increased intestinal adenocarcinoma incidence
|
J:143706
|
ApcMin/Apc+ Thbs1tm1Hyn/Thbs1tm1Hyn
(involves: C57BL/6J)
|
increased intestinal adenoma incidence
|
J:79641
|
ApcMin/Apc+ Tnfaip8l1em1Huwa/Tnfaip8l1em1Huwa
(involves: C57BL/6 * C57BL/6J)
|
increased colon tumor incidence
|
J:342074
|
ApcMin/Apc+ Trp53tm1Mlh/Trp53tm1Mlh
(involves: 129P2/OlaHsd * C57BL/6 * SWR)
|
increased pancreatic acinar cell carcinoma incidence
|
J:29664
|
ApcMin/Apc+ Trp53tm2.1Tyj/Trp53tm2.1Tyj Tg(Vil1-cre/ERT2)23Syr/0
(involves: 129S1/Sv * 129X1/SvJ * C57BL/6J * DBA/2)
|
increased colon adenoma incidence
|
J:291671
|
increased intestinal adenoma incidence
|
J:291671
|
ApcMin/Apc+ Zbtb33tm1.1Bird/Y
(involves: 129P2/OlaHsd * C57BL/6 * C57BL/6J)
|
increased intestinal adenoma incidence
|
J:104155
|
ApcMin/Apc+ Zfp82tm1.2Cya/Zfp82+
(involves: 129S4/SvJaeSor * BALB/cJ * C57BL/6NTac)
|
increased colon tumor incidence
|
J:316087
|
ApcMin/Apc+ Zfp82tm1.2Cya/Zfp82tm1.2Cya
(involves: 129S4/SvJaeSor * BALB/cJ * C57BL/6NTac)
|
increased colon tumor incidence
|
J:316087
|
ApcMin/ApcMin Asphtm1Jed/Asphtm1Jed
(involves: 129S6/SvEvTac * 129S7/SvEvBrd * C57BL/6J * C57BL/6NTac)
|
increased gastrointestinal tumor incidence
|
J:75888
|
ApcMin/ApcMin Ppardtm1.1Rev/Ppardtm1.1Rev
(involves: C57BL/6J)
|
increased intestinal adenoma incidence
|
J:73557
|
ApcMin/ApcMin Rr27tm1Rohl/Rr27+
(involves: 129S1/Sv * 129X1/SvJ * C57BL/6J)
|
increased colon adenoma incidence
|
J:97083
|
increased intestinal adenoma incidence
|
J:97083
|
ApcMin/Apctm1Tno Ctnnb1tm4.1Wbm/Ctnnb1+
(involves: 129 * 129P2/OlaHsd * 129S4/SvJae * C57BL/6)
|
increased hepatocellular carcinoma incidence
|
J:156864
|
Apctm1.1Alew/Apc+
(B6.129-Apctm1.1Alew)
|
increased intestinal adenoma incidence
|
J:180057,
J:180275
|
Apctm1.1Rsmi/Apc+
(involves: 129P2/OlaHsd)
|
increased gastrointestinal tumor incidence
|
J:149225
|
Apctm1.1Rsmi/Apc+
(involves: 129P2/OlaHsd * C57BL/6 * FVB/N)
|
increased gastrointestinal tumor incidence
|
J:159883
|
increased intestinal adenoma incidence
|
J:159883
|
increased large intestine adenocarcinoma incidence
|
J:159883
|
increased small intestine adenocarcinoma incidence
|
J:159883
|
Apctm1.1Tno/Apc+
(involves: 129S4/SvJae * C57BL/6)
|
increased intestinal adenoma incidence
|
J:127452
|
Apctm1.1Tyj/Apc+
(involves: 129S4/SvJaeSor * C57BL/6)
|
increased colon adenoma incidence
|
J:160399
|
increased intestinal adenoma incidence
|
J:160399
|
Apctm1Cip/Apc+
(involves: 129P2/OlaHsd * C57BL/6)
|
increased colon adenoma incidence
|
J:94108
|
increased intestinal adenocarcinoma incidence
|
J:94108
|
increased intestinal adenoma incidence
|
J:94108
|
increased mammary adenocarcinoma incidence
|
J:94108
|
Apctm1Cip/Apc+ Cdhr5tm1Lex/Cdhr5tm1Lex
(involves: 129P2/OlaHsd * 129S5/SvEvBrd * C57BL/6)
|
increased intestinal adenoma incidence
|
J:301471
|
Apctm1Cip/Apc+ H19tm1Lda/H19+
(involves: 129P2/OlaHsd * 129S2/SvPas * C57BL/6 * CBA)
|
increased intestinal adenocarcinoma incidence
|
J:138826
|
Apctm1Hsa/Apc+
(involves: 129P2/OlaHsd * C57BL/6)
|
increased gastrointestinal tumor incidence
|
J:61978
|
increased mammary adenocarcinoma incidence
|
J:61978
|
increased mammary gland tumor incidence
|
J:61978
|
increased stomach tumor incidence
|
J:61978
|
Apctm1Kk/Apctm1Kk Tg(Lck-cre)1Cwi/?
(involves: 129S6/SvEvTac * C57BL/6 * DBA/2)
|
increased intestinal adenoma incidence
|
J:104334
|
Apctm1Mmt/Apc+
(involves: 129S2/SvPas * C57BL/6J)
|
increased intestinal adenoma incidence
|
J:25200,
J:79668
|
Apctm1Mmt/Apc+ Smad2tm1Kato/Smad2+
(involves: 129S2/SvPas * 129S4/SvJae * C57BL/6J)
|
increased intestinal adenoma incidence
|
J:79668
|
Apctm1Mmt/Apc+ Smad2tm2Kato/Smad2+
(involves: 129S2/SvPas * 129S4/SvJae * C57BL/6J)
|
increased intestinal adenoma incidence
|
J:79668
|
Apctm1Mmt/Apc+ Smad4tm1Mmt/Smad4+
(involves: 129S2/SvPas * C57BL/6)
|
increased intestinal adenocarcinoma incidence
|
J:46242
|
increased pancreatic ductal adenocarcinoma incidence
|
J:46242
|
Apctm1Rak/Apc+
(involves: 129P2/OlaHsd * C57BL/6)
|
increased hepatocellular carcinoma incidence
|
J:20443
|
increased intestinal adenocarcinoma incidence
|
J:20443
|
increased intestinal adenoma incidence
|
J:20443
|
Apctm1Rak/Apc+
(involves: 129P2/OlaHsd * C57BL/6J)
|
increased intestinal adenocarcinoma incidence
|
J:65142
|
increased stomach tumor incidence
|
J:65142
|
Apctm1Rak/Apc+
((C57BL/6J x 129P2/OlaHsd)F1)
|
increased gastrointestinal tumor incidence
|
J:151494
|
increased stomach tumor incidence
|
J:151494
|
Apctm1Rak/Apc+ Cdh1tm1Cbm/Cdh1+
(involves: 129P2/OlaHsd * C57BL/6J)
|
increased intestinal adenocarcinoma incidence
|
J:65142
|
increased stomach tumor incidence
|
J:65142
|
Apctm1Rak/Apc+ Dcctm1.1Mehl/Dcctm1.1Mehl
(involves: 129P2/OlaHsd * C57BL/6)
|
increased gastrointestinal tumor incidence
|
J:181517
|
increased intestinal adenocarcinoma incidence
|
J:181517
|
Apctm1Rak/Apc+ Mbd4tm1Wed/Mbd4tm1Wed
(involves: 129/Sv * 129P2/OlaHsd * C57BL/6 * SJL)
|
increased gastrointestinal tumor incidence
|
J:80319
|
Apctm1Rak/Apc+ Mlh1tm1Rak/Mlh1+
(involves: 129P2/OlaHsd * C57BL/6)
|
increased gastrointestinal tumor incidence
|
J:53451
|
Apctm1Rak/Apc+ Mlh1tm1Rak/Mlh1tm1Rak
(involves: 129P2/OlaHsd * C57BL/6)
|
increased gastrointestinal tumor incidence
|
J:53451
|
increased lymphoma incidence
|
J:53451
|
increased skin tumor incidence
|
J:53451
|
Apctm1Rak/Apc+ Smad4E6sad/Smad4+
(B6.129P2-Apctm1Rak Smad4E6sad/+ +)
|
increased intestinal adenoma incidence
|
J:107273
|
Apctm1Rak/Apc+ Smad4E6sad/Smad4+
(B6.129P2-Apctm1Rak +/+ Smad4E6sad)
|
increased intestinal adenocarcinoma incidence
|
J:107273
|
increased intestinal adenoma incidence
|
J:107273
|
Apctm1Rsmi/Apc+ Ctnnb1tm1Wvv/Ctnnb1+ Tg(Fabp1-cre)1Jig/?
(involves: 129P2/OlaHsd * C57BL/6J * FVB/N)
|
increased gastrointestinal tumor incidence
|
J:185942
|
Apctm1Rsmi/Apc+ Tg(Fabp1-cre)1Jig/0
(involves: 129P2/OlaHsd * FVB/N)
|
increased gastrointestinal tumor incidence
|
J:159883
|
increased intestinal adenocarcinoma incidence
|
J:159883
|
increased intestinal adenoma incidence
|
J:159883
|
increased large intestine adenocarcinoma incidence
|
J:159883
|
increased small intestine adenocarcinoma incidence
|
J:159883
|
Apctm1Rsmi/Apctm1Rsmi Pgrtm2(cre)Lyd/Pgr+
(involves: 129P2/OlaHsd * 129S1/Sv * 129X1/SvJ * C57BL/6J)
|
increased granulosa cell tumor incidence
|
J:210095
|
increased ovary tumor incidence
|
J:210095
|
increased reproductive system tumor incidence
|
J:210095
|
Apctm1Tno/Apc+
(involves: 129 * 129S4/SvJae * C57BL/6)
|
increased hepatocellular carcinoma incidence
|
J:156864
|
Apctm1Tno/Apc+ Brf1tm1Arte/Brf1tm1Arte Tg(Cyp1a1-cre)1Dwi/0
(involves: C57BL/6 * CBA)
|
increased pancreatic ductal adenocarcinoma incidence
|
J:285667
|
Apctm1Tno/Apc+ Ptentm2Mak/Ptentm2Mak Tg(Cyp1a1-cre/ERT)1Dwi/0
(involves: 129P2/OlaHsd * 129S4/SvJae * C57BL/6 * CBA)
|
increased intestinal adenocarcinoma incidence
|
J:143082
|
Apctm1Tno/Apc+ Tg(CDX2-cre)101Erf/0
(involves: 129S4/SvJae * C57BL/6 * SJL)
|
increased gastrointestinal tumor incidence
|
J:126018
|
increased mammary adenocarcinoma incidence
|
J:126018
|
Apctm1Tno/Apc+ Tg(CDX2-cre/ERT)#Erf/0
(involves: 129S4/SvJae)
|
increased gastrointestinal tumor incidence
|
J:189226
|
Apctm1Tno/Apc+ Tg(Vil1-cre)997Gum/0
(involves: 129S4/SvJae * C57BL/6 * SJL)
|
increased gastrointestinal tumor incidence
|
J:126018
|
increased small intestine adenocarcinoma incidence
|
J:126018
|
Apctm1Tno/Apctm1Tno
(involves: 129S4/SvJae * C57BL/6)
|
increased colon adenoma incidence
|
J:43301
|
Apctm1Tno/Apctm1Tno
(involves: 129 * 129S4/SvJae * C57BL/6)
|
increased hepatocellular carcinoma incidence
|
J:156864
|
Apctm1Tno/Apctm1Tno Lgr5tm1(cre/ERT2)Cle/Lgr5+
(involves: 129P2/OlaHsd * 129S4/SvJae * C57BL/6)
|
increased intestinal adenoma incidence
|
J:227334
|
Apctm1Tno/Apctm1Tno Ptentm2Mak/Ptentm2Mak
(involves: 129P2/OlaHsd * 129S4/SvJae)
|
increased ovarian carcinoma incidence
|
J:120955
|
Apctm1Tno/Apctm1Tno Tg(Cdh16-cre)91Igr/0
(involves: 129S4/SvJae * ICR)
|
increased renal cystadenoma incidence
|
J:95502
|
Apctm1Tno/Apctm1Tno Tg(CDX2-cre*)189Erf/0
(involves: 129S4/SvJae * C57BL/6 * SJL)
|
increased colon adenoma incidence
|
J:148161
|
Apctm1Tno/Apctm1Tno Tg(Pbsn-cre)4Prb/0
(involves: 129S4/SvJae * C57BL/6 * C57BL/6J * DBA/2)
|
increased prostate gland adenocarcinoma incidence
|
J:120308
|
increased prostate intraepithelial neoplasia incidence
|
J:120308
|
Apctm1Tyj/Apc+ Tg(Vil1-cre)20Syr/0
(involves: C57BL/6 * DBA/2)
|
increased colon adenoma incidence
|
J:160399
|
increased intestinal adenoma incidence
|
J:160399
|
Apctm2.1Alew/Apc+
(B6.129-Apctm2.1Alew)
|
increased intestinal adenoma incidence
|
J:180057
|
Apctm2.1Cip/Apc+ Krastm4Tyj/Kras+ Tg(Fabp1-cre)1Jig/0
(involves: 129P2/OlaHsd * 129S4/SvJae * FVB)
|
increased intestinal adenocarcinoma incidence
|
J:132357
|
Apctm2.1Cip/Apc+ Lrig1tm1.1(cre/ERT2)Rjc/Lrig1+
(involves: 129 * 129P2/OlaHsd * C57BL/6)
|
increased intestinal adenoma incidence
|
J:186084
|
Apctm2.1Cip/Apc+ Tg(Fabp1-cre)1Jig/0
(involves: 129P2/OlaHsd * FVB/N)
|
increased intestinal adenocarcinoma incidence
|
J:132357
|
Apctm2.1Cip/Apc+ Tg(Vil1-cre)20Syr/0
(involves: 129P2/OlaHsd * C57BL/6 * DBA/2)
|
increased colon adenoma incidence
|
J:160399
|
increased intestinal adenoma incidence
|
J:160399
|
Apctm2.1Cip/Apc+ Tg(Vil1-cre/ERT2)23Syr/0
(involves: 129P2/OlaHsd * C57BL/6 * DBA/2)
|
increased colon adenoma incidence
|
J:227287
|
increased intestinal adenoma incidence
|
J:227287
|
Apctm2.1Cip/Apctm2.1Cip
(involves: 129P2/OlaHsd * C57BL/6N)
|
increased hepatocellular carcinoma incidence
|
J:94721
|
Apctm2.1Rak/Apc+
(involves: 129/Sv * C57BL/6J * SJL)
|
increased gastrointestinal tumor incidence
|
J:114152
|
increased intestinal adenoma incidence
|
J:114152
|
Apctm2Mmt/Apc+
(involves: 129X1/SvJ)
|
increased intestinal adenoma incidence
|
J:81402
|
Apctm2Rak/Apc+ Krastm1.1Khai/Kras+ Tg(Fabp1-cre)1Jig/0
(involves: 129S4/SvJae * 129S6/SvEvTac * C57BL/6 * FVB/N * SJL)
|
increased colon adenoma incidence
|
J:276349
|
Apctm2Rak/Apc+ Krastm4Tyj/Kras+ Tg(Fabp1-cre)1Jig/0
(involves: 129S4/SvJae * C57BL/6 * FVB/N * SJL)
|
increased colon adenoma incidence
|
J:276349
|
Apctm2Rak/Apc+ Tg(Car1-cre)5Flt/0
(involves: 129/Sv * C57BL/6J * SJL)
|
increased intestinal adenoma incidence
|
J:164247
|
Apctm2Rak/Apc+ Trp53tm1Brn/Trp53tm1Brn Tg(Pdx1-cre)6Tuv/0
(involves: 129/Sv * 129P2/OlaHsd * C57BL/6J * FVB/N * SJL)
|
increased pancreas tumor incidence
|
J:234310
|
Apctm2Rak/Apctm2Rak
(involves: 129/Sv * C57BL/6J * SJL)
|
increased colon adenoma incidence
|
J:156532
|
increased organ/body region tumor incidence
|
J:156532
|
Apctm2Rak/Apctm2Rak Krastm4Tyj/Kras+
(involves: 129 * 129S4/SvJae * C57BL/6J * SJL)
|
increased colon adenoma incidence
|
J:156532
|
increased organ/body region tumor incidence
|
J:156532
|
Apctm2Rak/Apctm2Rak Tg(Car1-cre)5Flt/0
(involves: 129/Sv * C57BL/6J * SJL)
|
increased intestinal adenoma incidence
|
J:164247
|
Apctm2Rfo/Apc+
(B6.129P2-Apctm2Rfo)
|
increased liver tumor incidence
|
J:151494
|
increased mammary adenocarcinoma incidence
|
J:151494
|
increased mammary gland tumor incidence
|
J:151494
|
Apctm2Rfo/Apc+
((C57BL/6J x 129P2/OlaHsd)F1)
|
increased liver tumor incidence
|
J:151494
|
increased mammary adenocarcinoma incidence
|
J:204440,
J:151494
|
increased mammary gland tumor incidence
|
J:151494
|
Apctm2Rfo/Apc+
(129P2/OlaHsd-Apctm2Rfo)
|
increased gastrointestinal tumor incidence
|
J:151494
|
increased liver tumor incidence
|
J:151494
|
increased mammary adenocarcinoma incidence
|
J:151494
|
Apctm2Rfo/Apc+ Smad4E6sad/Smad4+
(involves: 129P2/OlaHsd * C57BL/6J)
|
increased gastrointestinal tumor incidence
|
J:151494
|
increased mammary adenocarcinoma incidence
|
J:151494
|
Apctm2Tno/Apc+
(Not Specified)
|
increased intestinal adenoma incidence
|
J:47857
|
Apctm3Mmt/Apc+
(B6.129X1-Apctm3Mmt)
|
increased intestinal adenoma incidence
|
J:101604
|
Apctm4Mmt/Apc+
(B6.129X1-Apctm4Mmt)
|
increased intestinal adenoma incidence
|
J:101604
|
Apex1tm1Ecf/Apex1+
(either: (involves: 129/Sv) or (involves: 129/Sv * C57BL/6))
|
increased lymphoma incidence
|
J:70397
|
Apmt1FVB/NJ/Apmt1FVB/NJ
(involves: FVB/NJ * I/LnJ)
|
increased mammary gland tumor incidence
|
J:64663
|
Apmt1FVB/NJ/Apmt1FVB/NJ Apmt2I/LnJ/Apmt2FVB/NJ
(involves: FVB/NJ * FVB/N-Tg(MMTVPyVT)634Mul * I/LnJ)
|
increased mammary gland tumor incidence
|
J:64663
|
Apmt1FVB/NJ/Apmt1I/LnJ
(involves: FVB/NJ * I/LnJ)
|
increased mammary gland tumor incidence
|
J:64663
|
Apmt2I/LnJ/?
(involves: FVB/NJ * FVB/N-Tg(MMTVPyVT)634Mul * I/LnJ)
|
increased mammary gland tumor incidence
|
J:64663
|
Aptxtm1Pmc/Aptx+ Atmtm2.1Mfgc/Atmtm2.1Mfgc
(involves: 129 * C57BL/6)
|
increased thymoma incidence
|
J:316365
|
Aptxtm1Pmc/Aptxtm1Pmc Atmtm2.1Mfgc/Atmtm2.1Mfgc
(involves: 129 * C57BL/6)
|
increased thymoma incidence
|
J:316365
|
ArTfm/Y
(involves: NMRI * STOCK EdaTa Atp7aMo-blo)
|
increased testis tumor incidence
|
J:140803
|
ArTfm/Y Tg(TSPY)9Jshm/0
(involves: NMRI * STOCK EdaTa Atp7aMo-blo)
|
increased testis tumor incidence
|
J:140803
|
Artm1(AR)Dmr/Y Tg(TRAMP)8247Ng/0
(involves: 129S1/Sv * C57BL/6)
|
increased prostate gland tumor incidence
|
J:108849
|
Artm1Verh/Y Ptentm1Hwu/Ptentm1Hwu Tg(Pbsn-cre)4Prb/0
(involves: 129S1/Sv * 129S4/SvJae * 129X1/SvJ * C57BL/6 * DBA/2)
|
increased prostate gland adenocarcinoma incidence
|
J:172730
|
Artm2(AR)Dmr/Y Tg(TRAMP)8247Ng/0
(involves: 129S1/Sv * C57BL/6)
|
increased prostate gland tumor incidence
|
J:108849
|
Artm3.1(AR)Ska/Y Tg(KLKB1-cre/ERT2)1Pcn/0 Tg(TRAMP)8247Ng/0
(involves: C57BL/6 * C57BL/6J * CBA)
|
increased prostate gland tumor incidence
|
J:170092
|
Arid1atm1.1Mag/Arid1atm1.1Mag Gt(ROSA)26Sortm1(Pik3ca*H1047R)Egan/Gt(ROSA)26Sor+
(involves: 129S6/SvEvTac * CD-1)
|
increased ovarian carcinoma incidence
|
J:219794
|
increased ovary tumor incidence
|
J:219794
|
Arid4atm1Alb/Arid4atm1Alb
(involves: 129S7/SvEvBrd)
|
increased leukemia incidence
|
J:141004
|
Arid4atm1Alb/Arid4atm1Alb Arid4btm1Alb/Arid4b+
(involves: 129S7/SvEvBrd)
|
increased leukemia incidence
|
J:141004
|
Asxl1tm1.1Mjxu/Asxl1+
(involves: 129 * C57BL/6)
|
increased leukemia incidence
|
J:208085
|
Atad5Gt(RRF055)Byg/Atad5+
(involves: 129P2/OlaHsd)
|
increased gland tumor incidence
|
J:176672
|
increased granulosa cell tumor incidence
|
J:176672
|
increased Harderian gland adenocarcinoma incidence
|
J:176672
|
increased liver adenocarcinoma incidence
|
J:176672
|
increased lung adenocarcinoma incidence
|
J:176672
|
increased lung carcinoma incidence
|
J:176672
|
increased lymphoma incidence
|
J:176672
|
increased T cell derived lymphoma incidence
|
J:176672
|
Atf2tm3Nicj/Atf2tm3Nicj Tg(KRT14-cre)1Efu/?
(involves: C57BL/6 * FVB/N)
|
increased skin papilloma incidence
|
J:131564
|
Atmtm1.1Mmpl/Atmtm1.1Mmpl
(involves: 129S4/SvJaeSor * 129S6/SvEvTac * C57BL/6J)
|
increased T cell derived lymphoma incidence
|
J:226414
|
Atmtm1Awb/Atm+ Rad50tm2Jpt/Rad50tm2Jpt
(involves: 129S6/SvEvTac * 129S7/SvEvBrd * C57BL/6)
|
increased lymphoma incidence
|
J:103922
|
Atmtm1Awb/Atmtm1Awb
(either: 129S6/SvEvTac-Atmtm1Awb or (involves: 129S6/SvEvTac * NIH Black Swiss))
|
increased T cell derived lymphoma incidence
|
J:34193
|
Atmtm1Awb/Atmtm1Awb
(involves: 129S6/SvEvTac * C57BL/6)
|
increased T cell derived lymphoma incidence
|
J:103922
|
Atmtm1Awb/Atmtm1Awb
(involves: 129S6/SvEvTac)
|
increased T cell derived lymphoma incidence
|
J:90941
|
Atmtm1Awb/Atmtm1Awb
(CByJ.129S6-Atmtm1Awb)
|
increased T cell derived lymphoma incidence
|
J:208539
|
Atmtm1Awb/Atmtm1Awb
(A.129S6-Atmtm1Awb)
|
increased hepatocellular carcinoma incidence
|
J:208539
|
Atmtm1Awb/Atmtm1Awb
(129S6/SvEvTac-Atmtm1Awb)
|
increased T cell derived lymphoma incidence
|
J:208539
|
Atmtm1Awb/Atmtm1Awb
(either: (129S6/SvEvTac-Atmtm1Awb x B6.129S6-Atmtm1Awb)F1 or (B6.129S6-Atmtm1Awb x 129S6/SvEvTac-Atmtm1Awb)F1)
|
increased T cell derived lymphoma incidence
|
J:208539
|
Atmtm1Awb/Atmtm1Awb
(either: (129S6/SvEvTac-Atmtm1Awb x A.129S6-Atmtm1Awb)F1 or (A.129S6-Atmtm1Awb x 129S6/SvEvTac-Atmtm1Awb)F1)
|
increased T cell derived lymphoma incidence
|
J:208539
|
Atmtm1Awb/Atmtm1Awb
(129S6/SvEvTac-Atmtm1Awb/J)
|
increased T cell derived lymphoma incidence
|
J:226414
|
Atmtm1Awb/Atmtm1Awb Rad50tm2Jpt/Rad50tm2Jpt
(involves: 129S6/SvEvTac * 129S7/SvEvBrd * C57BL/6)
|
increased lymphoma incidence
|
J:103922
|
Atmtm1Awb/Atmtm1Awb Rad52tm1Aps/Rad52tm1Aps
(involves: 129P2/OlaHsd * 129S6/SvEvTac)
|
increased T cell derived lymphoma incidence
|
J:90941
|
Atmtm1Bal/Atmtm1Bal
(involves: 129S4/SvJae)
|
increased T cell derived lymphoma incidence
|
J:35914
|
Atmtm1Fwa/Atmtm1Fwa
(involves: 129S4/SvJae * C57BL/6)
|
increased T cell derived lymphoma incidence
|
J:61201
|
Atmtm1Led/Atmtm1Led
(involves: 129S6/SvEvTac * Black Swiss)
|
increased T cell derived lymphoma incidence
|
J:69726
|
increased thymoma incidence
|
J:36561
|
Atmtm1Mfl/Atm+
(involves: 129T2/SvEms * C57BL/6J)
|
increased leukemia incidence
|
J:78527
|
increased lymphoma incidence
|
J:78527
|
increased ovary tumor incidence
|
J:78527
|
Atmtm1Mfl/Atmtm1Mfl
(involves: 129T2/SvEms * C57BL/6J)
|
increased T cell derived lymphoma incidence
|
J:69726
|
Atmtm1Pmc/Atmtm1Pmc
(involves: 129X1/SvJ * C57BL/6)
|
increased lymphoma incidence
|
J:47752
|
Atmtm2.1Fwa/Atmtm2.1Fwa Tg(VAV1-cre)1Graf/0
(involves: 129S6/SvEvTac)
|
increased T cell derived lymphoma incidence
|
J:277750
|
Atmtm2.1Mfgc/Atmtm2.1Mfgc
(C57BL/6-Atmtm2.1Mfgc)
|
increased thymoma incidence
|
J:316365
|
Atmintm1.1Jhh/Atmintm1.1Jhh Bcl2l11tm1.1Ast/Bcl2l11tm1.1Ast Cd79atm1(cre)Reth/Cd79a+ Tg(IghMyc)22Bri/0
(B6.Cg-Bcl2l11tm1.1Ast Cd79atm1(Cre)Reth Atmintm1.1Jhh Tg(IghMyc)22Bri)
|
increased lymphoma incidence
|
J:230105
|
Atp2a2tm1Ges/Atp2a2+
(involves: 129X1/SvJ * Black Swiss)
|
increased esophageal papilloma incidence
|
J:69754
|
increased skin papilloma incidence
|
J:69754
|
increased tongue papilloma incidence
|
J:69754
|
Atp2c1tm1Ges/Atp2c1+
(involves: 129X1/SvJ * Black Swiss)
|
increased esophageal papilloma incidence
|
J:124662
|
increased skin papilloma incidence
|
J:124662
|
Atp11atm1a(KOMP)Wtsi/Atp11atm1a(KOMP)Wtsi
(C57BL/6N-Atp11atm1a(KOMP)Wtsi/Wtsi)
|
increased trigeminal neuroma incidence
|
J:239583
|
Atp11cambr/Y
(C57BL/6-Atp11cambr)
|
increased hepatocellular carcinoma incidence
|
J:171924
|
Atrxtm1Rjg/Y Rb1tm3Tyj/Rb1tm3Tyj Trp53tm1Brn/Trp53tm1Brn Tg(Sp7-tTA,tetO-EGFP/cre)1Amc/0
(involves: 129P2/OlaHsd * 129S4/SvJae * CD-1)
|
increased osteosarcoma incidence
|
J:329449
|
Atrxtm1Rjg/Atrxtm1Rjg Rb1tm3Tyj/Rb1tm3Tyj Trp53tm1Brn/Trp53tm1Brn Tg(Sp7-tTA,tetO-EGFP/cre)1Amc/0
(involves: 129P2/OlaHsd * 129S4/SvJae * CD-1)
|
increased osteosarcoma incidence
|
J:329449
|
AurkaGt(XQ0149)Wtsi/Aurka+
(involves: 129P2/OlaHsd * C57BL/6)
|
increased hepatoma incidence
|
J:143099
|
increased lung carcinoma incidence
|
J:143099
|
increased lymphoma incidence
|
J:143099
|
Aurkbtm1.2Mama/Aurkb+
(involves: 129/Sv * BALB/cJ * C57BL/6 * CD-1 * SJL)
|
increased liver adenocarcinoma incidence
|
J:173575
|
increased skin papilloma incidence
|
J:173575
|
B2mtm1Unc/B2mtm1Unc Il2tm1Hor/Il2tm1Hor
(involves: 129 * C57BL/6)
|
increased intestinal adenocarcinoma incidence
|
J:51450
|
B2mtm1Unc/B2mtm1Unc Prkdcscid/Prkdcscid
(NOD.Cg-B2mtm1Unc Prkdcscid)
|
increased T cell derived lymphoma incidence
|
J:102141
|
B3gnt6tm1Lx/B3gnt6tm1Lx
(involves: 129S1/Sv * C57BL/6J)
|
increased gastrointestinal tumor incidence
|
J:123826
|
increased intestinal adenoma incidence
|
J:123826
|
B3gnt6tm1Lx/B3gnt6tm1Lx C1galt1tm1.1Rpmc/C1galt1tm1.1Rpmc Tg(Vil1-cre)997Gum/0
(involves: 129S1/Sv * C57BL/6J * SJL)
|
increased duodenum glandular epithelium tumor incidence
|
J:239765
|
B3gnt6tm1Lx/B3gnt6tm1Lx C1galt1tm1.1Rpmc/C1galt1tm1.1Rpmc Tg(Vil1-cre/ERT2)23Syr/0
(involves: 129S1/Sv * C57BL/6 * C57BL/6J * DBA/2)
|
increased duodenum adenocarcinoma incidence
|
J:239765
|
increased duodenum glandular epithelium tumor incidence
|
J:239765
|
Badtm1Sjk/Badtm1Sjk
(either: 129X1/SvJ or (involves: 129X1/SvJ * C57BL/6))
|
increased B cell derived lymphoma incidence
|
J:84987
|
increased lymphoma incidence
|
J:84987
|
Bap1em1Test/Bap1+
(involves: FVB)
|
increased colon tumor incidence
|
J:231692
|
increased granulosa cell tumor incidence
|
J:231692
|
increased lung carcinoma incidence
|
J:231692
|
increased mammary adenocarcinoma incidence
|
J:231692
|
increased ovary tumor incidence
|
J:231692
|
increased skin tumor incidence
|
J:231692
|
Bap1em2Test/Bap1+
(involves: FVB)
|
increased granulosa cell tumor incidence
|
J:231692
|
increased lung carcinoma incidence
|
J:231692
|
increased mammary adenocarcinoma incidence
|
J:231692
|
increased ovary tumor incidence
|
J:231692
|
increased pancreatic islet cell carcinoma incidence
|
J:231692
|
increased skin tumor incidence
|
J:231692
|
Bap1em3Test/Bap1+
(involves: FVB)
|
increased granulosa cell tumor incidence
|
J:231692
|
increased lung carcinoma incidence
|
J:231692
|
increased lymphoma incidence
|
J:231692
|
increased mammary adenocarcinoma incidence
|
J:231692
|
increased ovary tumor incidence
|
J:231692
|
increased skin tumor incidence
|
J:231692
|
Bap1tm1.1Geno/Bap1tm1.1Geno Gt(ROSA)26Sortm9(cre/ESR1)Arte/Gt(ROSA)26Sor+
(involves: C57BL/6 * C57BL/6NTac)
|
increased leukemia incidence
|
J:187380
|
Bard1tm1Thl/Bard1tm2Thl Waptm1(cre)Arge/0
(involves: 129S1/Sv * C57BL/6J)
|
increased mammary adenocarcinoma incidence
|
J:134977
|
Bard1tm2Thl/Bard1tm2Thl Brca1tm1Thl/Brca1tm1Thl Waptm1(cre)Arge/0
(involves: 129/Sv * 129S1/Sv * C57BL/6J)
|
increased mammary adenocarcinoma incidence
|
J:134977
|
Bard1tm2Thl/Bard1tm2Thl Waptm1(cre)Arge/0
(involves: 129/Sv * 129S1/Sv * C57BL/6J)
|
increased mammary adenocarcinoma incidence
|
J:134977
|
Bcl2tm1Mpin/Bcl2+ Tg(SFTPC-RAF1-BxB)1Urr/0
(involves: 129S2/SvPas * C57BL/6 * DBA/2)
|
increased lung adenoma incidence
|
J:79696
|
Bcl2tm1Mpin/Bcl2tm1Mpin Tg(H2-K-BCL2)1Josd/0 Tg(SFTPC-RAF1-BxB)1Urr/0
(involves: 129S2/SvPas * C3H * C57BL/6 * DBA/2)
|
increased lung adenoma incidence
|
J:79696
|
Bcl2tm1Mpin/Bcl2tm1Mpin Tg(SFTPC-RAF1-BxB)1Urr/0
(involves: 129S2/SvPas * C57BL/6 * DBA/2)
|
increased lung adenoma incidence
|
J:79696
|
Bcl2tm2.1Lbox/Bcl2+
(involves: 129S1/Sv * 129X1/SvJ * FVB/N)
|
increased B cell derived lymphoma incidence
|
J:175730
|
increased follicular lymphoma incidence
|
J:175730
|
Bcl2tm2.1Lbox/Bcl2tm2.1Lbox
(involves: 129S1/Sv * 129X1/SvJ * FVB/N)
|
increased B cell derived lymphoma incidence
|
J:175730
|
increased follicular lymphoma incidence
|
J:175730
|
Bcl2l1tm1.1Mam/Bcl2l1tm1.1Mam Tg(Ins2-cre)25Mgn/0 Tg(RIP1-Tag)2Dh/0
(involves: 129S6/SvEvTac * C57BL/6 * DBA)
|
increased pancreas tumor incidence
|
J:146436
|
Bcl2l1tm1.1Mam/Bcl2l1tm1.1Mam Tg(RIP1-Tag)2Dh/0
(involves: 129S6/SvEvTac * C57BL/6 * DBA)
|
increased pancreas tumor incidence
|
J:146436
|
Bcl2l11tm1.1Boui/Bcl2l11+ Tg(IghMyc)22Bri/0
(involves: C57BL/6 * SJL)
|
increased B cell derived lymphoma incidence
|
J:186117
|
increased T cell derived lymphoma incidence
|
J:186117
|
Bcl2l11tm1.1Boui/Bcl2l11tm1.1Boui Tg(IghMyc)22Bri/0
(involves: C57BL/6 * SJL)
|
increased B cell derived lymphoma incidence
|
J:186117
|
Bcl2l11tm2.1Boui/Bcl2l11+ Tg(IghMyc)22Bri/0
(involves: C57BL/6 * SJL)
|
increased B cell derived lymphoma incidence
|
J:186117
|
Bcl2l11tm2.1Boui/Bcl2l11tm2.1Boui Tg(IghMyc)22Bri/0
(involves: C57BL/6 * SJL)
|
increased B cell derived lymphoma incidence
|
J:186117
|
Bcl2l11tm3.1Boui/Bcl2l11+ Tg(IghMyc)22Bri/0
(involves: C57BL/6 * SJL)
|
increased B cell derived lymphoma incidence
|
J:186117
|
Bcl2l11tm3.1Boui/Bcl2l11tm3.1Boui Tg(IghMyc)22Bri/0
(involves: C57BL/6 * SJL)
|
increased B cell derived lymphoma incidence
|
J:186117
|
Bcl11btm2.1Jpk/Bcl11b+ Tg(Lck-cre)1Jtak/0
(involves: C57BL/6)
|
increased lymphoma incidence
|
J:210122
|
Becn1tm1Blev/Becn1+
(involves: 129X1/SvJ * C57BL/6J)
|
increased follicular lymphoma incidence
|
J:86953
|
increased hepatocellular carcinoma incidence
|
J:86953
|
increased histiocytic sarcoma incidence
|
J:86953
|
increased lung adenocarcinoma incidence
|
J:86953
|
increased lung adenoma incidence
|
J:86953
|
increased lung carcinoma incidence
|
J:86953
|
increased lymphoma incidence
|
J:86953
|
increased mammary gland tumor incidence
|
J:86953
|
Becn1tm1Htz/Becn1+
(involves: 129P2/OlaHsd * C57BL/6)
|
increased B cell derived lymphoma incidence
|
J:86982
|
increased hepatocellular carcinoma incidence
|
J:86982
|
increased lung adenocarcinoma incidence
|
J:86982
|
Bhlha15tm2(Kras)Skz/Bhlha15+
(involves: 129S6/SvEvTac * C57BL/6)
|
increased hepatocellular carcinoma incidence
|
J:105076
|
increased liver adenoma incidence
|
J:105076
|
increased pancreas adenoma incidence
|
J:105076
|
increased pancreatic acinar cell carcinoma incidence
|
J:105076
|
Bhlha15tm2(Kras)Skz/Bhlha15+ Trp53tm1Tyj/Trp53+
(involves: 129S2/SvPas * 129S6/SvEvTac * C57BL/6)
|
increased hepatocellular carcinoma incidence
|
J:105076
|
Bhmttm1.2Zei/Bhmttm1.2Zei
(involves: 129P2/OlaHsd * C57BL/6)
|
increased hepatocellular carcinoma incidence
|
J:177569
|
increased liver adenoma incidence
|
J:177569
|
increased liver tumor incidence
|
J:177569
|
Bin1tm1Gcp/Bin1tm2Gcp Tg(MMTV-Myc)141-3Led/0 Tg(Wap-cre)11738Mam/0
(involves: 129S6/SvEvTac * C57BL/6 * CD-1 * FVB/N * SJL)
|
increased lymphoma incidence
|
J:117330
|
increased mammary adenocarcinoma incidence
|
J:117330
|
Bin1tm1Gcp/Bin1tm2Gcp Tg(Wap-cre)11738Mam/0
(involves: 129S6/SvEvTac * C57BL/6 * FVB/N * SJL)
|
increased granulosa cell tumor incidence
|
J:117330
|
increased mammary gland tumor incidence
|
J:117330
|
Bin1tm2Gcp/Bin1+ Tg(Wap-cre)11738Mam/0
(involves: 129S6/SvEvTac * C57BL/6 * FVB/N * SJL)
|
increased mammary gland tumor incidence
|
J:117330
|
Bin3tm1Gcp/Bin3tm1Gcp
(involves: 129 * C57BL/6)
|
increased lung adenocarcinoma incidence
|
J:133313
|
increased lymphoma incidence
|
J:133313
|
Blmtm1Ches/Blmtm3Brd
(involves: 129S/SvEv * C57BL/6 * NIH Black Swiss)
|
increased lymphoma incidence
|
J:86827
|
Blmtm1Ches/Blmtm4Ches Tg(Hsp70-1-cre)6Arge/0
(involves: 129S6/SvEvTac * C57BL/6 * CBA)
|
increased mammary gland tumor incidence
|
J:112115
|
Blmtm1Ches/Blmtm4Ches Tg(KLK3-cre)1Ches/0
(involves: 129S6/SvEvTac)
|
increased mammary gland tumor incidence
|
J:112115
|
Blmtm1Ches/Blmtm4Ches Tg(LGB-cre)74Acl/0
(involves: 129S6/SvEvTac * C57BL/6 * CBA * SJL)
|
increased mammary adenocarcinoma incidence
|
J:112115
|
Blmtm3Brd/Blmtm3Brd
(involves: 129S7/SvEvBrd * C57BL/6)
|
increased lymphoma incidence
|
J:66261
|
Blnktm1Dkit/Blnktm1Dkit
(involves: C57BL/6)
|
increased leukemia incidence
|
J:84040
|
Blnktm1Dkit/Blnktm1Dkit Cd19tm1(cre)Cgn/Cd19tm1(cre)Cgn
(involves: 129P2/OlaHsd * C57BL/6 * NZB)
|
increased leukemia incidence
|
J:84040
|
Blnktm1Pjln/Blnktm1Pjln Btktm1Gsv/Y
(involves: 129P2/OlaHsd * BALB/c * C57BL/6)
|
increased B cell derived lymphoma incidence
|
J:94768
|
Bmftm1.1Ast/Bmftm1.1Ast
(B6.Cg-Bmftm1.1Anst)
|
increased T cell derived lymphoma incidence
|
J:133084
|
Bmi1tm1(cre/ERT)Mrc/Bmi1+ Ctnnb1tm1Mmt/Ctnnb1+
(involves: 129S1/Sv * 129X1/SvJ)
|
increased intestinal adenoma incidence
|
J:138364
|
Bmi1tm1Brn/Bmi1tm1Brn Apctm2Cip/Apc+ Cdkn2atm1Cjs/Cdkn2atm1Cjs Tg(Vil1-cre)20Syr/0
(involves: 129P2/OlaHsd * 129X1/SvJ * C57BL/6 * DBA/2)
|
increased intestinal adenoma incidence
|
J:204354
|
Bmpr1atm2.1Bhr/Bmpr1atm2.1Bhr Ctnnb1tm1Mmt/Ctnnb1+ Krt14tm1.1(cre)Wbm/Krt14+
(involves: 129P2/OlaHsd * 129S7/SvEvBrd * 129X1/SvJ)
|
increased salivary gland tumor incidence
|
J:199091
|
Boktm1.1Ast/Boktm1.1Ast Tg(IghMyc)22Bri/0
(involves: BALB/cJ * C57BL * C57BL/6 * SJL)
|
increased lymphoma incidence
|
J:203179
|
Bomb1NSF/N/Bomb1NSF/N
(involves: NFS/N * SL/Kh)
|
increased lymphoma incidence
|
J:55364
|
Bomb1SL/Kh/Bomb1SL/Kh
(involves: NFS/N * SL/Kh)
|
increased lymphoma incidence
|
J:55364
|
Braftm1.1Brd/Braf+ Cdkn2atm1.1Brn/Cdkn2atm1.1Brn Tg(Vil1-cre)997Gum/0
(involves: 129P2/OlaHsd * 129S7/SvEvBrd * C57BL/6 * SJL)
|
increased intestinal adenoma incidence
|
J:199307
|
Braftm1.1Brd/Braf+ Tg(Vil1-cre)997Gum/0
(involves: 129S7/SvEvBrd * C57BL/6 * SJL)
|
increased gastrointestinal tumor incidence
|
J:199307
|
increased intestinal adenoma incidence
|
J:199307
|
Braftm1Bbd/Braf+
(involves: 129S1/Sv * 129X1/SvJ * C57BL/6J * CD-1)
|
increased gland tumor incidence
|
J:170095
|
increased lung adenoma incidence
|
J:170095
|
increased pheochromocytoma incidence
|
J:170095
|
Braftm1Cpri/Braf+
(involves: 129P2/OlaHsd)
|
increased lung adenoma incidence
|
J:187371
|
increased lung tumor incidence
|
J:187371
|
Braftm1Cpri/Braf+ Tg(Mx1-cre)1Cgn/0
(involves: 129P2/OlaHsd * C57BL/6 * CBA)
|
increased leukemia incidence
|
J:104375
|
Braftm1Cpri/Braftm1Cpri Cdkn2atm1Rdp/Cdkn2atm1Rdp Tg(Tyr-cre/ERT2)1Lru/0
(involves: 129/Sv * 129P2/OlaHsd * C57BL/6 * DBA/2 * SJL)
|
increased skin tumor incidence
|
J:147434
|
Braftm1Cpri/Braftm1Cpri Gnastm3Lsw/Gnastm3Lsw Tg(TPO-cre)1Shk/0
(involves: 129P2/OlaHsd * 129S6/SvEvTac * FVB/NCr)
|
increased thyroid tumor incidence
|
J:168249
|
Braftm1Cpri/Braftm1Cpri Tg(TPO-cre)1Shk/0
(involves: 129P2/OlaHsd * FVB/NCr)
|
increased thyroid carcinoma incidence
|
J:168249
|
increased thyroid tumor incidence
|
J:168249
|
Braftm1Cpri/Braftm1Cpri Tg(Tyr-cre/ERT2)1Lru/0
(involves: 129P2/OlaHsd * C57BL/6 * DBA/2)
|
increased skin tumor incidence
|
J:147434
|
Braftm1Cpri/Braftm1Cpri Tshrtm1Rmar/Tshrtm1Rmar Tg(TPO-cre)1Shk/0
(involves: 129P2/OlaHsd * 129S1/Sv * FVB/NCr)
|
increased thyroid tumor incidence
|
J:168249
|
Braftm1Mmcm/Braf+
(involves: 129P2/OlaHsd)
|
increased lung adenocarcinoma incidence
|
J:121715
|
increased lung adenoma incidence
|
J:121715
|
increased lung tumor incidence
|
J:121715
|
Braftm1Mmcm/Braf+
(involves: 129P2/OlaHsd * 129S4/SvJae * C57BL/6)
|
increased thyroid carcinoma incidence
|
J:208854
|
Braftm1Mmcm/Braf+ Cdkn2atm4Rdp/Cdkn2atm4Rdp
(involves: 129P2/OlaHsd)
|
increased lung tumor incidence
|
J:121715
|
Braftm1Mmcm/Braf+ Polr2atm1(cre/ERT2)Bbd/Polr2a+
(involves: 129P2/OlaHsd * C57BL/6 * SJL)
|
increased lung adenoma incidence
|
J:121715
|
Braftm1Mmcm/Braf+ Ptentm1Mro/Ptentm1Mro Tg(Tyr-cre/ERT2)1Lru/0
(B6.Cg-Braftm1Mmcm Tg(Tyr-cre/ERT2)1Lru Ptentm1Mro)
|
increased cutaneous melanoma incidence
|
J:188523
|
Braftm1Mmcm/Braf+ Ptentm1Rdp/Ptentm1Rdp Tg(Tyr-cre/ERT2)13Bos/0
(involves: 129P2/OlaHsd * 129S6/SvEvTac * C57BL/6 * FVB/N)
|
increased cutaneous melanoma incidence
|
J:151023
|
Braftm1Mmcm/Braf+ Ptentm2.1Ppp/Pten+ Tg(Tyr-cre/ERT2)13Bos/0
(involves: 129P2/OlaHsd * 129S1/Sv * FVB)
|
increased cutaneous melanoma incidence
|
J:151023
|
Braftm1Mmcm/Braf+ Ptentm2.1Ppp/Ptentm2.1Ppp Tg(Tyr-cre/ERT2)13Bos/0
(involves: 129P2/OlaHsd * 129S1/Sv * FVB)
|
increased cutaneous melanoma incidence
|
J:151023
|
Braftm1Mmcm/Braf+ Tg(Tg-cre/ERT2)#Mmcm/0
(involves: 129P2/OlaHsd)
|
increased thyroid carcinoma incidence
|
J:172205
|
Braftm1Mmcm/Braf+ Tg(TPO-cre/ERT2)1139Tyj/0
(involves: 129P2/OlaHsd * 129S4/SvJae * C57BL/6 * C57BL/6NTac)
|
increased thyroid carcinoma incidence
|
J:208854
|
Braftm1Mmcm/Braf+ Tg(TPO-cre/ERT2)1139Tyj/0 Trp53tm1Brn/Trp53tm1Brn
(involves: 129P2/OlaHsd * 129S4/SvJae * C57BL/6 * C57BL/6NTac)
|
increased thyroid carcinoma incidence
|
J:208854
|
Braftm1Mmcm/Braf+ Trp53tm1Brn/Trp53tm1Brn
(involves: 129P2/OlaHsd)
|
increased lung adenocarcinoma incidence
|
J:121715
|
increased lung tumor incidence
|
J:121715
|
Braftm1Mmcm/Braf+ Trp53tm1Brn/Trp53tm3.1Tyj Tg(TPO-cre/ERT2)1139Tyj/0
(involves: 129P2/OlaHsd * 129S4/SvJae * C57BL/6 * C57BL/6NTac)
|
increased thyroid carcinoma incidence
|
J:208854
|
Braftm1Mmcm/Braf+ Trp53tm3.1Tyj/Trp53+ Tg(TPO-cre/ERT2)1139Tyj/0
(involves: 129P2/OlaHsd * 129S4/SvJae * C57BL/6 * C57BL/6NTac)
|
increased thyroid carcinoma incidence
|
J:208854
|
Braftm1Mmcm/Braftm1Mmcm Nkx3-1tm4(cre/ERT2)Mms/Nkx3-1+ Ptentm1Hwu/Pten+
(involves: 129P2/OlaHsd * 129S4/SvJae * 129S6/SvEvTac * C57BL/6)
|
increased prostate gland adenocarcinoma incidence
|
J:191327
|
increased prostate gland tumor incidence
|
J:191327
|
increased prostate intraepithelial neoplasia incidence
|
J:191327
|
Braftm1Sva/Braftm1Sva Krastm1Bbd/Kras+
(involves: 129S1/Sv * 129X1/SvJ)
|
increased lung non-small cell carcinoma incidence
|
J:172200
|
Braftm2Cpri/Braf+ Krastm4Tyj/Kras+
(involves: 129S4/SvJae * C57BL/6)
|
increased lung adenoma incidence
|
J:187371
|
Braftm2Cpri/Braf+ Tg(CMV-cre)1Cgn/0
(B6.Cg-Braftm2Cpri Tg(CMV-cre)1Cgn)
|
increased intestinal adenoma incidence
|
J:187371
|
increased skin papilloma incidence
|
J:187371
|
Brca1tm1Aash/Brca1tm1Aash Tg(LGB-cre)74Acl/0
(involves: 129S1/Sv * 129X1/SvJ * C57BL/6 * CBA)
|
increased mammary gland tumor incidence
|
J:119996
|
increased salivary adenocarcinoma incidence
|
J:119996
|
Brca1tm1Aash/Brca1tm1Aash Trp53tm1Brd/Trp53+ Tg(LGB-cre)74Acl/0
(involves: 129S1/Sv * 129S7/SvEvBrd * 129X1/SvJ * C57BL/6 * CBA)
|
increased mammary gland ductal carcinoma incidence
|
J:119996
|
increased mammary gland tumor incidence
|
J:119996
|
increased salivary adenocarcinoma incidence
|
J:119996
|
Brca1tm1Arge/Brca1tm1Thl Waptm1(cre)Arge/0
(involves: 129S/SvEv * 129S1/Sv * C57BL/6J)
|
increased mammary adenocarcinoma incidence
|
J:134977
|
Brca1tm1Bhk/Brca1+
(C.129P2-Brca1tm1Bhk)
|
increased mammary gland tumor incidence
|
J:198018
|
Brca1tm1Bhk/Brca1+ Cdkn2ctm1Yxi/Cdkn2ctm1Yxi
(C.129-Cdkn2ctm1Yxi Brca1tm1Bhk)
|
increased mammary adenocarcinoma incidence
|
J:198018
|
increased mammary gland tumor incidence
|
J:198018
|
Brca1tm1Brn/Brca1+ Trp53tm1Brn/Trp53tm1Brn Tg(KRT14-cre)8Brn/0
(involves: 129P2/OlaHsd * BALB/cJ * FVB/N)
|
increased mammary gland tumor incidence
|
J:126551
|
Brca1tm1Brn/Brca1tm1Brn Tg(Krt18-EGFP,-TAg121)36Ysng/0 Trp53tm1Brn/Trp53tm1Brn
(involves: 129P2/OlaHsd * C57BL/6 * DBA/2 * FVB/N)
|
increased ovary tumor incidence
|
J:189304
|
Brca1tm1Brn/Brca1tm1Brn Tg(Krt18-EGFP,-TAg121)36Ysng/0 Trp53tm1Brn/Trp53tm2Tyj
(involves: 129P2/OlaHsd * 129S4/SvJae * C57BL/6 * DBA/2 * FVB/N)
|
increased ovarian carcinoma incidence
|
J:189304
|
increased ovary tumor incidence
|
J:189304
|
Brca1tm1Brn/Brca1tm1Brn Trp53tm1Brn/Trp53+ Tg(KRT14-cre)8Brn/0
(involves: 129P2/OlaHsd * BALB/cJ * FVB/N)
|
increased mammary gland tumor incidence
|
J:126551
|
Brca1tm1Brn/Brca1tm1Brn Trp53tm1Brn/Trp53tm1Brn Tg(KRT14-cre)8Brn/0
(involves: 129P2/OlaHsd * BALB/cJ * FVB/N)
|
increased mammary gland tumor incidence
|
J:126551
|
Brca1tm1Brn/Brca1tm1Brn Trp53tm1Brn/Trp53tm1Brn Tg(KRT14-cre)8Brn/0
(involves: 129P2/OlaHsd * C57BL/6J * FVB/N)
|
increased mammary gland tumor incidence
|
J:178595
|
increased skin tumor incidence
|
J:178595
|
Brca1tm1Cxd/Brca1tm2Cxd Tg(KRT5-cre)5132Jlj/0
(involves: 129S6/SvEvTac * C57BL/6)
|
increased mouth tumor incidence
|
J:85354
|
increased skin tumor incidence
|
J:85354
|
Brca1tm1Cxd/Brca1tm2Cxd Tg(KRT5-cre)5132Jlj/0 Tg(KRT5-E2F1)2Dgj/0
(involves: 129S6/SvEvTac * C57BL/6 * SJL)
|
increased skin tumor incidence
|
J:85354
|
Brca1tm1Cxd/Brca1tm2Cxd Tg(KRT5-E2F1)2Dgj/0
(involves: 129S6/SvEvTac * C57BL/6 * SJL)
|
increased mouth tumor incidence
|
J:85354
|
increased reproductive system tumor incidence
|
J:85354
|
increased skin tumor incidence
|
J:85354
|
Brca1tm1Cxd/Brca1tm2Cxd Tg(MMTV-cre)4Mam/0
(involves: 129S6/SvEvTac * Black Swiss * FVB)
|
increased mammary adenocarcinoma incidence
|
J:54533
|
increased mammary gland tumor incidence
|
J:54533
|
Brca1tm1Cxd/Brca1tm2Cxd Tg(Wap-cre)11738Mam/0
(involves: 129S6/SvEvTac * Black Swiss)
|
increased mammary gland tumor incidence
|
J:54533
|
Brca1tm1Cxd/Brca1tm2Cxd Trp53tm1Brd/Trp53+ Tg(MMTV-cre)4Mam/0
(involves: 129S6/SvEvTac * 129S7/SvEvBrd * Black Swiss * FVB)
|
increased mammary gland tumor incidence
|
J:54533
|
Brca1tm1Thl/Brca1tm1Thl Waptm1(cre)Arge/0
(involves: 129S1/Sv * C57BL/6J)
|
increased mammary adenocarcinoma incidence
|
J:134977
|
Brca1tm2.1Cxd/Brca1tm2.1Cxd Trp53tm1Brd/Trp53+
(involves: 129S6/SvEvTac * 129S7/SvEvBrd)
|
increased mammary gland tumor incidence
|
J:70271
|
increased T cell derived lymphoma incidence
|
J:81541
|
Brca1tm2.1Cxd/Brca1tm2.1Cxd Trp53tm1Brd/Trp53tm1Brd
(involves: 129S6/SvEvTac * 129S7/SvEvBrd)
|
increased T cell derived lymphoma incidence
|
J:81541
|
Brca1tm2Arge/Brca1tm2Arge
(129-Brca1tm2Arge)
|
increased mammary gland tumor incidence
|
J:69187
|
Brca1tm2Arge/Brca1tm2Arge
(involves: 129/Sv * C57BL/6J * MF1)
|
increased mammary gland tumor incidence
|
J:69187
|
Brca1tm2Cxd/Brca1+ Tg(KRT5-E2F1)2Dgj/0
(involves: 129S6/SvEvTac * C57BL/6 * SJL)
|
increased skin tumor incidence
|
J:85354
|
Brca1tm2Cxd/Brca1tm2Cxd Pkmtm1.1Mgvh/Pkmtm1.1Mgvh Trp53tm1Brd/Trp53+ Tg(MMTV-cre)4Mam/0
(involves: 129S4/SvJaeSor * 129S6/SvEvTac * 129S7/SvEvBrd * FVB/N)
|
increased liver tumor incidence
|
J:205213
|
increased mammary gland tumor incidence
|
J:205213
|
Brca1tm2Cxd/Brca1tm2Cxd Tg(MMTV-cre)4Mam/0
(involves: 129S6/SvEvTac * C57BL/6 * FVB)
|
increased mammary gland tumor incidence
|
J:132088
|
Brca1tm2Cxd/Brca1tm2Cxd Tg(MMTV-cre)4Mam/0 Tg(MMTV-rtTA)1Lach/0 Tg(tetO-Esr1)#Paf/0 Trp53tm1Brd/Trp53+
(involves: 129S6/SvEvTac * 129S7/SvEvBrd * C57BL/6 * FVB)
|
increased mammary gland tumor incidence
|
J:132088
|
Brca1tm2Cxd/Brca1tm2Cxd Trp53tm1Brd/Trp53+ Tg(MMTV-cre)4Mam/0
(involves: 129S6/SvEvTac * 129S7/SvEvBrd * C57BL/6 * FVB)
|
increased mammary gland tumor incidence
|
J:132088
|
Brca1tm2Mak/Brca1tm2Mak Chek2tm1Mak/Chek2tm1Mak Tg(Lck-cre)548Jxm/?
(involves: 129P2/OlaHsd * C57BL/6 * CBA)
|
increased T cell derived lymphoma incidence
|
J:90512
|
Brca1tm2Mak/Brca1tm2Mak Chek2tm1Mak/Chek2tm1Mak Tg(Wap-cre)11738Mam/?
(involves: 129P2/OlaHsd * C57BL/6 * CBA * SJL)
|
increased mammary adenocarcinoma incidence
|
J:90512
|
Brca1tm2Mak/Brca1tm2Mak Tg(Lck-cre)548Jxm/? Trp53tm1Brd/Trp53tm1Brd
(involves: 129P2/OlaHsd * C57BL/6 * CBA)
|
increased T cell derived lymphoma incidence
|
J:90512
|
Brca1tm2Mak/Brca1tm2Mak Tg(Wap-cre)11738Mam/?
(involves: 129P2/OlaHsd * C57BL/6 * CBA * SJL)
|
increased mammary gland tumor incidence
|
J:90512
|
Brca1tm2Mak/Brca1tm2Mak Trp53tm1Brd/Trp53+ Tg(Wap-cre)11738Mam/?
(involves: 129P2/OlaHsd * C57BL/6 * CBA * SJL)
|
increased mammary adenocarcinoma incidence
|
J:90512
|
Brca1tm3Cxd/Brca1tm3Cxd
(involves: 129S6/SvEvTac * FVB/N)
|
increased hepatoma incidence
|
J:94114
|
increased lymphoma incidence
|
J:94114
|
increased mammary gland tumor incidence
|
J:94114
|
Brca1tm4Cxd/Brca1tm4Cxd
(involves: 129S6/SvEvTac * NIH Black Swiss)
|
increased mammary gland ductal carcinoma incidence
|
J:112308
|
increased mammary gland tumor incidence
|
J:112308
|
Brca1tm5.1Cxd/Brca1tm5.1Cxd
(involves: 129S6/SvEvTac * FVB/N)
|
increased liver tumor incidence
|
J:155810
|
increased lymphoma incidence
|
J:155810
|
increased mammary gland tumor incidence
|
J:155810
|
increased T cell derived lymphoma incidence
|
J:155810
|
Brca2tm1Arge/Brca2tm2Arge Waptm1(cre)Arge/Wap+
(involves: 129S/SvEv * C57BL/6)
|
increased mammary adenocarcinoma incidence
|
J:70564
|
Brca2tm1Brn/Brca2+ Trp53tm1Brn/Trp53tm1Brn Tg(KRT14-cre)8Brn/0
(involves: 129P2/OlaHsd * FVB/N)
|
increased mammary adenocarcinoma incidence
|
J:73028
|
increased mammary gland tumor incidence
|
J:73028
|
increased skin tumor incidence
|
J:73028
|
Brca2tm1Brn/Brca2tm1Brn Ptch1tm1Mps/Ptch1+ Trp53tm1Tyj/Trp53+ Tg(Nes-cre)1Kln/0
(involves: 129 * C57BL/6 * SJL)
|
increased medulloblastoma incidence
|
J:144617
|
Brca2tm1Brn/Brca2tm1Brn Ptch1tm1Mps/Ptch1+ Trp53tm1Tyj/Trp53tm1Tyj Tg(Nes-cre)1Kln/0
(involves: 129 * C57BL/6 * SJL)
|
increased medulloblastoma incidence
|
J:144617
|
Brca2tm1Brn/Brca2tm1Brn Tg(Krt18-EGFP,-TAg121)36Ysng/0 Trp53tm1Brn/Trp53tm2Tyj
(involves: 129P2/OlaHsd * 129S4/SvJae * C57BL/6 * DBA/2 * FVB/N)
|
increased ovary tumor incidence
|
J:189304
|
Brca2tm1Brn/Brca2tm1Brn Tg(Pbsn-cre)4Prb/0
(involves: 129P2/OlaHsd * C57BL/6 * DBA/2)
|
increased prostate intraepithelial neoplasia incidence
|
J:161511
|
Brca2tm1Brn/Brca2tm1Brn Trp53tm1Brn/Trp53+ Tg(KRT14-cre)8Brn/0
(involves: 129P2/OlaHsd * FVB/N)
|
increased mammary adenocarcinoma incidence
|
J:73028
|
increased mammary gland tumor incidence
|
J:73028
|
increased skin tumor incidence
|
J:73028
|
Brca2tm1Brn/Brca2tm1Brn Trp53tm1Brn/Trp53+ Tg(Pbsn-cre)4Prb/0
(involves: 129P2/OlaHsd * C57BL/6 * DBA/2)
|
increased prostate intraepithelial neoplasia incidence
|
J:161511
|
Brca2tm1Brn/Brca2tm1Brn Trp53tm1Brn/Trp53tm1Brn Tg(KRT14-cre)8Brn/0
(involves: 129P2/OlaHsd * FVB/N)
|
increased mammary adenocarcinoma incidence
|
J:73028
|
increased mammary gland tumor incidence
|
J:73028
|
increased skin tumor incidence
|
J:73028
|
Brca2tm1Brn/Brca2tm1Brn Trp53tm1Brn/Trp53tm1Brn Tg(Pbsn-cre)4Prb/0
(involves: 129P2/OlaHsd * C57BL/6 * DBA/2)
|
increased prostate intraepithelial neoplasia incidence
|
J:161511
|
Brca2tm1Brn/Brca2tm1Brn Trp53tm1Tyj/Trp53+ Tg(Nes-cre)1Kln/0
(involves: 129P2/OlaHsd * 129S2/SvPas * C57BL/6 * SJL)
|
increased medulloblastoma incidence
|
J:144617
|
Brca2tm1Brn/Brca2tm1Brn Trp53tm1Tyj/Trp53tm1Tyj Tg(Nes-cre)1Kln/0
(involves: 129P2/OlaHsd * 129S2/SvPas * C57BL/6 * SJL)
|
increased medulloblastoma incidence
|
J:144617
|
Brca2tm1Brn/Brca2tm1Cam Krastm4Tyj/Kras+ Trp53tm3Tyj/Trp53+ Tg(Pdx1-cre)6Tuv/0
(involves: 129P2/OlaHsd * 129S/SvEv * 129S4/SvJae * C57BL/6 * FVB/N)
|
increased pancreatic acinar cell carcinoma incidence
|
J:166678
|
increased pancreatic ductal adenocarcinoma incidence
|
J:166678
|
Brca2tm1Cam/Brca2+ Krastm4Tyj/Kras+ Tg(Pdx1-cre)6Tuv/0
(involves: 129S/SvEv * 129S4/SvJae * C57BL/6 * FVB/N)
|
increased pancreatic ductal adenocarcinoma incidence
|
J:166678
|
Brca2tm1Cam/Brca2+ Krastm4Tyj/Kras+ Trp53tm3Tyj/Trp53+ Tg(Pdx1-cre)6Tuv/0
(involves: 129S/SvEv * 129S4/SvJae * C57BL/6 * FVB/N)
|
increased pancreatic ductal adenocarcinoma incidence
|
J:166678
|
Brca2tm1Cam/Brca2tm1Brn Krastm4Tyj/Kras+ Tg(Pdx1-cre)6Tuv/0
(involves: 129P2/OlaHsd * 129S/SvEv * 129S4/SvJae * C57BL/6 * FVB/N)
|
increased pancreatic ductal adenocarcinoma incidence
|
J:166678
|
Brca2tm1Cam/Brca2tm1Cam
(involves: 129S/SvEv * MF1)
|
increased T cell derived lymphoma incidence
|
J:46812
|
Brca2tm1Cbl/Brca2tm1Cbl
(either: (involves: 129S2/SvPas * C57BL/10) or (involves: 129S2/SvPas * C57BL/6 * DBA/2))
|
increased T cell derived lymphoma incidence
|
J:44386
|
Brca2tm1Hst/Brca2tm1Hst
(involves: 129S7/SvEvBrd * C57BL/6)
|
increased lymphoma incidence
|
J:82434
|
Brca2tm1Kamc/Brca2tm1Kamc Trp53tm1Tyj/Trp53+
(involves: 129P2/OlaHsd * 129S2/SvPas * BALB/c * C57BL/6)
|
increased mammary gland tumor incidence
|
J:109193
|
increased osteosarcoma incidence
|
J:109193
|
increased stomach tumor incidence
|
J:109193
|
Brca2tm1Mak/Brca2tm2Mak Trp53tm1Brd/Trp53tm1Brd Tg(Lck-cre)548Jxm/0
(involves: 129P2/OlaHsd * 129S7/SvEvBrd * C57BL/6 * CBA)
|
increased lymphoma incidence
|
J:79697
|
increased osteosarcoma incidence
|
J:79697
|
Brca2tm1Mbn/Brca2+
(B6.Cg-Brca2tm1Mbn ApcMin)
|
increased mammary gland tumor incidence
|
J:67445
|
Brca2tm2Arge/Brca2tm2Arge Waptm1(cre)Arge/Waptm1(cre)Arge
(involves: 129S1/Sv * C57BL/6)
|
increased mammary adenocarcinoma incidence
|
J:70564
|
Brf1tm1Arte/Brf1tm1Arte Krastm4Tyj/Kras+ Trp53tm2Tyj/Trp53+ Tg(Pdx1-cre)6Tuv/0
(involves: 129S4/SvJae * 129S7/SvEvBrd * FVB/N)
|
increased pancreatic ductal adenocarcinoma incidence
|
J:285667
|
Brip1Gt(RRI409)Byg/Brip1Gt(RRI409)Byg
(involves: 129P2/OlaHsd)
|
increased Harderian gland adenoma incidence
|
J:227115
|
increased lymphoma incidence
|
J:227115
|
increased pituitary adenoma incidence
|
J:227115
|
Btg3tm1Tya/Btg3tm1Tya
(involves: 129P2/OlaHsd * C57BL/6J)
|
increased lung adenoma incidence
|
J:149382
|
increased lung carcinoma incidence
|
J:149382
|
increased lung tumor incidence
|
J:149382
|
Bub1tm1.1Jvd/Bub1tm2Jvd
(involves: 129/Sv * C57BL/6)
|
increased lung tumor incidence
|
J:135093
|
increased lymphoma incidence
|
J:135093
|
Bub1tm1.1Tvd/Bub1+
(involves: 129P2/OlaHsd * 129S7/SvEvBrd * C57BL/6J)
|
increased brain tumor incidence
|
J:143035
|
increased lung tumor incidence
|
J:143035
|
Bub1tm1.1Tvd/Bub1tm1.1Tvd
(involves: 129P2/OlaHsd * 129S7/SvEvBrd * C57BL/6J)
|
increased liver tumor incidence
|
J:143035
|
increased lung tumor incidence
|
J:143035
|
Bub1tm2Jvd/Bub1tm2Jvd
(involves: 129/Sv * C57BL/6)
|
increased hepatocellular carcinoma incidence
|
J:135093
|
Bub1bGt(neo-btk)1Dai/Bub1b+
(involves: 129S4/SvJae)
|
increased colon adenoma incidence
|
J:88094
|
increased intestinal adenocarcinoma incidence
|
J:88094
|
Bub1btm1.1Hsl/Bub1b+
(involves: 129 * C57BL/6)
|
increased B cell derived lymphoma incidence
|
J:201641
|
increased hepatocellular carcinoma incidence
|
J:201641
|
increased leukemia incidence
|
J:201641
|
increased lung adenocarcinoma incidence
|
J:201641
|
increased lymphoma incidence
|
J:201641
|
increased rectum adenocarcinoma incidence
|
J:201641
|
Cables1tm1Lrz/Cables1tm1Lrz
(involves: 129S1/Sv)
|
increased endometrial carcinoma incidence
|
J:87478
|
Calcatm1.1(cre/ERT2)Ptch/Calca+ Trp53tm1Brn/Trp53tm1Brn Rb1tm2Brn/Rb1tm2Brn
(involves: 129 * 129P2/OlaHsd * FVB/N)
|
increased lung small cell carcinoma incidence
|
J:190366
|
increased thyroid tumor incidence
|
J:190366
|
Calcatm1.1(cre/ERT2)Ptch/Calca+ Trp53tm1Brn/Trp53tm1Brn Rb1tm2Brn/Rb1tm2Brn Ptentm1Hwu/Ptentm1Hwu
(involves: 129 * 129P2/OlaHsd * 129S4/SvJae * BALB/c * FVB/N)
|
increased lung small cell carcinoma incidence
|
J:190366
|
increased thyroid tumor incidence
|
J:190366
|
Capza2tm1b(KOMP)Wtsi/Capza2tm1b(KOMP)Wtsi
(C57BL/6N-Capza2tm1b(KOMP)Wtsi/Wtsi)
|
increased trigeminal neuroma incidence
|
J:239583
|
Catb/Catb
(C3.Cg-Catb/Anl)
|
increased hepatoma incidence
|
J:154291
|
Cav1tm1Mls/Cav1+ Tg(MMTV-PyVT)634Mul/0
(involves: 129/Sv * C57BL/6J * FVB/N * SJL)
|
increased mammary gland tumor incidence
|
J:132472
|
Cav1tm1Mls/Cav1tm1Mls
(involves: 129/Sv * C57BL/6 * FVB/N * SJL)
|
increased mammary gland tumor incidence
|
J:147439
|
Cav1tm1Mls/Cav1tm1Mls Tg(MMTV-PyVT)634Mul/0
(involves: 129/Sv * C57BL/6J * FVB/N * SJL)
|
increased mammary gland tumor incidence
|
J:132472
|
Cbx7tm1Afus/Cbx7+
(involves: C57BL/6J)
|
increased hepatocellular carcinoma incidence
|
J:184383
|
increased liver adenoma incidence
|
J:184383
|
increased lung adenoma incidence
|
J:184383
|
Cbx7tm1Afus/Cbx7tm1Afus
(involves: C57BL/6J)
|
increased hepatocellular carcinoma incidence
|
J:184383
|
increased liver adenoma incidence
|
J:184383
|
increased liver tumor incidence
|
J:184383
|
increased lung carcinoma incidence
|
J:184383
|
increased lung tumor incidence
|
J:184383
|
Ccdc80tm1.1Ftk/Ccdc80tm1.1Ftk
(involves: 129P2/OlaHsd * BALB/cJ * C57BL/6N)
|
increased hepatocellular carcinoma incidence
|
J:216704
|
Ccdc80tm1Ppal/Ccdc80tm1Ppal
(Not Specified)
|
increased ovarian carcinoma incidence
|
J:217742
|
increased thyroid adenoma incidence
|
J:217742
|
Ccn6tm1.1Cgkl/Ccn6tm1.1Cgkl Tg(MMTV-cre)1Mam/0
(FVB/N-Ccn6tm1.1Cgkl Tg(MMTV-cre)1Mam)
|
increased mammary adenocarcinoma incidence
|
J:241259
|
Ccn6tm1.1Cgkl/Ccn6tm1.1Cgkl Tg(MMTV-cre)1Mam/0 Tg(MMTV-PyVT)634Mul/0
(FVB/N-Ccn6tm1.1Cgkl Tg(MMTV-cre)1Mam Tg(MMTV-PyVT)634Mul)
|
increased mammary adenocarcinoma incidence
|
J:241259
|
Ccnctm1.1Pisc/Ccnctm1.1Pisc Tg(Lck-LMO1)11Sjk/0 Tg(Mx1-cre)1Cgn/0
(Not Specified)
|
increased T cell derived lymphoma incidence
|
J:217695
|
Ccnd1tm1Dsn/Ccnd1tm1Dsn Cdkn1btm1Mlf/Cdkn1btm1Mlf
(involves: 129 * C57BL/6)
|
increased pituitary adenoma incidence
|
J:66707
|
Ccnd1tm1Wbg/Ccnd1+ Tg(MMTVneu)202Mul/0 Tg(tetO-Ccnd1*T286A,-luc)10897Kuw/0
(involves: 129S2/SvPas * FVB/N)
|
increased mammary gland tumor incidence
|
J:178842
|
Ccnd1tm1Wbg/Ccnd1+ Tg(MMTVneu)202Mul/0 Tg(tetO-Ccnd1*T286A,-luc)11233Kuw/0
(involves: 129S2/SvPas * FVB/N)
|
increased mammary gland tumor incidence
|
J:178842
|
Ccnd1tm1Wbg/Ccnd1tm1Wbg Tg(MMTVneu)202Mul/0 Tg(tetO-Ccnd1*T286A,-luc)10897Kuw/0
(involves: 129S2/SvPas * FVB/N)
|
increased mammary gland tumor incidence
|
J:178842
|
Ccnd1tm1Wbg/Ccnd1tm1Wbg Tg(MMTVneu)202Mul/0 Tg(tetO-Ccnd1*T286A,-luc)11233Kuw/0
(involves: 129S2/SvPas * FVB/N)
|
increased mammary gland tumor incidence
|
J:178842
|
Ccnd1tm4Pisc/Ccnd1tm4Pisc Tg(MMTV-Erbb2)NK1Mul/0
(involves: 129S4/SvJae * C57BL/6 * FVB/N)
|
increased mammary adenocarcinoma incidence
|
J:156591
|
Ccnd3tm1Pisc/Ccnd3tm1Pisc Tg(Lck)4220Rmp/0
(involves: C57BL/6J * DBA/2)
|
increased T cell derived lymphoma incidence
|
J:88120
|
Ccnd3tm1Pisc/Ccnd3tm1Pisc Trp53tm1Tyj/Trp53tm1Tyj
(involves: 129S2/SvPas)
|
increased T cell derived lymphoma incidence
|
J:88120
|
Ccndbp1tm1Riet/Ccndbp1tm1Riet
(involves: 129P2/OlaHsd * C57BL/6)
|
increased hepatocellular carcinoma incidence
|
J:121623
|
increased liver adenoma incidence
|
J:121623
|
Ccng1tm1Sst/Ccng1tm1Sst
(involves: 129S/SvEv * C57BL/6)
|
increased hepatoma incidence
|
J:106007
|
Cd3etm1Mal/Cd3etm1Mal Tg(Tcrb-TCF3/PBX1)23Gusa/0
(involves: C3H * C57BL/6 * C57BL/6J)
|
increased acute lymphoblastic leukemia incidence
|
J:95693
|
increased leukemia incidence
|
J:95693
|
Cd9tm1c(EUCOMM)Hmgu/Cd9+ Gt(ROSA)26Sortm1(EYFP)Cos/Gt(ROSA)26Sor+ Krastm4Tyj/Kras+ Tg(Pdx1-cre)6Tuv/0 Trp53tm1Brn/Trp53+
(involves: 129P2/OlaHsd * 129S4/SvJae * 129X1/SvJ * C57BL/6N * FVB/N)
|
increased pancreatic intraepithelial neoplasia incidence
|
J:280854
|
Cd9tm1c(EUCOMM)Hmgu/Cd9tm1c(EUCOMM)Hmgu Gt(ROSA)26Sortm1(EYFP)Cos/Gt(ROSA)26Sor+ Krastm4Tyj/Kras+ Tg(Pdx1-cre)6Tuv/0 Trp53tm1Brn/Trp53+
(involves: 129P2/OlaHsd * 129S4/SvJae * 129X1/SvJ * C57BL/6N * FVB/N)
|
increased pancreatic intraepithelial neoplasia incidence
|
J:280854
|
Cd19tm1(cre)Cgn/Cd19+ Gt(ROSA)26Sortm1(ITK/SYK)Jrld/Gt(ROSA)26Sor+
(involves: 129P2/OlaHsd)
|
increased T cell derived lymphoma incidence
|
J:160931
|
Cd19tm1(cre)Cgn/Cd19+ Gt(ROSA)26Sortm2(CARD11*L225LI)Jrld/Gt(ROSA)26Sor+
(involves: 129P2/OlaHsd)
|
increased B cell derived lymphoma incidence
|
J:228288
|
Cd19tm1(cre)Cgn/Cd19+ Inpp5dtm1Rav/Inpp5dtm1Rav Ptentm1Hwu/Ptentm1Hwu
(involves: 129P2/OlaHsd * 129S4/SvJae)
|
increased follicular lymphoma incidence
|
J:166155
|
increased lymphoma incidence
|
J:166155
|
increased splenic marginal zone lymphoma incidence
|
J:166155
|
Cd19tm1(cre)Cgn/Cd19+ Mirc30tm1.1Rdf/Mirc30tm1.1Rdf
(involves: 129P2/OlaHsd * 129S1/Sv * 129S4/SvJaeSor * C57BL/6)
|
increased B cell derived lymphoma incidence
|
J:156946
|
increased leukemia incidence
|
J:156946
|
Cd19tm1(cre)Cgn/Cd19+ Ptpn11tm1Ckq/Ptpn11+
(involves: 129P2/OlaHsd * 129S6/SvEvTac * C57BL/6J)
|
increased acute lymphoblastic leukemia incidence
|
J:177285
|
increased B cell derived lymphoma incidence
|
J:177285
|
Cd19tm1(cre)Cgn/Cd19+ Tbl1xr1tm1c(EUCOMM)Hmgu/Tbl1xr1tm1c(EUCOMM)Hmgu Tg(Vav-BCL2)69Jad/0
(involves: 129P2/OlaHsd * C57BL/6J * C57BL/6N)
|
increased organ/body region tumor incidence
|
J:292118
|
Cd28tm1Mak/Cd28tm1Mak Rc3h1san/Rc3h1+
(involves: 129S2/SvPas * C57BL/6 * C57BL/6JSfdAnu)
|
increased T cell derived lymphoma incidence
|
J:189087
|
Cd34tm1Szk/Cd34tm1Szk
(involves: 129P2/OlaHsd * C57BL/6J)
|
increased skin papilloma incidence
|
J:121305
|
Cd44tm1Mak/Cd44tm1Mak Trp53tm1Tyj/Trp53+
(involves: 129P2/OlaHsd * 129S2/SvPas * C57BL/6 * C57BL/6J)
|
increased lymphoma incidence
|
J:76201
|
Cdc20tm1.1Pzg/Cdc20+
(involves: 129S7/SvEvBrd * C57BL/6)
|
increased hepatoma incidence
|
J:150421
|
increased lymphoma incidence
|
J:150421
|
Cdc73Gt(RRE190)Byg/Cdc73+
(B6.129P2-Cdc73Gt(RRE190)Byg)
|
increased parathyroid adenoma incidence
|
J:243366
|
increased parathyroid gland tumor incidence
|
J:243366
|
increased uterus tumor incidence
|
J:243366
|
Cdc73tm1Btt/Cdc73+ Tg(PTH-cre)4167Slib/0
(Not Specified)
|
increased parathyroid adenoma incidence
|
J:243366
|
increased parathyroid gland tumor incidence
|
J:243366
|
Cdc73tm1Btt/Cdc73tm1Btt Tg(PTH-cre)4167Slib/0
(Not Specified)
|
increased parathyroid adenoma incidence
|
J:243366
|
increased parathyroid gland tumor incidence
|
J:243366
|
Cdh1tm1Jjon/Cdh1+ Trp53tm1Brn/Trp53tm1Brn Tg(KRT14-cre)8Brn/0
(involves: 129P2/OlaHsd * FVB/N)
|
increased mammary adenocarcinoma incidence
|
J:116152
|
increased pilomatricoma incidence
|
J:116152
|
increased skin tumor incidence
|
J:116152
|
Cdh1tm1Jjon/Cdh1+ Trp53tm1Brn/Trp53tm1Brn Tg(Wap-cre)51Nki/0
(involves: 129P2/OlaHsd * FVB/N)
|
increased mammary adenocarcinoma incidence
|
J:171765
|
increased mammary gland tumor incidence
|
J:171765
|
Cdh1tm1Jjon/Cdh1tm1Jjon Trp53tm1Brn/Trp53+ Tg(KRT14-cre)8Brn/0
(involves: 129P2/OlaHsd * FVB/N)
|
increased mammary adenocarcinoma incidence
|
J:116152
|
increased skin tumor incidence
|
J:116152
|
Cdh1tm1Jjon/Cdh1tm1Jjon Trp53tm1Brn/Trp53+ Tg(Wap-cre)51Nki/0
(involves: 129P2/OlaHsd * FVB/N)
|
increased mammary gland tumor incidence
|
J:171765
|
Cdh1tm1Jjon/Cdh1tm1Jjon Trp53tm1Brn/Trp53tm1Brn Tg(KRT14-cre)8Brn/0
(involves: 129P2/OlaHsd * FVB/N)
|
increased mammary adenocarcinoma incidence
|
J:116152
|
increased skin tumor incidence
|
J:116152
|
Cdh1tm1Jjon/Cdh1tm1Jjon Trp53tm1Brn/Trp53tm1Brn Tg(Wap-cre)51Nki/0
(involves: 129P2/OlaHsd * FVB/N)
|
increased mammary gland tumor incidence
|
J:171765
|
Cdh1tm2Kem/Cdh1+ Smad4tm2.1Cxd/Smad4tm2.1Cxd Trp53tm1Brn/Trp53tm1Brn Tg(MMTV-cre)7Mul/0
(involves: 129 * C57BL/6 * FVB/N)
|
increased mammary adenocarcinoma incidence
|
J:212549
|
Cdh1tm2Kem/Cdh1+ Smad4tm2.1Cxd/Smad4tm2.1Cxd Trp53tm1Brn/Trp53tm1Brn Tg(Pdx1-cre)6Tuv/0
(involves: 129 * C57BL/6 * FVB/N)
|
increased duodenum adenocarcinoma incidence
|
J:212549
|
increased gastric adenocarcinoma incidence
|
J:212549
|
Cdh1tm2Kem/Cdh1+ Smad4tm2.1Cxd/Smad4tm2.1Cxd Trp53tm1Brn/Trp53tm1Brn Tg(Vil1-cre)20Syr/0
(involves: 129 * C57BL/6 * DBA/2)
|
increased intestinal adenocarcinoma incidence
|
J:212549
|
Cdh1tm2Kem/Cdh1tm2Kem Smad4tm2.1Cxd/Smad4tm2.1Cxd Trp53tm1Brn/Trp53tm1Brn Tg(Pdx1-cre)6Tuv/0
(involves: 129 * C57BL/6 * FVB/N)
|
increased gastric adenocarcinoma incidence
|
J:212549
|
Cdh13tm1Brns/Cdh13tm1Brns Tg(MMTV-PyVT)634Mul/0
(involves: C57BL/6 * FVB/N)
|
increased mammary gland tumor incidence
|
J:132759
|
Cdk4+/Cdk4+ Tg(Mt1-Hgf)#Lmb/0
(B6.Cg-Cdk4tm1.1Bbd Tg(Mt1-Hgf)#Lmb)
|
increased skin tumor incidence
|
J:111992
|
Cdk4tm1.1Bbd/Cdk4+ Krastm1Bbd/Kras+ Tg(CMV-cre)1Cgn/?
(involves: 129S1/Sv * 129X1/SvJ * BALB/cJ * C57BL/6)
|
increased lung adenoma incidence
|
J:86101
|
increased pituitary adenoma incidence
|
J:86101
|
Cdk4tm1.1Bbd/Cdk4tm1.1Bbd Tg(Mt1-Hgf)#Lmb/0
(B6.Cg-Cdk4tm1.1Bbd Tg(Mt1-Hgf)#Lmb)
|
increased cutaneous melanoma incidence
|
J:111992
|
increased skin tumor incidence
|
J:111992
|
Cdk4tm1.1Bbd/Cdk4tm1.1Bbd Tg(Tyr-NRAS*Q61K)1Bee/0
(FVB.Cg-Cdk4tm1.1Bbd Tg(Tyr-NRAS*Q61K)1Bee)
|
increased cutaneous melanoma incidence
|
J:222847
|
Cdk5rap2an/Cdk5rap2an
(Not Specified)
|
increased ovary adenoma incidence
|
J:15165
|
Cdk5rap2an/Cdk5rap2an Tyrp1B-lt/Tyrp1B-lt
(WBB6F1)
|
increased histiocytic sarcoma incidence
|
J:102334
|
Cdk6tm1Bbd/Cdk6tm1Bbd Krastm1Bbd/Kras+ Polr2atm1(cre/ERT2)Bbd/Polr2atm1(cre/ERT2)Bbd
(involves: 129S1/Sv * 129X1/SvJ)
|
increased lung non-small cell carcinoma incidence
|
J:161780
|
Cdk6tm1Phin/Cdk6+ Tg(Lck-Akt1*E40K)E-3Pnt/0
(involves: 129S4/SvJae)
|
increased T cell derived lymphoma incidence
|
J:144975
|
Cdk11bGt(XG836)Byg/Cdk11bGt(XG836)Byg
(involves: 129P2/OlaHsd * C57BL/6J)
|
increased skin papilloma incidence
|
J:125424
|
Cdkn1atm1(HBsAg)Xya/Cdkn1a+
(either: (involves: 129S6/SvEvTac * C57BL/6) or (involves: 129S6/SvEvTac * Black Swiss))
|
increased hepatocellular carcinoma incidence
|
J:88078
|
Cdkn1atm1(HBsAg)Xya/Cdkn1atm1(HBsAg)Xya
(either: (involves: 129S6/SvEvTac * C57BL/6) or (involves: 129S6/SvEvTac * Black Swiss))
|
increased hepatocellular carcinoma incidence
|
J:88078
|
Cdkn1atm1Led/Cdkn1atm1Led Ctnnb1tm1Mmt/Ctnnb1tm1Mmt Tg(Upk2-cre)6Xrw/0
(involves: 129S6/SvEvTac * 129X1/SvJ * FVB/N)
|
increased urinary bladder carcinoma incidence
|
J:234236
|
Cdkn1atm1Tyj/Cdkn1atm1Tyj
(involves: 129S2/SvPas * C57BL/6)
|
increased B cell derived lymphoma incidence
|
J:70894
|
increased histiocytic sarcoma incidence
|
J:70894
|
increased Leydig cell tumor incidence
|
J:70894
|
increased lung carcinoma incidence
|
J:70894
|
increased sebaceous gland adenoma incidence
|
J:70894
|
increased skin tumor incidence
|
J:70894
|
increased T cell derived lymphoma incidence
|
J:70894
|
increased urinary system tumor incidence
|
J:70894
|
Cdkn1atm1Tyj/Cdkn1atm1Tyj Fahtm1Mgo/Fahtm1Mgo
(involves: 129S2/SvPas * 129S7/SvEvBrd * C57BL/6)
|
increased hepatocellular carcinoma incidence
|
J:138701
|
increased renal carcinoma incidence
|
J:138701
|
Cdkn1atm1Tyj/Cdkn1atm1Tyj Ptentm1Hwu/Ptentm1Hwu Tg(Fabp1-cre)1Jig/0
(involves: 129S2/SvPas * 129S4/SvJae * FVB/N)
|
increased urinary bladder carcinoma incidence
|
J:106662
|
Cdkn1atm1Tyj/Cdkn1atm1Tyj Tg(MMTV-vHaras)SH1Led/0
(involves: 129S2/SvPas * C57BL/6J * CD-1 * FVB/N)
|
increased mammary adenocarcinoma incidence
|
J:66183
|
increased salivary adenocarcinoma incidence
|
J:66183
|
Cdkn1atm2(HBx)Xya/Cdkn1a+
(either: (involves: 129S6/SvEvTac * C57BL/6) or (involves: 129S6/SvEvTac * Black Swiss))
|
increased hepatocellular carcinoma incidence
|
J:88078
|
Cdkn1atm2(HBx)Xya/Cdkn1atm2(HBx)Xya
(either: (involves: 129S6/SvEvTac * C57BL/6) or (involves: 129S6/SvEvTac * Black Swiss))
|
increased hepatocellular carcinoma incidence
|
J:88078
|
Cdkn1btm1Ako/Cdkn1b+ KitW-v/KitW-v
(involves: 129S1/Sv * C57BL/6J)
|
increased ovary adenoma incidence
|
J:236161
|
increased ovary tumor incidence
|
J:236161
|
Cdkn1btm1Ako/Cdkn1b+ Ptentm2.1Ppp/Ptentm2.1Ppp Tg(TPO-cre)1Shk/0
(129S1.Cg-Cdkn1btm1Ako Tg(TPO-cre)1Shk Ptentm2.1Ppp)
|
increased thyroid adenoma incidence
|
J:165293
|
increased thyroid carcinoma incidence
|
J:165293
|
Cdkn1btm1Ako/Cdkn1btm1Ako
(involves: 129S1/Sv * C57BL/6)
|
increased pituitary gland tumor incidence
|
J:50053
|
Cdkn1btm1Ako/Cdkn1btm1Ako
(involves: 129S1/Sv)
|
increased lung adenocarcinoma incidence
|
J:120835
|
increased ovary tumor incidence
|
J:236161
|
Cdkn1btm1Ako/Cdkn1btm1Ako Cdkn2ctm1Yxi/Cdkn2ctm1Yxi
(involves: 129/Sv * 129S1/Sv * C57BL/6 * DBA/2)
|
increased pituitary adenoma incidence
|
J:50053
|
Cdkn1btm1Ako/Cdkn1btm1Ako KitW-v/KitW-v
(involves: 129S1/Sv * C57BL/6J)
|
increased ovary adenoma incidence
|
J:236161
|
increased ovary tumor incidence
|
J:236161
|
Cdkn1btm1Ako/Cdkn1btm1Ako Men1tm1.1Ctre/Men1+
(involves: 129S1/Sv * 129S6/SvEvTac * C57BL/6)
|
increased adrenal gland tumor incidence
|
J:120835
|
increased lung adenoma incidence
|
J:120835
|
increased pancreas tumor incidence
|
J:120835
|
increased parathyroid gland tumor incidence
|
J:120835
|
increased pituitary gland tumor incidence
|
J:120835
|
increased testis tumor incidence
|
J:120835
|
increased thyroid tumor incidence
|
J:120835
|
Cdkn1btm1Jro/Cdkn1btm1Jro Rb1tm3Tyj/Rb1tm3Tyj Trp53tm1Brn/Trp53tm1Brn Tg(Sp7-tTA,tetO-EGFP/cre)1Amc/0
(involves: 129P2/OlaHsd * 129S4/SvJae * C57BL/6J * CD-1 * FVB/N)
|
increased osteosarcoma incidence
|
J:318035
|
Cdkn1btm1Kin/Cdkn1btm1Kin
(involves: 129P2/OlaHsd * C57BL/6)
|
increased pituitary adenoma incidence
|
J:33402
|
Cdkn1btm1Mlf/Cdkn1b+ Crebbptm1Jvd/Crebbptm1Jvd Tg(MMTV-cre)4Mam/0
(involves: 129 * C57BL/6 * CBA * FVB)
|
increased T cell derived lymphoma incidence
|
J:88323
|
Cdkn1btm1Mlf/Cdkn1b+ Ptch1tm1Mps/Ptch1+
(involves: 129S1/Sv * 129S4/SvJaeSor * 129X1/SvJ * C57BL/6)
|
increased gastrointestinal tumor incidence
|
J:205254
|
increased lymphoma incidence
|
J:205254
|
increased medulloblastoma incidence
|
J:205254
|
increased rhabdomyosarcoma incidence
|
J:205254
|
Cdkn1btm1Mlf/Cdkn1b+ Tg(TG-TPR/NTRK1)#Rstn/0
(involves: 129S4/SvJaeSor * C3H * C57BL/6 * C57BL/6J)
|
increased thyroid carcinoma incidence
|
J:210015
|
Cdkn1btm1Mlf/Cdkn1btm1Mlf
(involves: 129S4/SvJaeSor * C57BL/6J)
|
increased pituitary adenoma incidence
|
J:33400
|
Cdkn1btm1Mlf/Cdkn1btm1Mlf Nkx3-1tm1.1Saa/Nkx3-1tm1.1Saa
(involves: 129S4/SvJaeSor * C57BL/6 * FVB/N)
|
increased prostate intraepithelial neoplasia incidence
|
J:89571
|
Cdkn1btm1Mlf/Cdkn1btm1Mlf Ptch1tm1Mps/Ptch1+
(involves: 129S1/Sv * 129S4/SvJaeSor * 129X1/SvJ * C57BL/6)
|
increased gastrointestinal tumor incidence
|
J:205254
|
increased lymphoma incidence
|
J:205254
|
increased medulloblastoma incidence
|
J:205254
|
increased rhabdomyosarcoma incidence
|
J:205254
|
Cdkn1btm1Mlf/Cdkn1btm1Mlf Tg(TG-TPR/NTRK1)#Rstn/0
(involves: 129S4/SvJaeSor * C3H * C57BL/6 * C57BL/6J)
|
increased thyroid carcinoma incidence
|
J:210015
|
Cdkn1btm1Mlf/Cdkn1btm1Mlf Trp53tm1Brd/Trp53tm1Brd
(involves: C3H * C57BL/6J * NIH)
|
increased T cell derived lymphoma incidence
|
J:87536
|
Cdkn1btm1Mlf/Cdkn1btm1Mlf Trp53tm1Brd/Trp53tm1Brd
(involves: 129S4/SvJaeSor * 129S7/SvEvBrd * C57BL/6J)
|
increased T cell derived lymphoma incidence
|
J:87536
|
Cdkn1btm2Mlf/Cdkn1btm2Mlf Tg(Pomc1-cre)1Mlf/0
(involves: 129S4/SvJaeSor)
|
increased pituitary gland tumor incidence
|
J:107588
|
Cdkn1btm3Mlf/Cdkn1btm3Mlf
(involves: 129S4/SvJaeSor)
|
increased pituitary gland tumor incidence
|
J:107588
|
Cdkn2aem1Cjs/Cdkn2aem1Cjs
(B6.Cg-Cdkn2aem1Cjs)
|
increased acute lymphoblastic leukemia incidence
|
J:244260
|
Cdkn2atm1(GFP)Cjs/Cdkn2atm1(GFP)Cjs
(involves: 129S1/Sv * C57BL/6)
|
increased gastrointestinal stromal tumor incidence
|
J:87339
|
increased histiocytic sarcoma incidence
|
J:87339
|
increased lymphoma incidence
|
J:87339
|
Cdkn2atm1.1Brn/Cdkn2a+ Nf2tm2Gth/Nf2tm2Gth Trp53tm1Brn/Trp53tm1Brn
(involves: 129P2/OlaHsd * 129S7/SvEvBrd)
|
increased rhabdomyosarcoma incidence
|
J:132943
|
Cdkn2atm1.1Brn/Cdkn2atm1.1Brn Cdkn2btm2Brn/Cdkn2btm2Brn
(involves: 129P2/OlaHsd * FVB/N)
|
increased skin tumor incidence
|
J:125189
|
Cdkn2atm1.1Brn/Cdkn2atm1.1Brn Nf2tm2Gth/Nf2tm2Gth
(involves: 129P2/OlaHsd * FVB/N)
|
increased liver tumor incidence
|
J:131179
|
increased meningioma incidence
|
J:131179
|
increased osteoma incidence
|
J:131179
|
Cdkn2atm1.1Brn/Cdkn2atm1.1Brn Nf2tm2Gth/Nf2tm2Gth Ptgdstm1.1(cre)Gvn/Ptgds+
(involves: 129P2/OlaHsd * FVB/N)
|
increased meningioma incidence
|
J:173718
|
Cdkn2atm1.1Brn/Cdkn2atm1.1Brn Nf2tm2Gth/Nf2tm2Gth Trp53tm1Brn/Trp53tm1Brn
(involves: 129P2/OlaHsd * 129S7/SvEvBrd)
|
increased rhabdomyosarcoma incidence
|
J:132943
|
increased Schwannoma incidence
|
J:132943
|
Cdkn2atm1.1Gsu/Cdkn2atm1.1Gsu Krastm4Tyj/Kras+ Tg(Pdx1-cre)6Tuv/0
(involves: 129S4/SvJae * 129S4/SvJaeSor * C57BL/6J * FVB/N)
|
increased pancreas adenoma incidence
|
J:198619
|
increased pancreas tumor incidence
|
J:198619
|
increased pancreatic intraepithelial neoplasia incidence
|
J:198619
|
Cdkn2atm1Cjs/Cdkn2a+ Tg(CKMM-tTA)A3Rhvh/0 Tg(tetO-Hgf,-EGFP)24Tcre/0
(involves: 129X1/SvJ * FVB)
|
increased rhabdomyosarcoma incidence
|
J:237183
|
Cdkn2atm1Cjs/Cdkn2atm1Cjs
(involves: 129X1/SvJ * C57BL/6)
|
increased acute lymphoblastic leukemia incidence
|
J:244260
|
increased fibrohistocytoma incidence
|
J:44427
|
increased lymphoma incidence
|
J:44427
|
increased T cell derived lymphoma incidence
|
J:44427
|
Cdkn2atm1Cjs/Cdkn2atm1Cjs Pax7tm1Pgr/Pax7+ Tg(CKMM-tTA)A3Rhvh/0 Tg(tetO-Hgf,-EGFP)24Tcre/0
(involves: 129S2/SvPas * 129X1/SvJ * FVB)
|
increased rhabdomyosarcoma incidence
|
J:237183
|
Cdkn2atm1Cjs/Cdkn2atm1Cjs Pax7tm1Pgr/Pax7tm1Pgr Tg(CKMM-tTA)A3Rhvh/0 Tg(tetO-Hgf,-EGFP)24Tcre/0
(involves: 129S2/SvPas * 129X1/SvJ * FVB)
|
increased rhabdomyosarcoma incidence
|
J:237183
|
Cdkn2atm1Cjs/Cdkn2atm1Cjs Sclt1Tg(CAG-sb10)1Dla/0 TgTn(sb-T2/Onc)68Dla/0
(involves: 129X1/SvJ * FVB/N)
|
increased leukemia incidence
|
J:99991
|
increased lung adenocarcinoma incidence
|
J:99991
|
increased lymphoma incidence
|
J:99991
|
increased osteosarcoma incidence
|
J:99991
|
Cdkn2atm1Cjs/Cdkn2atm1Cjs Sclt1Tg(CAG-sb10)1Dla/0 TgTn(sb-T2/Onc)76Dla/0
(involves: 129X1/SvJ * FVB/N)
|
increased leukemia incidence
|
J:99991
|
increased lung adenocarcinoma incidence
|
J:99991
|
increased lymphoma incidence
|
J:99991
|
increased osteosarcoma incidence
|
J:99991
|
Cdkn2atm1Cjs/Cdkn2atm1Cjs Tacstd2tm1Lsm/Tacstd2tm1Lsm
(involves: 129X1/SvJ * C57BL/6)
|
increased skin squamous cell carcinoma incidence
|
J:182647
|
Cdkn2atm1Cjs/Cdkn2atm1Cjs Tg(CKMM-tTA)A3Rhvh/0 Tg(tetO-Hgf,-EGFP)24Tcre/0
(involves: 129X1/SvJ * FVB)
|
increased rhabdomyosarcoma incidence
|
J:237183
|
Cdkn2atm1Cjs/Cdkn2atm1Cjs Tg(GFAP-TVA)5Hev/0
(involves: 129X1/SvJ * BALB/c * C57BL/6 * FVB/N)
|
increased glioma incidence
|
J:125535
|
increased oligodendroglioma incidence
|
J:125535
|
Cdkn2atm1Cjs/Cdkn2atm1Cjs Tg(NES-TVA)J12Ech/0
(involves: 129X1/SvJ * C57BL/6 * FVB/N)
|
increased glioma incidence
|
J:125535
|
increased oligodendroglioma incidence
|
J:125535
|
Cdkn2atm1Nesh/Cdkn2atm1Nesh
(involves: 129S6/SvEvTac * FVB/N)
|
increased lung carcinoma incidence
|
J:88365
|
increased osteosarcoma incidence
|
J:88365
|
increased small lymphocytic lymphoma incidence
|
J:88365
|
Cdkn2atm1Rdp/Cdkn2a+ Nf1tm1Tyj/Nf1+
(involves: 129S2/SvPas * 129S6/SvEvTac)
|
increased neurofibrosarcoma incidence
|
J:131914
|
Cdkn2atm1Rdp/Cdkn2a+ Terctm1Rdp/Terctm1Rdp
(involves: 129/Sv * C57BL/6J * SJL)
|
increased lymphoma incidence
|
J:120065
|
Cdkn2atm1Rdp/Cdkn2a+ Tg(CAG-Bgeo,-tTA,-EGFP)2A11Kuw/0 Tg(Pdx1-cre)6Tuv/0 Tg(tetO-MYC)36Bop/0
(involves: 129/Sv * 129P2/OlaHsd * C57BL/6J * FVB/N * SJL)
|
increased pancreas tumor incidence
|
J:197052
|
increased pancreatic ductal adenocarcinoma incidence
|
J:197052
|
Cdkn2atm1Rdp/Cdkn2a+ Tg(NES-TVA)J12Ech/0
(involves: 129 * C57BL/6 * FVB/N * SJL)
|
increased glioma incidence
|
J:52161
|
Cdkn2atm1Rdp/Cdkn2a+ Tg(S100b-v-erbB)4496Waw/0
(involves: 129/Sv * C57BL/6J * DBA/2J * FVB/N * SJL)
|
increased glioma incidence
|
J:82649
|
Cdkn2atm1Rdp/Cdkn2a+ X/Tg(Tyr-HRAS)60Lc
(involves: 129/Sv * C57BL/6J * CBA/J * FVB/N * SJL)
|
increased intraocular melanoma incidence
|
J:140820
|
Cdkn2atm1Rdp/Cdkn2a+ Tg(Tyr-NRAS*Q61K)1Bee/?
(involves: 129/Sv * C57BL/6 * DBA/2 * SJL)
|
increased cutaneous melanoma incidence
|
J:98545
|
Cdkn2atm1Rdp/Cdkn2atm1Rdp
(involves: 129/Sv * C57BL/6 * SJL)
|
increased B cell derived lymphoma incidence
|
J:53805
|
increased cutaneous melanoma incidence
|
J:98545
|
Cdkn2atm1Rdp/Cdkn2atm1Rdp
(involves: 129/Sv * C57BL/6J * FVB/N * SJL)
|
increased lymphoma incidence
|
J:88365
|
Cdkn2atm1Rdp/Cdkn2atm1Rdp
(involves: 129/Sv * C57BL/6J * SJL)
|
increased brain tumor incidence
|
J:163931
|
Cdkn2atm1Rdp/Cdkn2atm1Rdp Col1a1tm1(CAG-EGFR)Char/Col1a1tm1(CAG-EGFR)Char Ptentm1Hwu/Ptentm1Hwu
(involves: 129/Sv * 129S4/SvJae * C57BL/6 * SJL)
|
increased glioblastoma incidence
|
J:146494
|
Cdkn2atm1Rdp/Cdkn2atm1Rdp Col1a1tm1(CAG-EGFR)Char/Col1a1tm2(CAG-EGFR*)Char Ptentm1Hwu/Ptentm1Hwu
(involves: 129/Sv * 129S4/SvJae * C57BL/6 * SJL)
|
increased glioblastoma incidence
|
J:146494
|
Cdkn2atm1Rdp/Cdkn2atm1Rdp Col1a1tm2(CAG-EGFR*)Char/Col1a1tm2(CAG-EGFR*)Char Ptentm1Hwu/Ptentm1Hwu
(involves: 129/Sv * 129S4/SvJae * C57BL/6 * SJL)
|
increased glioblastoma incidence
|
J:146494
|
Cdkn2atm1Rdp/Cdkn2atm1Rdp Krastm4Tyj/Kras+
(involves: 129/Sv * 129S4/SvJae * C57BL/6 * FVB/N * SJL)
|
increased lung adenocarcinoma incidence
|
J:124682
|
Cdkn2atm1Rdp/Cdkn2atm1Rdp Nf1tm1Tyj/Nf1+
(involves: 129S2/SvPas * 129S6/SvEvTac)
|
increased leukemia incidence
|
J:131914
|
increased lymphoma incidence
|
J:131914
|
increased neurofibrosarcoma incidence
|
J:131914
|
Cdkn2atm1Rdp/Cdkn2atm1Rdp Rnf2tm1Mvi/Rnf2tm1Mvi Tg(Mx1-cre)1Cgn/0
(involves: 129 * C57BL/6 * C57BL/10 * CBA * SJL)
|
increased lymphoma incidence
|
J:130397
|
Cdkn2atm1Rdp/Cdkn2atm1Rdp Terctm1Rdp/Terctm1Rdp
(involves: 129/Sv * C57BL/6J * SJL)
|
increased lymphoma incidence
|
J:120065
|
Cdkn2atm1Rdp/Cdkn2atm1Rdp Tg(GFAP-TVA)5Hev/0
(involves: 129/Sv * BALB/c * C57BL/6 * FVB/N * SJL)
|
increased glioma incidence
|
J:125535
|
increased oligodendroglioma incidence
|
J:125535
|
Cdkn2atm1Rdp/Cdkn2atm1Rdp Tg(GFAP-TVA)10Ech/0
(involves: 129 * BALB/c * C57BL/6 * FVB/N * SJL)
|
increased glioma incidence
|
J:52161
|
Cdkn2atm1Rdp/Cdkn2atm1Rdp Tg(Mt1-Hgf)19Lmb/0
(involves: 129/Sv * C57BL/6J * FVB/N * SJL)
|
increased rhabdomyosarcoma incidence
|
J:79704
|
Cdkn2atm1Rdp/Cdkn2atm1Rdp Tg(NES-TVA)J12Ech/0
(involves: 129 * C57BL/6 * FVB/N * SJL)
|
increased glioma incidence
|
J:52161
|
Cdkn2atm1Rdp/Cdkn2atm1Rdp Tg(NES-TVA)J12Ech/0
(involves: 129/Sv * C57BL/6 * FVB/N * SJL)
|
increased glioma incidence
|
J:125535
|
increased oligodendroglioma incidence
|
J:153220
|
Cdkn2atm1Rdp/Cdkn2atm1Rdp Tg(S100b-v-erbB)4496Waw/0
(involves: 129/Sv * C57BL/6J * DBA/2J * FVB/N * SJL)
|
increased glioma incidence
|
J:82649
|
increased oligodendroglioma incidence
|
J:82649
|
Cdkn2atm1Rdp/Cdkn2atm1Rdp Tg(Scgb1a1-rtTA)1Jaw/0 Tg(tetO-Kras2)12Hev/0
(involves: 129 * C57BL/6J * FVB/N * SJL)
|
increased lung adenocarcinoma incidence
|
J:166963,
J:73468
|
increased lung tumor incidence
|
J:73468
|
Cdkn2atm1Rdp/Cdkn2atm1Rdp Tg(tetO-BRAF*V600E)29Lc/0 Tg(Tyr-rtTA)37Lc/0
(involves: 129/Sv * C57BL/6J * SJL)
|
increased prostate gland adenocarcinoma incidence
|
J:144358
|
Cdkn2atm1Rdp/Cdkn2atm1Rdp Tg(tetO-Nras*Q61K)#Lc/0 Tg(Tyr-rtTA)37Lc/0
(FVB.Cg-Cdkn2atm1Rdp Tg(tetO-Nras*Q61K)#Lc Tg(Tyr-rtTA)37Lc)
|
increased cutaneous melanoma incidence
|
J:238049
|
Cdkn2atm1Rdp/Cdkn2atm1Rdp Tg(Tyr-NRAS*Q61K)1Bee/?
(involves: 129/Sv * C57BL/6 * DBA/2 * SJL)
|
increased cutaneous melanoma incidence
|
J:98545
|
Cdkn2atm1Rdp/Cdkn2atm1Rdp Tg(Tyr-NRAS*Q61K)1Bee/0
(involves: 129/Sv * C57BL/6J * DBA/2 * SJL)
|
increased cutaneous melanoma incidence
|
J:193443
|
Cdkn2atm2.1Brn/Cdkn2atm2.1Brn
(involves: 129P2/OlaHsd * FVB/N)
|
increased lymphoma incidence
|
J:71393
|
Cdkn2atm2.1Nesh/Cdkn2atm2.1Nesh Krastm4Tyj/Kras+ Tg(Tyr-cre/ERT2)13Bos/0
(B6J.Cg-Tg(Tyr-cre/ERT2)13Bos Cdkn2atm2.1Nesh Krastm4Tyj)
|
increased cutaneous melanoma incidence
|
J:220627
|
Cdkn2atm2.1Nesh/Cdkn2atm2.1Nesh Nrastm1.1Nesh/Nrastm1.1Nesh Stk11tm1.1Rdp/Stk11tm1.1Rdp Tg(Tyr-cre/ERT2)13Bos/0
(B6J.Cg-Tg(Tyr-cre/ERT2)13Bos Nrastm1.1Nesh Cdkn2atm2.1Nesh Stk11tm1.1Rdp)
|
increased cutaneous melanoma incidence
|
J:220627
|
Cdkn2atm2.1Nesh/Cdkn2atm2.1Nesh Nrastm1.1Nesh/Nrastm1.1Nesh Tg(Tyr-cre/ERT2)13Bos/0
(B6J.Cg-Tg(Tyr-cre/ERT2)13Bos Nrastm1.1Nesh Cdkn2atm2.1Nesh)
|
increased cutaneous melanoma incidence
|
J:220627
|
Cdkn2atm2.1Nesh/Cdkn2atm2.1Nesh Nrastm1Tyj/Nrastm1Tyj Tg(Tyr-cre/ERT2)13Bos/0
(B6J.Cg-Tg(Tyr-cre/ERT2)13Bos Nrastm1Tyj Cdkn2atm2.1Nesh)
|
increased cutaneous melanoma incidence
|
J:220627
|
Cdkn2atm2.1Rdp/Cdkn2a+ Krastm4Tyj/Kras+ Trp53tm1Brn/Trp53+ Tg(Pdx1-cre)89.1Dam/0
(involves: 129 * C57BL/6 * CBA * FVB/N)
|
increased pancreas tumor incidence
|
J:108298
|
increased pancreatic ductal adenocarcinoma incidence
|
J:108298
|
Cdkn2atm2.1Rdp/Cdkn2a+ Krastm4Tyj/Kras+ Trp53tm1Brn/Trp53tm1Brn Tg(Pdx1-cre)89.1Dam/0
(involves: 129 * C57BL/6 * CBA * FVB/N)
|
increased pancreas tumor incidence
|
J:108298
|
increased pancreatic ductal adenocarcinoma incidence
|
J:108298
|
Cdkn2atm2.1Rdp/Cdkn2atm2.1Rdp
(involves: 129S6/SvEvTac * FVB/N)
|
increased lymphoma incidence
|
J:88365
|
increased osteosarcoma incidence
|
J:88365
|
increased small lymphocytic lymphoma incidence
|
J:88365
|
Cdkn2atm2.1Rdp/Cdkn2atm2.1Rdp Krastm4Tyj/Kras+
(involves: 129S4/SvJae * 129S6/SvEvTac * C57BL/6 * FVB/N)
|
increased lung adenocarcinoma incidence
|
J:124682
|
Cdkn2atm2.1Rdp/Cdkn2atm2.1Rdp Krastm4Tyj/Kras+ Tg(Pdx1-cre)6Tuv/0
(involves: 129S4/SvJae * 129S6/SvEvTac * FVB/N)
|
increased pancreas adenoma incidence
|
J:198619
|
increased pancreas tumor incidence
|
J:198619
|
increased pancreatic intraepithelial neoplasia incidence
|
J:198619
|
Cdkn2atm2.1Rdp/Cdkn2atm2.1Rdp Krastm4Tyj/Kras+ Tg(Pdx1-cre)89.1Dam/0
(involves: 129 * C57BL/6 * CBA * FVB/N)
|
increased pancreas tumor incidence
|
J:108298
|
Cdkn2atm2.1Rdp/Cdkn2atm2.1Rdp Krastm4Tyj/Kras+ Trp53tm1Brn/Trp53+ Tg(Pdx1-cre)89.1Dam/0
(involves: 129 * C57BL/6 * CBA * FVB/N)
|
increased pancreas tumor incidence
|
J:108298
|
increased pancreatic ductal adenocarcinoma incidence
|
J:108298
|
Cdkn2atm2.1Rdp/Cdkn2atm2.1Rdp Krastm4Tyj/Kras+ Trp53tm1Brn/Trp53tm1Brn Tg(Pdx1-cre)89.1Dam/0
(involves: 129 * C57BL/6 * CBA * FVB/N)
|
increased pancreas tumor incidence
|
J:108298
|
increased pancreatic ductal adenocarcinoma incidence
|
J:108298
|
Cdkn2atm2.1Rdp/Cdkn2atm2.1Rdp Nf1tm1Tyj/Nf1+
(involves: 129S2/SvPas * 129S6/SvEvTac)
|
increased lymphoma incidence
|
J:131914
|
Cdkn2atm2.1Rdp/Cdkn2atm2.1Rdp Tg(GFAP-TVA)5Hev/0
(involves: 129S6/SvEvTac * BALB/c * C57BL/6 * FVB/N)
|
increased glioma incidence
|
J:125535
|
increased oligodendroglioma incidence
|
J:125535
|
Cdkn2atm2.1Rdp/Cdkn2atm2.1Rdp Tg(NES-TVA)J12Ech/0
(involves: 129S6/SvEvTac * C57BL/6 * FVB/N)
|
increased glioma incidence
|
J:125535
|
increased oligodendroglioma incidence
|
J:125535
|
Cdkn2atm2.1Rdp/Cdkn2atm2.1Rdp Trp53tm1Brn/Trp53tm1Brn
(involves: 129P2/OlaHsd * 129S6/SvEvTac * C57BL/6 * FVB/N)
|
increased lung tumor incidence
|
J:124682
|
Cdkn2atm2Brn/Cdkn2a+ Nf2tm2Gth/Nf2tm2Gth
(involves: 129P2/OlaHsd)
|
increased leukemia incidence
|
J:132943
|
increased uterus leiomyoma incidence
|
J:132943
|
Cdkn2atm2Brn/Cdkn2atm2Brn Nf2tm2Gth/Nf2+
(involves: 129P2/OlaHsd)
|
increased leukemia incidence
|
J:132943
|
increased uterus leiomyoma incidence
|
J:132943
|
Cdkn2atm2Brn/Cdkn2atm2Brn Nf2tm2Gth/Nf2tm2Gth
(involves: 129P2/OlaHsd)
|
increased leukemia incidence
|
J:132943
|
increased rhabdomyosarcoma incidence
|
J:132943
|
increased uterus leiomyoma incidence
|
J:132943
|
Cdkn2atm2Brn/Cdkn2atm2Brn Tg(Tyr-cre/ERT,-Hras1*,-Trap1a)10BJvde/0
(involves: C57BL/6 * FVB/N)
|
increased cutaneous melanoma incidence
|
J:107175
|
increased neurofibrosarcoma incidence
|
J:107175
|
Cdkn2atm4Rdp/Cdkn2a+ Krastm4Tyj/Kras+ Ptf1atm1.1(cre)Cvw/Ptf1a+
(involves: 129S1/Sv * 129S4/SvJae * 129X1/SvJ)
|
increased pancreatic ductal adenocarcinoma incidence
|
J:116130
|
Cdkn2atm4Rdp/Cdkn2a+ Krastm4Tyj/Kras+ Smad4tm1Rdp/Smad4tm1Rdp Ptf1atm1.1(cre)Cvw/Ptf1a+
(involves: 129 * FVB/N)
|
increased pancreatic ductal adenocarcinoma incidence
|
J:116130
|
Cdkn2atm4Rdp/Cdkn2a+ Krastm4Tyj/Kras+ Smad4tm1Rdp/Smad4tm1Rdp Tg(Pdx1-cre)89.1Dam/0
(involves: 129S/SvEv * 129S4/SvJae * C57BL/6 * CBA * FVB/N)
|
increased pancreatic ductal adenocarcinoma incidence
|
J:116130
|
increased stomach tumor incidence
|
J:116130
|
Cdkn2atm4Rdp/Cdkn2a+ Krastm4Tyj/Kras+ Tg(Pdx1-cre)89.1Dam/0
(involves: 129S4/SvJae * C57BL/6 * CBA)
|
increased pancreatic ductal adenocarcinoma incidence
|
J:116130
|
Cdkn2atm4Rdp/Cdkn2a+ Krastm4Tyj/Kras+ Tg(Pdx1-cre)89.1Dam/0
(involves: 129S4/SvJae * C57BL/6 * CBA * FVB/N)
|
increased pancreas tumor incidence
|
J:108298
|
increased pancreatic ductal adenocarcinoma incidence
|
J:108298
|
Cdkn2atm4Rdp/Cdkn2atm4Rdp Krastm4Tyj/Kras+
(involves: 129S4/SvJae)
|
increased lung adenocarcinoma incidence
|
J:195492
|
Cdkn2atm4Rdp/Cdkn2atm4Rdp Krastm4Tyj/Kras+ Ptf1atm1.1(cre)Cvw/Ptf1a+
(involves: 129S1/Sv * 129S4/SvJae * 129X1/SvJ)
|
increased pancreatic ductal adenocarcinoma incidence
|
J:116130
|
Cdkn2atm4Rdp/Cdkn2atm4Rdp Krastm4Tyj/Kras+ Smad4tm1Rdp/Smad4tm1Rdp Ptf1atm1.1(cre)Cvw/Ptf1a+
(involves: 129 * FVB/N)
|
increased pancreatic ductal adenocarcinoma incidence
|
J:116130
|
Cdkn2atm4Rdp/Cdkn2atm4Rdp Krastm4Tyj/Kras+ Smad4tm1Rdp/Smad4tm1Rdp Tg(Pdx1-cre)89.1Dam/0
(involves: 129S/SvEv * 129S4/SvJae * C57BL/6 * CBA * FVB/N)
|
increased pancreatic ductal adenocarcinoma incidence
|
J:116130
|
increased stomach tumor incidence
|
J:116130
|
Cdkn2atm4Rdp/Cdkn2atm4Rdp Krastm4Tyj/Kras+ Tg(Pdx1-cre)89.1Dam/0
(involves: 129S4/SvJae * C57BL/6 * CBA * FVB/N)
|
increased pancreas tumor incidence
|
J:108298,
J:87196
|
increased pancreatic ductal adenocarcinoma incidence
|
J:116130,
J:108298,
J:87196
|
increased pancreatic intraepithelial neoplasia incidence
|
J:87196
|
Cdkn2atm4Rdp/Cdkn2atm4Rdp Krastm4Tyj/Kras+ Tg(Pdx1-cre)89.1Dam/0
(involves: 129S4/SvJae * C57BL/6 * CBA)
|
increased pancreatic ductal adenocarcinoma incidence
|
J:187012
|
Cdkn2atm4Rdp/Cdkn2atm4Rdp Krastm4Tyj/Krastm4Tyj Tg(Pdx1-cre)89.1Dam/0
(involves: 129S4/SvJae * C57BL/6 * DBA/2)
|
increased pancreas tumor incidence
|
J:151781
|
Cdkn2atm4Rdp/Cdkn2atm4Rdp Myf6tm1(cre)Mrc/Myf6+ Pax3tm1Mrc/Pax3tm1Mrc
(involves: 129S1/Sv * 129X1/SvJ * C57BL/6 * SJL)
|
increased rhabdomyosarcoma incidence
|
J:93444
|
Cdkn2atm4Rdp/Cdkn2atm4Rdp Nf1tm1Par/Nf1tm1Par
(involves: 129S1/Sv * 129X1/SvJ)
|
increased neurofibrosarcoma incidence
|
J:234760
|
increased rhabdomyosarcoma incidence
|
J:234760
|
Cdkn2btm1Bbd/Cdkn2btm1Bbd Cdkn2ctm1Bbd/Cdkn2ctm1Bbd
(involves: 129S1/Sv * C57BL/6)
|
increased lymphoma incidence
|
J:63299
|
increased pituitary adenoma incidence
|
J:63299
|
increased testis tumor incidence
|
J:63299
|
Cdkn2ctm1Bbd/Cdkn2c+ Trp53tm1Tyj/Trp53+
(involves: 129S1/Sv * 129S2/SvPas * C57BL/6)
|
increased medulloblastoma incidence
|
J:102702
|
Cdkn2ctm1Bbd/Cdkn2c+ Trp53tm1Tyj/Trp53tm1Tyj
(involves: 129S1/Sv * 129S2/SvPas * C57BL/6)
|
increased medulloblastoma incidence
|
J:102702
|
Cdkn2ctm1Bbd/Cdkn2ctm1Bbd
(involves: 129S1/Sv * C57BL/6)
|
increased B cell derived lymphoma incidence
|
J:63299
|
increased pheochromocytoma incidence
|
J:63299
|
increased pituitary adenoma incidence
|
J:63299
|
increased renal carcinoma incidence
|
J:63299
|
increased T cell derived lymphoma incidence
|
J:63299
|
increased testis tumor incidence
|
J:63299
|
Cdkn2ctm1Bbd/Cdkn2ctm1Bbd Cdkn2dtm1Maro/Cdkn2dtm1Maro
(involves: 129P2/OlaHsd * 129S1/Sv * C57BL/6)
|
increased pheochromocytoma incidence
|
J:68829
|
increased pituitary adenoma incidence
|
J:68829
|
Cdkn2ctm1Bbd/Cdkn2ctm1Bbd Ptch1tm1Mps/Ptch1+
(involves: 129S1/Sv * 129S2/SvPas * 129X1/SvJ)
|
increased medulloblastoma incidence
|
J:102702
|
Cdkn2ctm1Bbd/Cdkn2ctm1Bbd Ptch1tm1Mps/Ptch1+
(involves: 129S1/Sv * 129X1/SvJ * C57BL/6)
|
increased medulloblastoma incidence
|
J:205254
|
Cdkn2ctm1Bbd/Cdkn2ctm1Bbd Trp53tm1Brn/Trp53tm1Tyj Tg(Nes-cre)1Kln/0
(involves: 129P2/OlaHsd * 129S1/Sv * 129S2/SvPas * C57BL/6 * SJL)
|
increased medulloblastoma incidence
|
J:102702
|
Cdkn2ctm1Bbd/Cdkn2ctm1Bbd Trp53tm1Tyj/Trp53tm1Tyj
(involves: 129S1/Sv * 129S2/SvPas * C57BL/6)
|
increased medulloblastoma incidence
|
J:102702
|
Cdkn2ctm1Yxi/Cdkn2ctm1Yxi
(involves: 129/Sv * C57BL/6 * DBA/2)
|
increased pituitary adenoma incidence
|
J:50053
|
Cdkn2ctm1Yxi/Cdkn2ctm1Yxi
(B6.129-Cdkn2ctm1Yxi)
|
increased lung adenocarcinoma incidence
|
J:120835
|
increased lung adenoma incidence
|
J:120835
|
increased lung tumor incidence
|
J:120835
|
Cdkn2ctm1Yxi/Cdkn2ctm1Yxi
(C.129-Cdkn2ctm1Yxi)
|
increased mammary gland tumor incidence
|
J:198018
|
Cdkn2ctm1Yxi/Cdkn2ctm1Yxi Men1tm1.1Ctre/Men1+
(involves: 129/Sv * 129S6/SvEvTac * C57BL/6)
|
increased adrenal gland tumor incidence
|
J:120835
|
increased Leydig cell tumor incidence
|
J:120835
|
increased lung adenocarcinoma incidence
|
J:120835
|
increased lung adenoma incidence
|
J:120835
|
increased lung tumor incidence
|
J:120835
|
increased pancreas tumor incidence
|
J:120835
|
increased parathyroid gland tumor incidence
|
J:120835
|
increased testis tumor incidence
|
J:120835
|
increased thyroid tumor incidence
|
J:120835
|
Cdsntm1.1Ics/Cdsntm1.1Ics Tg(KRT14-cre)1Ipc/0
(involves: 129S2/SvPas * C57BL/6 * SJL)
|
increased skin papilloma incidence
|
J:153292
|
Cdx2tm1Fbe/Cdx2+
(involves: 129S1/Sv * C57BL/6J)
|
increased colon adenoma incidence
|
J:38772
|
increased intestinal adenoma incidence
|
J:38772
|
Cdx2tm1Mmt/Cdx2+
(involves: 129X1/SvJ * C57BL/6)
|
increased colon hamartoma incidence
|
J:47050
|
Cebpatm1Gonz/Cebpatm1Gonz Tg(KRT5-cre)5132Jlj/0
(involves: 129X1/SvJ * C57BL/6 * DBA/2J)
|
increased skin papilloma incidence
|
J:123139
|
increased skin tumor incidence
|
J:123139
|
Cebpatm8.1Nerl/Cebpatm8.1Nerl
(involves: 129P2/OlaHsd * BALB/cJ * C57BL/6)
|
increased leukemia incidence
|
J:136134
|
Cep57em1Jvd/Cep57+
(involves: 129 * C57BL/6)
|
increased lung adenoma incidence
|
J:264300
|
Cep57em2Jvd/Cep57+
(involves: FVB/N)
|
increased lung adenoma incidence
|
J:264300
|
Cers2Gt(S16-4B1)Sor/Cers2Gt(S16-4B1)Sor
(involves: 129S4/SvJaeSor * C57BL/6)
|
increased hepatocellular carcinoma incidence
|
J:156841
|
increased liver tumor incidence
|
J:156841
|
Chd2Gt(RRBO46)Byg/Chd2+
(involves: 129P2/OlaHsd * C57BL/6)
|
increased lymphoma incidence
|
J:146176
|
increased T cell derived lymphoma incidence
|
J:146176
|
Chek1tm1Sje/Chek1+ Tg(Wnt1)1Hev/0
(Not Specified)
|
increased mammary adenocarcinoma incidence
|
J:62919
|
Chek1tm2.1Sje/Chek1+ Trp53tm1Brn/Trp53+ Tg(MMTV-cre)#Mam/0
(involves: 129P2/OlaHsd * FVB)
|
increased mammary adenocarcinoma incidence
|
J:162126
|
increased mammary gland tumor incidence
|
J:162126
|
Chek1tm2.1Sje/Chek1+ Trp53tm1Brn/Trp53tm1Brn Tg(MMTV-cre)#Mam/0
(involves: 129P2/OlaHsd * FVB)
|
increased mammary gland tumor incidence
|
J:162126
|
Chek1tm2.1Sje/Chek1tm2.1Sje Trp53tm1Brn/Trp53+ Tg(MMTV-cre)#Mam/0
(involves: 129P2/OlaHsd * FVB)
|
increased mammary gland tumor incidence
|
J:162126
|
Chek2tm1Mak/Chek2tm1Mak Rad50tm2Jpt/Rad50tm2Jpt
(involves: 129P2/OlaHsd * 129S7/SvEvBrd * C57BL/6)
|
increased lymphoma incidence
|
J:103922
|
Chfrtm1Jc/Chfr+
(involves: 129S/SvEv * C57BL/6)
|
increased lymphoma incidence
|
J:97428
|
Chfrtm1Jc/Chfrtm1Jc
(involves: 129S/SvEv * C57BL/6)
|
increased lymphoma incidence
|
J:97428
|
Chordc1tm1Mbra/Chordc1+
(involves: 129 * C57BL/6)
|
increased chronic myelocytic leukemia incidence
|
J:222040
|
Chuktm1Yhu/Chuktm1Yhu Tg(Krt1-5-cre/ERT)1Ipc/0
(involves: 129S1/Sv * 129X1/SvJ * C57BL/6 * SJL)
|
increased skin tumor incidence
|
J:141162
|
Chuktm1Yhu/Chuktm1Yhu Tg(Krt1-15-cre/PGR*)22Cot/0
(involves: 129S1/Sv * 129X1/SvJ * C57BL/6 * SJL)
|
increased skin papilloma incidence
|
J:141162
|
increased skin tumor incidence
|
J:141162
|
Chuktm1Yhu/Chuktm1Yhu Tg(MMTV-cre)4Mam/0
(involves: 129S1/Sv * 129X1/SvJ * C57BL/6 * FVB)
|
increased skin tumor incidence
|
J:141162
|
Chuktm2Yhu/Chuktm2Yhu
(involves: 129S1/Sv * 129X1/SvJ * FVB/N)
|
increased lung tumor incidence
|
J:197037
|
Chuktm2Yhu/Chuktm2Yhu
(involves: 129S1/Sv * 129X1/SvJ * C57BL/6)
|
increased skin squamous cell carcinoma incidence
|
J:197037
|
Chuktm2Yhu/Chuktm2Yhu Tg(Lor-CHUK)8Yhu/0
(involves: 129S1/Sv * 129X1/SvJ * FVB/N)
|
increased lung squamous cell carcinoma incidence
|
J:197037
|
increased lung tumor incidence
|
J:197037
|
Cibar1tm1b(KOMP)Wtsi/Cibar1tm1b(KOMP)Wtsi
(C57BL/6N-Cibar1tm1b(KOMP)Wtsi/Wtsi)
|
increased osteoma incidence
|
J:274784
|
Cks1btm1Sir/Cks1b+ Tg(IghMyc)22Bri/?
(involves: C57BL * C57BL/6 * SJL)
|
increased lymphoma incidence
|
J:121564
|
Cks1btm1Sir/Cks1btm1Sir Tg(IghMyc)22Bri/?
(involves: C57BL * C57BL/6 * SJL)
|
increased lymphoma incidence
|
J:121564
|
Col1a1tm1(CAG-EGFR*T790M*C797S*L858R)Mje/Col1a1+
(involves: 129S4/SvJae * BALB/c * C57BL/6)
|
increased lung adenocarcinoma incidence
|
J:235747
|
Col1a1tm1(CAG-Mir22)Ppp/Col1a1tm1(CAG-Mir22)Ppp Tg(Mx1-cre)1Cgn/0
(Not Specified)
|
increased leukemia incidence
|
J:199366
|
increased T cell derived lymphoma incidence
|
J:199366
|
Col1a1tm1(tetO-EML4/ALK)Kkw/Col1a1+ Tg(Scgb1a1-rtTA)1Jaw/0
(involves: 129 * C57BL/6)
|
increased lung carcinoma incidence
|
J:166724
|
increased lung tumor incidence
|
J:166724
|
Col1a1tm1(tetO-URI1)Ndj/Col1a1+ Tg(Cebpb-tTA)#Bjd/0
(B6.Cg-Col1a1tm1(tetO-URI1)Ndj Tg(Cebpb-tTA)#Bjd)
|
increased hepatocellular carcinoma incidence
|
J:217463
|
increased liver adenoma incidence
|
J:217463
|
Col1a1tm1(tetO-URI1)Ndj/Col1a1+ Tg(Cebpb-tTA)#Bjd/0 Trp53tm1Gev/Trp53+
(B6.Cg-Trp53tm1Gev Col1a1tm1(tetO-URI1)Ndj Tg(Cebpb-tTA)#Bjd)
|
increased hepatocellular carcinoma incidence
|
J:217463
|
Col1a1tm1(tetO-URI1)Ndj/Col1a1tm1(tetO-URI1)Ndj Tg(Cebpb-tTA)#Bjd/0
(B6.Cg-Col1a1tm1(tetO-URI1)Ndj Tg(Cebpb-tTA)#Bjd)
|
increased hepatocellular carcinoma incidence
|
J:217463
|
Col1a1tm1(tetO-YAP1*)Fcam/Col1a1+ Gt(ROSA)26Sortm1(rtTA,EGFP)Nagy/Gt(ROSA)26Sor+ Tg(KRT14-cre)1Amc/0
(involves: 129S1/Sv * 129S4/SvJae * 129X1/SvJ * C57BL/6 * CBA)
|
increased skin squamous cell carcinoma incidence
|
J:171057
|
Col1a1tm1(tetO-YAP1*)Fcam/Col1a1+ Gt(ROSA)26Sortm1(rtTA,EGFP)Nagy/Gt(ROSA)26Sor+ Tg(Pbsn-cre)4Prb/0
(involves: 129S1/Sv * 129S4/SvJae * 129X1/SvJ * C57BL/6 * DBA/2)
|
increased prostate gland adenocarcinoma incidence
|
J:222916
|
increased prostate gland tumor incidence
|
J:222916
|
Col1a1tm2(tetO-IDH2*R140Q)Ppp/Col1a1tm2(tetO-IDH2*R140Q)Ppp Flt3tm1.1Dosm/Flt3tm1.1Dosm Gt(ROSA)26Sortm1(rtTA*M2)Jae/?
(involves: 129 * C57BL/6)
|
increased leukemia incidence
|
J:210097
|
Col1a1tm2(tetO-IDH2*R140Q)Ppp/Col1a1tm2(tetO-IDH2*R140Q)Ppp Gt(ROSA)26Sortm1(rtTA*M2)Jae/?
(involves: 129S4/SvJae * C57BL/6)
|
increased leukemia incidence
|
J:210097
|
Col1a1tm2(tetO-LIN28B)Gqda/Col1a1+ Gt(ROSA)26Sortm1(rtTA,EGFP)Nagy/Gt(ROSA)26Sor+ Wt1tm2(cre/ERT2)Wtp/Wt1+
(involves: 129S1/Sv * 129S4/SvJae * 129X1/SvJ * C57BL/6)
|
increased kidney tumor incidence
|
J:211179
|
Col1a1tm2(tetO-Pou5f1)Jae/Col1a1+ Gt(ROSA)26Sortm1(rtTA*M2)Jae/Gt(ROSA)26Sor+
(involves: 129S4/SvJae * C57BL/6)
|
increased skin tumor incidence
|
J:98920
|
Col1a1tm3(tetO-GFP/RNAi:Apc)Slowe/Col1a1+ Gt(ROSA)26Sortm1(rtTA*M2)Jae/Gt(ROSA)26Sor+
(involves: 129S4/SvJae * C57BL/6)
|
increased leukemia incidence
|
J:171191
|
increased lymphoma incidence
|
J:171191
|
increased T cell derived lymphoma incidence
|
J:171191
|
Col1a1tm4(CAG-FGFR2_iIIIb*K660N)Kkw/Col1a1+
(involves: 129S4/SvJae * BALB/c * C57BL/6)
|
increased lung tumor incidence
|
J:214230
|
Col1a1tm4(CAG-FGFR2_iIIIb*K660N)Kkw/Col1a1+ Trp53tm1Brn/Trp53tm1Brn
(involves: 129P2/OlaHsd * 129S4/SvJae * BALB/c * C57BL/6)
|
increased lung adenocarcinoma incidence
|
J:214230
|
increased lung tumor incidence
|
J:214230
|
Col1a1tm4(tetO-GFP/RNAi:Apc)Slowe/Col1a1+ Gt(ROSA)26Sortm1(rtTA*M2)Jae/Gt(ROSA)26Sor+
(involves: 129S4/SvJae * C57BL/6)
|
increased leukemia incidence
|
J:171191
|
increased lymphoma incidence
|
J:171191
|
increased T cell derived lymphoma incidence
|
J:171191
|
Col1a1tm5(CAG-FGFR2_iIIIb*W290C)Kkw/Col1a1+ Trp53tm1Brn/Trp53tm1Brn
(involves: 129P2/OlaHsd * 129S4/SvJae * BALB/c * C57BL/6)
|
increased lung tumor incidence
|
J:214230
|
Col1a1tm5(tetO-GFP/RNAi:Cdkn2a)Slowe/Col1a1+ Gt(ROSA)26Sortm1(Luc)Kael/Gt(ROSA)26Sortm1(rtTA*M2)Jae Krastm4Tyj/Kras+ Tg(Scgb1a1-rtTA)1Jaw/0
(involves: 129S4/SvJae * 129S6/SvEvTac * C57BL/6)
|
increased lung adenoma incidence
|
J:171191
|
Col1a1tm6(tetO-MSI2)Jae/Col1a1+ Gt(ROSA)26Sortm1(rtTA*M2)Jae/Gt(ROSA)26Sor+
(involves: 129S4/SvJae * C57BL/6)
|
increased leukemia incidence
|
J:163322
|
Col1a1tm11(tetO-Nup88)Jvd/Col1a1+
(involves: 129S4/SvJae * C57BL/6)
|
increased lung tumor incidence
|
J:231166
|
Col1a1tm13(tetO-Nup88)Jvd/Col1a1+
(involves: 129S4/SvJae * C57BL/6)
|
increased lung tumor incidence
|
J:231166
|
Col4a2em1(IMPC)Wtsi/Col4a2em1(IMPC)Wtsi
(C57BL/6N-Col4a2em1(IMPC)Wtsi/WtsiOulu)
|
increased trigeminal neuroma incidence
|
J:239583
|
Cop1Gt(XR0653)1.1Wtsi/Cop1Gt(XR0653)1.1Wtsi
(involves: 129P2/OlaHsd * C57BL/6 * CBA)
|
increased B cell derived lymphoma incidence
|
J:178271
|
increased histiocytic sarcoma incidence
|
J:178271
|
increased T cell derived lymphoma incidence
|
J:178271
|
increased testicular teratoma incidence
|
J:178271
|
increased uterus tumor incidence
|
J:178271
|
Cop1tm2.1Vmd/Cop1+ Tg(Pbsn-cre)4Prb/0
(B6N.CgCop1tm2.1Vmd Ptentm1Hwu Tg(Pbsn-cre)4Prb)
|
increased prostate gland adenocarcinoma incidence
|
J:172653
|
increased prostate intraepithelial neoplasia incidence
|
J:172653
|
Cop1tm2.1Vmd/Cop1tm2.1Vmd Tg(Pbsn-cre)4Prb/0
(B6N.Cg-Cop1tm2.1Vmd Tg(Pbsn-cre)4Prb)
|
increased prostate intraepithelial neoplasia incidence
|
J:172653
|
Coro1ctm1c(KOMP)Wtsi/Coro1ctm1c(KOMP)Wtsi Ptentm2Mak/Ptentm2Mak Trp53tm1Brn/Trp53tm1Brn Tg(GFAP-cre/Esr1*,-lacZ)ASbk/0
(involves: 129P2/OlaHsd * C57BL/6N * FVB/NJ)
|
increased glioblastoma incidence
|
J:290447
|
Crebbptm1Dli/Crebbp+
(involves: 129S6/SvEvTac * C57BL/6)
|
increased hemolymphoid system tumor incidence
|
J:60630
|
increased histiocytic sarcoma incidence
|
J:60630
|
increased leukemia incidence
|
J:60630
|
Crebbptm1Jvd/Crebbptm1Jvd Tg(Lck-cre)548Jxm/0
(involves: 129 * C57BL/6 * CBA)
|
increased T cell derived lymphoma incidence
|
J:105505
|
Crebbptm1Jvd/Crebbptm1Jvd Tg(MMTV-cre)4Mam/0
(involves: 129 * C57BL/6 * FVB)
|
increased T cell derived lymphoma incidence
|
J:88323
|
Crkltm1Hkp/Crkltm1Hkp Tg(BCR/ABL)623Hkp/?
(involves: 129S1/Sv * 129X1/SvJ * Black Swiss * C57BL/6 * CBA)
|
increased B cell derived lymphoma incidence
|
J:76680
|
increased leukemia incidence
|
J:76680
|
Csf2tm1Dran/Csf2tm1Dran Ifngtm1Ts/Ifngtm1Ts Il3tm1Glli/Il3tm1Glli
(involves: 129S2/SvPas * 129S7/SvEvBrd * C57BL/6)
|
increased B cell derived lymphoma incidence
|
J:83086
|
increased ovarian carcinoma incidence
|
J:83086
|
Csf2tm1Mlg/Csf2tm1Mlg Ifngtm1Ts/Ifngtm1Ts Il3tm1Glli/Il3tm1Glli
(B6.129S-Csf2tm1Mlg Il3tm1Glli Ifngtm1TsIfngtm1Ts)
|
increased pituitary adenoma incidence
|
J:145518
|
Ctnnb1tm1.2Wvv/Ctnnb1+
(involves: 129P2/OlaHsd * C57BL/6J)
|
increased gastrointestinal tumor incidence
|
J:185942
|
increased intestinal adenocarcinoma incidence
|
J:185942
|
increased intestinal adenoma incidence
|
J:185942
|
Ctnnb1tm1Mmt/Ctnnb1+
(involves: 129S1/Sv * 129S4/SvJaeSor * 129X1/SvJ)
|
increased intestinal adenoma incidence
|
J:169830
|
Ctnnb1tm1Mmt/Ctnnb1+ Fgfr3tm4Cxd/Fgfr3+ Tg(Upk2-cre)6Xrw/0
(involves: 129S6/SvEvTac * 129X1/SvJ * FVB/N)
|
increased lung tumor incidence
|
J:174242
|
Ctnnb1tm1Mmt/Ctnnb1+ Gt(ROSA)26Sortm1(EYFP)Cos/Gt(ROSA)26Sor+ Prom1tm1(cre/ERT2)Gilb/Prom1+
(involves: 129S6/SvEvTac * 129X1/SvJ)
|
increased intestinal adenocarcinoma incidence
|
J:144215
|
Ctnnb1tm1Mmt/Ctnnb1+ Igs2tm1(CAG-Met)Zsu/Igs2+ Tg(Pbsn-cre)4Prb/0
(involves: 129S1/Sv * 129X1/SvJ * C57BL/6 * DBA/2 * FVB/N)
|
increased prostate gland adenocarcinoma incidence
|
J:284956
|
increased prostate intraepithelial neoplasia incidence
|
J:284956
|
Ctnnb1tm1Mmt/Ctnnb1+ Krastm1Bbd/Kras+ Tg(Pbsn-cre)4Prb/0
(involves: 129S1/Sv * 129X1/SvJ * C57BL/6 * DBA/2)
|
increased prostate gland tumor incidence
|
J:143034
|
Ctnnb1tm1Mmt/Ctnnb1+ Krastm4Tyj/Kras+ Amhr2tm3(cre)Bhr/Amhr2+
(involves: 129S4/SvJae * 129S7/SvEvBrd * 129X1/SvJ * C57BL/6)
|
increased granulosa cell tumor incidence
|
J:186144
|
increased testis tumor incidence
|
J:186144
|
Ctnnb1tm1Mmt/Ctnnb1+ Krastm4Tyj/Kras+ Tg(CYP19A1-cre)1Jri/0
(involves: 129S4/SvJae * 129X1/SvJ * C57BL/6)
|
increased granulosa cell tumor incidence
|
J:186144
|
increased ovary tumor incidence
|
J:186144
|
Ctnnb1tm1Mmt/Ctnnb1+ Krastm4Tyj/Kras+ Tg(Upk2-cre)6Xrw/0
(involves: 129S4/SvJae * 129X1/SvJ * FVB/N)
|
increased lung tumor incidence
|
J:174242
|
Ctnnb1tm1Mmt/Ctnnb1+ Krt19tm1(cre)Mmt/Krt19+
(involves: 129X1/SvJ)
|
increased intestinal adenoma incidence
|
J:58367
|
Ctnnb1tm1Mmt/Ctnnb1+ Pik3catm1Gilb/Pik3ca+ Trp53tm1Brn/Trp53+ Tg(Fabp7-cre,-lacZ)3Gtm/0
(involves: 129P2/OlaHsd * 129X1/SvJ * C57BL/6 * CBA)
|
increased medulloblastoma incidence
|
J:186709
|
Ctnnb1tm1Mmt/Ctnnb1+ Ptentm1Hwu/Ptentm1Hwu Tg(CYP19A1-cre)1Jri/0
(involves: 129S4/SvJae * 129X1/SvJ * C57BL/6)
|
increased granulosa cell tumor incidence
|
J:186144
|
increased ovary tumor incidence
|
J:186144
|
Ctnnb1tm1Mmt/Ctnnb1+ Ptentm1Hwu/Ptentm1Hwu Tg(Upk2-cre)6Xrw/0
(involves: 129S4/SvJae * 129X1/SvJ * FVB/N)
|
increased urinary bladder carcinoma incidence
|
J:164579
|
Ctnnb1tm1Mmt/Ctnnb1+ Sox2tm1.1(cre/ERT2)Jpmb/Sox2+
(involves: 129P2/OlaHsd * 129X1/SvJ * C57BL/6)
|
increased pituitary gland tumor incidence
|
J:201265
|
Ctnnb1tm1Mmt/Ctnnb1+ Tg(Col1a1-cre)1Kry/0
(involves: 129X1/SvJ * FVB)
|
increased osteoma incidence
|
J:98430
|
Ctnnb1tm1Mmt/Ctnnb1+ Tg(CYP19A1-cre)1Jri/0
(involves: 129X1/SvJ * C57BL/6)
|
increased granulosa cell tumor incidence
|
J:186144
|
increased ovary tumor incidence
|
J:186144
|
Ctnnb1tm1Mmt/Ctnnb1+ Tg(Fabp1-cre)1Mmt/?
(involves: 129X1/SvJ)
|
increased intestinal adenoma incidence
|
J:58367
|
Ctnnb1tm1Mmt/Ctnnb1+ Tg(Msx2-rtTA)885Lma/0 Tg(tetO-cre)1Jaw/0
(involves: 129 * 129X1/SvJ * C57BL/6)
|
increased urinary bladder carcinoma incidence
|
J:202618
|
Ctnnb1tm1Mmt/Ctnnb1+ Tg(Mx1-cre)1Cgn/0
(involves: 129S1/Sv * C57BL/6 * CBA)
|
increased hepatoblastoma incidence
|
J:112659
|
Ctnnb1tm1Mmt/Ctnnb1+ Tg(Pbsn-cre)4Prb/0
(involves: 129X1/SvJ * C57BL/6 * DBA/2)
|
increased prostate gland adenocarcinoma incidence
|
J:143034,
J:284956
|
increased prostate intraepithelial neoplasia incidence
|
J:143034,
J:284956
|
Ctnnb1tm1Mmt/Ctnnb1+ Tg(Wap-cre)11738Mam/0
(FVB.Cg-Ctnnb1tm1Mmt Tg(Wap-cre)11738Mam)
|
increased mammary gland tumor incidence in breeding females
|
J:206839
|
Ctnnb1tm1Mmt/Ctnnb1+ Tg(Wap-cre)11738Mam/0 Tg(Wap-Hgf)402Mig/0
(FVB.Cg-Ctnnb1tm1Mmt Tg(Wap-cre)11738Mam Tg(Wap-Hgf)402Mig)
|
increased mammary gland tumor incidence in breeding females
|
J:206839
|
increased mammary gland tumor incidence in virgin females
|
J:206839
|
Ctnnb1tm1Mmt/Ctnnb1+ Trp53tm1Brn/Trp53+ Tg(Fabp7-cre,-lacZ)3Gtm/0
(involves: 129P2/OlaHsd * 129X1/SvJ * C57BL/6 * CBA)
|
increased medulloblastoma incidence
|
J:186709
|
Ctnnb1tm1Mmt/Ctnnb1tm1Mmt Krastm4Tyj/Kras+ Tg(Upk2-cre)6Xrw/0
(involves: 129S4/SvJae * 129X1/SvJ * FVB/N)
|
increased urinary bladder carcinoma incidence
|
J:234236
|
Ctnnb1tm1Mmt/Ctnnb1tm1Mmt Ptentm1Hwu/Ptentm1Hwu Tg(Upk2-cre)6Xrw/0
(involves: 129S4/SvJae * 129X1/SvJ * FVB/N)
|
increased urinary bladder carcinoma incidence
|
J:164579
|
Ctnnb1tm1Mmt/Ctnnb1tm1Mmt Tg(Mx1-cre)1Cgn/0
(involves: 129S1/Sv * C57BL/6 * CBA)
|
increased hepatoblastoma incidence
|
J:112659
|
Ctnnb1tm1Mmt/Ctnnb1tm1Mmt Tg(Upk2-cre)6Xrw/0 Tg(Upk2-HRAS*Q61L)5Xrw/0
(involves: 129X1/SvJ * FVB/N)
|
increased urinary bladder carcinoma incidence
|
J:234236
|
Ctnnd1tm1Abre/Ctnnd1tm1Abre Tg(KRT14-cre)1Efu/?
(involves: 129S6/SvEvTac)
|
increased skin tumor incidence
|
J:143096
|
Ctsbtm1Jde/Ctsbtm1Jde Ctsztm1Thre/Ctsztm1Thre Tg(MMTV-PyVT)634Mul/0
(FVB.129P2-Ctsztm1Thre Ctsbtm1Jde Tg(MMTV-PyVT)634Mul)
|
increased mammary gland tumor incidence
|
J:157541
|
Ctsbtm1Jde/Ctsbtm1Jde Tg(MMTV-PyVT)634Mul/0
(FVB.129P2-Ctsbtm1Jde Tg(MMTV-PyVT)634Mul)
|
increased mammary gland tumor incidence
|
J:157541
|
Ctsgtm1Ley/Ctsgtm2.1(PML/RARA)Ley
(involves: 129X1/SvJ * C57BL/6)
|
increased leukemia incidence
|
J:84230
|
Ctsgtm2.1(PML/RARA)Ley/Ctsg+
(involves: 129X1/SvJ * C57BL/6)
|
increased leukemia incidence
|
J:84230,
J:86458
|
Ctsgtm2.1(PML/RARA)Ley/Ctsg+
(involves: 129 * 129X1/SvJ * C57BL/6)
|
increased acute promyelocytic leukemia incidence
|
J:166479
|
Ctsgtm2.1(PML/RARA)Ley/Ctsg+ Elanetm1Sds/Elanetm1Sds
(involves: 129S/SvEv * 129X1/SvJ * C57BL/6)
|
increased leukemia incidence
|
J:86458
|
Ctsgtm2.1(PML/RARA)Ley/Ctsgtm2.1(PML/RARA)Ley
(involves: 129X1/SvJ * C57BL/6)
|
increased leukemia incidence
|
J:84230
|
Ctsgtm3.1(PML/RARA)Ley/Ctsg+
(involves: 129 * C57BL/6)
|
increased acute promyelocytic leukemia incidence
|
J:166479
|
Ctsztm1Thre/Ctsztm1Thre Tg(MMTV-PyVT)634Mul/0
(FVB.129P2-Ctsztm1Thre Tg(MMTV-PyVT)634Mul)
|
increased mammary gland tumor incidence
|
J:157541
|
Cul9tm1.2Yxi/Cul9+
(involves: 129P2/OlaHsd * C57BL/6 * FVB/N)
|
increased insulinoma incidence
|
J:170976
|
increased lung tumor incidence
|
J:170976
|
increased lymphoma incidence
|
J:170976
|
increased pituitary gland tumor incidence
|
J:170976
|
Cul9tm1.2Yxi/Cul9+ Tg(IghMyc)22Bri/0
(involves: 129P2/OlaHsd * C57BL * C57BL/6 * FVB/N * SJL)
|
increased B cell derived lymphoma incidence
|
J:170976
|
increased lymphoma incidence
|
J:170976
|
Cul9tm1.2Yxi/Cul9tm1.2Yxi
(involves: 129P2/OlaHsd * C57BL/6 * FVB/N)
|
increased liver tumor incidence
|
J:170976
|
increased lung tumor incidence
|
J:170976
|
increased lymphoma incidence
|
J:170976
|
increased ovary tumor incidence
|
J:170976
|
increased pituitary gland tumor incidence
|
J:170976
|
Cul9tm1.2Yxi/Cul9tm1.2Yxi Tg(IghMyc)22Bri/0
(involves: 129P2/OlaHsd * C57BL * C57BL/6 * FVB/N * SJL)
|
increased B cell derived lymphoma incidence
|
J:170976
|
increased lymphoma incidence
|
J:170976
|
Cxcr6tm1Lex/Cxcr6+
(involves: 129S/SvEvBrd * C57BL/6J)
|
increased medulloblastoma incidence
|
J:120952
|
Cxcr6tm1Lex/Cxcr6tm1Lex
(involves: 129S/SvEvBrd * C57BL/6J)
|
increased medulloblastoma incidence
|
J:120952
|
Cyldtm1Ref/Cyld+
(B6.129-Cyldtm1Ref)
|
increased skin papilloma incidence
|
J:108769
|
Cyldtm1Ref/Cyldtm1Ref
(B6.129-Cyldtm1Ref)
|
increased skin papilloma incidence
|
J:108769
|
Dcctm1.1Mehl/Dcctm1.1Mehl
(Not Specified)
|
increased intestinal adenocarcinoma incidence
|
J:181517
|
increased intestinal adenoma incidence
|
J:181517
|
Dcctm1Nki/Dcctm1Nki Trp53tm1Brn/Trp53tm1Brn Tg(KRT14-cre)8Brn/?
(involves: 129P2/OlaHsd * FVB/N)
|
increased mammary adenocarcinoma incidence
|
J:181090
|
Dclre1atm1Rleg/Dclre1a+
(involves: 129S7/SvEvBrd)
|
increased histiocytic sarcoma incidence
|
J:102381
|
increased lymphoma incidence
|
J:102381
|
Dclre1atm1Rleg/Dclre1atm1Rleg
(involves: 129S7/SvEvBrd)
|
increased histiocytic sarcoma incidence
|
J:102381
|
increased lung adenoma incidence
|
J:102381
|
increased lymphoma incidence
|
J:102381
|
increased ovarian teratoma incidence
|
J:102381
|
Dclre1atm1Rleg/Dclre1atm1Rleg Trp53tm1Tyj/Trp53tm1Tyj
(involves: 129S2/SvPas * 129S7/SvEvBrd)
|
increased lymphoma incidence
|
J:102381
|
increased T cell derived lymphoma incidence
|
J:102381
|
Dcntm1Ioz/Dcn+ Trp53tm1Brd/Trp53tm1Brd
(involves: 129/Sv * Black Swiss * C57BL/6)
|
increased T cell derived lymphoma incidence
|
J:53511
|
Dcntm1Ioz/Dcntm1Ioz Trp53tm1Brd/Trp53tm1Brd
(involves: 129/Sv * Black Swiss * C57BL/6)
|
increased T cell derived lymphoma incidence
|
J:53511
|
Ddit3tm1.1Irt/Ddit3tm1.1Irt Speer6-ps1Tg(Alb-cre)21Mgn/Speer6-ps1+ Tg(Mup3-Plau)350-2Eps/?
(involves: C57BL/6 * DBA)
|
increased hepatocellular carcinoma incidence
|
J:233146
|
Ddr2tm1a(EUCOMM)Wtsi/Ddr2tm1a(EUCOMM)Wtsi Tg(MMTV-PyVT)634Mul/0
(involves: C57BL/6N * FVB/N)
|
increased mammary gland tumor incidence
|
J:236031
|
Ddr2tm1b(EUCOMM)Wtsi/Ddr2tm1b(EUCOMM)Wtsi Tg(MMTV-PyVT)634Mul/0
(involves: C57BL/6N * FVB/N)
|
increased mammary gland tumor incidence
|
J:236031
|
Ddr2tm1c(EUCOMM)Wtsi/Ddr2tm1c(EUCOMM)Wtsi Tg(KRT14-cre)1Amc/0 Tg(MMTV-PyVT)634Mul/0
(involves: C57BL/6 * C57BL/6N * CBA * FVB/N)
|
increased mammary gland tumor incidence
|
J:236031
|
Ddr2tm1c(EUCOMM)Wtsi/Ddr2tm1c(EUCOMM)Wtsi Tg(MMTV-cre)#Mam/0 Tg(MMTV-PyVT)634Mul/0
(involves: C57BL/6N * FVB * FVB/N)
|
increased mammary gland tumor incidence
|
J:236031
|
Del(4C4-C5)1Lap/Del(4C4-C5)1Lap
(involves: 129S6/SvEvTac)
|
increased osteosarcoma incidence
|
J:158126
|
Del(4Cdkn2a-Cdkn2b)1Brn/+
(involves: 129P2/OlaHsd)
|
increased intestinal adenoma incidence
|
J:125189
|
increased leukemia incidence
|
J:125189
|
increased lymphoma incidence
|
J:125189
|
increased skin tumor incidence
|
J:125189
|
Del(4Cdkn2a-Cdkn2b)2Brn/+
(involves: 129P2/OlaHsd * FVB/N)
|
increased intestinal adenocarcinoma incidence
|
J:125189
|
increased leukemia incidence
|
J:125189
|
increased lymphoma incidence
|
J:125189
|
increased skin tumor incidence
|
J:125189
|
Del(4D4Mit190-D4Mit51)2Aam/+
(involves: 129S7/SvEvBrd)
|
increased lymphoma incidence
|
J:121726
|
Del(14Trim13-Dleu2)4Rdf/+
(involves: 129S1/Sv * 129S4/SvJaeSor * C57BL/6)
|
increased B cell derived lymphoma incidence
|
J:156946
|
Del(14Trim13-Dleu2)4Rdf/Del(14Trim13-Dleu2)4Rdf
(involves: 129S1/Sv * 129S4/SvJaeSor * C57BL/6)
|
increased B cell derived lymphoma incidence
|
J:156946
|
increased leukemia incidence
|
J:156946
|
Del(14Trim13-Rnaseh2b)6Rdf/+ Cd19tm1(cre)Cgn/Cd19+
(involves: 129P2/OlaHsd * 129S1/Sv * 129S4/SvJaeSor * C57BL/6)
|
increased chronic lymphocytic leukemia incidence
|
J:179879
|
increased lymphoma incidence
|
J:179879
|
increased small lymphocytic lymphoma incidence
|
J:179879
|
Del(15Krt7-Krt18)1Tmm/+ Igs11tm1Tmm/Igs11+ Krt1ctm1Tmm/Krt1c+ Tg(ACTB-KRAS*G12V,-luc)#Lche/0
(involves: 129S7/SvEvBrd * C57BL/6 * FVB/N)
|
increased lung adenocarcinoma incidence
|
J:199528
|
increased lung adenoma incidence
|
J:199528
|
increased lung tumor incidence
|
J:199528
|
Del(15Krt7-Krt18)1Tmm/+ Tg(ACTB-KRAS*G12V,-luc)#Lche/0
(involves: 129S7/SvEvBrd * C57BL/6 * FVB/N)
|
increased lung tumor incidence
|
J:199528
|
Del(16Tmprss2-Erg)1Sho/Del(16Tmprss2-Erg)1Sho Ptentm1.1Hwu/Pten+
(involves: 129S4/SvJae * C57BL/6 * DBA/2)
|
increased prostate intraepithelial neoplasia incidence
|
J:212219
|
Deptortm1.2Ysun/Deptortm1.2Ysun Krastm4Tyj/Kras+ Ube2cem1Gpt/Ube2cem1Gpt
(involves: 129S4/SvJae * C57BL/6J)
|
increased lung tumor incidence
|
J:333347
|
Dicer1tm1Mmk/Dicer1tm1Mmk Tg(Sp7-tTA,tetO-EGFP/cre)1Amc/0
(involves: 129 * C57BL/6 * CD-1)
|
increased facial tumor incidence
|
J:158901
|
increased hemolymphoid system tumor incidence
|
J:158901
|
increased leukemia incidence
|
J:158901
|
increased myeloid sarcoma incidence
|
J:158901
|
Dicer1tm1Snj/Dicer1tm1Snj Trp53tm1Brn/Trp53+ Tg(KRT5-cre/PGR)1Der/0
(involves: 129P2/OlaHsd * 129S7/SvEvBrd * C57BL/6N * FVB/N * ICR)
|
increased basal cell carcinoma incidence
|
J:216813
|
increased skin tumor incidence
|
J:216813
|
Dicer1tm1Snj/Dicer1tm1Snj Trp53tm1Brn/Trp53tm1Brn Tg(KRT5-cre/PGR)1Der/0
(involves: 129P2/OlaHsd * 129S7/SvEvBrd * C57BL/6N * FVB/N * ICR)
|
increased skin squamous cell carcinoma incidence
|
J:216813
|
increased skin tumor incidence
|
J:216813
|
Dicer1tm1Tara/Dicer1tm1Tara Ptentm1Hwu/Ptentm1Hwu Amhr2tm3(cre)Bhr/Amhr2+
(involves: 129P2/OlaHsd * 129S4/SvJae * 129S7/SvEvBrd)
|
increased ovarian carcinoma incidence
|
J:182161
|
Dicer1tm1Tara/Dicer1tm1Tara Ptentm1Hwu/Ptentm1Hwu Trp53tm2Tyj/Trp53+ Amhr2tm3(cre)Bhr/Amhr2+
(involves: 129P2/OlaHsd * 129S4/SvJae * 129S7/SvEvBrd)
|
increased ovarian carcinoma incidence
|
J:222579
|
Diras2em1Gpt/Diras2em1Gpt Krastm4Tyj/Kras+ Ptf1atm1(cre)Hnak/Ptf1a+
(involves: 129S4/SvJae * C57BL/6J * C57BL/6JGpt)
|
increased pancreatic ductal adenocarcinoma incidence
|
J:348744
|
Diras2em1Gpt/Diras2em1Gpt Krastm4Tyj/Kras+ Ptf1atm1(cre)Hnak/Ptf1a+ Ube2ftm1c(EUCOMM)Hmgu/Ube2ftm1c(EUCOMM)Hmgu
(involves: 129S4/SvJae * C57BL/6)
|
increased pancreas tumor incidence
|
J:348744
|
Dkc1tm1Ppp/Y
(involves: 129S1/Sv)
|
increased B cell derived lymphoma incidence
|
J:81054
|
increased lung carcinoma incidence
|
J:81054
|
increased mammary adenocarcinoma incidence
|
J:81054
|
increased pheochromocytoma incidence
|
J:81054
|
increased renal carcinoma incidence
|
J:81054
|
Dlg2tm1a(EUCOMM)Wtsi/Dlg2tm1a(EUCOMM)Wtsi Rb1tm2Brn/Rb1tm2Brn Trp53tm1Brn/Trp53tm1Brn Tg(Col1a1-cre)1Kry/0
(involves: 129 * 129P2/OlaHsd * C57BL/6N * FVB/N)
|
increased osteosarcoma incidence
|
J:269943
|
Dmq1FVB/NJ/?
(involves: FVB/NJ * M16i)
|
increased mammary gland tumor incidence
|
J:136011
|
Dmq2FVB/NJ/?
(involves: FVB/NJ * M16i)
|
increased mammary gland tumor incidence
|
J:136011
|
Dmtf1tm1Cjs/Dmtf1+ Krastm2Tyj/Kras+
(involves: 129S2/SvPas * C57BL/6)
|
increased cholangiocarcinoma incidence
|
J:126002
|
increased lung adenocarcinoma incidence
|
J:126002
|
increased lung adenoma incidence
|
J:126002
|
increased lung tumor incidence
|
J:126002
|
increased neurofibroma incidence
|
J:126002
|
increased osteosarcoma incidence
|
J:126002
|
increased skin papilloma incidence
|
J:126002
|
increased T cell derived lymphoma incidence
|
J:126002
|
Dmtf1tm1Cjs/Dmtf1+ Krastm3Tyj/Kras+
(involves: 129S4/SvJae * C57BL/6)
|
increased lung adenocarcinoma incidence
|
J:126002
|
increased lung adenoma incidence
|
J:126002
|
increased lung tumor incidence
|
J:126002
|
increased skin papilloma incidence
|
J:126002
|
increased T cell derived lymphoma incidence
|
J:126002
|
Dmtf1tm1Cjs/Dmtf1tm1Cjs Krastm2Tyj/Kras+
(involves: 129S2/SvPas * C57BL/6)
|
increased lung adenocarcinoma incidence
|
J:126002
|
increased lung adenoma incidence
|
J:126002
|
increased lung tumor incidence
|
J:126002
|
increased ovary tumor incidence
|
J:126002
|
increased skin papilloma incidence
|
J:126002
|
increased T cell derived lymphoma incidence
|
J:126002
|
Dmtf1tm1Cjs/Dmtf1tm1Cjs Krastm3Tyj/Kras+
(involves: 129S4/SvJae * C57BL/6)
|
increased lung adenocarcinoma incidence
|
J:126002
|
increased lung adenoma incidence
|
J:126002
|
increased lung tumor incidence
|
J:126002
|
increased skin papilloma incidence
|
J:126002
|
increased T cell derived lymphoma incidence
|
J:126002
|
Dna2tm1.1Lzhg/Dna2+
(involves: 129S1/Sv)
|
increased hepatoma incidence
|
J:198831
|
increased lung adenocarcinoma incidence
|
J:198831
|
increased lymphoma incidence
|
J:198831
|
Dnai7Gt(VICTR21)709Lex/Dnai7+
(involves: 129S5/SvEvBrd)
|
increased lung adenocarcinoma incidence
|
J:111629
|
Dnai7Gt(VICTR21)709Lex/Dnai7Gt(VICTR21)709Lex
(involves: 129S5/SvEvBrd)
|
increased lung adenocarcinoma incidence
|
J:111629
|
increased lung adenoma incidence
|
J:111629
|
Dnd1Ter/?
(129S1/Sv-KitW Oca2p Tyrc-ch)
|
increased testicular teratoma incidence
|
J:29502
|
Dnd1Ter/Dnd1+
(129S1/Sv-KitW Oca2p Tyrc-ch)
|
increased testicular teratoma incidence
|
J:7954
|
Dnd1Ter/Dnd1+
(involves: 129S1/Sv * C57BL/6)
|
increased testicular teratoma incidence
|
J:7954
|
increased testis tumor incidence
|
J:7954
|
Dnd1Ter/Dnd1+
(involves: 129P3/J)
|
increased testis tumor incidence
|
J:221231
|
Dnd1Ter/Dnd1Ter
(129S1/Sv-KitW Oca2p Tyrc-ch)
|
increased testicular teratoma incidence
|
J:7954
|
Dnd1Ter/Dnd1Ter
(involves: 129S1/Sv * C57BL/6)
|
increased testicular teratoma incidence
|
J:7954
|
Dnd1Ter/Dnd1Ter Sf1Gt(XD130)Byg/Sf1+
(involves: 129P2/OlaHsd * 129S1/SvImJ * 129T1/Sv)
|
increased testis tumor incidence
|
J:164224
|
Dnmt1tm1(tetO-BCL2)Sjk/Dnmt1+ Tg(IghMyc)22Bri/0 Tg(MMTVtTA)1Mam/0
(involves: 129S4/SvJae * C57BL/6)
|
increased B cell derived lymphoma incidence
|
J:93549
|
increased leukemia incidence
|
J:93549
|
Dnmt1tm1Jae/Dnmt1+ Mlh1tm1Lisk/Mlh1tm1Lisk
(involves: 129S4/SvJae * 129S7/SvEvBrd * C57BL/6)
|
increased intestinal adenocarcinoma incidence
|
J:75745
|
increased intestinal adenoma incidence
|
J:75745
|
increased lymphoma incidence
|
J:75745
|
Dnmt1tm1Jae/Dnmt1tm1Pwl Mlh1tm1Lisk/Mlh1tm1Lisk
(involves: 129S4/SvJae * 129S7/SvEvBrd * C57BL/6)
|
increased lymphoma incidence
|
J:75745
|
Dnmt1tm1Pwl/Dnmt1+ Mlh1tm1Lisk/Mlh1tm1Lisk
(involves: 129S4/SvJae * 129S7/SvEvBrd * C57BL/6)
|
increased intestinal adenocarcinoma incidence
|
J:75745
|
increased intestinal adenoma incidence
|
J:75745
|
increased lymphoma incidence
|
J:75745
|
Dock1tm2.1Jfco/Dock1+ Tg(MMTV-Erbb2*,-cre)1Mul/0
(involves: C57BL/6 * FVB/NJ)
|
increased mammary adenocarcinoma incidence
|
J:196659
|
increased mammary gland tumor incidence
|
J:196659
|
Dock1tm2.1Jfco/Dock1tm2.1Jfco Tg(MMTV-Erbb2*,-cre)1Mul/0
(involves: C57BL/6 * FVB/NJ)
|
increased mammary adenocarcinoma incidence
|
J:196659
|
increased mammary gland tumor incidence
|
J:196659
|
Dok1tm1Ppp/Dok1+ Tg(Tec-BCR/ABL1)5Hhi/0
(involves: 129S1/Sv)
|
increased leukemia incidence
|
J:95334
|
Dok1tm1Ppp/Dok1tm1Ppp
(129S1/Sv-Dok1tm1Ppp)
|
increased lung adenocarcinoma incidence
|
J:158011
|
Dok1tm1Ppp/Dok1tm1Ppp Dok2tm1Ppp/Dok2tm1Ppp
(129S1/Sv-Dok1tm1Ppp Dok2tm1Ppp)
|
increased leukemia incidence
|
J:95334
|
increased lung adenocarcinoma incidence
|
J:158011
|
Dok1tm1Ppp/Dok1tm1Ppp Dok2tm1Ppp/Dok2tm1Ppp Dok3tm1Ppp/Dok3tm1Ppp
(129S1/Sv-Dok1tm1Ppp Dok2tm1Ppp Dok3tm1Ppp)
|
increased chronic myelocytic leukemia incidence
|
J:158011
|
increased lung adenocarcinoma incidence
|
J:158011
|
increased lung tumor incidence
|
J:158011
|
Dok1tm1Ppp/Dok1tm1Ppp Dok3tm1Ppp/Dok3tm1Ppp
(129S1/Sv-Dok1tm1Ppp Dok3tm1Ppp)
|
increased lung adenocarcinoma incidence
|
J:158011
|
Dok1tm1Ppp/Dok1tm1Ppp Tg(Tec-BCR/ABL1)5Hhi/0
(involves: 129S1/Sv)
|
increased leukemia incidence
|
J:95334
|
Dok1tm1Yyam/Dok1tm1Yyam Dok2tm1Yyam/Dok2tm1Yyam
(B6.129-Dok1tm1Yyam Dok2tm1Yyam)
|
increased leukemia incidence
|
J:95335
|
Dok1tm1Yyam/Dok1tm1Yyam Dok2tm1Yyam/Dok2tm1Yyam Dok3tm1Brs/Dok3tm1Brs
(involves: 129P2/OlaHsd * 129S4/SvJae * C57BL/6)
|
increased histiocytic sarcoma incidence
|
J:163407
|
Dok1tm1Yyam/Dok1tm1Yyam Dok2tm1Yyam/Dok2tm1Yyam Tg(Tec-BCR/ABL1)5Hhi/0
(involves: C57BL/6)
|
increased leukemia incidence
|
J:95335
|
Dok1tm1Yyam/Dok1tm1Yyam Tg(Tec-BCR/ABL1)5Hhi/0
(involves: C57BL/6)
|
increased leukemia incidence
|
J:95335
|
Dok2tm1Ppp/Dok2+
(129S1/Sv-Dok2tm1Ppp)
|
increased lung tumor incidence
|
J:158011
|
Dok2tm1Ppp/Dok2+ Tg(Tec-BCR/ABL1)5Hhi/0
(involves: 129S1/Sv)
|
increased leukemia incidence
|
J:95334
|
Dok2tm1Ppp/Dok2tm1Ppp
(129S1/Sv-Dok2tm1Ppp)
|
increased lung adenocarcinoma incidence
|
J:158011
|
Dok2tm1Ppp/Dok2tm1Ppp Tg(Tec-BCR/ABL1)5Hhi/0
(involves: 129S1/Sv)
|
increased leukemia incidence
|
J:95334
|
Dok2tm1Yyam/Dok2tm1Yyam Tg(Tec-BCR/ABL1)5Hhi/0
(involves: C57BL/6)
|
increased leukemia incidence
|
J:95335
|
Dok3tm1Ppp/Dok3tm1Ppp
(129S1/Sv-Dok3tm1Ppp)
|
increased lung adenocarcinoma incidence
|
J:158011
|
Drd2tm1Ebo/Drd2tm1Ebo
(involves: 129S2/SvPas * C57BL/6)
|
increased pituitary adenoma incidence
|
J:41857
|
Ds/Ds+
(involves: 129T1/Sv * DA/Hu * DBA/1J)
|
increased skin hamartoma incidence
|
J:13012
|
E2f1tm1Meg/E2f1tm1Meg
(either: (involves: 129/Sv * 129S4/SvJae) or (involves: 129/Sv * 129S4/SvJae * C57BL/6))
|
increased T cell derived lymphoma incidence
|
J:33100
|
E2f1tm1Njd/E2f1+ Rb1tm1Tyj/Rb1+
(either: 129S2/SvPas or (involves: 129S2/SvPas * C57BL/6))
|
increased thyroid adenoma incidence
|
J:47108
|
E2f1tm1Njd/E2f1tm1Njd
(involves: 129S2/SvPas * C57BL/6)
|
increased histiocytic sarcoma incidence
|
J:33099
|
increased lung adenocarcinoma incidence
|
J:33099
|
increased lung non-small cell carcinoma incidence
|
J:33099
|
increased lymphoma incidence
|
J:33099
|
increased reproductive system tumor incidence
|
J:33099
|
E2f1tm1Njd/E2f1tm1Njd Rb1tm1Tyj/Rb1+
(either: 129S2/SvPas or (involves: 129S2/SvPas * C57BL/6))
|
increased pituitary gland tumor incidence
|
J:47108
|
increased thyroid adenoma incidence
|
J:47108
|
E2f4tm1Lees/E2f4+ Rb1tm1Tyj/Rb1+
(involves: 129S2/SvPas * C57BL/6)
|
increased pituitary gland tumor incidence
|
J:81082
|
increased thyroid tumor incidence
|
J:81082
|
Eaf1tm1.1Zhow/Eaf1tm1.1Zhow Eaf2tm1Zhow/Eaf2tm1Zhow Tg(Pbsn-cre)4Prb/0
(involves: 129P2/OlaHsd * 129S6/SvEvTac * C57BL/6J * DBA/2)
|
increased prostate intraepithelial neoplasia incidence
|
J:288972
|
Eaf1tm1.1Zhow/Eaf1tm1.1Zhow Tg(Pbsn-cre)4Prb/0
(B6(Cg)-Eaf1tm1.1Zhow Tg(Pbsn-cre)4Prb)
|
increased prostate intraepithelial neoplasia incidence
|
J:288972
|
Eaf2tm1Zhow/Eaf2+
(involves: 129P2/OlaHsd * C57BL/6J)
|
increased lung adenocarcinoma incidence
|
J:145228
|
increased lymphoma incidence
|
J:145228
|
Eaf2tm1Zhow/Eaf2tm1Zhow
(involves: 129P2/OlaHsd * C57BL/6J)
|
increased B cell derived lymphoma incidence
|
J:145228
|
increased hepatocellular carcinoma incidence
|
J:145228
|
increased lung adenocarcinoma incidence
|
J:145228
|
increased prostate intraepithelial neoplasia incidence
|
J:145228
|
increased skin tumor incidence
|
J:145228
|
Eaf2tm1Zhow/Eaf2tm1Zhow
(involves: 129P2/OlaHsd)
|
increased prostate intraepithelial neoplasia incidence
|
J:288972
|
Eef1a1tm1(Kras*)Arge/Eef1a1+ Igf1rtm2Arge/Igf1r+ Waptm1(cre)Arge/Wap+
(involves: 129S1/Sv)
|
increased mammary gland tumor incidence
|
J:146290
|
Eef1a1tm1(Kras*)Arge/Eef1a1+ Igf1rtm2Arge/Igf1rtm2Arge Waptm1(cre)Arge/Wap+
(involves: 129S1/Sv)
|
increased mammary gland tumor incidence
|
J:146290
|
Eef1a1tm1(Kras*)Arge/Eef1a1+ Waptm1(cre)Arge/Wap+
(involves: 129S1/Sv)
|
increased mammary adenocarcinoma incidence
|
J:146290
|
increased mammary gland tumor incidence
|
J:146290
|
Eef1a1tm2Arge/Eef1a1+ Tg(Mx1-cre)1Cgn/0
(involves: C57BL/6 * CBA)
|
increased acute lymphoblastic leukemia incidence
|
J:197167
|
Egfrwa2/Egfr+ Fostm2(Fosl1)Wag/Fostm2(Fosl1)Wag Tg(KRT5-SOS1)892A6Wag/0
(involves: 129P2/OlaHsd * C57BL/6 * CBA)
|
increased skin papilloma incidence
|
J:175064
|
Egfrwa2/Egfr+ Fostm3.1Wag/Fostm3.1Wag Tg(KRT5-SOS1)892A6Wag/0
(involves: 129P2/OlaHsd * C57BL/6 * CBA * SJL)
|
increased skin papilloma incidence
|
J:175064
|
Egfrwa2/Egfr+ Fostm4.1Wag/Fostm4.1Wag Tg(KRT5-SOS1)892A6Wag/0
(involves: 129P2/OlaHsd * C57BL/6 * CBA)
|
increased skin papilloma incidence
|
J:175064
|
Egfrwa2/Egfr+ Fostm5.1Wag/Fostm5.1Wag Tg(KRT5-SOS1)892A6Wag/0
(involves: 129P2/OlaHsd * C57BL/6 * CBA * SJL)
|
increased skin papilloma incidence
|
J:175064
|
increased skin tumor incidence
|
J:175064
|
Egfrwa2/Egfr+ Fostm6.1Wag/Fostm6.1Wag Tg(KRT5-SOS1)892A6Wag/0
(involves: 129P2/OlaHsd * C57BL/6 * CBA * SJL)
|
increased skin papilloma incidence
|
J:175064
|
Egfrwa2/Egfr+ Rps6ka3tm1.1Kry/Y Tg(KRT5-SOS1)892A6Wag/0
(involves: 129X1/SvJ * C57BL/6 * CBA)
|
increased skin papilloma incidence
|
J:175064
|
Egfrwa2/Egfr+ Tg(KRT5-SOS1)892A6Wag/0
(involves: C57BL/6 * CBA)
|
increased skin papilloma incidence
|
J:175064
|
increased skin tumor incidence
|
J:175064
|
Egr1tm1Jmi/Egr1tm1Jmi
(involves: 129 * C57BL/6)
|
increased skin papilloma incidence
|
J:99386
|
increased T cell derived lymphoma incidence
|
J:123870
|
Ehbp1l1tm1a(EUCOMM)Wtsi/Ehbp1l1tm1a(EUCOMM)Wtsi
(C57BL/6N-Ehbp1l1tm1a(EUCOMM)Wtsi/Wtsi)
|
increased trigeminal neuroma incidence
|
J:239583
|
Elac2em1Afi/Elac2em1Afi Tg(TRAMP)8247Ng/0
(involves: C57BL/6 * C57BL/6N)
|
increased prostate intraepithelial neoplasia incidence
|
J:336403
|
Elavl1tm1.1Dkon/Elavl1tm1.1Dkon Lyz2tm1(cre)Ifo/Lyz2+
(B6.129P2-Elavl1tm1.1Dkon Lyz2tm1(cre)Ifo)
|
increased colon adenocarcinoma incidence
|
J:184388
|
increased colon adenoma incidence
|
J:184388
|
Emv30b/Emv30b Prkdcscid/Prkdcscid
(NOD.Cg-Emv30b Prkdcscid/Dvs)
|
increased T cell derived lymphoma incidence
|
J:29951
|
Entpd5tm1Rre/Entpd5tm1Rre
(involves: 129S5/SvEvBrd * C57BL/6J)
|
increased hepatocellular carcinoma incidence
|
J:163795
|
increased liver adenoma incidence
|
J:163795
|
Epm2aTg(TcraK,TcrbK)TG-BFlv/Epm2a+
(involves: C57BL/6 * C57BL/10 * C57BR/cd * CBA/J)
|
increased T cell derived lymphoma incidence
|
J:112696
|
Erbb2tm8(Erbb2)Mul/Erbb2+ Ptentm1Hwu/Pten+ Tg(MMTV-cre)7Mul/0
(involves: 129S1/Sv * 129S4/SvJae * 129X1/SvJ * FVB/N)
|
increased mammary gland tumor incidence
|
J:133305
|
Erbb2tm8(Erbb2)Mul/Erbb2+ Ptentm1Hwu/Ptentm1Hwu Tg(MMTV-cre)7Mul/0
(involves: 129S1/Sv * 129S4/SvJae * 129X1/SvJ * FVB/N)
|
increased mammary gland tumor incidence
|
J:133305
|
Erbb2tm8(Erbb2)Mul/Erbb2+ Tg(MMTV-cre)7Mul/?
(involves: 129S1/Sv * 129X1/SvJ * FVB/N)
|
increased mammary gland tumor incidence
|
J:89255
|
Erbb3tm1.1(ERBB3)Mul/Erbb3+ Tg(MMTV-Erbb2*)NDL2-5Mul/0
(involves: 129P2/OlaHsd * C57BL/6 * FVB/N)
|
increased mammary gland tumor incidence
|
J:189292
|
Erbb3tm1.1(ERBB3)Mul/Erbb3tm1.1(ERBB3)Mul Tg(MMTV-Erbb2*)NDL2-5Mul/0
(involves: 129P2/OlaHsd * C57BL/6 * FVB/N)
|
increased mammary gland tumor incidence
|
J:189292
|
Ercc2tm1Jhjh/Ercc2tm2(ERCC2)Jhjh
(involves: 129P2/OlaHsd * C57BL/6)
|
increased skin tumor incidence
|
J:48256
|
Ergtm1.1Sho/Ergtm1.1Sho Ptentm1Hwu/Ptentm1Hwu Tmprss2tm3Sho/Tmprss2tm3Sho Tg(Pbsn-cre)4Prb/0
(involves: 129S4/SvJae * C57BL/6 * DBA/2)
|
increased prostate gland adenocarcinoma incidence
|
J:212219
|
Errfi1tm1.1Jwj/Errfi1tm1.1Jwj
(involves: 129 * C57BL/6 * FVB/N * SJL)
|
increased skin papilloma incidence
|
J:129106
|
Errfi1tm1Jwj/Errfi1tm1Jwj Gt(ROSA)26Sortm1(cre/ERT2)Thl/Gt(ROSA)26Sor+
(involves: 129/Sv * 129S1/Sv * 129X1/SvJ * C57BL/6 * SJL)
|
increased skin papilloma incidence
|
J:153715
|
Errfi1tm1Jwj/Errfi1tm1Jwj Pgrtm2(cre)Lyd/Pgr+
(involves: 129S1/Sv * 129X1/SvJ)
|
increased endometrial carcinoma incidence
|
J:150007
|
Errfi1tm1Jwj/Errfi1tm1Jwj Pgrtm2(cre)Lyd/Pgr+ Ptentm1Hwu/Ptentm1Hwu
(involves: 129S1/Sv * 129S4/SvJae * 129X1/SvJ)
|
increased endometrial carcinoma incidence
|
J:162027
|
Errfi1tm1Kln/Errfi1tm1Kln
(involves: 129P2/OlaHsd * C57BL/6N)
|
increased skin papilloma incidence
|
J:109556
|
Esl1NFS/N/Esl1SL/Kh
(involves: SL/Kh * NFS/N)
|
increased B cell derived lymphoma incidence
|
J:16441
|
Esl1SL/Kh/Esl1SL/Kh
(involves: SL/Kh * NFS/N)
|
increased B cell derived lymphoma incidence
|
J:16441
|
Espl1Gt(XL058)Byg/Espl1+ Trp53tm1Tyj/Trp53tm1Tyj
(B6.129-Trp53tm1Tyj Espl1Gt(XL058)Byg)
|
increased lymphoma incidence
|
J:174926
|
Esr1tm1Ksk/Esr1tm1Ksk Esr2tm1Unc/Esr2tm1Unc Inhatm1Bay/Inha+
(involves: 129P2/OlaHsd * 129S6/SvEvTac * 129S7/SvEvBrd)
|
increased ovary tumor incidence
|
J:84989
|
Esr1tm1Ksk/Esr1tm1Ksk Esr2tm1Unc/Esr2tm1Unc Inhatm1Bay/Inhatm1Bay
(involves: 129P2/OlaHsd * 129S6/SvEvTac * 129S7/SvEvBrd)
|
increased ovary tumor incidence
|
J:84989
|
increased testis tumor incidence
|
J:84989
|
Esr1tm1Ksk/Esr1tm1Ksk Inhatm1Bay/Inhatm1Bay
(involves: 129P2/OlaHsd * 129S6/SvEvTac * 129S7/SvEvBrd)
|
increased ovary tumor incidence
|
J:84989
|
increased testis tumor incidence
|
J:84989
|
Esr1tm1Ksk/Esr1tm1Ksk Tg(MMTV-Erbb2)NK1Mul/0
(involves: 129P2/OlaHsd * C57BL/6J * FVB/N)
|
increased mammary gland tumor incidence
|
J:76653
|
Esr1tm1Ksk/Esr1tm1Ksk Tg(Wnt1)1Hev/0
(involves: 129P2/OlaHsd * C57BL/6 * SJL)
|
increased mammary adenocarcinoma incidence
|
J:54215
|
Esr2tm1Unc/Esr2tm1Unc
(involves: 129P2/OlaHsd * C57BL/6J)
|
increased chronic myelocytic leukemia incidence
|
J:83617
|
Esr2tm1Unc/Esr2tm1Unc Inhatm1Bay/Inhatm1Bay
(involves: 129P2/OlaHsd * 129S6/SvEvTac * 129S7/SvEvBrd)
|
increased ovary tumor incidence
|
J:84989
|
increased testis tumor incidence
|
J:84989
|
Etn3Ppd/Y
(either: (involves: CD-1) or (involves: C3H/HeJ * CD-1))
|
increased skin papilloma incidence
|
J:112867
|
Etn3Ppd/?
(either: (involves: CD-1) or (involves: C3H/HeJ * CD-1))
|
increased skin papilloma incidence
|
J:112867
|
Ets2tm1Rgo/Ets2tm5.1Rgo Ptentm1.1Mwst/Ptentm1.1Mwst Tg(S100a4-cre)1Gle/0
(involves: 129S2/SvPas * FVB/N)
|
increased mammary gland tumor incidence
|
J:153747
|
Ets2tm3Rgo/Ets2+ Meox2tm1(cre)Sor/? Tg(MMTV-cre)7Mul/?
(involves: 129S4/SvJaeSor * FVB/N)
|
increased mammary gland tumor incidence
|
J:102368
|
Ets2tm3Rgo/Ets2+ Meox2tm1(cre)Sor/? Tg(MMTV-PyVT*Y315F*Y322F)Db-1Mul/?
(involves: 129S4/SvJae * C57BL/6 * FVB/N)
|
increased mammary gland tumor incidence
|
J:102368
|
Ets2tm3Rgo/Ets2tm3.1Rgo Meox2tm1(cre)Sor/? Tg(MMTV-PyVT*Y315F*Y322F)Db-1Mul/?
(involves: 129S4/SvJae * C57BL/6 * FVB/N)
|
increased mammary gland tumor incidence
|
J:102368
|
Ets2tm3Rgo/Ets2tm3Rgo Meox2tm1(cre)Sor/? Tg(MMTV-cre)7Mul/?
(involves: 129S4/SvJaeSor * FVB/N)
|
increased mammary gland tumor incidence
|
J:102368
|
Etv4tm1Hass/Etv4tm1Hass Tg(MMTVneu)202Mul/Tg(MMTVneu)202Mul
(involves: FVB/N)
|
increased mammary gland tumor incidence
|
J:87017
|
Etv6tm1(RUNX1)Haho/Etv6+ Tg(Mx1-cre)1Cgn/0
(involves: 129S1/Sv * C57BL/6 * CBA)
|
increased leukemia incidence
|
J:151639
|
Etv6tm1.1(RUNX1,hsb5)Lvdw/Etv6+
(involves: 129P2/OlaHsd * 129S4/SvJaeSor * C57BL/6J)
|
increased leukemia incidence
|
J:174866
|
Etv6tm1.1(RUNX1,hsb5)Lvdw/Etv6+ TgTn(sb-T2/Onc)76Dla/0
(involves: 129P2/OlaHsd * 129S4/SvJaeSor * C57BL/6J * FVB/N)
|
increased leukemia incidence
|
J:174866
|
Etv6tm3(NTRK3)Sho/Etv6+
(involves: 129S1/Sv)
|
increased mammary gland tumor incidence
|
J:130323
|
Etv6tm3(NTRK3)Sho/Etv6+ Tg(MMTV-cre)FMam/0
(involves: 129S1/Sv * FVB/N)
|
increased chronic myelocytic leukemia incidence
|
J:130323
|
Etv6tm3(NTRK3)Sho/Etv6+ Tg(Wap-cre)11738Mam/0
(involves: 129S1/Sv * C57BL/6 * SJL)
|
increased mammary gland tumor incidence
|
J:130323
|
Ewsr1tm1(ERG)Thr/Ewsr1+ Rag1tm1(cre)Thr/Rag1+
(involves: 129S/SvEv)
|
increased leukemia incidence
|
J:98679
|
increased T cell derived lymphoma incidence
|
J:98679
|
Exo1tm1Wed/Exo1tm1Wed
(involves: 129/Sv * C57BL/6J * SJL)
|
increased lymphoma incidence
|
J:82426
|
Exo1tm2Wed/Exo1tm2Wed
(involves: 129 * C57BL/6)
|
increased lymphoma incidence
|
J:198719
|
Exo1tm3.1Wed/Exo1tm3.1Wed
(involves: 129 * C57BL/6)
|
increased lymphoma incidence
|
J:198719
|
Exo1tm3.1Wed/Exo1tm3.1Wed Trp53tm1Tyj/Trp53tm1Tyj
(involves: 129S2/SvPas * C57BL/6)
|
increased lymphoma incidence
|
J:198719
|
Ext1tm1.1Vcs/Ext1tm1.1Vcs Tg(Col2a1-cre/ERT)KA3Smac/0
(involves: 129S1/Sv * 129X1/SvJ * FVB/N)
|
increased osteochondroma incidence
|
J:242977
|
Ext1tm1.1Vcs/Ext1tm1.1Vcs Tg(Col2a1-rtTA,tetO-cre)22Pjro/0
(involves: 129S1/Sv * 129X1/SvJ * C57BL/6 * SJL)
|
increased osteochondroma incidence
|
J:157599
|
Ext1tm1.1Yama/Ext1+
(involves: 129S4/SvJaeSor * 129S5/SvEvBrd)
|
increased osteochondroma incidence
|
J:161395
|
Ext1tm1Vcs/Ext1tm1Vcs Tg(Col2a1-rtTA,tetO-cre)22Pjro/0
(involves: 129S1/Sv * 129X1/SvJ * C57BL/6)
|
increased osteochondroma incidence
|
J:157599
|
Ext1tm1Yama/Ext1tm1Yama Acantm1(cre/ERT2)Crm/Acan+
(involves: 129S5/SvEvBrd * 129S6/SvEvTac * C57BL/6NCrl)
|
increased osteochondroma incidence
|
J:242977
|
Ext1tm1Yama/Ext1tm1Yama Tg(Col2a1-cre/ERT)KA3Smac/0
(involves: 129S5/SvEvBrd * FVB/N)
|
increased osteochondroma incidence
|
J:161395
|
Ezh2tm1.1Nesh/Ezh2+ Cd19tm1(cre)Cgn/Cd19+
(involves: 129 * 129P2/OlaHsd * C57BL/6)
|
increased B cell derived lymphoma incidence
|
J:239472
|
increased leukemia incidence
|
J:239472
|
Ezh2tm1.1Nesh/Ezh2tm1.1Nesh Cd19tm1(cre)Cgn/Cd19+
(involves: 129 * 129P2/OlaHsd * C57BL/6)
|
increased B cell derived lymphoma incidence
|
J:239472
|
Ezh2tm2Sho/Ezh2tm2.1Sho Tg(Mx1-cre)1Cgn/0
(involves: 129S1/Sv * C57BL/6 * CBA)
|
increased leukemia incidence
|
J:182211
|
Ezh2tm2Sho/Ezh2tm2Sho Tg(Mx1-cre)1Cgn/0
(involves: 129S1/Sv * C57BL/6 * CBA)
|
increased leukemia incidence
|
J:182211
|
F2rtm1Pago/F2rtm1Pago Tg(MMTV-PyVT)634Mul/0
(B6.Cg-F2rtm1Pago Tg(MMTV-PyVT)634Mul)
|
increased mammary adenocarcinoma incidence
|
J:138924
|
F2rl1tm1Bpd/F2rl1tm1Bpd Tg(MMTV-PyVT)634Mul/0
(B6.Cg-F2rl1tm1Bpd Tg(MMTV-PyVT)634Mul)
|
increased mammary adenocarcinoma incidence
|
J:138924
|
F3tm1(F3)Lasn/F3tm1(F3)Lasn
(involves: 129S/SvEvBrd * C57BL/6)
|
increased lung adenoma incidence
|
J:133293
|
increased lung carcinoma incidence
|
J:133293
|
Fahtm1Mgo/Fahtm1Mgo
(involves: 129S7/SvEvBrd * C57BL/6)
|
increased hepatocellular carcinoma incidence
|
J:138701
|
Fahtm1Mgo/Fahtm1Mgo
(involves: 129S7/SvEvBrd * C57BL)
|
increased hepatocellular carcinoma incidence
|
J:27735
|
increased hepatoma incidence
|
J:27735
|
increased liver adenoma incidence
|
J:27735
|
increased liver tumor incidence
|
J:27735
|
Fancftm1Nki/Fancftm1Nki
(involves: 129P2/OlaHsd * FVB)
|
increased granulosa cell tumor incidence
|
J:180025
|
increased ovary tumor incidence
|
J:180025
|
Fancmtm1.1Htr/Fancmtm1.1Htr
(involves: C57BL/6 * FVB)
|
increased hepatoma incidence
|
J:151714
|
Fasldel1Hong/Fasldel1Hong
(either: (involves: 129 * BALB/c * C57BL/6) or (involves: 129X1/SvJ * C3H/HeJ * C57BL/6))
|
increased lymphoma incidence
|
J:112563
|
Faslgld/Faslgld
(involves: C3H/HeJ * C57BL/6)
|
increased histiocytic sarcoma incidence
|
J:153501
|
Fasltm1.1Ast/Fasltm1.1Ast
(involves: BALB/cJ * C57BL/6)
|
increased histiocytic sarcoma incidence
|
J:153501
|
increased liver tumor incidence
|
J:153501
|
Fbxo4tm1.1Jadi/Fbxo4+
(Not Specified)
|
increased hepatic hemangioma incidence
|
J:178645
|
increased hepatocellular carcinoma incidence
|
J:178645
|
increased histiocytic sarcoma incidence
|
J:178645
|
increased lymphoma incidence
|
J:178645
|
increased mammary gland tumor incidence
|
J:178645
|
increased myeloid sarcoma incidence
|
J:178645
|
increased uterus tumor incidence
|
J:178645
|
Fbxo4tm1.1Jadi/Fbxo4tm1.1Jadi
(Not Specified)
|
increased hepatic hemangioma incidence
|
J:178645
|
increased hepatocellular carcinoma incidence
|
J:178645
|
increased histiocytic sarcoma incidence
|
J:178645
|
increased lymphoma incidence
|
J:178645
|
increased mammary gland tumor incidence
|
J:178645
|
increased myeloid sarcoma incidence
|
J:178645
|
increased uterus tumor incidence
|
J:178645
|
Fbxw7tm1Iaai/Fbxw7tm1Iaai Tg(Lck-cre)1Cwi/0
(involves: 129/Sv * C57BL/6)
|
increased T cell derived lymphoma incidence
|
J:137138
|
Fbxw7tm1Iken/Fbxw7tm1Iken Krastm4Tyj/Kras+ Speer6-ps1Tg(Alb-cre)21Mgn/Speer6-ps1+
(involves: 129S4/SvJae * C57BL/6 * C57BL/6N * DBA)
|
increased cholangiocarcinoma incidence
|
J:258194
|
Fbxw7tm1Kei/Fbxw7tm1Kei Tg(Lck-cre)1Cwi/?
(involves: 129P2/OlaHsd * C57BL/6)
|
increased lymphoma incidence
|
J:128523
|
Fbxw7tm1Kei/Fbxw7tm1Kei Trp53tm1Tyj/Trp53tm1Tyj Tg(Lck-cre)1Cwi/?
(involves: 129P2/OlaHsd * 129S2/SvPas * C57BL/6)
|
increased lymphoma incidence
|
J:128523
|
increased T cell derived lymphoma incidence
|
J:128523
|
Fdxrtm1Xch/Fdxr+
(B6.Cg-Fdxrtm1Xch)
|
increased B cell derived lymphoma incidence
|
J:244082
|
increased hepatocellular carcinoma incidence
|
J:244082
|
increased liver tumor incidence
|
J:244082
|
increased lung carcinoma incidence
|
J:244082
|
increased lymphoma incidence
|
J:244082
|
increased myeloid sarcoma incidence
|
J:244082
|
increased T cell derived lymphoma incidence
|
J:244082
|
Fem1atm1Seno/Fem1atm1Seno
(C57BL/6-Fem1atm1Seno)
|
increased colon tumor incidence
|
J:228893
|
Fen1tm1Rak/Fen1+
(involves: 129/Sv * C57BL/6 * SJL/J)
|
increased B cell derived lymphoma incidence
|
J:77962
|
Fen1tm1Rak/Fen1+ Apctm1Rak/Apc+
(involves: 129/Sv * 129P2/OlaHsd * C57BL/6 * SJL/J)
|
increased gastrointestinal tumor incidence
|
J:77962
|
Fen1tm2.1Bhsh/Fen1tm2.1Bhsh
(involves: 129S1/Sv)
|
increased liver tumor incidence
|
J:218627
|
increased lung tumor incidence
|
J:218627
|
increased thymus tumor incidence
|
J:218627
|
Fen1tm2Klng/Fen1tm2Klng
(involves: 129X1/SvJ * C57BL/6)
|
increased B cell derived lymphoma incidence
|
J:138901
|
increased lung adenoma incidence
|
J:138901
|
Fen1tm3.1Bhsh/Fen1+
(Not Specified)
|
increased lung adenoma incidence
|
J:231218
|
Fen1tm3.1Bhsh/Fen1tm3.1Bhsh
(Not Specified)
|
increased gonad tumor incidence
|
J:231218
|
increased liver tumor incidence
|
J:231218
|
increased lung adenocarcinoma incidence
|
J:231218
|
increased lung adenoma incidence
|
J:231218
|
Fgf2tm1Bee/Fgf2tm1Bee Tg(Tyrp1-TAg)3434Bee/?
(involves: 129P2/OlaHsd * BALB/c * C57BL/6)
|
increased eye tumor incidence
|
J:75629
|
Fgfr2tm1Dsn/Fgfr2tm1Dsn Tg(KRT5-cre)5132Jlj/0
(involves: 129P2/OlaHsd * C57BL/6J * DBA/2J)
|
increased skin papilloma incidence
|
J:119723
|
Fgfr3tm4Cxd/Fgfr3+ Krastm4Tyj/Kras+ Tg(Upk2-cre)6Xrw/0
(involves: 129S4/SvJae * 129S6/SvEvTac * FVB/N)
|
increased skin papilloma incidence
|
J:174242
|
Fgfr4tm1Axul/Fgfr4+ Tg(WapTgfa)215Bri/0
(B6.Cg-Fgfr4tm1Axul Tg(WapTgfa)215Bri)
|
increased mammary adenocarcinoma incidence
|
J:156750
|
Fgfr4tm1Axul/Fgfr4tm1Axul Tg(WapTgfa)215Bri/0
(B6.Cg-Fgfr4tm1Axul Tg(WapTgfa)215Bri)
|
increased mammary adenocarcinoma incidence
|
J:156750
|
Fgfr4tm1Axul/Fgfr4tm1Axul Tg(WapTgfa)215Bri/0
(FVB.Cg-Fgfr4tm1Axul Tg(WapTgfa)215Bri)
|
increased mammary adenocarcinoma incidence
|
J:156750
|
Fhittm1Tko/Fhit+
(involves: 129X1/SvJ)
|
increased B cell derived lymphoma incidence
|
J:93269
|
increased lymphoma incidence
|
J:93269
|
Fhittm1Tko/Fhittm1Tko
(involves: 129X1/SvJ)
|
increased B cell derived lymphoma incidence
|
J:93269
|
increased hepatocellular carcinoma incidence
|
J:93269
|
increased lymphoma incidence
|
J:93269
|
FlcnGt(RRX115)Byg/Flcn+
(involves: 129P2/OlaHsd * C57BL/6)
|
increased kidney tumor incidence
|
J:147582
|
increased lymphoma incidence
|
J:147582
|
Flcntm1Btt/Flcntm1Btt Tg(Cdh16-cre)91Igr/0
(involves: 129S4/SvJaeSor * C57BL/6 * ICR)
|
increased renal carcinoma incidence
|
J:143922
|
Fli1tm1Ber/Fli1+
(involves: 129S1/Sv * 129X1/SvJ * C57BL/6 * CD-1)
|
increased leukemia incidence
|
J:33052
|
Fli1tm1Ber/Fli1tm1Ber
(involves: 129S1/Sv * 129X1/SvJ * C57BL/6 * CD-1)
|
increased leukemia incidence
|
J:33052
|
Flot2tm1Mak/Flot2tm1Mak Tg(MMTV-PyVT)634Mul/0
(involves: 129P2/OlaHsd * C57BL/6 * FVB/N)
|
increased mammary gland tumor incidence
|
J:203238
|
Flt3tm1Dgg/Flt3+ Kmt2atm1Clgr/Kmt2a+
(involves: 129S1/Sv * 129X1/SvJ * BALB/c * C57BL/6J)
|
increased leukemia incidence
|
J:189096
|
Flt3tm1Dgg/Flt3tm1Dgg Kmt2atm1Clgr/Kmt2a+
(involves: 129S1/Sv * 129X1/SvJ * BALB/c * C57BL/6J)
|
increased leukemia incidence
|
J:189096
|
Flt3tm2.1Dosm/Flt3+
(B6.129(C)-Flt3tm2.1Dosm)
|
increased B cell derived lymphoma incidence
|
J:205200
|
increased histiocytic sarcoma incidence
|
J:205200
|
Fnip1tm1.2Baba/Fnip1+ Fnip2tm1.2Lss/Fnip2tm1.2Lss
(involves: C57BL/6)
|
increased kidney tumor incidence
|
J:220672
|
Fntbtm1.1Mbrg/Fntbtm1.2Mbrg Krastm4Tyj/Kras+ Lyz2tm1(cre)Ifo/Lyz2+
(involves: 129P2/OlaHsd * 129S4/SvJae * BALB/cJ * C57BL/6 * FVB/N)
|
increased lung tumor incidence
|
J:158937
|
Fntbtm1.1Mbrg/Fntbtm1.2Mbrg Krastm4Tyj/Kras+ Pggt1btm1Mbrg/Pggt1btm1.1Mbrg
(involves: 129P2/OlaHsd * 129S4/SvJae * BALB/cJ * C57BL/6 * FVB/N)
|
increased lung adenoma incidence
|
J:158937
|
increased lung carcinoma incidence
|
J:158937
|
increased lung tumor incidence
|
J:158937
|
Fntbtm1.1Mbrg/Fntbtm1.2Mbrg Krastm4Tyj/Kras+ Pggt1btm1Mbrg/Pggt1btm1.1Mbrg Lyz2tm1(cre)Ifo/Lyz2+
(involves: 129P2/OlaHsd * 129S4/SvJae * BALB/cJ * C57BL/6 * FVB/N)
|
increased lung tumor incidence
|
J:158937
|
Fntbtm1Bbd/Fntbtm1Bbd Krastm1Bbd/Kras+ Polr2atm1(cre/ERT2)Bbd/Polr2atm1(cre/ERT2)Bbd
(involves: 129S1/Sv * 129X1/SvJ * C57BL/6 * CD-1 * SJL)
|
increased lung adenocarcinoma incidence
|
J:98944
|
increased lung adenoma incidence
|
J:98944
|
Foc1NFS/N/Foc1NFS/N
(involves: SL/Kh * NFS/N)
|
increased B cell derived lymphoma incidence
|
J:16441
|
Fostm1Wag/Fostm1Wag Trp53tm1Tyj/Trp53+
(involves: 129S2/SvPas * C57BL/6)
|
increased rhabdomyosarcoma incidence
|
J:89283
|
Fostm1Wag/Fostm1Wag Trp53tm1Tyj/Trp53tm1Tyj
(involves: 129S2/SvPas * C57BL/6)
|
increased rhabdomyosarcoma incidence
|
J:89283
|
Foxa1tm1Khk/Foxa1tm1Khk Foxa2tm1Khk/Foxa2tm1Khk Tg(Alb1-cre)1Khk/0
(involves: 129P2/OlaHsd * 129S1/Sv * 129X1/SvJ * C57BL/6 * SJL)
|
increased hepatocellular carcinoma incidence
|
J:181296
|
Foxm1tm1Rhc/Foxm1tm1Rhc
(involves: 129X1/SvJ)
|
increased hepatocellular carcinoma incidence
|
J:89472
|
Foxm1tm1Rhc/Foxm1tm1Rhc Tg(Tek-cre)1Ywa/0
(involves: 129X1/SvJ * C57BL/6 * SJL)
|
increased lung adenoma incidence
|
J:167773
|
Foxo1tm1Rdp/Foxo1tm1.1Rdp Foxo3tm1Rdp/Foxo3tm1.1Rdp Amhr2tm3(cre)Bhr/Amhr2+
(involves: 129S6/SvEvTac * 129S7/SvEvBrd)
|
increased granulosa cell tumor incidence
|
J:232961
|
Foxo1tm1Rdp/Foxo1tm1.1Rdp Foxo3tm1Rdp/Foxo3tm1.1Rdp Ptentm1Hwu/Ptentm1Hwu Tg(CYP19A1-cre)1Jri/0
(involves: 129S4/SvJae * 129S6/SvEvTac)
|
increased granulosa cell tumor incidence
|
J:232961
|
Foxo1tm1Rdp/Foxo1tm1.1Rdp Foxo3tm1Rdp/Foxo3tm1.1Rdp Tg(CYP19A1-cre)1Jri/0
(involves: 129S6/SvEvTac)
|
increased granulosa cell tumor incidence
|
J:232961
|
Foxo1tm1Rdp/Foxo1tm1Rdp Foxo3tm1Rdp/Foxo3tm1Rdp Foxo4tm1Rdp/Foxo4tm1Rdp Tg(Mx1-cre)1Cgn/0
(involves: 129S6/SvEvTac * C57BL/6 * CBA * FVB/N)
|
increased T cell derived lymphoma incidence
|
J:118179
|
Foxo1tm1Rdp/Foxo1tm1Rdp Foxo3tm1Rdp/Foxo3tm1Rdp Tg(Mx1-cre)1Cgn/0
(involves: 129S1/Sv * 129S6/SvEvTac * C57BL/6 * CBA * FVB/N)
|
increased hepatic hemangioma incidence
|
J:118179
|
Foxo1tm1Rdp/Foxo1tm1Rdp Foxo4tm1Rdp/Foxo4tm1Rdp Tg(Mx1-cre)1Cgn/0
(involves: 129S6/SvEvTac * C57BL/6 * CBA * FVB/N)
|
increased hepatic hemangioma incidence
|
J:118179
|
Foxo3mommeR1/Foxo3mommeR1 Tg(HBA1-GFP)1Ew/Tg(HBA1-GFP)1Ew
(FVB/NJ-Foxo3mommeR1 Tg(HBA1-Gfp)1Ew)
|
increased ovarian teratoma incidence
|
J:170710
|
Foxo3tm1.1Rdp/Foxo3+ Foxo4tm1.1Rdp/Foxo4tm1.1Rdp
(involves: 129S1/Sv * 129S6/SvEvTac * FVB/N)
|
increased Harderian gland tumor incidence
|
J:118179
|
increased ovary tumor incidence
|
J:118179
|
increased pituitary adenoma incidence
|
J:118179
|
Foxo3tm1.1Rdp/Foxo3tm1.1Rdp
(involves: 129S6/SvEvTac * FVB/N)
|
increased ovary tumor incidence
|
J:118179
|
increased prolactinoma incidence
|
J:118179
|
Foxo3tm1.1Rdp/Foxo3tm1.1Rdp Foxo4tm1.1Rdp/Foxo4tm1.1Rdp
(involves: 129S1/Sv * 129S6/SvEvTac * FVB/N)
|
increased Harderian gland tumor incidence
|
J:118179
|
increased lung adenoma incidence
|
J:118179
|
increased ovarian teratoma incidence
|
J:118179
|
increased ovary tumor incidence
|
J:118179
|
increased pituitary adenoma incidence
|
J:118179
|
Foxq1sa/Foxq1sa Lystbg/Lystbg
(involves: 101/Rl * C3H/Rl * C57BL/6J * C57BL10/Rl)
|
increased lymphoma incidence
|
J:5311
|
Fpr2tm1.2Jimw/Fpr2tm1.2Jimw
(involves: 129X1/SvJ)
|
increased colon adenoma incidence
|
J:197568
|
Fshrtm1Saco/Fshr+
(involves: 129)
|
increased ovary tumor incidence
|
J:140008
|
Fshrtm1Saco/Fshr+
(involves: 129T2/SvEmsJ)
|
increased uterus tumor incidence
|
J:81460
|
Fshrtm1Saco/Fshrtm1Saco
(involves: 129)
|
increased ovarian carcinoma incidence
|
J:70933
|
Fzr1tm1.1Mama/Fzr1+
(involves: BALB/cJ * C57BL/6 * SJL)
|
increased liver tumor incidence
|
J:137456
|
increased lung tumor incidence
|
J:137456
|
increased mammary adenocarcinoma incidence
|
J:137456
|
increased mammary gland tumor incidence
|
J:137456
|
increased testis tumor incidence
|
J:137456
|
G6pc1tm1.1Ics/G6pc1tm1.1Ics Albtm1(cre/ERT2)Mtz/Alb+
(involves: 129S2/SvPas * C57BL/6J)
|
increased liver adenoma incidence
|
J:195257
|
Gadd45atm1Ajf/Gadd45atm1Ajf Xpctm1Ecf/Xpctm1Ecf
(either: (involves: 129/Sv * 129P2/OlaHsd * C57BL/6) or (involves: 129/Sv * 129X1/SvJ * C57BL/6))
|
increased lung adenocarcinoma incidence
|
J:101421
|
increased lung adenoma incidence
|
J:101421
|
increased lung tumor incidence
|
J:101421
|
Gas2l2tm1a(KOMP)Wtsi/Gas2l2tm1a(KOMP)Wtsi
(C57BL/6N-Gas2l2tm1a(KOMP)Wtsi/Wtsi)
|
increased trigeminal neuroma incidence
|
J:239583
|
Gasttm1Lcs/Gasttm1Lcs
(involves: 129S1/Sv * 129X1/SvJ * C57BL/6J)
|
increased stomach tumor incidence
|
J:97527
|
Gcgrtm1Jcp/Gcgrtm1Jcp
(DBA/1LacJ-Gcgrtm1Jcp)
|
increased glucagonoma incidence
|
J:176507
|
increased pancreas tumor incidence
|
J:176507
|
Gct1SJL/Bm/Gct1SWR/Bm
(involves: SJL * SWR)
|
increased granulosa cell tumor incidence
|
J:49710
|
Gct1SWR/Bm/Gct1SWR/Bm
(involves: SJL * SWR)
|
increased granulosa cell tumor incidence
|
J:49710
|
Gct4SJL/Bm/?
(involves: SJL * SWR)
|
increased granulosa cell tumor incidence
|
J:49710
|
Gct4SJL/Bm/Gct4SJL/Bm
(involves: SJL * SWR)
|
increased granulosa cell tumor incidence
|
J:87114
|
Gct4SJL/Bm/Gct4SJL/Bm Gct6SJL/Gct6SJL
(involves: CAST/Ei * SJL * SWR)
|
increased granulosa cell tumor incidence
|
J:87114
|
Gct5SWXJ9/BmJ/Gct5SWXJ9/BmJ
(involves: CAST/Ei * SWXJ9/BmJ)
|
increased granulosa cell tumor incidence
|
J:96787
|
Gct7SWXJ9/BmJ/Gct7SWXJ9/BmJ
(involves: CAST/Ei * SWXJ9/BmJ)
|
increased granulosa cell tumor incidence
|
J:96787
|
Gct8SWXJ9/BmJ/Gct8SWXJ9/BmJ
(involves: CAST/Ei * SWXJ9/BmJ)
|
increased granulosa cell tumor incidence
|
J:96787
|
Gct9SWXJ9/BmJ/Gct9SWXJ9/BmJ
(involves: CAST/Ei * SWXJ9/BmJ)
|
increased granulosa cell tumor incidence
|
J:96787
|
Gfertm1.1Crg/Gfertm1.1Crg Speer6-ps1Tg(Alb-cre)21Mgn/Speer6-ps1+
(involves: 129 * C57BL/6 * DBA)
|
increased hepatocellular carcinoma incidence
|
J:227242
|
Gkn2tm1.1(KOMP)Vlcg/Gkn2tm1.1(KOMP)Vlcg Il6sttm1Ern/Il6sttm1Ern
(involves: 129S1/Sv * C57BL/6NTac)
|
increased stomach tumor incidence
|
J:234656
|
Gli1tm3(cre/ERT2)Alj/Gli1+ Gt(ROSA)26Sortm1(Smo/EYFP)Amc/Gt(ROSA)26Sortm1(Smo/EYFP)Amc
(involves: 129S6/SvEvTac * 129X1/SvJ)
|
increased medulloblastoma incidence
|
J:139574
|
Gnai2tm1Lbi/Gnai2tm1Lbi
(involves: 129S7/SvEvBrd * C57BL/6J)
|
increased intestinal adenocarcinoma incidence
|
J:24434
|
Gnai2tm1Lbi/Gnai2tm1Lbi
(involves: 129S7/SvEvBrd)
|
increased intestinal adenocarcinoma incidence
|
J:24434
|
Gnmttm1Ymac/Gnmttm1Ymac
(involves: 129 * C57BL/6)
|
increased hepatic hemangioma incidence
|
J:146081
|
increased hepatocellular carcinoma incidence
|
J:146081
|
Gon4ljusty/Gon4ljusty
(C3HeB/FeJ-Gon4ljusty)
|
increased salivary adenocarcinoma incidence
|
J:197352
|
Gpr37l1tm1.2Gtva/Gpr37l1tm1.2Gtva Ptch1tm1Zim/Ptch1+
(STOCK Gpr37l1tm1.2Gtva Ptch1tm1Zim/Cnrm)
|
increased medulloblastoma incidence
|
J:272049
|
Gprc5atm1Rlo/Gprc5a+
(involves: 129 * C57BL/6)
|
increased lung tumor incidence
|
J:127821
|
Gprc5atm1Rlo/Gprc5atm1Rlo
(involves: 129 * C57BL/6)
|
increased lung adenocarcinoma incidence
|
J:127821
|
increased lung adenoma incidence
|
J:127821
|
increased lung tumor incidence
|
J:127821
|
Gpx7tm1Whle/Gpx7tm1Whle
(involves: 129P2/OlaHsd * C57BL/6)
|
increased leukemia incidence
|
J:193993
|
increased lung adenocarcinoma incidence
|
J:193993
|
increased lymphoma incidence
|
J:193993
|
increased mammary adenocarcinoma incidence
|
J:193993
|
increased salivary gland tumor incidence
|
J:193993
|
Grb2tm1Paw/Grb2+ Ptentm1Mak/Pten+
(involves: 129P2/OlaHsd * 129S1/Sv * 129X1/SvJ * C57BL/6)
|
increased adrenal gland tumor incidence
|
J:93530
|
increased endometrial carcinoma incidence
|
J:93530
|
increased lymphoma incidence
|
J:93530
|
Grb2tm1Paw/Grb2+ Ptentm2Mak/Ptentm2Mak Tg(Lck-cre)548Jxm/0
(involves: 129P2/OlaHsd * C57BL/6 * CBA)
|
increased T cell derived lymphoma incidence
|
J:93530
|
Grb2tm1Paw/Grb2+ Tg(MMTV-PyVT)634Mul/?
(involves: 129S1/Sv * 129X1/SvJ * FVB/N)
|
increased mammary adenocarcinoma incidence
|
J:51424
|
Grhl3tm1Jane/Grhl3+ Ptentm1Mak/Pten+
(involves: 129P2/OlaHsd * 129S1/Sv)
|
increased skin papilloma incidence
|
J:178952
|
increased skin squamous cell carcinoma incidence
|
J:178952
|
Grhl3tm1Jane/Grhl3tm3.1Jane Tg(KRT14-cre)8Brn/0
(involves: 129S1/Sv * C57BL/6 * FVB/N)
|
increased skin papilloma incidence
|
J:178952
|
increased skin squamous cell carcinoma incidence
|
J:178952
|
Grm1Tg(p18A4.B)1352Szc/0
(Not Specified)
|
increased cutaneous melanoma incidence
|
J:83183,
J:32786
|
Gstp1/Gstp2tm1Wolf/Gstp1/Gstp2tm1Wolf
(involves: 129P2/OlaHsd * MF1)
|
increased skin papilloma incidence
|
J:47638
|
Gstp1/Gstp2tm1Wolf/Gstp1/Gstp2tm1Wolf
(involves: 129P2/OlaHsd * MF1)
|
increased skin papilloma incidence
|
J:47638
|
Gt(ROSA)26Sortm1(CAG-AR)Zsu/Gt(ROSA)26Sor+ Tg(Osr1-cre)4Mrt/0
(involves: 129S1/Sv * 129X1/SvJ * C57BL/6J * FVB/N)
|
increased prostate gland adenocarcinoma incidence
|
J:234601
|
increased prostate intraepithelial neoplasia incidence
|
J:234601
|
Gt(ROSA)26Sortm1(CAG-AR)Zsu/Gt(ROSA)26Sortm1(CAG-AR)Zsu Tg(Osr1-cre)4Mrt/0
(involves: 129S1/Sv * 129X1/SvJ * C57BL/6J * FVB/N)
|
increased prostate gland adenocarcinoma incidence
|
J:234601
|
increased prostate intraepithelial neoplasia incidence
|
J:234601
|
Gt(ROSA)26Sortm1(CAG-Bmi1,-EGFP)Nki/Gt(ROSA)26Sor+ Ptentm1Mro/Pten+ Tg(Pbsn-cre)4Prb/0
(involves: 129P2/OlaHsd * C57BL/6 * DBA/2 * FVB/N)
|
increased prostate gland adenocarcinoma incidence
|
J:184533
|
increased prostate intraepithelial neoplasia incidence
|
J:184533
|
Gt(ROSA)26Sortm1(CAG-Bmi1,-EGFP)Nki/Gt(ROSA)26Sor+ Rb1tm2Brn/Rb1tm2Brn Tg(Gfap-cre)2Brn/0
(either: (involves: 129 * 129P2/OlaHsd * FVB/N) or (involves: 129 * 129P2/OlaHsd * C57BL/6 * FVB/N))
|
increased pituitary gland tumor incidence
|
J:187257
|
Gt(ROSA)26Sortm1(CAG-Bmi1,-EGFP)Nki/Gt(ROSA)26Sor+ Rb1tm2Brn/Rb1tm2Brn Trp53tm1Brn/Trp53tm1Brn Tg(Gfap-cre)2Brn/0
(either: (involves: 129 * 129P2/OlaHsd * FVB/N) or (involves: 129 * 129P2/OlaHsd * C57BL/6 * FVB/N))
|
increased medulloblastoma incidence
|
J:187257
|
increased pituitary gland tumor incidence
|
J:187257
|
Gt(ROSA)26Sortm1(CAG-Bmi1,-EGFP)Nki/Gt(ROSA)26Sor+ Tg(Gfap-cre)2Brn/0
(either: (involves: 129P2/OlaHsd * FVB/N) or (involves: 129P2/OlaHsd * C57BL/6 * FVB/N))
|
increased mammary gland tumor incidence
|
J:187257
|
increased pituitary gland tumor incidence
|
J:187257
|
Gt(ROSA)26Sortm1(CAG-Bmi1,-EGFP)Nki/Gt(ROSA)26Sor+ Tg(Pbsn-cre)4Prb/0
(involves: 129P2/OlaHsd * C57BL/6 * DBA/2 * FVB/N)
|
increased prostate intraepithelial neoplasia incidence
|
J:184533
|
Gt(ROSA)26Sortm1(CAG-MYCN,-luc)Jhsc/Gt(ROSA)26Sor+ Ptentm2.1Ppp/Ptentm2.1Ppp Rb1tm2Brn/Rb1+ Tg(Pbsn-cre)4Prb/0
(involves: 129 * 129S1/Sv * 129S6/SvEvTac * C57BL/6 * DBA/2)
|
increased prostate gland tumor incidence
|
J:307910
|
Gt(ROSA)26Sortm1(CAG-MYCN,-luc)Jhsc/Gt(ROSA)26Sor+ Ptentm2.1Ppp/Ptentm2.1Ppp Rb1tm2Brn/Rb1tm2Brn Tg(Pbsn-cre)4Prb/0
(involves: 129 * 129S1/Sv * 129S6/SvEvTac * C57BL/6 * DBA/2)
|
increased prostate gland tumor incidence
|
J:307910
|
Gt(ROSA)26Sortm1(CAG-MYCN,-luc)Jhsc/Gt(ROSA)26Sor+ Ptentm2.1Ppp/Ptentm2.1Ppp Tg(Pbsn-cre)4Prb/0
(involves: 129 * 129S1/Sv * 129S6/SvEvTac * C57BL/6 * DBA/2)
|
increased prostate intraepithelial neoplasia incidence
|
J:307910
|
Gt(ROSA)26Sortm1(CAG-MYCN,-luc)Jhsc/Gt(ROSA)26Sor+ Tg(Dbh-icre)1Gsc/0
(involves: 129S6/SvEvTac * C57BL/6)
|
increased neuroblastoma incidence
|
J:222527
|
Gt(ROSA)26Sortm1(CAG-PIK3CA*H1047R,-EGFP)Balj/Gt(ROSA)26Sor+ Tg(MMTV-cre)7Mul/0
(involves: BALB/c * FVB/N)
|
increased mammary adenocarcinoma incidence
|
J:173655
|
Gt(ROSA)26Sortm1(CAG-PIK3CA*H1047R,-EGFP)Balj/Gt(ROSA)26Sor+ Tg(Wap-cre)1Gsc/0
(involves: BALB/c * C57BL/6 * FVB/N)
|
increased mammary adenocarcinoma incidence
|
J:173655
|
increased mammary gland tumor incidence
|
J:173655
|
Gt(ROSA)26Sortm1(CAG-PTPN1,-EGFP)Mtr/Gt(ROSA)26Sor+ Tg(Pbsn-cre)4Prb/0
(involves: 129S1/Sv * 129X1/SvJ * C57BL/6 * DBA/2)
|
increased prostate intraepithelial neoplasia incidence
|
J:231906
|
Gt(ROSA)26Sortm1(CAG-Sox2,-EGFP)Blh/Gt(ROSA)26Sor+ Tg(Sftpc-cre)1Blh/0
(involves: 129S/SvEv * C57BL/6 * DBA/2)
|
increased lung adenocarcinoma incidence
|
J:161806
|
Gt(ROSA)26Sortm1(CAG-Sox2,-EGFP)Blh/Gt(ROSA)26Sortm1(CAG-Sox2,-EGFP)Blh Scgb1a1tm1(cre/ERT)Blh/Scgb1a1+
(involves: 129S6/SvEv * C57BL/6)
|
increased lung adenocarcinoma incidence
|
J:161806
|
Gt(ROSA)26Sortm1(cre/ERT2)Tyj/Gt(ROSA)26Sor+ Tacc3tm1.1Tno/Tacc3+ Trp53tm1Tyj/Trp53tm1Tyj
(involves: 129S2/SvPas * 129S4/SvJae * C57BL/6)
|
increased T cell derived lymphoma incidence
|
J:179414
|
Gt(ROSA)26Sortm1(cre/ERT2)Tyj/Gt(ROSA)26Sor+ Tacc3tm1.1Tno/Tacc3tm1.2Tno Trp53tm1Tyj/Trp53tm1Tyj
(involves: 129S2/SvPas * 129S4/SvJae * C57BL/6)
|
increased T cell derived lymphoma incidence
|
J:179414
|
Gt(ROSA)26Sortm1(cre/ERT)Nat/Gt(ROSA)26Sor+ Ptentm1Hwu/Ptentm1Hwu
(involves: 129 * 129S4/SvJae * BALB/c * C57BL/6)
|
increased gastrointestinal tumor incidence
|
J:130367
|
increased prostate gland tumor incidence
|
J:130367
|
increased prostate intraepithelial neoplasia incidence
|
J:130367
|
increased skin squamous cell carcinoma incidence
|
J:130367
|
increased T cell derived lymphoma incidence
|
J:130367
|
Gt(ROSA)26Sortm1(EWSR1/FLI1)Sbk/Gt(ROSA)26Sor+ Tg(Mx1-cre)1Cgn/?
(involves: 129S1/Sv * C57BL/6 * CBA)
|
increased leukemia incidence
|
J:129039
|
Gt(ROSA)26Sortm1(EYFP)Cos/Gt(ROSA)26Sor+ Ighg1tm1(cre)Cgn/Ighg1+ Prdm1tm2Masu/Prdm1tm2Masu
(involves: 129P2/OlaHsd * 129X1/SvJ)
|
increased B cell derived lymphoma incidence
|
J:167612
|
Gt(ROSA)26Sortm1(EYFP)Cos/Gt(ROSA)26Sor+ Krastm4Tyj/Kras+ Tg(Pdx1-cre)6Tuv/0 Trp53tm1Brn/Trp53+
(involves: 129P2/OlaHsd * 129S4/SvJae * 129X1/SvJ * FVB/N)
|
increased pancreatic ductal adenocarcinoma incidence
|
J:280854
|
increased pancreatic intraepithelial neoplasia incidence
|
J:280854
|
Gt(ROSA)26Sortm1(EYFP)Cos/Gt(ROSA)26Sor+ Krastm4Tyj/Kras+ Tg(Pdx1-cre)89.1Dam/0 Trp53tm1Brn/Trp53+
(involves: 129 * C57BL/6 * CBA)
|
increased pancreas tumor incidence
|
J:289183
|
increased pancreatic ductal adenocarcinoma incidence
|
J:289183
|
increased pancreatic intraepithelial neoplasia incidence
|
J:289183
|
Gt(ROSA)26Sortm1(GNAQ*)Cvrk/Gt(ROSA)26Sor+ Tg(Mitf-cre)7114Gsb/0
(C3FeJ.Cg-Gt(ROSA)26Sortm1(GNAQ*)Cvkr Tg(Mitf-cre)7114Gsb/Cvrk)
|
increased intraocular melanoma incidence
|
J:225597
|
Gt(ROSA)26Sortm1(gp80,EGFP)Eces/Gt(ROSA)26Sor+ Cd19tm1(cre)Cgn/Cd19+
(either: (involves: 129/Sv * 129P2/OlaHsd * C57BL/6) or (involves: 129/Sv * 129P2/OlaHsd * BALB/c * C57BL/6))
|
increased histiocytic sarcoma incidence
|
J:172031
|
Gt(ROSA)26Sortm1(gp80,EGFP)Eces/Gt(ROSA)26Sor+ Ighg1tm1(cre)Cgn/Ighg1+
(either: (involves: 129/Sv * 129P2/OlaHsd * C57BL/6) or (involves: 129/Sv * 129P2/OlaHsd * BALB/c * C57BL/6))
|
increased histiocytic sarcoma incidence
|
J:172031
|
Gt(ROSA)26Sortm1(H1/tetO-RNAi:Pdpk1)Mrl/Gt(ROSA)26Sor+ Ptentm1.1Hwu/Pten+
(involves: 129S4/SvJae * C57BL/6NTac)
|
increased lymphoma incidence
|
J:170965
|
increased thyroid adenoma incidence
|
J:170965
|
Gt(ROSA)26Sortm1(H1/tetO-RNAi:Pdpk1)Mrl/Gt(ROSA)26Sor+ Ptentm1Hwu/Ptentm1Hwu Tg(Pbsn-cre)4Prb/0
(involves: 129S4/SvJae * C57BL/6 * DBA/2)
|
increased prostate gland tumor incidence
|
J:170965
|
Gt(ROSA)26Sortm1(H1/tetO-RNAi:Pdpk1)Mrl/Gt(ROSA)26Sortm9(cre/ESR1)Arte Ptentm1Hwu/Ptentm1Hwu
(involves: 129S4/SvJae * C57BL/6)
|
increased acute lymphoblastic leukemia incidence
|
J:170965
|
Gt(ROSA)26Sortm1(ITK/SYK)Jrld/Gt(ROSA)26Sor+ Tg(Cd4-cre)1Cwi/0
(involves: 129P2/OlaHsd * C57BL/6 * DBA/2)
|
increased T cell derived lymphoma incidence
|
J:160931
|
Gt(ROSA)26Sortm1(JAG1)Xin/Gt(ROSA)26Sor+ Ptentm1Hwu/Ptentm1Hwu Tg(Pbsn-cre)20Fwan/?
(involves: 129S4/SvJae * C57BL/6 * FVB/NCrl)
|
increased prostate gland adenocarcinoma incidence
|
J:238768
|
increased prostate intraepithelial neoplasia incidence
|
J:238768
|
Gt(ROSA)26Sortm1(MYC/ERT2)Gev/Gt(ROSA)26Sortm1(MYC/ERT2)Gev Krastm4Tyj/Krastm4Tyj
(involves: 129S4/SvJae * C57BL/6 * FVB/N)
|
increased lung adenoma incidence
|
J:142030
|
increased lung tumor incidence
|
J:142030
|
Gt(ROSA)26Sortm1(Notch1)Dam/Gt(ROSA)26Sor+ Krastm4Tyj/Krastm4Tyj Tg(Cela1-cre/ERT)1Dam/0
(involves: 129S4/SvJae * 129S4/SvJaeSor)
|
increased pancreatic intraepithelial neoplasia incidence
|
J:142188
|
Gt(ROSA)26Sortm1(Notch1)Dam/Gt(ROSA)26Sor+ Krastm4Tyj/Krastm4Tyj Tg(Pdx1-cre/Esr1*)35.10Dam/0
(involves: 129S4/SvJae * 129S4/SvJaeSor * C57BL/6 * CBA)
|
increased pancreatic intraepithelial neoplasia incidence
|
J:142188
|
Gt(ROSA)26Sortm1(Notch1)Dam/Gt(ROSA)26Sor+ Tg(Mx1-cre)1Cgn/0
(involves: 129S4/SvJaeSor * C57BL/6 * CBA)
|
increased leukemia incidence
|
J:167000
|
Gt(ROSA)26Sortm1(NOTCH1/GFP)Xhsu/Gt(ROSA)26Sor+ Tg(Lck-cre)548Jxm/0
(B6.Cg-Gt(ROSA)26Sortm1(NOTCH1/GFP)Xhsu Tg(Lck-cre)548Jxm)
|
increased T cell derived lymphoma incidence
|
J:185287
|
Gt(ROSA)26Sortm1(pb)Peli/Gt(ROSA)26Sor+ TgTn(pb-sb-ATP2)H27Brd/0
(involves: 129S7/SvEvBrd * C57BL/6)
|
increased leukemia incidence
|
J:166063
|
increased lymphoma incidence
|
J:166063
|
Gt(ROSA)26Sortm1(pb)Peli/Gt(ROSA)26Sor+ TgTn(pb-sb-ATP2)H32Brd/0
(involves: 129S7/SvEvBrd * C57BL/6)
|
increased leukemia incidence
|
J:166063
|
increased lymphoma incidence
|
J:166063
|
Gt(ROSA)26Sortm1(pb)Peli/Gt(ROSA)26Sor+ TgTn(pb-sb-ATP2)S1Brd/0
(involves: 129S7/SvEvBrd * FVB)
|
increased leukemia incidence
|
J:166063
|
increased lymphoma incidence
|
J:166063
|
Gt(ROSA)26Sortm1(pb)Peli/Gt(ROSA)26Sor+ TgTn(pb-sb-ATP2)S2Brd/0
(involves: 129S7/SvEvBrd * FVB)
|
increased leukemia incidence
|
J:166063
|
increased lymphoma incidence
|
J:166063
|
Gt(ROSA)26Sortm1(Pik3ca*H1047R)Egan/Gt(ROSA)26Sor+ Tg(MMTV-cre)1Mam/0
(involves: 129S6/SvEvTac * FVB/N)
|
increased mammary gland tumor incidence
|
J:170898
|
Gt(ROSA)26Sortm1(Pik3ca*H1047R)Egan/Gt(ROSA)26Sor+ Tg(MMTV-cre)#Tfln/0
(involves: 129S6/SvEvTac)
|
increased mammary adenocarcinoma incidence
|
J:170898
|
increased mammary gland tumor incidence
|
J:170898
|
Gt(ROSA)26Sortm1(Pik3ca*H1047R)Egan/Gt(ROSA)26Sor+ Tg(MMTV-cre)#Tfln/0 Trp53tm1Brn/Trp53+
(involves: 129P2/OlaHsd * 129S6/SvEvTac)
|
increased lymphoma incidence
|
J:170898
|
increased mammary adenocarcinoma incidence
|
J:170898
|
increased mammary gland tumor incidence
|
J:170898
|
increased T cell derived lymphoma incidence
|
J:170898
|
Gt(ROSA)26Sortm1(Pik3ca*H1047R)Egan/Gt(ROSA)26Sor+ Trp53tm1Brn/Trp53tm1Brn Tg(MMTV-cre)#Tfln/0
(involves: 129P2/OlaHsd * 129S6/SvEvTac)
|
increased lymphoma incidence
|
J:170898
|
increased mammary gland tumor incidence
|
J:170898
|
increased T cell derived lymphoma incidence
|
J:170898
|
Gt(ROSA)26Sortm1(RAC1*)Jkis/Gt(ROSA)26Sor+ Krastm4Tyj/Kras+
(involves: 129S4/SvJae)
|
increased lung adenocarcinoma incidence
|
J:187582
|
Gt(ROSA)26Sortm1(RICTOR)Jger/Gt(ROSA)26Sortm1(RICTOR)Jger Tg(GFAP-cre)25Mes/0
(involves: 129 * FVB/N)
|
increased glioma incidence
|
J:192206
|
increased oligodendroglioma incidence
|
J:192206
|
Gt(ROSA)26Sortm1(RICTOR)Jger/Gt(ROSA)26Sortm1(RICTOR)Jger Tg(GFAP-cre)25Mes/0 Tg(GFAP-EGFR*,-lacZ)#Agu/0
(involves: 129S1/Sv * 129X1/SvJ * FVB/N)
|
increased astrocytoma incidence
|
J:192206
|
increased glioma incidence
|
J:192206
|
increased oligodendroglioma incidence
|
J:192206
|
Gt(ROSA)26Sortm1(rtTA,EGFP)Nagy/Gt(ROSA)26Sor+ Ptf1atm1.1(cre)Cvw/Ptf1a+ Tg(tetO-Kras2)12Hev/0
(involves: 129S1/Sv * 129X1/SvJ * C57BL/6J * FVB/N)
|
increased pancreas tumor incidence
|
J:184378
|
increased pancreatic intraepithelial neoplasia incidence
|
J:184378
|
Gt(ROSA)26Sortm1(rtTA,EGFP)Nagy/Gt(ROSA)26Sor+ Ptf1atm1.1(cre)Cvw/Ptf1a+ Tg(tetO-Kras2)12Hev/0 Trp53tm1Tyj/Trp53+
(involves: 129S1/Sv * 129X1/SvJ * C57BL/6J * FVB/N)
|
increased pancreatic ductal adenocarcinoma incidence
|
J:184378
|
increased pancreatic intraepithelial neoplasia incidence
|
J:184378
|
Gt(ROSA)26Sortm1(rtTA,EGFP)Nagy/Gt(ROSA)26Sor+ Ptf1atm1.1(cre)Cvw/Ptf1a+ Tg(tetO-Kras*G12D)#Rdp/0
(involves: 129S1/Sv * 129X1/SvJ * C57BL/6 * FVB/N)
|
increased pancreatic ductal adenocarcinoma incidence
|
J:186194
|
increased pancreatic intraepithelial neoplasia incidence
|
J:186194
|
Gt(ROSA)26Sortm1(rtTA,EGFP)Nagy/Gt(ROSA)26Sor+ Ptf1atm1.1(cre)Cvw/Ptf1a+ Tg(tetO-Kras*G12D)#Rdp/0 Trp53tm1Brn/Trp53+
(involves: 129P2/OlaHsd * 129S1/Sv * 129X1/SvJ * C57BL/6 * FVB/N)
|
increased pancreatic ductal adenocarcinoma incidence
|
J:186194
|
Gt(ROSA)26Sortm1(rtTA,EGFP)Nagy/Gt(ROSA)26Sor+ Ptf1atm1.1(cre)Cvw/Ptf1a+ Tg(tetO-Kras*G12D)#Rdp/0 Trp53tm1Brn/Trp53tm1Brn
(involves: 129P2/OlaHsd * 129S/Sv * 129X1/SvJ * C57BL/6 * FVB/N)
|
increased pancreatic ductal adenocarcinoma incidence
|
J:186194
|
Gt(ROSA)26Sortm1(sb11)Njen/Gt(ROSA)26Sor+ Hprt1tm1(sb-Onco-Array)Peli/Y
(involves: 129S7/SvEvBrd)
|
increased lung adenocarcinoma incidence
|
J:166283
|
increased lung adenoma incidence
|
J:166283
|
increased lymphoma incidence
|
J:166283
|
increased medulloblastoma incidence
|
J:166283
|
increased rhabdomyosarcoma incidence
|
J:166283
|
increased skin squamous cell carcinoma incidence
|
J:166283
|
Gt(ROSA)26Sortm1(sb11)Njen/Gt(ROSA)26Sor+ Hprt1tm1(sb-Onco-Array)Peli/Hprt1+
(involves: 129S7/SvEvBrd)
|
increased lung adenocarcinoma incidence
|
J:166283
|
increased lung adenoma incidence
|
J:166283
|
increased lymphoma incidence
|
J:166283
|
increased medulloblastoma incidence
|
J:166283
|
increased rhabdomyosarcoma incidence
|
J:166283
|
increased skin squamous cell carcinoma incidence
|
J:166283
|
Gt(ROSA)26Sortm1(sb11)Njen/Gt(ROSA)26Sor+ TgTn(sb-T2/Onc2)6057Njen/0
(involves: C3H * C57BL/6)
|
increased B cell derived lymphoma incidence
|
J:102234
|
increased lymphoma incidence
|
J:102234
|
increased medulloblastoma incidence
|
J:102234
|
increased T cell derived lymphoma incidence
|
J:102234
|
Gt(ROSA)26Sortm1(sb11)Njen/Gt(ROSA)26Sor+ TgTn(sb-T2/Onc2)6070Njen/0
(involves: C3H * C57BL/6)
|
increased B cell derived lymphoma incidence
|
J:102234
|
increased lymphoma incidence
|
J:102234
|
increased medulloblastoma incidence
|
J:102234
|
increased T cell derived lymphoma incidence
|
J:102234
|
Gt(ROSA)26Sortm1(sb11)Njen/Gt(ROSA)26Sor+ TgTn(sb-T2/Onc2)6113Njen/0
(involves: C3H * C57BL/6)
|
increased B cell derived lymphoma incidence
|
J:102234
|
increased lymphoma incidence
|
J:102234
|
increased T cell derived lymphoma incidence
|
J:102234
|
Gt(ROSA)26Sortm1(sb11)Njen/Gt(ROSA)26Sor+ TgTn(sb-T2/Onc3)12740Njen/0
(involves: C3H * C57BL/6J)
|
increased B cell derived lymphoma incidence
|
J:153656
|
increased basal cell carcinoma incidence
|
J:153656
|
increased hepatocellular carcinoma incidence
|
J:153656
|
increased liver adenoma incidence
|
J:153656
|
increased liver tumor incidence
|
J:153656
|
increased lung carcinoma incidence
|
J:153656
|
increased lymphoma incidence
|
J:153656
|
increased pheochromocytoma incidence
|
J:153656
|
increased skin squamous cell carcinoma incidence
|
J:153656
|
increased T cell derived lymphoma incidence
|
J:153656
|
Gt(ROSA)26Sortm1(Smo/EYFP)Amc/? Tg(CAG-cre/Esr1*)5Amc/?
(involves: 129X1/SvJ * C57BL/6 * CBA)
|
increased basal cell carcinoma incidence
|
J:114992
|
increased medulloblastoma incidence
|
J:114992
|
increased rhabdomyosarcoma incidence
|
J:114992
|
Gt(ROSA)26Sortm1(Smo/EYFP)Amc/Gt(ROSA)26Sor+ Hk2tm1.1Uku/Hk2+ Tg(GFAP-cre)25Mes/0
(involves: 129P2/OlaHsd * 129X1/SvJ * C57BL/6 * FVB/N)
|
increased medulloblastoma incidence
|
J:210113
|
Gt(ROSA)26Sortm1(Smo/EYFP)Amc/Gt(ROSA)26Sor+ Hk2tm1.1Uku/Hk2tm1.1Uku Tg(GFAP-cre)25Mes/0
(involves: 129P2/OlaHsd * 129X1/SvJ * C57BL/6 * FVB/N)
|
increased medulloblastoma incidence
|
J:210113
|
Gt(ROSA)26Sortm1(Smo/EYFP)Amc/Gt(ROSA)26Sortm1(Smo/EYFP)Amc Olig2tm2(TVA,cre)Rth/Olig2+
(involves: 129 * 129X1/SvJ)
|
increased medulloblastoma incidence
|
J:139574
|
Gt(ROSA)26Sortm1(Smo/EYFP)Amc/Gt(ROSA)26Sortm1(Smo/EYFP)Amc Tg(Atoh1-cre/Esr1*)14Fsh/0
(involves: 129X1/SvJ * FVB/N)
|
increased medulloblastoma incidence
|
J:139574
|
Gt(ROSA)26Sortm1(Smo/EYFP)Amc/Gt(ROSA)26Sortm1(Smo/EYFP)Amc Tg(GFAP-cre)25Mes/0
(involves: 129X1/SvJ * FVB/N)
|
increased medulloblastoma incidence
|
J:139574
|
Gt(ROSA)26Sortm1(Smo/EYFP)Amc/Gt(ROSA)26Sortm1(Smo/EYFP)Amc Tg(Krt1-5-cre/ERT)1Ipc/0
(involves: 129X1/SvJ * C57BL/6 * SJL)
|
increased basal cell carcinoma incidence
|
J:158915
|
Gt(ROSA)26Sortm1(Smo/EYFP)Amc/Gt(ROSA)26Sortm1(Smo/EYFP)Amc Tlx3tm1(cre)Qima/Tlx3+
(involves: 129X1/SvJ)
|
increased medulloblastoma incidence
|
J:139574
|
Gt(ROSA)26Sortm1(Smo/EYFP)Amc/Gt(ROSA)26Sortm2(EGFP/cre)Alj Pgbd5tm1.1Aken/Pgbd5tm1.1Aken
(involves: 129 * C57BL/6J * C57BL/6NTac * SW)
|
increased medulloblastoma incidence
|
J:346387
|
Gt(ROSA)26Sortm1(SPOP*F133V)Mrbn/Gt(ROSA)26Sor+ Ptentm2.1Ppp/Pten+ Tg(Pbsn-cre)4Prb/0
(involves: 129S1/Sv * C57BL/6 * DBA/2)
|
increased prostate gland adenocarcinoma incidence
|
J:239660
|
increased prostate intraepithelial neoplasia incidence
|
J:239660
|
Gt(ROSA)26Sortm1(SPOP*F133V)Mrbn/Gt(ROSA)26Sor+ Ptentm2.1Ppp/Ptentm2.1Ppp Tg(Pbsn-cre)4Prb/0
(involves: 129S1/Sv * C57BL/6 * DBA/2)
|
increased prostate gland adenocarcinoma incidence
|
J:239660
|
Gt(ROSA)26Sortm1(TMPRSS2/ERG)Key/Gt(ROSA)26Sortm1(TMPRSS2/ERG)Key Ptentm2.1Ppp/Ptentm2.1Ppp Tg(Pbsn-cre)4Prb/0
(involves: 129S1/Sv * C57BL/6 * DBA/2)
|
increased prostate gland adenocarcinoma incidence
|
J:200002
|
increased prostate intraepithelial neoplasia incidence
|
J:200002
|
Gt(ROSA)26Sortm1(tTA,tetO-Mir21)Fjsl/Gt(ROSA)26Sor+ Tg(Nes-cre)1Wmz/0
(involves: C57BL/6 * C57BL/6J * SJL/J)
|
increased lymphoma incidence
|
J:163919
|
Gt(ROSA)26Sortm1(tTA,tetO-Mir155)Fjsl/Gt(ROSA)26Sor+ Tg(Nes-cre)1Wmz/0
(involves: 129 * C57BL/6 * FVB/N * SJL/J)
|
increased B cell derived lymphoma incidence
|
J:185598
|
Gt(ROSA)26Sortm1(Tva)Dsa/Gt(ROSA)26Sor+ Krastm4Tyj/Kras+ Ptf1atm1(cre)Hnak/Ptf1a+
(involves: 129S4/SvJae * 129S6/SvEvTac * C57BL/6J)
|
increased pancreatic ductal adenocarcinoma incidence
|
J:140423
|
Gt(ROSA)26Sortm1(Tva)Dsa/Gt(ROSA)26Sor+ Ptf1atm1(cre)Hnak/Ptf1a+
(involves: 129S6/SvEvTac * C57BL/6J)
|
increased pancreatic ductal adenocarcinoma incidence
|
J:140423
|
increased pancreatic intraepithelial neoplasia incidence
|
J:140423
|
Gt(ROSA)26Sortm1.1(rtTA2S*M2)Whsu/Gt(ROSA)26Sor+ Ncstntm1.1Akli/Ncstntm1.1Akli Tg(tetO-cre)1Jaw/0
(involves: 129 * 129S6/SvEvTac * C57BL/6)
|
increased urinary bladder carcinoma incidence
|
J:227748
|
Gt(ROSA)26Sortm1Jus/Gt(ROSA)26Sor+ Tg(MMTV-cre)4Mam/0
(involves: C57BL/6J * C57BL/6N * FVB/N)
|
increased acute lymphoblastic leukemia incidence
|
J:202090
|
Gt(ROSA)26Sortm1Jus/Gt(ROSA)26Sor+ Tg(Mx1-cre)1Cgn/0
(involves: C57BL/6 * C57BL/6J * C57BL/6N * CBA)
|
increased acute lymphoblastic leukemia incidence
|
J:202090
|
Gt(ROSA)26Sortm1Sor/Gt(ROSA)26Sor+ Krastm4Tyj/Kras+ Pms2tm2(cre)Lisk/Pms2tm2(cre)Lisk
(involves: 129S4/SvJae * 129S4/SvJaeSor)
|
increased lung tumor incidence
|
J:204653
|
Gt(ROSA)26Sortm1Sor/Gt(ROSA)26Sortm1Sor Ptentm1Mro/Ptentm1Mro Rb1tm2Brn/Rb1tm2Brn Trp53tm1Brn/Trp53tm1Brn
(involves: 129 * 129P2/OlaHsd * 129S4/SvJaeSor * C57BL/6 * FVB/N)
|
increased nervous system tumor incidence
|
J:204385
|
Gt(ROSA)26Sortm1Sor/Gt(ROSA)26Sortm1Sor Ptentm1Mro/Ptentm1Mro Slc1a3tm1(cre/ERT2)Mgoe/Slc1a3+ Trp53tm1Brn/Trp53tm1Brn
(involves: 129P2/OlaHsd * 129S2/SvPas * 129S4/SvJaeSor)
|
increased astrocytoma incidence
|
J:229481
|
increased glioma incidence
|
J:229481
|
increased oligodendroglioma incidence
|
J:229481
|
Gt(ROSA)26Sortm1Sor/Gt(ROSA)26Sortm1Sor Ptentm1Mro/Ptentm1Mro Trp53tm1Brn/Trp53tm1Brn
(involves: 129P2/OlaHsd * 129S4/SvJaeSor * C57BL/6 * FVB)
|
increased astrocytoma incidence
|
J:204385
|
increased glioma incidence
|
J:204385
|
increased oligodendroglioma incidence
|
J:204385
|
Gt(ROSA)26Sortm1Sor/Gt(ROSA)26Sortm1Sor Ptentm1Mro/Ptentm1Mro Trp53tm1Brn/Trp53tm1Brn
(involves: 129P2/OlaHsd * 129S4/SvJaeSor)
|
increased astrocytoma incidence
|
J:229481
|
increased glioma incidence
|
J:229481
|
increased oligodendroglioma incidence
|
J:229481
|
Gt(ROSA)26Sortm1Sor/Gt(ROSA)26Sortm1Sor Rb1tm2Brn/Rb1tm2Brn Trp53tm1Brn/Trp53tm1Brn
(involves: 129 * 129P2/OlaHsd * 129S4/SvJaeSor * C57BL/6 * FVB/N)
|
increased nervous system tumor incidence
|
J:204385
|
Gt(ROSA)26Sortm2(CAG-Lin28b,-luc)Jhsc/Gt(ROSA)26Sor+ Tg(Dbh-icre)1Gsc/0
(involves: 129S6/SvEvTac * 129X1/SvJ * C57BL/6)
|
increased neuroblastoma incidence
|
J:241988
|
Gt(ROSA)26Sortm2(cre/ERT2)Brn/Gt(ROSA)26Sor+ Ptentm2Mak/Ptentm2Mak Tg(RasE)290Biat/0
(involves: 129P2/OlaHsd * C57BL/6 * DBA/2)
|
increased lung tumor incidence
|
J:226601
|
increased pancreas tumor incidence
|
J:226601
|
Gt(ROSA)26Sortm2(cre/ERT2)Brn/Gt(ROSA)26Sor+ Tg(GFP/KRAS2/ALPP)1Brn/0
(involves: 129P2/OlaHsd * FVB/N)
|
increased keratoacanthoma incidence
|
J:127226
|
increased lung tumor incidence
|
J:127226
|
increased lymphoma incidence
|
J:127226
|
Gt(ROSA)26Sortm2(cre/ERT2)Brn/Gt(ROSA)26Sor+ Tg(RasE)290Biat/0
(involves: 129P2/OlaHsd * C57BL/6 * DBA/2)
|
increased lung adenocarcinoma incidence
|
J:226601
|
increased lung tumor incidence
|
J:226601
|
increased pancreas tumor incidence
|
J:226601
|
increased pancreatic ductal adenocarcinoma incidence
|
J:226601
|
increased pancreatic intraepithelial neoplasia incidence
|
J:226601
|
increased sebaceous gland tumor incidence
|
J:226601
|
Gt(ROSA)26Sortm2(H1/tetO-RNAi:Pdpk1)Mrl/Gt(ROSA)26Sor+ Ptentm1Hwu/Ptentm1Hwu Tg(Pbsn-cre)4Prb/0
(involves: 129S4/SvJae * C57BL/6 * DBA/2)
|
increased prostate gland tumor incidence
|
J:170965
|
Gt(ROSA)26Sortm2(Lmp1/CD40)Uzs/Gt(ROSA)26Sor+ Cd19tm1(cre)Cgn/Cd19+
(involves: 129P2/OlaHsd * BALB/c * C57BL/6)
|
increased B cell derived lymphoma incidence
|
J:137122
|
Gt(ROSA)26Sortm2(myc*T58A)Rcse/Gt(ROSA)26Sortm2(myc*T58A)Rcse Tg(Wap-cre)11738Mam/0
(involves: 129 * C57BL/6 * SJL)
|
increased brain tumor incidence
|
J:169403
|
increased mammary adenocarcinoma incidence
|
J:169403
|
increased pituitary gland tumor incidence
|
J:169403
|
Gt(ROSA)26Sortm2(Pik3ca*)Dsa/Gt(ROSA)26Sor+ Ptf1atm1(cre)Hnak/Ptf1a+
(involves: 129S6/SvEvTac)
|
increased pancreatic ductal adenocarcinoma incidence
|
J:197054
|
increased pancreatic intraepithelial neoplasia incidence
|
J:197054
|
Gt(ROSA)26Sortm2(Pik3ca*)Dsa/Gt(ROSA)26Sor+ Tg(Cela1-cre/ERT)1Dam/0
(involves: 129S6/SvEvTac)
|
increased pancreatic intraepithelial neoplasia incidence
|
J:197054
|
Gt(ROSA)26Sortm2(sb11)Njen/Gt(ROSA)26Sor+ Speer6-ps1Tg(Alb-cre)21Mgn/Speer6-ps1+ TgTn(sb-T2/Onc)68Dla/0
(involves: C57BL/6 * DBA/2 * FVB/N)
|
increased hepatocellular carcinoma incidence
|
J:147264
|
increased liver adenoma incidence
|
J:147264
|
Gt(ROSA)26Sortm2(sb11)Njen/Gt(ROSA)26Sor+ Tg(Vil1-cre)20Syr/0 TgTn(sb-T2/Onc)68Dla/0
(involves: C57BL/6 * DBA/2 * FVB/N)
|
increased gastrointestinal tumor incidence
|
J:146887
|
increased intestinal adenoma incidence
|
J:146887
|
increased small intestine adenocarcinoma incidence
|
J:146887
|
Gt(ROSA)26Sortm2(sb11)Njen/Gt(ROSA)26Sor+ Tg(Vil1-cre)20Syr/0 TgTn(sb-T2/Onc)76Dla/0
(involves: C57BL/6 * DBA/2 * FVB/N)
|
increased gastrointestinal tumor incidence
|
J:146887
|
increased intestinal adenoma incidence
|
J:146887
|
increased small intestine adenocarcinoma incidence
|
J:146887
|
Gt(ROSA)26Sortm2(sb11)Njen/Gt(ROSA)26Sor+ Trp53tm3Tyj/Trp53+ Speer6-ps1Tg(Alb-cre)21Mgn/Speer6-ps1+ TgTn(sb-T2/Onc)68Dla/0
(involves: 129S4/SvJae * C57BL/6 * DBA/2 * FVB/N)
|
increased hepatocellular carcinoma incidence
|
J:147264
|
increased liver adenoma incidence
|
J:147264
|
Gt(ROSA)26Sortm2.1(sb11)Njen/Gt(ROSA)26Sor+ TgTn(sb-T2/Onc2)6070Njen/0
(involves: 129 * C57BL/6 * C57BL/6J)
|
increased hemolymphoid system tumor incidence
|
J:153656
|
increased leukemia incidence
|
J:153656
|
increased T cell derived lymphoma incidence
|
J:153656
|
Gt(ROSA)26Sortm2Thl/Gt(ROSA)26Sor+ Ptentm1Hwu/Ptentm1Hwu Trp53tm1Thl/Trp53tm1Thl Tyrc-Brd/Tyrc-Brd
(involves: 129/Sv * 129S4/SvJae * C57BL/6)
|
increased glioblastoma incidence
|
J:172585
|
Gt(ROSA)26Sortm2Thl/Gt(ROSA)26Sor+ Ptentm1Hwu/Ptentm1Hwu Tyrc-Brd/Tyrc-Brd
(involves: 129/Sv * 129S4/SvJae * C57BL/6)
|
increased glioblastoma incidence
|
J:172585
|
Gt(ROSA)26Sortm3(myc*S62A)Rcse/Gt(ROSA)26Sortm3(myc*S62A)Rcse Tg(Wap-cre)11738Mam/0
(involves: 129 * C57BL/6 * SJL)
|
increased brain tumor incidence
|
J:169403
|
Gt(ROSA)26Sortm4(CAG-hsb5)Nki/Gt(ROSA)26Sor+ Npm1tm1Gsva/Npm1+ TgTn(pb-sb-GrOnc)#aGsva/0 Tg(Mx1-cre)1Cgn/0
(involves: 129P2/OlaHsd * C57BL/6 * CBA)
|
increased acute promyelocytic leukemia incidence
|
J:172071
|
increased B cell derived lymphoma incidence
|
J:172071
|
increased leukemia incidence
|
J:172071
|
increased lymphoma incidence
|
J:172071
|
Gt(ROSA)26Sortm4(CAG-hsb5)Nki/Gt(ROSA)26Sor+ Tg(Mx1-cre)1Cgn/0 Tg(Tal1-tTA)19Dgt/0 Tg(tetO-BCR/ABL1)2Dgt/0 TgTn(pb-sb-GrOnc)#aGsva/0
(involves: 129P2/OlaHsd * C57BL/6 * CBA/J * DBA/2 * FVB/N)
|
increased chronic myelocytic leukemia incidence
|
J:227558
|
Gt(ROSA)26Sortm4(CAG-hsb5)Nki/Gt(ROSA)26Sor+ Tg(Mx1-cre)1Cgn/0 Tg(tetO-BCR/ABL1)2Dgt/0 TgTn(pb-sb-GrOnc)#aGsva/0
(involves: 129P2/OlaHsd * C57BL/6 * CBA/J * FVB/N)
|
increased leukemia incidence
|
J:227558
|
Gt(ROSA)26Sortm4(Ikbkb)Rsky/Gt(ROSA)26Sor+ Ighg1tm1(cre)Cgn/Ighg1+ Prdm1tm2Masu/Prdm1tm2Masu
(involves: 129P2/OlaHsd * C57BL/6)
|
increased B cell derived lymphoma incidence
|
J:167612
|
Gt(ROSA)26Sortm5(ASPSCR1/TFE3)Mrc/Gt(ROSA)26Sor+ Tg(Prrx1-cre/ERT2)1Mlgn/0
(involves: 129S1/Sv * 129X1/SvJ * C57BL/6)
|
increased organ/body region tumor incidence
|
J:217462
|
Gt(ROSA)26Sortm7(Pik3ca*,EGFP)Rsky/Gt(ROSA)26Sortm13(CAG-MYC,-CD2*)Rsky Ighg1tm1(cre)Cgn/Ighg1+
(involves: 129P2/OlaHsd * C57BL/6)
|
increased B cell derived lymphoma incidence
|
J:191824
|
Gt(ROSA)26Sortm9(CAG-tdTomato)Hze/Gt(ROSA)26Sor+ Hmga2tm1.1Mmw/Hmga2+ Krastm4Tyj/Kras+ Tg(Pdx1-cre)6Tuv/0 Trp53tm2Tyj/Trp53+
(involves: 129S4/SvJae * 129S6/SvEvTac * C57BL/6 * C57BL/6NCrl * FVB/N)
|
increased pancreatic ductal adenocarcinoma incidence
|
J:245611
|
Gt(ROSA)26Sortm9(CAG-tdTomato)Hze/Gt(ROSA)26Sor+ Krastm4Tyj/Kras+ Prdm1tm1Clme/Prdm1tm1Clme Tg(Pdx1-cre)6Tuv/0 Trp53tm2Tyj/Trp53+
(involves: 129 * C57BL/6NCrl * FVB/N)
|
increased pancreatic ductal adenocarcinoma incidence
|
J:245611
|
increased pancreatic intraepithelial neoplasia incidence
|
J:245611
|
Gt(ROSA)26Sortm9(CAG-tdTomato)Hze/Gt(ROSA)26Sor+ Krastm4Tyj/Kras+ Tg(Pdx1-cre)6Tuv/0 Trp53tm2Tyj/Trp53+
(involves: 129 * C57BL/6NCrl * FVB/N)
|
increased pancreatic ductal adenocarcinoma incidence
|
J:245611
|
increased pancreatic intraepithelial neoplasia incidence
|
J:245611
|
Gt(ROSA)26Sortm9(cre/ESR1)Arte/Gt(ROSA)26Sor+ Ptentm1Hwu/Ptentm1Hwu
(involves: 129S4/SvJae * C57BL/6)
|
increased acute lymphoblastic leukemia incidence
|
J:170965
|
Gt(ROSA)26Sortm10(Lmp1)Rsky/Gt(ROSA)26Sor+ Tcrbtm1Mom/Tcrbtm1Mom Tcrdtm1Mom/Tcrdtm1Mom Cd19tm1(cre)Cgn/Cd19+
(involves: 129P2/OlaHsd * 129S2/SvPas * BALB/cJ)
|
increased B cell derived lymphoma incidence
|
J:181546
|
Gt(ROSA)26Sortm11(Lmp1)Rsky/Gt(ROSA)26Sor+ Tcrbtm1Mom/Tcrbtm1Mom Tcrdtm1Mom/Tcrdtm1Mom Cd19tm1(cre)Cgn/Cd19+
(involves: 129P2/OlaHsd * 129S2/SvPas * C57BL/6)
|
increased B cell derived lymphoma incidence
|
J:181546
|
Gt(ROSA)26Sortm18(Zeb2)Jhai/Gt(ROSA)26Sor+ Tg(Tek-cre)1Ywa/0 Trp53tm1Brn/Trp53tm1Brn
(involves: 129P2/OlaHsd * C57BL/6 * CD-1 * SJL)
|
increased T cell derived lymphoma incidence
|
J:263520
|
Gt(ROSA)26Sortm18(Zeb2)Jhai/Gt(ROSA)26Sortm18(Zeb2)Jhai Tg(Cd4-cre)1Cwi/0
(involves: C57BL/6 * CD-1 * DBA/2)
|
increased T cell acute lymphoblastic leukemia incidence
|
J:263520
|
Gt(ROSA)26Sortm18(Zeb2)Jhai/Gt(ROSA)26Sortm18(Zeb2)Jhai Tg(Tek-cre)1Ywa/0
(involves: C57BL/6 * CD-1 * SJL)
|
increased T cell acute lymphoblastic leukemia incidence
|
J:263520
|
increased thymus tumor incidence
|
J:263520
|
Gt(ROSA)26Sortm18(Zeb2)Jhai/Gt(ROSA)26Sortm18(Zeb2)Jhai Tg(Tek-cre)1Ywa/0 Trp53tm1Brn/Trp53tm1Brn
(involves: 129P2/OlaHsd * C57BL/6 * CD-1 * SJL)
|
increased leukemia incidence
|
J:263520
|
increased T cell derived lymphoma incidence
|
J:263520
|
increased thymoma incidence
|
J:263520
|
Gtf2ird1Tg(Alb1-Myc)166.8Sst/0 Tg(MtTGFA)42Lmb/0
(involves: C57BL/6 * CBA * CD-1)
|
increased hepatocellular carcinoma incidence
|
J:4527
|
Gtf2ird1Tg(Alb1-Myc)166.8Sst/Gtf2ird1+
(involves: C57BL/6 * CBA)
|
increased hepatocellular carcinoma incidence
|
J:34434,
J:101128
|
increased liver adenoma incidence
|
J:34434
|
increased liver tumor incidence
|
J:101128
|
Gtf2ird1Tg(Alb1-Myc)166.8Sst/Gtf2ird1+ Tg(Alb-E2F1)8Sst/0
(involves: C57BL/6 * CBA)
|
increased hepatocellular carcinoma incidence
|
J:101128
|
increased liver tumor incidence
|
J:101128
|
Gtf2ird1Tg(Alb1-Myc)166.8Sst/Gtf2ird1+ Tg(MtTGFA)42Lmb/0
(involves: C57BL/6 * CBA * CD-1)
|
increased hepatocellular carcinoma incidence
|
J:34434
|
increased liver adenoma incidence
|
J:34434
|
H2u/H2u Tg(TCRA)B1Jg/0
(B10.PL-H2u H2-T18a/(73NS)Sn-Tg(TCRA)B1Jg/J)
|
increased T cell derived lymphoma incidence
|
J:92992
|
H2u/H2u Tg(TCRA)B1Jg/0 Tg(TCRB)C14Jg/0
(B10.PL-H2u H2-T18a/(73NS)Sn-Tg(TCRA)B1Jg Tg(TCRB)C14Jg)
|
increased T cell derived lymphoma incidence
|
J:92992
|
H2axtm1Fwa/H2ax+ Trp53tm1Brd/Trp53tm1Brd
(involves: 129S6/SvEvTac * 129S7/SvEvBrd * C57BL/6)
|
increased B cell derived lymphoma incidence
|
J:84879
|
increased lymphoma incidence
|
J:84879
|
increased T cell derived lymphoma incidence
|
J:84879
|
H2axtm1Fwa/H2axtm1Fwa
(involves: 129S6/SvEvTac)
|
increased T cell derived lymphoma incidence
|
J:84879
|
H2axtm1Fwa/H2axtm1Fwa Trp53tm1Brd/Trp53tm1Brd
(involves: 129S6/SvEvTac * 129S7/SvEvBrd * C57BL/6)
|
increased B cell derived lymphoma incidence
|
J:84879
|
increased colon adenocarcinoma incidence
|
J:84879
|
increased T cell derived lymphoma incidence
|
J:84879
|
H2axtm1Nus/H2axtm1Nus Trp53tm1Brd/Trp53tm1Brd
(involves: 129S7/SvEvBrd * C57BL/6J)
|
increased lymphoma incidence
|
J:86590
|
H19tm1Tilg/H19+ Tg(CRP-TAg)60-3Urt/0
(involves: 129S/SvEv * BALB/c * C57BL/6 * SJL)
|
increased liver tumor incidence
|
J:90036
|
Hace1tm1Pngr/Hace1+
(involves: 129P2/OlaHsd * C57BL/6)
|
increased lung tumor incidence
|
J:125183
|
Hace1tm1Pngr/Hace1tm1Pngr
(involves: 129P2/OlaHsd * C57BL/6)
|
increased lung tumor incidence
|
J:125183
|
increased T cell derived lymphoma incidence
|
J:125183
|
Hat1tm1.1Mrpa/Hat1+
(B6.Cg-Hat1tm1.1Mrpa)
|
increased histiocytic sarcoma incidence
|
J:296531
|
increased kidney tumor incidence
|
J:296531
|
increased liver tumor incidence
|
J:296531
|
increased spleen neoplasm incidence
|
J:296531
|
Hcif1C57BL/6J/Hcif1C57BR/cdJ Hcif2C57BL/6J/Hcif2C57BR/cdJ
(involves: C57BL/6J * C57BR/cdJ)
|
increased hepatoma incidence
|
J:33543
|
Hcif1C57BR/cdJ/?
(involves: C57BL/6J * C57BR/cdJ)
|
increased hepatoma incidence
|
J:33543
|
Hcktm1Ern/Hcktm1Ern
(involves: 129S1/Sv * C57BL/6)
|
increased lung adenocarcinoma incidence
|
J:111432
|
Hcs1C3H/He/?
(involves: A/J * C3H/He)
|
increased hepatoma incidence
|
J:3657
|
Hcs2C3H/He/?
(involves: A/J * C3H/He)
|
increased hepatoma incidence
|
J:3657
|
Hcs3A/J/?
(involves: A/J * C3H/He)
|
increased hepatoma incidence
|
J:3657
|
Hcs4C3H/He/Hcs4C57BL/6ByJ
(involves: C3H/He * C57BL/6JBy * M. spretus)
|
increased hepatoma incidence
|
J:20738
|
Hcs5C3H/He/?
(involves: C3H/He * C57BL/6ByJ * M. spretus)
|
increased hepatoma incidence
|
J:20738
|
Hcs6M. spretus/?
(involves: C3H/He * C57BL/6ByJ * M. spretus)
|
increased hepatoma incidence
|
J:20738
|
Hcs7C3H/HeJ/?
(involves: C3H/HeJ * C57BL/6J)
|
increased hepatoma incidence
|
J:31507
|
Hcs7C3H/HeJ/Hcs7C3H/HeJ
(involves: C3H/HeJ * C57BL/6J)
|
increased hepatoma incidence
|
J:91132
|
Hcs7C3H/HeJ/Hcs7C57BL/6J
(involves: C3H/HeJ * C57BL/6J)
|
increased hepatoma incidence
|
J:91132
|
Hcs8CBA/J/Hcs8CBA/J
(involves: C57BL/6J * CBA/J)
|
increased hepatoma incidence
|
J:91132
|
Hcs9C57BR/cdJ/Hcs9C57BR/cdJ
(B6.BR-(D1Mit5-D1Mit17))
|
increased hepatoma incidence
|
J:91132
|
Hdac1tm1.1Shmc/Hdac1tm1.1Shmc Hdac2tm1.1Shmc/Hdac2tm1.1Shmc Tg(Lck-cre)1Cwi/0
(involves: 129S7/SvEvBrd)
|
increased T cell derived lymphoma incidence
|
J:194769
|
HelqGt(RRF112)Byg/Helq+
(involves: 129P2/OlaHsd * C57BL/6)
|
increased Harderian gland tumor incidence
|
J:206104
|
increased intestinal adenoma incidence
|
J:206104
|
increased pituitary adenoma incidence
|
J:206104
|
HelqGt(RRF112)Byg/HelqGt(RRF112)Byg
(involves: 129P2/OlaHsd * C57BL/6)
|
increased gland tumor incidence
|
J:206104
|
increased granulosa cell tumor incidence
|
J:206104
|
increased Harderian gland tumor incidence
|
J:206104
|
increased mammary gland tumor incidence
|
J:206104
|
increased ovary tumor incidence
|
J:206104
|
increased pituitary adenoma incidence
|
J:206104
|
Hephl1cw/Hephl1cw
(CWD/LeJ)
|
increased B cell derived lymphoma incidence
|
J:24875
|
increased lymphoma incidence
|
J:24875
|
Hic1tm1Sbb/Hic1+
(involves: 129S4/SvJae * C57BL/6)
|
increased hepatocellular carcinoma incidence
|
J:81448
|
increased lung adenocarcinoma incidence
|
J:81448
|
increased lymphoma incidence
|
J:81448
|
increased pancreatic islet cell carcinoma incidence
|
J:81448
|
Hif1atm3Rsjo/Hif1atm3Rsjo Hprt1tm1(Pck1-cre)Vhh/Y Vhltm1Jae/Vhltm1Jae
(involves: 129 * BALB/c * C57BL/6)
|
increased hepatic hemangioma incidence
|
J:97652
|
Hip1tm4Tsr/Hip1+ Runx1tm3Dow/Runx1+ Tg(Mx1-cre)1Cgn/0
(involves: 129X1/SvJ * C57BL/6 * CBA)
|
increased chronic myelocytic leukemia incidence
|
J:151974
|
Hip1tm4Tsr/Hip1+ Tg(Mx1-cre)1Cgn/0
(involves: 129X1/SvJ * C57BL/6 * CBA)
|
increased hepatocellular carcinoma incidence
|
J:151974
|
increased liver tumor incidence
|
J:151974
|
increased T cell derived lymphoma incidence
|
J:151974
|
Hmga1tm1Afus/Hmga1tm1Afus
(involves: 129S7/SvEvBrd * C57BL/6)
|
increased B cell derived lymphoma incidence
|
J:106702
|
increased leukemia incidence
|
J:106702
|
Hmga1tm1Mina/Hmga1tm1Mina Tg(Krt19-Ptgs2,Krt19-Ptges)8Tko/0 Tg(Krt19-Wnt1)2Maos/0
(involves: C3H * C57BL/6 * CBA)
|
increased stomach tumor incidence
|
J:153058
|
Hmgn1tm1Mbus/Hmgn1tm1Mbus
(involves: 129X1/SvJ)
|
increased pheochromocytoma incidence
|
J:100773
|
Hprt1tm1(CAG-BRF1)Gu/Hprt1+ Krastm4Tyj/Kras+ Trp53tm2Tyj/Trp53+ Tg(Pdx1-cre)6Tuv/0
(involves: 129P2/OlaHsd * 129S4/SvJae * 129S7/SvEvBrd * FVB/N)
|
increased pancreatic ductal adenocarcinoma incidence
|
J:285667
|
Hprt1tm1(CUX1)Anep/Hprt1+
(FVB.129P2-Hprt1tm1(CUX1)Anep)
|
increased mammary adenocarcinoma incidence
|
J:152682
|
increased mammary gland tumor incidence
|
J:152682
|
Hprt1tm1(Pbsn*-cre/ERT2)Jir/Y Ptentm2Mak/Ptentm2Mak
(involves: 129P2/OlaHsd * C57BL/6)
|
increased prostate gland adenocarcinoma incidence
|
J:144357
|
increased prostate intraepithelial neoplasia incidence
|
J:144357
|
Hprt1tm1(Pck1-cre)Vhh/Y Vhltm1Jae/Vhltm1Jae
(involves: 129P2/OlaHsd * 129S4/SvJae * BALB/c * C57BL/6)
|
increased hepatic hemangioma incidence
|
J:97652
|
Hprt1tm2(CUX1)Anep/Hprt1+
(FVB.129P2-Hprt1tm2(CUX1)Anep)
|
increased mammary adenocarcinoma incidence
|
J:152682
|
increased mammary gland tumor incidence
|
J:152682
|
Hrhr/Hrhr
(HRS/J)
|
increased leukemia incidence
|
J:5726,
J:5908,
J:24786
|
Hrhr/Hrhr Msh2tm1Htr/Msh2tm1Htr
(involves: 129P2/OlaHsd)
|
increased lymphoma incidence
|
J:79734
|
increased skin papilloma incidence
|
J:79734
|
increased skin squamous cell carcinoma incidence
|
J:79734
|
increased skin tumor incidence
|
J:79734
|
Hrhr/Hrhr Msh2tm1Htr/Msh2tm1Htr Xpatm1Tnka/Xpatm1Tnka
(involves: 129P2/OlaHsd * C57BL/6 * CBA)
|
increased lymphoma incidence
|
J:79734
|
increased skin papilloma incidence
|
J:79734
|
increased skin squamous cell carcinoma incidence
|
J:79734
|
increased skin tumor incidence
|
J:79734
|
Hrhr/Hrhr Xpatm1Tnka/Xpatm1Tnka
(involves: C57BL/6 * CBA)
|
increased skin tumor incidence
|
J:79734
|
Hrastm1Jaf/Hras+ Tg(CAG-cre)13Miya/0
(involves: 129S6/SvEvTac * Black Swiss * C57BL/6)
|
increased skin papilloma incidence
|
J:148393
|
increased stomach tumor incidence
|
J:148393
|
Hrastm1Jaf/Hrastm1Jaf Nf2tm2Gth/Nf2tm2Gth Tg(TPO-cre)1Shk/0
(involves: 129P2/OlaHsd * 129S6/SvEvTac * Black Swiss * C57BL/6 * FVB/NCr)
|
increased thyroid tumor incidence
|
J:231492
|
Hrastm1Jaf/Hrastm1Jaf Ptentm2.1Ppp/Ptentm2.1Ppp Tg(TPO-cre)1Shk/0
(involves: 129S1/Sv * 129S6/SvEvTac * FVB/NCr)
|
increased thyroid tumor incidence
|
J:231492
|
Hrastm1Jaf/Hrastm1Jaf Trp53tm1Brn/Trp53tm1Brn Tg(TPO-cre)1Shk/0
(involves: 129P2/OlaHsd * 129S6/SvEvTac * Black Swiss * C57BL/6 * FVB/NCr)
|
increased thyroid tumor incidence
|
J:231492
|
Hrastm2Xbr/Hrastm2Xbr
(involves: 129S1/Sv * 129X1/SvJ * C57BL/6 * FVB/N)
|
increased mammary adenocarcinoma incidence
|
J:137729
|
Hspa5tm1Alee/Hspa5+ Ptentm1Hwu/Ptentm1Hwu Tg(Pbsn-cre)4Prb/?
(involves: 129 * 129S4/SvJae * C57BL/6 * DBA/2)
|
increased prostate gland adenocarcinoma incidence
|
J:142106
|
increased prostate intraepithelial neoplasia incidence
|
J:142106
|
Htatip2tm1Hx/Htatip2+
(involves: 129P2/OlaHsd * C57BL/6J)
|
increased hepatocellular carcinoma incidence
|
J:87066
|
increased neuroblastoma incidence
|
J:87066
|
increased ovary tumor incidence
|
J:87066
|
increased thymoma incidence
|
J:87066
|
increased urinary bladder transitional cell carcinoma incidence
|
J:87066
|
Htatip2tm1Hx/Htatip2tm1Hx
(involves: 129P2/OlaHsd * C57BL/6J)
|
increased duodenum adenocarcinoma incidence
|
J:87066
|
increased hepatocellular carcinoma incidence
|
J:87066
|
increased uterus leiomyoma incidence
|
J:87066
|
Icostm1Flv/Icostm1Flv Rc3h1san/Rc3h1+
(involves: 129S1/Sv * C57BL/6 * C57BL/6JSfdAnu)
|
increased T cell derived lymphoma incidence
|
J:189087
|
Id1tm1Zhu/Id1tm1Zhu Tcf3tm1Wein/Tcf3tm1Wein
(involves: 129S1/Sv * 129S4/SvJaeSor * C57BL/6)
|
increased T cell derived lymphoma incidence
|
J:44278
|
Id2tm1Yyk/Id2+ Tg(Wnt1)1Hev/0
(involves: 129S1/Sv * 129X1/SvJ * C57BL/6 * FVB * SJL)
|
increased mammary gland tumor incidence
|
J:96305
|
Id2tm1Yyk/Id2tm1Yyk Tg(Wnt1)1Hev/0
(involves: 129S1/Sv * 129X1/SvJ * C57BL/6 * FVB * SJL)
|
increased mammary gland tumor incidence
|
J:96305
|
Ifngtm1Ts/Ifngtm1Ts
(B6.129S7-Ifngtm1Ts)
|
increased lymphoma incidence
|
J:77491
|
increased T cell derived lymphoma incidence
|
J:77491
|
Ifngtm1Ts/Ifngtm1Ts
(C.129S7-Ifngtm1Ts)
|
increased lung adenocarcinoma incidence
|
J:77491
|
Ifngtm1Ts/Ifngtm1Ts Prf1tm1Sdz/Prf1tm1Sdz
(C.Cg-Prf1tm1Sdz Ifngtm1Ts)
|
increased B cell derived lymphoma incidence
|
J:77491
|
increased lymphoma incidence
|
J:77491
|
Ifngr1tm1Agt/Ifngr1tm1Agt Tg(GZMB-Tax)#Lera/0
(involves: 129S7/SvEvBrd * C57BL/6)
|
increased skeletal tumor incidence
|
J:147601
|
Igh-Vtm1(Igh-Vx24)Hmb/Igh-Vtm1(Igh-Vx24)Hmb
(involves: 129/Sv * C57BL/6)
|
increased lymphoma incidence
|
J:54380
|
increased T cell derived lymphoma incidence
|
J:54380
|
Ightm1(Myc)Janz/Igh+
(involves: 129X1/SvJ * C57BL/6)
|
increased B cell derived lymphoma incidence
|
J:160845,
J:96785
|
Ightm1(Myc)Janz/Igh+ Mdm4tm1.1Wahl/Mdm4tm1.1Wahl
(involves: 129S/Sv * C57BL/6)
|
increased B cell derived lymphoma incidence
|
J:150341
|
increased lymphoma incidence
|
J:150341
|
Ightm1(Myc)Janz/Igh+ Tg(Emu-FGFR3)A5Wmk/0
(involves: 129X1/SvJ * C57BL/6 * FVB/N)
|
increased B cell derived lymphoma incidence
|
J:160845
|
Ightm1(Myc)Janz/Igh+ Tg(Emu-FGFR3)D3Wmk/0
(involves: 129X1/SvJ * C57BL/6 * FVB/N)
|
increased B cell derived lymphoma incidence
|
J:160845
|
Ightm1(PAX5)Mbu/Igh+
(B6.Cg-Ightm1(PAX5)Mbu)
|
increased lymphoma incidence
|
J:118111
|
increased T cell derived lymphoma incidence
|
J:118111
|
Ightm1(PAX5)Mbu/Ightm1(PAX5)Mbu
(B6.Cg-Ightm1(PAX5)Mbu)
|
increased lymphoma incidence
|
J:118111
|
increased T cell derived lymphoma incidence
|
J:118111
|
Ightm1.1(Tag)Rwhe/Igh+
(involves: 129P2/OlaHsd * C57BL/6)
|
increased chronic lymphocytic leukemia incidence
|
J:150315
|
increased leukemia incidence
|
J:150315
|
Ightm1.1(Tag)Rwhe/Igh+ Trp53tm1Tyj/Trp53tm1Tyj
(involves: 129P2/OlaHsd * 129S2/SvPas * C57BL/6)
|
increased chronic lymphocytic leukemia incidence
|
J:150315
|
increased leukemia incidence
|
J:150315
|
Ightm2.1(Tag)Rwhe/Igh+
(involves: 129P2/OlaHsd * C57BL/6)
|
increased chronic lymphocytic leukemia incidence
|
J:150315
|
increased leukemia incidence
|
J:150315
|
Ightm2.1(Tag)Rwhe/Igh+ Trp53tm1Tyj/Trp53tm1Tyj
(involves: 129P2/OlaHsd * 129S2/SvPas * C57BL/6)
|
increased chronic lymphocytic leukemia incidence
|
J:150315
|
increased leukemia incidence
|
J:150315
|
Ighatm1(Myc)Janz/Igha+
(involves: 129S1/Sv * C57BL/6)
|
increased B cell derived lymphoma incidence
|
J:90901
|
Ighatm1(Myc)Janz/Igha+ Tg(Igk-V21-Bax)1967Bvn/0
(involves: 129S1/Sv * C57BL/6 * FVB/N)
|
increased leukemia incidence
|
J:90901
|
Ighatm1(Myc)Janz/Igha+ Tg(Tnfsf13b)1Fma/0
(involves: 129S1/Sv * C57BL/6 * DBA/2J)
|
increased chronic lymphocytic leukemia incidence
|
J:166158
|
Ighmtm1(Bcl6)Rdf/?
(involves: 129/Sv * C57BL/6)
|
increased B cell derived lymphoma incidence
|
J:98937
|
Ighmtm1Cgn/Ighmtm1Cgn Tg(IghelMD4)4Ccg/Tg(IghelMD4)4Ccg
(NOD.Cg-Ighmtm1Cgn Tg(IghelMD4)4Ccg/DvsJ)
|
increased lymphoma incidence
|
J:80859
|
Ighmtm1Cgn/Ighmtm1Cgn Tg(IghMyc)22Bri/0
(involves: 129S2/SvPas * C57BL * SJL)
|
increased lymphoma incidence
|
J:187318
|
Igs2tm1(CAG-Met)Zsu/Igs2+ Ptentm1Hwu/Ptentm1Hwu Tg(Pbsn-cre)4Prb/0
(involves: 129 * C57BL/6 * DBA/2 * FVB/N)
|
increased prostate gland adenocarcinoma incidence
|
J:268934
|
increased prostate gland tumor incidence
|
J:268934
|
increased prostate intraepithelial neoplasia incidence
|
J:268934
|
Igs2tm1(CAG-Met)Zsu/Igs2+ Tg(Pbsn-cre)4Prb/0
(involves: 129S1/Sv * 129X1/SvJ * C57BL/6 * DBA/2 * FVB/N)
|
increased prostate intraepithelial neoplasia incidence
|
J:268934
|
Ikbkgtm1.1Chtr/Y Tg(Alb1-cre)7Gsc/0
(involves: C57BL/6 * FVB/N * SJL)
|
increased hepatocellular carcinoma incidence
|
J:151485
|
Ikbkgtm1.1Chtr/Ikbkgtm1.1Chtr Tg(Alb1-cre)7Gsc/0
(involves: C57BL/6 * FVB/N * SJL)
|
increased hepatocellular carcinoma incidence
|
J:151485
|
Ikbkgtm1.1Chtr/Ikbkgtm1.1Chtr Tg(Alb1-cre)7Gsc/0
(involves: FVB/N)
|
increased hepatocellular carcinoma incidence
|
J:160521
|
Ikbkgtm1.1Mpa/Ikbkgtm1.1Mpa Tg(Alb1-cre)7Gsc/0
(involves: C57BL/6 * FVB/N)
|
increased hepatocellular carcinoma incidence
|
J:118336
|
Ikzf1plstc/Ikzf1+
(C57BL/6JSfdAnu-Ikzf1plstc)
|
increased leukemia incidence
|
J:84569
|
increased T cell derived lymphoma incidence
|
J:84569
|
Ikzf1tm1(Pax5)Mbu/Ikzf1+ Tg(Lck-cre)1Cwi/0
(involves: 129P2/OlaHsd * C57BL/6)
|
increased T cell derived lymphoma incidence
|
J:118111
|
Ikzf1tm1.1(Pax5)Mbu/Ikzf1+
(involves: 129P2/OlaHsd * C57BL/6)
|
increased lymphoma incidence
|
J:118111
|
increased T cell derived lymphoma incidence
|
J:118111
|
Ikzf1tm1Kast/Ikzf1+ Tg(BCR/ABL)623Hkp/0
(involves: 129S2/SvPas * C57BL/6 * CBA)
|
increased acute lymphoblastic leukemia incidence
|
J:160846
|
Ikzf1tm1Kge/Ikzf1+
(involves: 129S4/SvJae * C57BL/6)
|
increased leukemia incidence
|
J:29355
|
Ikzf1tm1Kge/Ikzf1+
(involves: 129S4/SvJae * BALB/c)
|
increased leukemia incidence
|
J:29355
|
Ikzf1tm2.1Smale/Ikzf1tm2.1Smale
(B6.Cg-Ikzf1tm2.1Smale)
|
increased lymphoma incidence
|
J:208211
|
Ikzf1tm3.1Mbu/Ikzf1tm3.1Mbu Il7rtm1.1(icre)Hrr/Il7r+
(involves: 129P2/OlaHsd * C57BL/6 * SJL)
|
increased T cell derived lymphoma incidence
|
J:209928
|
Ikzf1tm3Kge/Ikzf1tm3Kge Tg(CD2-icre)4Kio/?
(involves: C57BL/10 * CBA/Ca)
|
increased T cell derived lymphoma incidence
|
J:209927
|
Ikzf3tm1Kge/Ikzf3tm1Kge
(involves: 129S4/SvJae * C57BL/6)
|
increased B cell derived lymphoma incidence
|
J:50626
|
Il6tm1Kopf/Il6+ Ncoa5tm1Hxia/Ncoa5+
(involves: 129S2/SvPas * C57BL/6)
|
increased hepatocellular carcinoma incidence
|
J:207622
|
Il10tm1Cgn/Il10tm1Cgn
(involves: 129P2/OlaHsd * C57BL/6)
|
increased intestinal adenocarcinoma incidence
|
J:68476
|
increased large intestine adenocarcinoma incidence
|
J:35020
|
Il10tm1Cgn/Il10tm1Cgn
(B6.129P2-Il10tm1Cgn/J)
|
increased colon adenocarcinoma incidence
|
J:149347
|
Il10tm1Cgn/Il10tm1Cgn Tg(MUC1)79.24Gend/0
(B6.Cg-Il10tm1Cgn Tg(MUC1)79.24Gend)
|
increased colon adenocarcinoma incidence
|
J:149347
|
Il12rb2tm1Jm/Il12rb2tm1Jm
(B6;129S1-Il12rb2tm1Jm/J)
|
increased lung carcinoma incidence
|
J:106805
|
Immp2lTg(HLA-A/H2-D)2Enge/0 Tg(Mt1-RET)304Ina/0
(involves: BALB/c * C57BL/6 * CBA/Ca)
|
increased eye tumor incidence
|
J:130879
|
increased organ/body region tumor incidence
|
J:130879
|
Ing1Gt(OST206270)Lex/Ing1+
(involves: 129S5/SvEvBrd * C57BL/6)
|
increased B cell derived lymphoma incidence
|
J:118602
|
Ing1Gt(OST206270)Lex/Ing1Gt(OST206270)Lex
(involves: 129S5/SvEvBrd * C57BL/6)
|
increased B cell derived lymphoma incidence
|
J:118602
|
Ing1tm1Avg/Ing1tm1Avg
(involves: 129S1/Sv * C57BL/6)
|
increased B cell derived lymphoma incidence
|
J:105658
|
Ing2tm1.1Ccha/Ing2tm1.1Ccha
(involves: 129 * C57BL/6J * FVB/N)
|
increased Harderian gland adenoma incidence
|
J:167311
|
increased histiocytic sarcoma incidence
|
J:167311
|
Inhatm1Bay/Inhatm1Bay
(involves: 129S7/SvEvBrd * C57BL/6)
|
increased adrenal gland tumor incidence
|
J:125349,
J:20450
|
increased gonad tumor incidence
|
J:3315
|
increased ovary tumor incidence
|
J:125349,
J:3315
|
increased testis tumor incidence
|
J:125349
|
Inhatm1Bay/Inhatm1Bay
(involves: 129S6/SvEvTac * 129S7/SvEvBrd)
|
increased ovary tumor incidence
|
J:84989
|
increased testis tumor incidence
|
J:84989
|
Inhatm1Bay/Inhatm1Bay Smad3tm1Par/Smad3+
(involves: 129S1/Sv * 129S7/SvEvBrd * 129X1/Sv * C57BL/6)
|
increased adrenal gland tumor incidence
|
J:125349
|
increased ovary tumor incidence
|
J:125349
|
Inhatm1Bay/Inhatm1Bay Smad3tm1Par/Smad3tm1Par
(involves: 129S1/Sv * 129S7/SvEvBrd * 129X1/Sv * C57BL/6)
|
increased ovary tumor incidence
|
J:125349
|
Ino80tm1.1Schg/Ino80+ Trp53tm1Tyj/Trp53tm1Tyj
(involves: 129S2/SvPas * C57BL/6J)
|
increased T cell derived lymphoma incidence
|
J:221224
|
Inpp5dm1Anu/Inpp5dm1Anu
(C57BL/6JAnu-Inpp5dm1Anu)
|
increased B cell derived lymphoma incidence
|
J:104190
|
Inpp5jtm1.1Cmit/Inpp5jtm1.1Cmit Tg(MMTV-PyVT)634Mul/0
(involves: C57BL/6)
|
increased mammary gland tumor incidence
|
J:224914
|
Ints15em1Takas/Ints15em1Takas
(involves: C57BL/6 * DBA/2)
|
increased retina hemangioma incidence
|
J:337973
|
Ints15em2Takas/Ints15+
(involves: C57BL/6 * DBA/2)
|
increased retina hemangioma incidence
|
J:337973
|
Iqgap1tm1Aber/Iqgap1tm1Aber Iqgap2tm1Vs/Iqgap2tm1Vs
(involves: 129S4/SvJae)
|
increased hepatocellular carcinoma incidence
|
J:132670
|
Iqgap2tm1Vs/Iqgap2tm1Vs
(either: 129S4/SvJae-Iqgap2tm1Vs or B6.129S4-Iqgap2tm1Vs)
|
increased hepatocellular carcinoma incidence
|
J:132670
|
Iqgap2tm1Vs/Iqgap2tm1Vs
(involves: 129S4/SvJae)
|
increased hepatocellular carcinoma incidence
|
J:205882
|
Irf1tm1Mak/Irf1tm1Mak
(B6.129S2-Irf1tm1Mak/J)
|
increased lymphoma incidence
|
J:91927
|
Irf1tm1Mak/Irf1tm1Mak Trp53tm1Sia/Trp53tm1Sia
(involves: 129S2/SvPas * C57BL/6 * CBA)
|
increased lymphoma incidence
|
J:55418
|
Irf8myls/Irf8myls Slc11a1r/Slc11a1r
(BXH2/TyJ)
|
increased chronic myelocytic leukemia incidence
|
J:97931
|
Irf8myls/Irf8myls Slc11a1r/Slc11a1r
(involves: A/J * BXH2/TyJ)
|
increased chronic myelocytic leukemia incidence
|
J:97931
|
Irf8tm1Hor/Irf8+
(either: (involves: 129P2/OlaHsd) or (involves: 129P2/OlaHsd * C57BL/6))
|
increased chronic myelocytic leukemia incidence
|
J:36038
|
Irf8tm1Hor/Irf8tm1Hor
(either: (involves: 129P2/OlaHsd) or (involves: 129P2/OlaHsd * C57BL/6))
|
increased chronic myelocytic leukemia incidence
|
J:36038
|
increased lymphoma incidence
|
J:36038
|
Is(14)1Rdf Is(14)2Rdf/Del(14Trim13-Dleu2)4Rdf Cd19tm1(cre)Cgn/Cd19+
(involves: 129P2/OlaHsd * 129S1/Sv * 129S4/SvJaeSor * C57BL/6)
|
increased B cell derived lymphoma incidence
|
J:156946
|
increased leukemia incidence
|
J:156946
|
Is(14)1Rdf Is(14)5Rdf/Del(14Trim13-Rnaseh2b)6Rdf Cd19tm1(cre)Cgn/Cd19+
(involves: 129P2/OlaHsd * 129S1/Sv * 129S4/SvJaeSor * C57BL/6)
|
increased chronic lymphocytic leukemia incidence
|
J:179879
|
increased lymphoma incidence
|
J:179879
|
increased small lymphocytic lymphoma incidence
|
J:179879
|
Is(14)1Rdf/Is(14)1Rdf Is(14)5Rdf/Is(14)5Rdf Cd19tm1(cre)Cgn/Cd19+
(involves: 129P2/OlaHsd * 129S1/Sv * 129S4/SvJaeSor * C57BL/6)
|
increased chronic lymphocytic leukemia incidence
|
J:179879
|
increased lymphoma incidence
|
J:179879
|
increased small lymphocytic lymphoma incidence
|
J:179879
|
Itgavtm2Hyn/Itgavtm2.1Hyn Tg(Tek-cre)1Ywa/?
(involves: 129S2/SvPas * C57BL/6 * FVB * SJL)
|
increased intestinal adenocarcinoma incidence
|
J:125508
|
Jak2tm1(JAK2)Argr/Jak2+ Dppa3tm1(cre)Peli/Dppa3+
(involves: 129S5/SvEvBrd * 129S7/SvEvBrd * C57BL/6)
|
increased chronic myelocytic leukemia incidence
|
J:233169
|
Jak2tm1.2Ble/Jak2+
(involves: 129S6/SvEvTac * C57BL/6 * FVB/N)
|
increased hemolymphoid system tumor incidence
|
J:160883
|
Junbtm3Wag/Junbtm3Wag Meox2tm1(cre)Sor/Meox2+
(involves: 129P2/OlaHsd * 129S4/SvJaeSor * C57BL/6)
|
increased chronic myelocytic leukemia incidence
|
J:88126
|
Kat5tm1Jwl/Kat5+ Tg(IghMyc)22Bri/0
(involves: 129S1/Sv * 129X1/SvJ * C57BL * C57BL/6 * SJL)
|
increased B cell derived lymphoma incidence
|
J:125164
|
Kat5tm1Jwl/Kat5+ Tg(IghMyc)22Bri/0 Trp53tm1Tyj/Trp53+
(involves: 129 * C57BL * C57BL/6 * SJL)
|
increased B cell derived lymphoma incidence
|
J:125164
|
Kdm5atm1.1Kael/Kdm5a+ Rb1tm1Tyj/Rb1+
(involves: 129S2/SvPas * 129S6/SvEvTac * FVB/N)
|
increased pituitary gland tumor incidence
|
J:175625
|
increased thyroid tumor incidence
|
J:175625
|
Kdm5atm1.1Kael/Kdm5atm1.1Kael Rb1tm1Tyj/Rb1+
(involves: 129S2/SvPas * 129S6/SvEvTac * FVB/N)
|
increased pituitary gland tumor incidence
|
J:175625
|
increased thyroid tumor incidence
|
J:175625
|
Kdm5atm1Kael/Kdm5atm1Kael Men1tm2.1Mmey/Men1tm2.1Mmey Tg(Ins2-cre)23Herr/0
(involves: 129S6/SvEvTac * C57BL/6 * CBA/J * FVB/N)
|
increased insulinoma incidence
|
J:175625
|
Kdm6atm1Cdcn/Y Tg(CAG-cre/Esr1*)5Amc/0
(involves: C57BL/6J * CBA)
|
increased chronic myelocytic leukemia incidence
|
J:263565
|
Kdm6atm1Cdcn/Y Tg(CAG-cre/Esr1*)5Amc/0 Trp53tm1Tyj/Trp53tm1Tyj
(involves: 129S2/SvPas * C57BL/6J * CBA * FVB/N)
|
increased chronic myelocytic leukemia incidence
|
J:263565
|
Kdm6atm1Cdcn/Kdm6atm1Cdcn Tg(CAG-cre/Esr1*)5Amc/0
(involves: C57BL/6J * CBA)
|
increased chronic myelocytic leukemia incidence
|
J:263565
|
Kifbptm1a(KOMP)Wtsi/Kifbptm1a(KOMP)Wtsi
(C57BL/6N-Kifbptm1a(KOMP)Wtsi/Wtsi)
|
increased trigeminal neuroma incidence
|
J:239583
|
Kittm1Bpr/Kit+
(either: (involves: 129/Sv) or (involves: 129/Sv * C57BL/6))
|
increased gastrointestinal stromal tumor incidence
|
J:100778
|
Kittm1Bpr/Kittm1Bpr
(either: (involves: 129/Sv) or (involves: 129/Sv * C57BL/6))
|
increased gastrointestinal stromal tumor incidence
|
J:100778
|
Kittm1Shta/Kit+
(involves: 129S6/SvEvTac * C57BL/6 * FVB/N)
|
increased gastrointestinal stromal tumor incidence
|
J:130890
|
Kittm1Shta/Kittm1Shta
(involves: 129S6/SvEvTac * C57BL/6 * FVB/N)
|
increased gastrointestinal stromal tumor incidence
|
J:130890
|
Kittm2Bsm/Kit+
(involves: 129X1/SvJ * C57BL/6J)
|
increased gastrointestinal stromal tumor incidence
|
J:83616
|
Kittm4.1Bsm/Kit+
(involves: 129S1/Sv * C57BL/6J * FVB/N)
|
increased gastrointestinal tumor incidence
|
J:188434
|
Kittm5.1Bsm/Kit+
(involves: 129S1/Sv * C57BL/6J * FVB/N)
|
increased gastrointestinal tumor incidence
|
J:188434
|
KitW-v/KitW-v Trp53tm1Brn/Trp53tm1Brn
(involves: 129P2/OlaHsd * C57BL/6J * FVB/N)
|
increased ovary tumor incidence
|
J:236161
|
KitW/KitW-v
(involves: C57BL/6 * WB)
|
increased esophageal papilloma incidence
|
J:6393
|
KitlSl-J/Kitl+
(involves: 129)
|
increased testicular teratoma incidence
|
J:50508
|
KitlSl/Kitl+
(involves: 129/Sv * C3H)
|
increased testicular teratoma incidence
|
J:50508
|
KitlSl/KitlSl-d
(involves: C57BL/6 * WC)
|
increased leukemia incidence
|
J:5758
|
Klf14em1Cgw/Klf14em1Cgw
(C57BL/6J-Klf14em1Cgw)
|
increased lung adenoma incidence
|
J:227200
|
increased lymphoma incidence
|
J:227200
|
Klrk1tm1Dhr/Klrk1tm1Dhr Tg(IghMyc)22Bri/?
(involves: C57BL/6 * CD-1)
|
increased B cell derived lymphoma incidence
|
J:134509
|
Klrk1tm1Dhr/Klrk1tm1Dhr Tg(TRAMP)8247Ng/?
(involves: C57BL/6 * CD-1)
|
increased prostate gland tumor incidence
|
J:134509
|
Kmt2atm1(AFF1)Ksy/Kmt2a+
(involves: 129S1/Sv * C57BL/6 * FVB)
|
increased B cell derived lymphoma incidence
|
J:110241
|
increased leukemia incidence
|
J:110241
|
increased spleen neoplasm incidence
|
J:110241
|
Kmt2atm1(MLL1/ERT)Divo/?
(involves: 129S4/SvJae * C57BL/6)
|
increased acute promyelocytic leukemia incidence
|
J:189329
|
Kmt2atm1.1(Sh3gl1)Lcc/Kmt2a+ Lyz2tm1(cre)Ifo/Lyz2+
(involves: 129P2/OlaHsd * 129S/SvEv * C57BL/6)
|
increased leukemia incidence
|
J:205605
|
Kmt2atm1Saam/Kmt2a+ Tg(Mx1-cre)1Cgn/0
(involves: 129S1/Sv * C57BL/6 * CBA)
|
increased leukemia incidence
|
J:140628
|
Kmt2atm1Thr/Kmt2a+ Mllt3tm2Thr/Mllt3+ Tg(Lck-cre)1Thr/?
(involves: 129S/SvEv)
|
increased hemolymphoid system tumor incidence
|
J:100794
|
increased leukemia incidence
|
J:100794
|
increased T cell derived lymphoma incidence
|
J:100794
|
Kmt2atm2(MLLT3)Thr/Kmt2a+
(involves: 129P2/OlaHsd)
|
increased leukemia incidence
|
J:56340
|
Kmt2atm2(MLLT3)Thr/Kmt2atm2(MLLT3)Thr
(involves: 129P2/OlaHsd * C57BL/6 * FVB)
|
increased B cell derived lymphoma incidence
|
J:110241
|
increased hemolymphoid system tumor incidence
|
J:110241
|
increased leukemia incidence
|
J:110241
|
Kmt2dtm1.1Kaig/Kmt2d+ Ighg1tm1(cre)Cgn/Ighg1+ Tg(Vav-BCL2)69Jad/0
(involves: 129P2/OlaHsd * C57BL/6 * C57BL/6J)
|
increased B cell derived lymphoma incidence
|
J:228913
|
increased follicular lymphoma incidence
|
J:228913
|
Kmt2dtm1.1Kaig/Kmt2dtm1.1Kaig Ighg1tm1(cre)Cgn/Ighg1+ Tg(Vav-BCL2)69Jad/0
(involves: 129P2/OlaHsd * C57BL/6 * C57BL/6J)
|
increased B cell derived lymphoma incidence
|
J:228913
|
increased follicular lymphoma incidence
|
J:228913
|
Krasa/Krasa
(multiple strains)
|
increased lung adenoma incidence
|
J:17778,
J:17850
|
Krastm1.1Hbji/Krastm1.1Hbji Trp53tm5Tyj/Trp53tm5Tyj
(involves: 129S4/SvJae)
|
increased lung adenoma incidence
|
J:220921
|
Krastm1.1Khai/Kras+ Tg(Pdx1-cre)6Tuv/0 Trp53tm3.1Tyj/Trp53+
(involves: 129S4/SvJae * 129S6/SvEvTac * C57BL/6 * FVB/N)
|
increased pancreatic ductal adenocarcinoma incidence
|
J:276349
|
Krastm1Bbd/Kras+
(involves: 129S1/Sv * 129X1/SvJ)
|
increased lung non-small cell carcinoma incidence
|
J:172200
|
Krastm1Bbd/Kras+ Map2k1tm1Chrn/Map2k1tm1Chrn
(involves: 129S1/Sv * 129X1/SvJ)
|
increased lung non-small cell carcinoma incidence
|
J:172200
|
Krastm1Bbd/Kras+ Map2k2tm1Chrn/Map2k2tm1Chrn
(involves: 129/Sv * 129S1/Sv * 129X1/SvJ * C57BL/6J * SJL)
|
increased lung non-small cell carcinoma incidence
|
J:172200
|
Krastm1Bbd/Kras+ Mapk1tm1.1Hed/Mapk1tm1.1Hed
(involves: 129S1/Sv * 129X1/SvJ)
|
increased lung non-small cell carcinoma incidence
|
J:172200
|
Krastm1Bbd/Kras+ Mapk3tm1Gpg/Mapk3tm1Gpg
(involves: 129/Sv * 129S1/Sv * 129X1/SvJ)
|
increased lung non-small cell carcinoma incidence
|
J:172200
|
Krastm1Bbd/Kras+ Mapk14tm1Nbr/Mapk14tm2Nbr Polr2atm1(cre/ERT2)Bbd/Polr2a+
(involves: 129S1/Sv * 129X1/SvJ * C57BL/6 * CD-1 * SJL)
|
increased lung adenocarcinoma incidence
|
J:122397
|
increased lung adenoma incidence
|
J:122397
|
increased lung tumor incidence
|
J:122397
|
Krastm1Bbd/Kras+ Mapk14tm2Nbr/Mapk14+ Polr2atm1(cre/ERT2)Bbd/Polr2a+
(involves: 129S1/Sv * 129X1/SvJ * C57BL/6 * CD-1 * SJL)
|
increased hemolymphoid system tumor incidence
|
J:122397
|
increased lung adenoma incidence
|
J:122397
|
increased lung tumor incidence
|
J:122397
|
Krastm1Bbd/Kras+ Polr2atm1(cre/ERT2)Bbd/Polr2atm1(cre/ERT2)Bbd
(involves: 129S1/Sv * 129X1/SvJ)
|
increased lung non-small cell carcinoma incidence
|
J:161780
|
Krastm1Bbd/Kras+ Tg(CMV-cre)1Cgn/?
(involves: 129S1/Sv * 129X1/SvJ * BALB/cJ * C57BL/6)
|
increased lung adenocarcinoma incidence
|
J:86101
|
increased lung adenoma incidence
|
J:86101
|
Krastm1Bbd/Kras+ Tg(CMV-cre/ERT)1Ipc/0
(involves: 129S1/Sv * 129X1/SvJ * C57BL/6 * SJL)
|
increased lung adenocarcinoma incidence
|
J:86101
|
increased lung adenoma incidence
|
J:86101
|
Krastm1Bbd/Kras+ Tg(Pbsn-cre)4Prb/0
(involves: 129S1/Sv * 129X1/SvJ * C57BL/6 * DBA/2)
|
increased prostate gland adenocarcinoma incidence
|
J:143034
|
increased prostate intraepithelial neoplasia incidence
|
J:143034
|
Krastm1Bbd/Kras+ Trp53tm1Brd/Trp53+ Tg(Cela1-tTA)#Eps/? Tg(tetO-cre)3Jig/?
(involves: 129S1/Sv * 129S7/SvEvBrd * 129X1/SvJ * FVB/N)
|
increased pancreatic ductal adenocarcinoma incidence
|
J:119988
|
Krastm1Bbd/Krastm1Bbd Tg(Cela1-tTA)#Eps/? Tg(tetO-cre)3Jig/?
(involves: 129S1/Sv * 129X1/SvJ * FVB/N)
|
increased pancreatic ductal adenocarcinoma incidence
|
J:119988
|
Krastm1Bbd/Krastm2Bbd Polr2atm1(cre/ERT2)Bbd/Polr2atm1(cre/ERT2)Bbd
(involves: 129S1/Sv * 129X1/SvJ)
|
increased lung non-small cell carcinoma incidence
|
J:161780
|
increased lung tumor incidence
|
J:161780
|
Krastm2Tyj/Kras+
(involves: 129S2/SvPas * C57BL/6)
|
increased lung adenocarcinoma incidence
|
J:68981
|
increased lung adenoma incidence
|
J:68981
|
increased lung tumor incidence
|
J:68981
|
increased skin papilloma incidence
|
J:68981
|
increased T cell derived lymphoma incidence
|
J:68981
|
Krastm2Tyj/Kras+
(involves: 129S2/SvPas)
|
increased lung adenocarcinoma incidence
|
J:136369
|
increased lymphoma incidence
|
J:129627
|
increased skin papilloma incidence
|
J:68981
|
increased T cell derived lymphoma incidence
|
J:68981
|
Krastm2Tyj/Kras+ Trp53tm1Glo/Trp53+
(involves: 129S2/SvPas * 129S7/SvEvBrd)
|
increased lung adenoma incidence
|
J:129627
|
increased lymphoma incidence
|
J:129627
|
Krastm2Tyj/Kras+ Trp53tm1Tyj/Trp53+
(involves: 129S2/SvPas * C57BL/6)
|
increased skin papilloma incidence
|
J:68981
|
increased T cell derived lymphoma incidence
|
J:68981
|
Krastm2Tyj/Kras+ Trp53tm1Tyj/Trp53tm1Tyj
(involves: 129S2/SvPas * C57BL/6)
|
increased skin papilloma incidence
|
J:68981
|
increased T cell derived lymphoma incidence
|
J:68981
|
Krastm3Tyj/Kras+
(involves: 129S4/SvJae * C57BL/6)
|
increased lung adenocarcinoma incidence
|
J:68981
|
increased lung adenoma incidence
|
J:68981
|
increased lung tumor incidence
|
J:68981
|
increased skin papilloma incidence
|
J:68981
|
increased T cell derived lymphoma incidence
|
J:68981
|
Krastm3Tyj/Kras+
(involves: 129S4/SvJae)
|
increased lung tumor incidence
|
J:119477
|
increased skin papilloma incidence
|
J:68981
|
increased T cell derived lymphoma incidence
|
J:68981
|
Krastm3Tyj/Kras+ Mir21atm1.1Eno/Mir21atm1.1Eno
(involves: 129S/SvEv * 129S4/SvJae * C57BL/6)
|
increased lung adenoma incidence
|
J:164198
|
increased T cell derived lymphoma incidence
|
J:164198
|
Krastm3Tyj/Kras+ Tg(CAG-Mir21,-EGFP)#Eno/0
(involves: 129S4/SvJae * C3H * C57BL/6)
|
increased lung non-small cell carcinoma incidence
|
J:164198
|
increased lung tumor incidence
|
J:164198
|
Krastm3Tyj/Krastm3Tyj
(involves: 129S4/SvJae)
|
increased lung tumor incidence
|
J:237900
|
increased skin papilloma incidence
|
J:237900
|
increased T cell derived lymphoma incidence
|
J:237900
|
Krastm4.1Tyj/Kras+ Spry2tm1Mrt/Spry2tm1Mrt
(involves: 129P2/OlaHsd)
|
increased lung tumor incidence
|
J:119477
|
Krastm4Tyj/Kras+
(involves: 129S4/SvJae)
|
increased lung adenocarcinoma incidence
|
J:207982,
J:333347
|
increased lung adenoma incidence
|
J:207982,
J:333347
|
increased lung tumor incidence
|
J:119477,
J:216266,
J:299900
|
Krastm4Tyj/Kras+
(involves: 129S4/SvJae)
|
increased lung adenocarcinoma incidence
|
J:147590
|
increased lung adenoma incidence
|
J:158937
|
increased lung carcinoma incidence
|
J:158937
|
increased lung tumor incidence
|
J:158937,
J:147590
|
Krastm4Tyj/Kras+
(B6.129S4-Krastm4Tyj)
|
increased lung adenocarcinoma incidence
|
J:177379
|
increased lung adenoma incidence
|
J:177379
|
Krastm4Tyj/Kras+
(involves: 129S4/SvJae * C57BL/6)
|
increased lung adenoma incidence
|
J:203686
|
Krastm4Tyj/Kras+
(involves: 129S4/SvJae * C57BL/6 * FVB/N)
|
increased lung adenocarcinoma incidence
|
J:124682
|
Krastm4Tyj/Kras+ Gt(ROSA)26Sortm1(sb13)Tuv/Gt(ROSA)26Sor+ Tg(Pdx1-cre)6Tuv/0 TgTn(sb-T2/Onc)#Dla/0
(involves: 129S4/SvJae * 129S6/SvEvTac * FVB/N)
|
increased pancreas tumor incidence
|
J:186717
|
increased pancreatic ductal adenocarcinoma incidence
|
J:186717
|
increased pancreatic intraepithelial neoplasia incidence
|
J:186717
|
Krastm4Tyj/Kras+ Gt(ROSA)26Sortm3(CAG-luc)Tyj/Gt(ROSA)26Sor+
(involves: 129S4/SvJae)
|
increased lung tumor incidence
|
J:141383
|
Krastm4Tyj/Kras+ Gt(ROSA)26Sortm4(ACTB-tdTomato,-EGFP)Luo/Gt(ROSA)26Sor+ Tg(Flt3-cre)#Ccb/0
(involves: 129S1/Sv * 129S4/SvJae * 129X1/SvJ * C57BL/6)
|
increased leukemia incidence
|
J:247853
|
Krastm4Tyj/Kras+ Krt19tm1(cre/ERT)Ggu/Krt19+
(involves: 129S4/SvJae * 129S6/SvEvTac)
|
increased lip tumor incidence
|
J:172048
|
increased skin papilloma incidence
|
J:172048
|
increased skin tumor incidence
|
J:172048
|
Krastm4Tyj/Kras+ Krt19tm1(cre/ERT)Ggu/Krt19+ Ptentm2Mak/Ptentm2Mak
(involves: 129P2/OlaHsd * 129S4/SvJae * 129S6/SvEvTac)
|
increased pancreatic intraepithelial neoplasia incidence
|
J:254370
|
Krastm4Tyj/Kras+ Lyz2tm1(cre)Ifo/Lyz2+
(involves: 129P2/OlaHsd * 129S4/SvJae)
|
increased lung tumor incidence
|
J:158937
|
Krastm4Tyj/Kras+ Map2k7tm1.1Twad/Map2k7tm1.2Twad
(B6.Cg-Krastm4Tyj Map2k7tm1.1Twad/Map2k7tm1.2Twad)
|
increased lung adenocarcinoma incidence
|
J:170904
|
increased lung tumor incidence
|
J:170904
|
Krastm4Tyj/Kras+ Map2k7tm1.1Twad/Map2k7tm1.2Twad Trp53tm1Tyj/Trp53tm1Tyj
(involves: 129P2/OlaHsd * 129S2/SvPas * 129S4/SvJae * C57BL/6)
|
increased lung adenocarcinoma incidence
|
J:170904
|
increased lung tumor incidence
|
J:170904
|
Krastm4Tyj/Kras+ Mapk8tm1Wag/Mapk8+ Mapk9tm1Mka/Mapk9tm1Mka
(involves: 129/Sv * 129P2/OlaHsd * 129S4/SvJae * C57BL/6)
|
increased lung tumor incidence
|
J:170904
|
Krastm4Tyj/Kras+ Mapkapk2tm1.1Yaff/Mapkapk2tm1.1Yaff
(involves: 129S4/SvJae * C57BL/6)
|
increased lung adenoma incidence
|
J:203686
|
Krastm4Tyj/Kras+ Mapkapk2tm1.1Yaff/Mapkapk2tm1.1Yaff Trp53tm1Brn/Trp53tm1Brn
(involves: 129P2/OlaHsd * 129S4/SvJae * C57BL/6)
|
increased lung adenoma incidence
|
J:203686
|
Krastm4Tyj/Kras+ Pdpk1tm1Mlw/Pdpk1tm1Mlw Tg(Cela1-cre/ERT)1Dam/0
(involves: 129S4/SvJae)
|
increased lung non-small cell carcinoma incidence
|
J:197054
|
Krastm4Tyj/Kras+ Pggt1btm1Mbrg/Pggt1b+ Lyz2tm1(cre)Ifo/Lyz2+
(involves: 129/Sv * 129P2/OlaHsd * C57BL/6)
|
increased lung adenocarcinoma incidence
|
J:122107
|
increased lung adenoma incidence
|
J:122107
|
increased lung tumor incidence
|
J:122107
|
Krastm4Tyj/Kras+ Pggt1btm1Mbrg/Pggt1btm1Mbrg Lyz2tm1(cre)Ifo/Lyz2+
(involves: 129/Sv * 129P2/OlaHsd * C57BL/6)
|
increased lung adenoma incidence
|
J:122107
|
increased lung tumor incidence
|
J:122107
|
Krastm4Tyj/Kras+ Pik3r1tm1Lca/Pik3r1+ Pik3r2tm1Lca/Pik3r2tm1Lca
(involves: 129S4/SvJae * 129S6/SvEvTac)
|
increased lung tumor incidence
|
J:142254
|
Krastm4Tyj/Kras+ Pik3r2tm1Lca/Pik3r2tm1Lca
(involves: 129S4/SvJae * 129S6/SvEvTac)
|
increased lung tumor incidence
|
J:142254
|
Krastm4Tyj/Kras+ Ptentm1Hwu/Pten+ Tg(Gfap-cre)77.6Mvs/0
(involves: 129S4/SvJae * BALB/c * C57BL/6NHsd)
|
increased neurofibroma incidence
|
J:154673
|
increased neurofibrosarcoma incidence
|
J:154673
|
Krastm4Tyj/Kras+ Ptentm1Hwu/Pten+ Tg(Pbsn-cre)4Prb/0
(involves: 129S4/SvJae * C57BL/6 * DBA/2)
|
increased prostate gland adenocarcinoma incidence
|
J:184935
|
Krastm4Tyj/Kras+ Ptentm1Hwu/Pten+ Tg(Pdx1-cre)89.1Dam/0
(involves: 129S4/SvJae * BALB/c * C57BL/6)
|
increased pancreas tumor incidence
|
J:164210
|
increased pancreatic ductal adenocarcinoma incidence
|
J:164210
|
increased pancreatic intraepithelial neoplasia incidence
|
J:164210
|
Krastm4Tyj/Kras+ Ptentm1Hwu/Pten+ Tg(Upk2-cre)6Xrw/0
(involves: 129S4/SvJae * FVB/N)
|
increased skin papilloma incidence
|
J:174242
|
Krastm4Tyj/Kras+ Ptentm1Hwu/Ptentm1Hwu
(involves: 129S4/SvJae * C57BL/6J)
|
increased endometrial carcinoma incidence
|
J:96296
|
Krastm4Tyj/Kras+ Ptentm1Hwu/Ptentm1Hwu
(involves: 129S4/SvJae)
|
increased ovary tumor incidence
|
J:161953
|
Krastm4Tyj/Kras+ Ptentm1Hwu/Ptentm1Hwu Scgb1a1tm1.1(cre)Fjd/Scgb1a1+
(involves: 129S1/Sv * 129S4/SvJae * 129X1/SvJ)
|
increased lung adenocarcinoma incidence
|
J:131721
|
increased lung adenoma incidence
|
J:131721
|
increased lung carcinoma incidence
|
J:131721
|
increased lung tumor incidence
|
J:131721
|
Krastm4Tyj/Kras+ Ptentm1Hwu/Ptentm1Hwu Tg(Pbsn-cre)4Prb/0
(involves: 129S4/SvJae * C57BL/6 * DBA/2)
|
increased prostate gland adenocarcinoma incidence
|
J:184935
|
Krastm4Tyj/Kras+ Ptentm1Hwu/Ptentm1Hwu Tg(Pdx1-cre)89.1Dam/0
(involves: 129S4/SvJae * BALB/c * C57BL/6 * CBA)
|
increased pancreatic ductal adenocarcinoma incidence
|
J:164210
|
increased pancreatic intraepithelial neoplasia incidence
|
J:164210
|
Krastm4Tyj/Kras+ Ptentm2.1Ppp/Ptentm2.1Ppp Tg(TPO-cre)1Shk/0
(129.Cg-Krastm4Tyj Tg(Tpo-cre)1Shk Ptentm2.1Ppp)
|
increased thyroid carcinoma incidence
|
J:147732
|
Krastm4Tyj/Kras+ Ptentm2Mak/Pten+ Speer6-ps1Tg(Alb-cre)21Mgn/Speer6-ps1+
(involves: 129P2/OlaHsd * 129S4/SvJae * C57BL/6 * DBA)
|
increased cholangiocarcinoma incidence
|
J:254370
|
increased hepatocellular carcinoma incidence
|
J:254370
|
increased liver tumor incidence
|
J:254370
|
Krastm4Tyj/Kras+ Ptentm2Mak/Ptentm2Mak Speer6-ps1Tg(Alb-cre)21Mgn/Speer6-ps1+
(involves: 129P2/OlaHsd * 129S4/SvJae * C57BL/6 * DBA)
|
increased cholangiocarcinoma incidence
|
J:254370
|
increased liver tumor incidence
|
J:254370
|
Krastm4Tyj/Kras+ Ptf1atm1.1(cre)Cvw/Ptf1a+
(involves: 129S1/Sv * 129S4/SvJae * 129X1/SvJ)
|
increased pancreatic ductal adenocarcinoma incidence
|
J:116130,
J:87973
|
increased pancreatic intraepithelial neoplasia incidence
|
J:262746
|
Krastm4Tyj/Kras+ Ptf1atm1.1(cre)Cvw/Ptf1a+
(involves: 129S1/Sv * 129X1/SvJ * C57BL/6 * DBA/2)
|
increased pancreatic intraepithelial neoplasia incidence
|
J:116129
|
Krastm4Tyj/Kras+ Ptf1atm1.1(cre)Cvw/Ptf1a+
(B6.129(Cg)-Krastm4Tyj Ptf1atm1.1(cre)Cvw)
|
increased pancreas tumor incidence
|
J:138959
|
increased pancreatic ductal adenocarcinoma incidence
|
J:138959
|
increased pancreatic intraepithelial neoplasia incidence
|
J:138959
|
Krastm4Tyj/Kras+ Ptf1atm1.1(cre)Cvw/Ptf1a+ Tg(MUC1)79.24Gend/0
(B6.Cg-Krastm4Tyj Ptf1atm1.1(cre)Cvw Tg(MUC1)79.24Gend)
|
increased pancreas tumor incidence
|
J:138959,
J:234412
|
increased pancreatic ductal adenocarcinoma incidence
|
J:138959
|
increased pancreatic intraepithelial neoplasia incidence
|
J:138959,
J:234412
|
Krastm4Tyj/Kras+ Raf1tm2Bacc/Raf1tm2Bacc Ptf1atm1(cre)Hnak/Ptf1a+
(involves: 129P2/OlaHsd * 129S4/SvJae)
|
increased pancreatic ductal adenocarcinoma incidence
|
J:197054
|
Krastm4Tyj/Kras+ Rb1tm3Tyj/Rb1tm3Tyj
(involves: 129S4/SvJae)
|
increased lung adenocarcinoma incidence
|
J:147590
|
increased lung tumor incidence
|
J:147590
|
Krastm4Tyj/Kras+ Rbl2tm2Tyj/Rbl2tm2Tyj
(involves: 129S4/SvJae)
|
increased lung adenocarcinoma incidence
|
J:147590
|
increased lung tumor incidence
|
J:147590
|
Krastm4Tyj/Kras+ Rnf7Gt(XE423)Byg/Rnf7+
(involves: 129P2/OlaHsd * 129S4/SvJae)
|
increased lung adenocarcinoma incidence
|
J:207982
|
increased lung adenoma incidence
|
J:207982
|
Krastm4Tyj/Kras+ Scgb1a1tm1(cre/ERT)Blh/Scgb1a1+ Trp53tm5Tyj/Trp53+
(involves: 129S4/SvJaeSor * 129S6/SvEvTac * C57BL/6)
|
increased lung adenoma incidence
|
J:182218
|
Krastm4Tyj/Kras+ Scgb1a1tm1.1(cre)Fjd/Scgb1a1+
(involves: 129S1/Sv * 129S4/SvJae * 129X1/SvJ)
|
increased lung adenoma incidence
|
J:131721
|
increased lung tumor incidence
|
J:131721
|
Krastm4Tyj/Kras+ Scribtm1.1Phum/Scrib+
(involves: 129S4/SvJae)
|
increased lung tumor incidence
|
J:216266
|
Krastm4Tyj/Kras+ Scribtm1.1Phum/Scrib+ Tg(Pbsn-cre)20Fwan/0
(involves: 129S4/SvJae * FVB/NCrl)
|
increased prostate gland adenocarcinoma incidence
|
J:178461
|
increased prostate intraepithelial neoplasia incidence
|
J:178461
|
Krastm4Tyj/Kras+ Scribtm1.1Phum/Scribtm1.1Phum
(involves: 129S4/SvJae)
|
increased lung tumor incidence
|
J:216266
|
Krastm4Tyj/Kras+ Scribtm1.1Phum/Scribtm1.1Phum Tg(Pbsn-cre)20Fwan/0
(involves: 129S4/SvJae * FVB/NCrl)
|
increased prostate gland adenocarcinoma incidence
|
J:178461
|
increased prostate intraepithelial neoplasia incidence
|
J:178461
|
Krastm4Tyj/Kras+ Sftpctm1(cre/ERT2)Blh/Sftpc+ Trp53tm5Tyj/Trp53+
(involves: 129S4/SvJaeSor * 129S6/SvEvTac * C57BL/6)
|
increased lung adenoma incidence
|
J:182218
|
Krastm4Tyj/Kras+ Sftpctm1.1(cre/ERT2)Ptch/Sftpc+
(involves: 129P2/OlaHsd * C57BL/6 * FVB)
|
increased lung adenoma incidence
|
J:195738
|
Krastm4Tyj/Kras+ Sftpctm1.1(cre/ERT2)Ptch/Sftpc+ Trp53tm1Brn/Trp53tm1Brn
(involves: 129P2/OlaHsd * 129S4/SvJae * C57BL/6 * FVB)
|
increased lung adenocarcinoma incidence
|
J:195738
|
increased lung adenoma incidence
|
J:195738
|
Krastm4Tyj/Kras+ Smad4tm1Rdp/Smad4tm1Rdp Ptf1atm1.1(cre)Cvw/Ptf1a+
(involves: 129 * FVB/N)
|
increased pancreatic ductal adenocarcinoma incidence
|
J:116130
|
Krastm4Tyj/Kras+ Smad4tm1Rdp/Smad4tm1Rdp Tg(Pdx1-cre)89.1Dam/0
(involves: 129S/SvEv * 129S4/SvJae * C57BL/6 * CBA * FVB/N)
|
increased stomach tumor incidence
|
J:116130
|
Krastm4Tyj/Kras+ Smad4tm2.1Cxd/Smad4tm2.1Cxd Tg(Krt1-15-cre/PGR*)22Cot/0
(involves: 129S4/SvJae * 129S6/SvEvTac * C57BL/6 * C57BL/6J * SJL/J)
|
increased skin squamous cell carcinoma incidence
|
J:203922
|
increased skin tumor incidence
|
J:203922
|
increased trichoepithelioma incidence
|
J:203922
|
Krastm4Tyj/Kras+ Speer6-ps1Tg(Alb-cre)21Mgn/Speer6-ps1+
(involves: 129S4/SvJae * C57BL/6 * DBA)
|
increased cholangiocarcinoma incidence
|
J:184949
|
increased liver tumor incidence
|
J:254370
|
Krastm4Tyj/Kras+ Stk11tm1.1Rdp/Stk11tm1.1Rdp
(involves: 129S4/SvJae * 129S6/SvEvTac * C57BL/6 * FVB/N)
|
increased lung adenocarcinoma incidence
|
J:124682
|
increased lung large cell carcinoma incidence
|
J:124682
|
increased lung squamous cell carcinoma incidence
|
J:124682
|
increased lung tumor incidence
|
J:124682
|
Krastm4Tyj/Kras+ Stk11tm1.1Rdp/Stk11tm1.2Rdp
(involves: 129S4/SvJae * 129S6/SvEvTac * C57BL/6 * FVB/N)
|
increased lung adenocarcinoma incidence
|
J:124682
|
increased lung large cell carcinoma incidence
|
J:124682
|
increased lung squamous cell carcinoma incidence
|
J:124682
|
increased lung tumor incidence
|
J:124682
|
Krastm4Tyj/Kras+ Tg(CAG-Bgeo,-tsA58T)T26Ichi/0 Tg(Pdx1-cre)6Tuv/0
(involves: 129P2/OlaHsd * 129S4/SvJae * C57BL/6 * FVB/N)
|
increased pancreatic ductal adenocarcinoma incidence
|
J:214846
|
increased pancreatic intraepithelial neoplasia incidence
|
J:214846
|
Krastm4Tyj/Kras+ Tg(CAG-HPV16E6E7,-luc)#Mspi/0 Tg(KRT14-cre/ERT)20Efu/0
(involves: 129S4/SvJae * C57BL/6 * CD-1 * FVB/N * FVB/NJ)
|
increased oral papilloma incidence
|
J:210533
|
Krastm4Tyj/Kras+ Tg(Cela1-cre/ERT)1Dam/0
(involves: 129S4/SvJae)
|
increased lung non-small cell carcinoma incidence
|
J:197054
|
increased pancreas tumor incidence
|
J:197054
|
Krastm4Tyj/Kras+ Tg(Erbb2*)#Maed/0 Ptf1atm1.1(cre)Cvw/Ptf1a+
(involves: 129S1/Sv * 129S4/SvJae * 129X1/SvJ * C57BL/6J)
|
increased pancreatic intraepithelial neoplasia incidence
|
J:262746
|
Krastm4Tyj/Kras+ Tg(IVL-cre/ERT2)1Blpn/0
(involves: 129S4/SvJae * C57BL/6)
|
increased facial tumor incidence
|
J:172048
|
increased lip tumor incidence
|
J:172048
|
increased skin papilloma incidence
|
J:172048
|
increased skin tumor incidence
|
J:172048
|
Krastm4Tyj/Kras+ Tg(Krt1-15-cre/PGR*)22Cot/0
(involves: 129S4/SvJae * C57BL/6J * SJL/J)
|
increased facial tumor incidence
|
J:172048
|
increased lip tumor incidence
|
J:172048
|
increased skin papilloma incidence
|
J:172048
|
increased skin tumor incidence
|
J:172048
|
Krastm4Tyj/Kras+ Tg(KRT5-cre/PGR)1Der/?
(involves: 129/Sv * C57BL/6 * FVB * ICR)
|
increased skin papilloma incidence
|
J:124222
|
Krastm4Tyj/Kras+ Tg(KRT14-cre/ERT)20Efu/0
(involves: 129S4/SvJae * C57BL/6 * CD-1 * FVB/N)
|
increased mouth tumor incidence
|
J:210533
|
Krastm4Tyj/Kras+ Tg(Mx1-cre)1Cgn/0
(involves: 129S4/SvJae * BALB/c * C57BL/6 * CBA)
|
increased esophageal papilloma incidence
|
J:88163
|
increased lung adenoma incidence
|
J:88163
|
increased lymphoblastic lymphoma incidence
|
J:88163
|
increased oral papilloma incidence
|
J:88163
|
increased skin papilloma incidence
|
J:88163
|
Krastm4Tyj/Kras+ Tg(Pbsn-cre)20Fwan/0
(involves: 129S4/SvJae * FVB/NCrl)
|
increased prostate intraepithelial neoplasia incidence
|
J:178461
|
Krastm4Tyj/Kras+ Tg(Pdx1-cre)6Tuv/?
(involves: 129S4/SvJae * FVB/N)
|
increased pancreatic ductal adenocarcinoma incidence
|
J:87973
|
Krastm4Tyj/Kras+ Tg(Pdx1-cre)6Tuv/0
(involves: 129S4/SvJae * C57BL/6 * FVB/N)
|
increased pancreatic intraepithelial neoplasia incidence
|
J:276349,
J:214846,
J:98936
|
Krastm4Tyj/Kras+ Tg(Pdx1-cre)6Tuv/0 Trp53tm1Gev/Trp53tm1Gev
(involves: 129P2/OlaHsd * 129S4/SvJae * C57BL/6 * FVB/N)
|
increased pancreatic ductal adenocarcinoma incidence
|
J:220300
|
Krastm4Tyj/Kras+ Tg(Pdx1-cre)6Tuv/0 Trp53tm3.1Tyj/Trp53+
(involves: 129S4/SvJae * C57BL/6 * FVB/N)
|
increased pancreatic ductal adenocarcinoma incidence
|
J:276349
|
Krastm4Tyj/Kras+ Tg(Pdx1-cre)6Tuv/0 Trp53tm3Tyj/Trp53+
(involves: 129S4/SvJae * C57BL/6 * FVB/N)
|
increased pancreatic ductal adenocarcinoma incidence
|
J:166678
|
Krastm4Tyj/Kras+ Tg(Pdx1-cre)6Tuv/0 Usp9xtm1Tuv/Y
(involves: 129S4/SvJae * FVB/N)
|
increased oral papilloma incidence
|
J:186717
|
increased pancreas tumor incidence
|
J:186717
|
increased pancreatic intraepithelial neoplasia incidence
|
J:186717
|
increased skin papilloma incidence
|
J:186717
|
Krastm4Tyj/Kras+ Tg(Pdx1-cre)6Tuv/0 Usp9xtm1Tuv/Usp9x+
(involves: 129S4/SvJae * FVB/N)
|
increased oral papilloma incidence
|
J:186717
|
increased pancreas tumor incidence
|
J:186717
|
increased pancreatic intraepithelial neoplasia incidence
|
J:186717
|
increased skin papilloma incidence
|
J:186717
|
Krastm4Tyj/Kras+ Tg(Pdx1-cre)89.1Dam/0
(involves: 129S4/SvJae * C57BL/6 * CBA)
|
increased pancreatic ductal adenocarcinoma incidence
|
J:116130,
J:164210
|
increased pancreatic intraepithelial neoplasia incidence
|
J:87196,
J:164210
|
Krastm4Tyj/Kras+ Tg(Pdx1-cre)89.1Dam/0
(involves: 129S4/SvJae * C57BL/6 * CBA * FVB/N)
|
increased pancreas tumor incidence
|
J:108298
|
Krastm4Tyj/Kras+ Tg(Scgb1a1-cre)1Kkw/?
(involves: 129 * C57BL/6 * FVB/N)
|
increased lung adenocarcinoma incidence
|
J:107260
|
Krastm4Tyj/Kras+ Tgfbr2tm1.2Hlm/Tgfbr2+ Ptf1atm1.1(cre)Cvw/Ptf1a+
(involves: 129S1/Sv * 129S4/SvJae * 129X1/SvJ * C57BL/6 * DBA/2)
|
increased pancreas tumor incidence
|
J:116129
|
increased pancreatic ductal adenocarcinoma incidence
|
J:116129
|
increased pancreatic intraepithelial neoplasia incidence
|
J:116129
|
Krastm4Tyj/Kras+ Tgfbr2tm1.2Hlm/Tgfbr2tm1.2Hlm
(B6.129-Krastm4Tyj Tgfbr2tm1.2Hlm)
|
increased lung adenocarcinoma incidence
|
J:177379
|
Krastm4Tyj/Kras+ Tgfbr2tm1.2Hlm/Tgfbr2tm1.2Hlm Ptf1atm1.1(cre)Cvw/Ptf1a+
(involves: 129S1/Sv * 129S4/SvJae * 129X1/SvJ * C57BL/6 * DBA/2)
|
increased pancreas tumor incidence
|
J:116129
|
increased pancreatic ductal adenocarcinoma incidence
|
J:116129
|
increased pancreatic intraepithelial neoplasia incidence
|
J:116129
|
Krastm4Tyj/Kras+ Trp53tm1Brn/Trp53+
(involves: 129P2/OlaHsd * 129S4/SvJae)
|
increased lung adenoma incidence
|
J:103407
|
increased lung tumor incidence
|
J:103407
|
Krastm4Tyj/Kras+ Trp53tm1Brn/Trp53+ Speer6-ps1Tg(Alb-cre)21Mgn/Speer6-ps1+
(involves: 129P2/OlaHsd * 129S4/SvJae * C57BL/6 * DBA)
|
increased cholangiocarcinoma incidence
|
J:184949
|
Krastm4Tyj/Kras+ Trp53tm1Brn/Trp53+ Tg(Pdx1-cre)89.1Dam/0
(involves: 129 * C57BL/6 * CBA * FVB/N)
|
increased pancreas tumor incidence
|
J:108298
|
increased pancreatic ductal adenocarcinoma incidence
|
J:108298
|
Krastm4Tyj/Kras+ Trp53tm1Brn/Trp53tm1Brn
(involves: 129P2/OlaHsd * 129S4/SvJae)
|
increased lung adenocarcinoma incidence
|
J:195492,
J:154041,
J:103407
|
increased lung adenoma incidence
|
J:203686,
J:103407
|
increased lung tumor incidence
|
J:103407
|
Krastm4Tyj/Kras+ Trp53tm1Brn/Trp53tm1Brn
(involves: 129P2/OlaHsd * 129S4/SvJae * C57BL/6 * FVB/N)
|
increased lung adenocarcinoma incidence
|
J:124682
|
Krastm4Tyj/Kras+ Trp53tm1Brn/Trp53tm1Brn Krt19tm1(cre/ERT)Ggu/Krt19+
(involves: 129P2/OlaHsd * 129S4/SvJae * 129S6/SvEvTac)
|
increased gastrointestinal tumor incidence
|
J:172048
|
increased skin tumor incidence
|
J:172048
|
Krastm4Tyj/Kras+ Trp53tm1Brn/Trp53tm1Brn Speer6-ps1Tg(Alb-cre)21Mgn/Speer6-ps1+
(involves: 129P2/OlaHsd * 129S4/SvJae * C57BL/6 * DBA)
|
increased cholangiocarcinoma incidence
|
J:184949
|
Krastm4Tyj/Kras+ Trp53tm1Brn/Trp53tm1Brn Tg(KRT14-cre/ERT)20Efu/0
(involves: 129P2/OlaHsd * 129S4/SvJae * CD-1)
|
increased skin squamous cell carcinoma incidence
|
J:172048
|
Krastm4Tyj/Kras+ Trp53tm1Brn/Trp53tm1Brn Tg(Pdx1-cre)89.1Dam/0
(involves: 129 * C57BL/6 * CBA * FVB/N)
|
increased pancreas tumor incidence
|
J:108298
|
increased pancreatic ductal adenocarcinoma incidence
|
J:108298
|
Krastm4Tyj/Kras+ Trp53tm1Brn/Trp53tm2Tyj
(involves: 129P2/OlaHsd * 129S4/SvJae)
|
increased lung tumor incidence
|
J:103407
|
Krastm4Tyj/Kras+ Trp53tm1Brn/Trp53tm2Tyj Ptf1atm1(cre)Hnak/Ptf1a+
(involves: 129P2/OlaHsd * 129S4/SvJae)
|
increased pancreatic ductal adenocarcinoma incidence
|
J:197054
|
Krastm4Tyj/Kras+ Trp53tm1Lejo/Trp53tm1Lejo
(involves: 129S4/SvJae)
|
increased lung adenocarcinoma incidence
|
J:187012
|
increased lung non-small cell carcinoma incidence
|
J:187012
|
Krastm4Tyj/Kras+ Trp53tm2Tyj/Trp53+
(involves: 129S4/SvJae)
|
increased lung adenocarcinoma incidence
|
J:191425
|
increased lung non-small cell carcinoma incidence
|
J:191425
|
increased lung tumor incidence
|
J:191425,
J:103407
|
Krastm4Tyj/Kras+ Trp53tm2Tyj/Trp53+ Tg(Pdx1-cre)6Tuv/0
(involves: 129S4/SvJae * C57BL/6 * FVB/N)
|
increased esophageal papilloma incidence
|
J:98936
|
increased pancreatic ductal adenocarcinoma incidence
|
J:98936
|
increased pancreatic intraepithelial neoplasia incidence
|
J:98936
|
increased T cell derived lymphoma incidence
|
J:98936
|
Krastm4Tyj/Kras+ Trp53tm3Tyj/Trp53+
(involves: 129S4/SvJae)
|
increased lung tumor incidence
|
J:103407
|
Krastm4Tyj/Kras+ Trp53tm4Att/Trp53tm4Att
(involves: 129S4/SvJae)
|
increased organ/body region tumor incidence
|
J:173395
|
Krastm4Tyj/Kras+ Ube2sem1Ysun/Ube2sem1Ysun
(involves: 129S4/SvJae)
|
increased lung tumor incidence
|
J:333347
|
Krastm4Tyj/Krastm4Tyj Bhlha15tm3(cre/ERT2)Skz/Bhlha15+
(involves: 129S1/Sv * 129S4/SvJae * 129X1/SvJ)
|
increased pancreatic intraepithelial neoplasia incidence
|
J:142189
|
Krastm4Tyj/Krastm4Tyj Ptf1atm1(cre)Hnak/Ptf1a+
(involves: 129S4/SvJae)
|
increased pancreatic intraepithelial neoplasia incidence
|
J:162125
|
Krastm4Tyj/Krastm4Tyj Tg(Cela1-cre/ERT2)1Stof/0
(involves: 129S4/SvJae * C57BL/6 * SJL)
|
increased pancreatic intraepithelial neoplasia incidence
|
J:142189
|
Krastm4Tyj/Krastm4Tyj Tg(Cela1-cre/ERT)1Dam/0
(involves: 129S4/SvJae)
|
increased pancreatic intraepithelial neoplasia incidence
|
J:142188
|
Krastm4Tyj/Krastm4Tyj Tg(Pdx1-cre)89.1Dam/0
(involves: 129S4/SvJae * C57BL/6 * DBA/2)
|
increased pancreatic intraepithelial neoplasia incidence
|
J:151781
|
Krastm4Tyj/Krastm4Tyj Tg(Pdx1-cre/Esr1*)35.10Dam/0
(involves: 129S4/SvJae * C57BL/6 * CBA)
|
increased pancreatic intraepithelial neoplasia incidence
|
J:142188
|
Krastm4Tyj/Krastm4Tyj Trim33tm1Los/Trim33tm1Los Tg(Pdx1-cre)89.1Dam/0
(involves: 129S2/SvPas * 129S4/SvJae * C57BL/6 * DBA/2)
|
increased pancreas tumor incidence
|
J:151781
|
increased pancreatic intraepithelial neoplasia incidence
|
J:151781
|
Krastm4Tyj/Krastm4Tyj Yap1tm1.1Dupa/Yap1tm1.1Dupa Speer6-ps1Tg(Alb-cre)21Mgn/Speer6-ps1+
(involves: 129P2/OlaHsd * 129S4/SvJae * C57BL/6 * DBA)
|
increased hepatocellular carcinoma incidence
|
J:162628
|
Krastm5Tyj/Kras+
(involves: 129S4/SvJae * C57BL/6)
|
increased lung tumor incidence
|
J:172206
|
Krastm5Tyj/Kras+ Pdx1tm1.1(flpo)Most/Pdx1+ Trp53tm1.1Dgk/Trp53+
(involves: 129S1/Sv * 129S1/SvImJ * 129X1/SvJ * Black Swiss * C57BL/6)
|
increased pancreatic ductal adenocarcinoma incidence
|
J:248550
|
increased pancreatic intraepithelial neoplasia incidence
|
J:248550
|
Krastm5Tyj/Kras+ Pdx1tm1.1(flpo)Most/Pdx1+ Trp53tm1.1Dgk/Trp53tm1.1Dgk
(involves: 129S1/Sv * 129S1/SvImJ * 129X1/SvJ * Black Swiss * C57BL/6)
|
increased pancreatic ductal adenocarcinoma incidence
|
J:248550
|
increased pancreatic intraepithelial neoplasia incidence
|
J:248550
|
Krastm5Tyj/Kras+ Trp53tm1.1Dgk/Trp53tm1.1Dgk
(involves: 129S1/Sv * 129S4/SvJaeSor * 129X1/SvJ * C57BL/6)
|
increased lung adenocarcinoma incidence
|
J:180576
|
Krit1tm1Kwhi/Krit1tm1.1Kwhi Tg(Pdgfb-icre/ERT2,-EGFP)1Frut/0
(involves: 129S6/SvEvTac * C57BL/6 * C57BL/6NCrl * CBA)
|
increased retina hemangioma incidence
|
J:215458
|
Krt9tm1(KOMP)Vlcg/Krt9tm1(KOMP)Vlcg
(involves: C57BL/6J * C57BL/6NTac)
|
increased skin papilloma incidence
|
J:206051
|
Krt14tm1(Krt10)Pko/Krt14tm1(Krt10)Pko
(B6.Cg-Krt14tm1(Krt10)Pko)
|
increased skin papilloma incidence
|
J:117347
|
Krt14tm1.1(cre)Wbm/Krt14+ Tg(KRT14-Snai1)1Efu/0 Trp53tm1Brn/Trp53tm1Brn
(involves: 129P2/OlaHsd * CD-1)
|
increased basal cell carcinoma incidence
|
J:229072
|
increased sebaceous gland tumor incidence
|
J:229072
|
increased skin squamous cell carcinoma incidence
|
J:229072
|
increased skin tumor incidence
|
J:229072
|
Krt18tm1Tmm/Krt18+
(involves: 129P2/OlaHsd)
|
increased liver tumor incidence
|
J:309021
|
Krt18tm1Tmm/Krt18tm1Tmm
(involves: 129P2/OlaHsd)
|
increased hepatocellular carcinoma incidence
|
J:309021
|
increased liver tumor incidence
|
J:309021
|
Lats1tm1Tx/Lats1tm1Tx
(involves: 129S2/SvPas * C57BL/6J)
|
increased ovary tumor incidence
|
J:52536
|
Ldahtm1Mrtn/Ldahtm1Mrtn
(CBACa.129S4(B6)-Ldahtm1Mrtn)
|
increased prostate intraepithelial neoplasia incidence
|
J:101977
|
Lect2tm1Ymg/Lect2tm1Ymg Tg(Pklr-Myc)73Ak/0
(B6.Cg-Lect2tm1Ymg Tg(Pklr-Myc)73Ak)
|
increased hepatocellular carcinoma incidence
|
J:184496
|
Lgals3tm1Ftl/Lgals3tm1Ftl
(involves: 129S2/SvPas * CD-1)
|
increased hepatocellular carcinoma incidence
|
J:221030
|
Lgr5tm1(cre/ERT2)Cle/Lgr5+ Lrig1tm1.1(cre/ERT2)Rjc/Lrig1tm1.1(cre/ERT2)Rjc
(involves: 129 * 129P2/OlaHsd * C57BL/6)
|
increased intestinal adenoma incidence
|
J:186084
|
Lig1tm3Dwm/Lig1tm3Dwm
(involves: 129P2/OlaHsd * C57BL/6)
|
increased lymphoma incidence
|
J:77902
|
Lig4tm1Fwa/Lig4tm1Fwa Trp53tm1Brd/Trp53tm1Brd
(involves: 129S6/SvEvTac * 129S7/SvEvBrd)
|
increased lymphoma incidence
|
J:63078
|
Lig4tm1Icrf/Lig4tm1Icrf Trp53tm1Tyj/Trp53tm1Tyj
(either: (involves: 129P2/OlaHsd * 129S2/SvPas) or (involves: 129S1/Sv * 129S2/SvPas * 129X1/SvJ))
|
increased B cell derived lymphoma incidence
|
J:111068
|
increased medulloblastoma incidence
|
J:111068
|
Lig4tm1Pmc/Lig4tm1Pmc Trp53tm1Tyj/Trp53+ Xrcc2tm2Pmc/Xrcc2tm2Pmc Tg(Nes-cre)1Kln/0
(involves: 129S1/Sv * 129S2/SvPas * C57BL/6 * SJL)
|
increased medulloblastoma incidence
|
J:144617
|
Lig4tm1Pmc/Lig4tm1Pmc Trp53tm1Tyj/Trp53tm1Tyj Tg(Nes-cre)1Kln/0
(involves: 129S1/Sv * 129S2/SvPas * C57BL/6 * SJL)
|
increased medulloblastoma incidence
|
J:144617
|
Lig4tm1Pmc/Lig4tm1Pmc Trp53tm1Tyj/Trp53tm1Tyj Xrcc2tm2Pmc/Xrcc2tm2Pmc Tg(Nes-cre)1Kln/0
(involves: 129S1/Sv * 129S2/SvPas * C57BL/6 * SJL)
|
increased medulloblastoma incidence
|
J:144617
|
Lig4tm2.1Fwa/Lig4tm2.1Fwa
(involves: 129S6/SvEvTac)
|
increased colon adenocarcinoma incidence
|
J:157574
|
increased medulloblastoma incidence
|
J:157574
|
increased T cell derived lymphoma incidence
|
J:157574
|
ll/ll X/Yaa
(BXSB/MpJScr-ll)
|
increased lymphoma incidence
|
J:10973
|
increased T cell derived lymphoma incidence
|
J:10973
|
llaSL/Kh/llaSL/Kh
(involves: AKR/JMs * SL/Kh)
|
increased lymphoma incidence
|
J:41197,
J:33016
|
Lmo2tm2(cre)Thr/Lmo2+ Kmt2atm1Thr/Kmt2a+ Mllt1tm1Thr/Mllt1+
(involves: 129S/SvEv)
|
increased hemolymphoid system tumor incidence
|
J:100794
|
increased leukemia incidence
|
J:84518,
J:100794
|
Lmo7tm1Miyo/Lmo7+
(involves: 129X1/SvJ * C57BL/6 * DBA/2)
|
increased lung adenocarcinoma incidence
|
J:150612
|
Lmo7tm1Miyo/Lmo7+
(involves: 129X1/SvJ * C57BL/6)
|
increased lung adenocarcinoma incidence
|
J:150612
|
Lmo7tm1Miyo/Lmo7tm1Miyo
(involves: 129X1/SvJ * C57BL/6 * DBA/2)
|
increased lung adenocarcinoma incidence
|
J:150612
|
Lmo7tm1Miyo/Lmo7tm1Miyo
(involves: 129X1/SvJ * C57BL/6)
|
increased lung adenocarcinoma incidence
|
J:150612
|
Lpoem1Zlu/Lpoem1Zlu
(involves: C57BL/6 * SJL)
|
increased histiocytic sarcoma incidence
|
J:307289
|
increased lung carcinoma incidence
|
J:307289
|
increased lymphoma incidence
|
J:307289
|
Ltbp4Gt(U3Cre)1Vmel/Ltbp4Gt(U3Cre)1Vmel
(involves: 129S2/SvPas * C57BL/6)
|
increased gastrointestinal tumor incidence
|
J:85162
|
Ltbp4Gt(U3Cre)1Vmel/Ltbp4Gt(U3Cre)1Vmel
(B6.129S2-Ltbp4Gt(U3Cre)1Vmel)
|
increased large intestine adenocarcinoma incidence
|
J:78819
|
LyarGt(RRG292)Byg/LyarGt(RRG292)Byg Trp53tm1Tyj/Trp53tm1Tyj
(involves: 129P2/OlaHsd * 129S2/SvPas * C57BL/6)
|
increased T cell derived lymphoma incidence
|
J:263530
|
LyrBALB/cHeA/LyrBALB/cHeA
(involves: BALB/cHeA * STS/A)
|
increased lymphoma incidence
|
J:10558
|
Lzts1tm1Cro/Lzts1+
(involves: 129 * C57BL/6J)
|
increased gastric adenocarcinoma incidence
|
J:119989
|
increased hepatocellular carcinoma incidence
|
J:119989
|
increased lung adenoma incidence
|
J:119989
|
increased lymphoma incidence
|
J:119989
|
increased mammary gland tumor incidence
|
J:119989
|
increased stomach tumor incidence
|
J:119989
|
Lzts1tm1Cro/Lzts1tm1Cro
(involves: 129 * C57BL/6J)
|
increased gastric adenocarcinoma incidence
|
J:119989
|
increased hepatocellular carcinoma incidence
|
J:119989
|
increased lung adenocarcinoma incidence
|
J:119989
|
increased lymphoma incidence
|
J:119989
|
increased mammary gland tumor incidence
|
J:119989
|
increased stomach tumor incidence
|
J:119989
|
Mad1l1tm1.1Ktj/Mad1l1+
(involves: BALB/c * C57BL/6J)
|
increased hepatocellular carcinoma incidence
|
J:117337
|
increased lung adenocarcinoma incidence
|
J:117337
|
increased osteosarcoma incidence
|
J:117337
|
increased rhabdomyosarcoma incidence
|
J:117337
|
Mad2l1tm1Sorg/Mad2l1+
(involves: 129S2/SvPas * C57BL/6)
|
increased lung adenocarcinoma incidence
|
J:67456
|
Map2k7tm1.1Twad/Map2k7tm1.2Twad Tg(MMTV-cre)4Mam/0 Tg(MMTV-Erbb2)1Pv/0
(involves: 129P2/OlaHsd * C57BL/6 * CD-1 * DBA * FVB/N)
|
increased mammary adenocarcinoma incidence
|
J:170904
|
increased mammary gland tumor incidence
|
J:170904
|
Map3k1tm1Glj/Map3k1tm1Glj Tg(MMTV-PyVT)634Mul/0
(involves: 129S/SvEv * FVB/N)
|
increased mammary gland tumor incidence
|
J:112298
|
Map3k7tm1Aki/Map3k7tm1Aki Tg(Alb1-cre)7Gsc/0
(involves: 129P2/OlaHsd * FVB/N)
|
increased hepatocellular carcinoma incidence
|
J:160521
|
Map9tm1.1Bcgen/Map9tm1.1Bcgen Tg(CDX2-cre/ERT2)752Erf/0
(involves: 129S4/SvJaeSor * C57BL/6J * SJL/J)
|
increased colon tumor incidence
|
J:299895
|
Mapk14tm1Nbr/Mapk14tm2Nbr Polr2atm1(cre/ERT2)Bbd/Polr2a+
(involves: 129S1/Sv * 129X1/SvJ * C57BL/6 * CD-1 * SJL)
|
increased lung adenocarcinoma incidence
|
J:122397
|
increased lung adenoma incidence
|
J:122397
|
increased lung tumor incidence
|
J:122397
|
Mapkapk5tm1Pqs/Mapkapk5+
(involves: 129S1/Sv * 129X1/SvJ * C57BL/6)
|
increased skin papilloma incidence
|
J:117893
|
Mapkapk5tm1Pqs/Mapkapk5+ Tg(SV40-NRAS*G12D)1Sco/?
(involves: 129S1/Sv * 129X1/SvJ * C57BL/6)
|
increased lymphoma incidence
|
J:117893
|
Mapkapk5tm1Pqs/Mapkapk5tm1Pqs
(involves: 129S1/Sv * 129X1/SvJ * C57BL/6)
|
increased skin papilloma incidence
|
J:117893
|
Mapkapk5tm1Pqs/Mapkapk5tm1Pqs Tg(SV40-NRAS*G12D)1Sco/?
(involves: 129S1/Sv * 129X1/SvJ * C57BL/6)
|
increased lymphoma incidence
|
J:117893
|
Mapttm1(EGFP)Klt/Mapttm1(EGFP)Klt Tg(MAPT)8cPdav/?
(involves: 129S4/SvJae * C57BL/6 * Swiss Webster)
|
increased follicular lymphoma incidence
|
J:174270
|
increased lymphoma incidence
|
J:174270
|
Mc4rtm1Lowl/Mc4rtm1Lowl
(involves: 129S4/SvJae * C57BL/6J)
|
increased hepatocellular carcinoma incidence
|
J:177386
|
Mcctm1.1Maija/Mcctm1.1Maija Tg(Vil1-cre)997Gum/0
(involves: C57BL/6 * C57BL/6J * SJL)
|
increased large intestine adenocarcinoma incidence
|
J:294342
|
MclrRF/J/MclrSWR/J
(involves: RF/J * SWR/J)
|
increased T cell derived lymphoma incidence
|
J:9614
|
MclrSWR/J/MclrSWR/J
(involves: RF/J * SWR/J)
|
increased T cell derived lymphoma incidence
|
J:9614
|
Mcm2Gt(AB0178)Wtsi/Mcm2+ Mcm4chaos3/Mcm4chaos3
(involves: 129P2/OlaHsd * C3HeB/FeJ * C57BL/6J)
|
increased leukemia incidence
|
J:165667
|
increased T cell derived lymphoma incidence
|
J:165667
|
Mcm2tm1(cre/ERT2)Scpr/Mcm2tm1(cre/ERT2)Scpr
(involves: 129S6/SvEvTac)
|
increased thymoma incidence
|
J:141493
|
Mcm3Gt(RRR002)Byg/Mcm3+ Mcm4chaos3/Mcm4chaos3
(involves: 129P2/OlaHsd * C3HeB/FeJ * C57BL/6J)
|
increased mammary gland tumor incidence
|
J:165667
|
Mcm3Gt(RRR002)Byg/Mcm3+ Mcm4chaos3/Mcm4chaos3 Mcm6Gt(YHD248)Byg/Mcm6+
(involves: 129P2/OlaHsd * C3HeB/FeJ * C57BL/6J)
|
increased lymphoma incidence
|
J:165667
|
Mcm3Gt(RRR002)Byg/Mcm3+ Mcm4chaos3/Mcm4Gt(RRE056)Byg
(involves: 129P2/OlaHsd * C3HeB/FeJ * C57BL/6J)
|
increased lymphoma incidence
|
J:165667
|
increased mammary gland tumor incidence
|
J:165667
|
Mcm3tm1.1Geno/Mcm3+
(involves: 129S2/SvPas * C57BL/6)
|
increased lymphoma incidence
|
J:227638
|
Mcm3tm1.2Geno/Mcm3+
(involves: 129S2/SvPas * C57BL/6)
|
increased lymphoma incidence
|
J:227638
|
Mcm4chaos3/Mcm4chaos3
(involves: C57BL/6J)
|
increased lymphoma incidence
|
J:165667
|
increased mammary gland tumor incidence
|
J:165667
|
increased T cell derived lymphoma incidence
|
J:165667
|
Mcm4chaos3/Mcm4chaos3
(C3.B6-Mcm4chaos3)
|
increased hepatocellular carcinoma incidence
|
J:117494
|
increased lung adenocarcinoma incidence
|
J:117494
|
increased mammary adenocarcinoma incidence
|
J:117494
|
increased mammary gland tumor incidence
|
J:117494
|
Mcm4Sdla/Mcm4+
(involves: C57BL/6)
|
increased acute lymphoblastic leukemia incidence
|
J:194117
|
Mcm8tm1.1Geno/Mcm8tm1.1Geno
(involves: 129S2/SvPas * C57BL/6J)
|
increased ovary adenoma incidence
|
J:187623
|
increased ovary tumor incidence
|
J:187623
|
Mcm9Gt(AW0655)Wtsi/Mcm9Gt(AW0655)Wtsi
(involves: 129P2/OlaHsd * C3HeB/FeJ)
|
increased hepatocellular carcinoma incidence
|
J:177420
|
increased ovary tumor incidence
|
J:177420
|
Mcm9Gt(AW0655)Wtsi/Mcm9Gt(XG743)Byg
(involves: 129P2/OlaHsd * C3HeB/FeJ)
|
increased hepatocellular carcinoma incidence
|
J:177420
|
increased ovary tumor incidence
|
J:177420
|
Mcm9Gt(XG743)Byg/Mcm9Gt(XG743)Byg
(involves: 129P2/OlaHsd * C3HeB/FeJ)
|
increased hepatocellular carcinoma incidence
|
J:177420
|
increased ovary tumor incidence
|
J:177420
|
Mdm2tm1.1Ypz/Mdm2tm1.1Ypz Tg(IghMyc)22Bri/0
(B6.Cg-Mdm2tm1.1Ypz Tg(IghMyc)22Bri)
|
increased lymphoma incidence
|
J:164200
|
Mdm2tm2.1Snj/Mdm2tm2.1Snj
(involves: 129S4/SvJae * C57BL/6)
|
increased B cell derived lymphoma incidence
|
J:189297
|
increased T cell derived lymphoma incidence
|
J:189297
|
Mdm2tm3.1Glo/Mdm2tm3.1Glo
(B6.129S6-Mdm2tm3.1Glo)
|
increased lymphoma incidence
|
J:164201
|
increased mammary adenocarcinoma incidence
|
J:164201
|
Mdm2tm3.1Glo/Mdm2tm3.1Glo Trp53tm3.1Glo/Trp53+
(B6.129S-Mdm2tm3.1Glo Trp53tm3.1Glo)
|
increased histiocytic sarcoma incidence
|
J:164201
|
increased leiomyosarcoma incidence
|
J:164201
|
increased liver adenocarcinoma incidence
|
J:164201
|
increased liver adenoma incidence
|
J:164201
|
increased lung adenoma incidence
|
J:164201
|
increased lymphoma incidence
|
J:164201
|
increased mammary adenocarcinoma incidence
|
J:164201
|
increased osteosarcoma incidence
|
J:164201
|
Mdm2tm3.1Snj/Mdm2tm3.1Snj
(involves: 129S4/SvJae * C57BL/6)
|
increased salivary gland tumor incidence
|
J:189297
|
Mdm2tm4.1Glo/Mdm2tm4.1Glo Trp53tm3.1Glo/Trp53+
(B6.129S-Mdm2tm4.1Glo Trp53tm3.1Glo)
|
increased histiocytic sarcoma incidence
|
J:164201
|
increased liver adenocarcinoma incidence
|
J:164201
|
increased lymphoma incidence
|
J:164201
|
increased osteosarcoma incidence
|
J:164201
|
Mdm4tm1Glo/Mdm4+ Tg(IghMyc)22Bri/0
(involves: 129S6/SvEvTac * C57BL * C57BL/6 * SJL)
|
increased B cell derived lymphoma incidence
|
J:123661
|
Mef2btm2Rdf/Mef2b+ Tg(BCL2/IGH)M23Tjd/0 Tg(Cr2-cre)3Cgn/0
(involves: C3H/He * C57BL/6)
|
increased follicular lymphoma incidence
|
J:265465
|
increased lymphoma incidence
|
J:265465
|
Mef2btm2Rdf/Mef2b+ Tg(Cr2-cre)3Cgn/0
(involves: C57BL/6)
|
increased B cell derived lymphoma incidence
|
J:265465
|
Melm1C57BL/6J/Melm1C57BL/6J
(involves: BALB/cJ * C57BL/6J)
|
increased skin tumor incidence
|
J:66211
|
Melm2C57BL/6J/Melm2C57BL/6J
(involves: BALB/cJ * C57BL/6J)
|
increased skin tumor incidence
|
J:66211
|
Melm3C57BL/6J/Melm3C57BL/6J
(involves: BALB/cJ * C57BL/6J)
|
increased skin tumor incidence
|
J:66211
|
Men1tm1.1Ctre/Men1+
(either: (involves: 129S6/SvEvTac * FVB/N) or (involves: 129S6/SvEvTac * Black Swiss * FVB/N))
|
increased pancreas tumor incidence
|
J:67128
|
Men1tm1.1Ctre/Men1+
(involves: 129S6/SvEvTac * FVB/N)
|
increased adrenal gland tumor incidence
|
J:133299
|
increased lung tumor incidence
|
J:133299
|
increased pancreatic islet cell adenoma incidence
|
J:133299
|
increased parathyroid adenoma incidence
|
J:133299
|
increased pheochromocytoma incidence
|
J:133299
|
increased pituitary adenohypophysis tumor incidence
|
J:133299
|
Men1tm1.1Ctre/Men1+
(involves: 129S6/SvEvTac * C57BL/6)
|
increased adrenal gland tumor incidence
|
J:120835
|
increased gland tumor incidence
|
J:120835
|
increased lung adenocarcinoma incidence
|
J:120835
|
increased pancreas tumor incidence
|
J:120835
|
increased parathyroid gland tumor incidence
|
J:120835
|
increased pituitary gland tumor incidence
|
J:120835
|
increased testis tumor incidence
|
J:120835
|
increased thyroid tumor incidence
|
J:120835
|
Men1tm1.1Ctre/Men1+ Rb1tm1Tyj/Rb1+
(involves: 129S2/SvPas * 129S6/SvEvTac * C57BL/6J * FVB/N)
|
increased adrenal gland tumor incidence
|
J:133299
|
increased pancreas tumor incidence
|
J:133299
|
increased parathyroid gland tumor incidence
|
J:133299
|
increased pheochromocytoma incidence
|
J:133299
|
increased pituitary adenohypophysis tumor incidence
|
J:133299
|
increased pituitary melanotroph tumor incidence
|
J:133299
|
increased thyroid C-cell carcinoma incidence
|
J:133299
|
Men1tm1.1Gfk/Men1+
(involves: 129T2/SvEms * C57BL/6)
|
increased adrenal gland adenoma incidence
|
J:116086
|
increased glucagonoma incidence
|
J:116086
|
increased insulinoma incidence
|
J:116086
|
increased Leydig cell tumor incidence
|
J:116086
|
increased ovary tumor incidence
|
J:116086
|
increased pancreas adenoma incidence
|
J:116086
|
increased parathyroid adenoma incidence
|
J:116086
|
increased pituitary adenoma incidence
|
J:116086
|
increased prolactinoma incidence
|
J:116086
|
Men1tm1.2Ctre/Men1+ Tg(Ins2-cre)1Dh/0
(involves: 129S6/SvEvTac * C57BL/6 * FVB/N)
|
increased insulinoma incidence
|
J:85042
|
Men1tm1.2Ctre/Men1+ Tg(Ins2-cre)1Heed/0
(involves: 129S6/SvEvTac * C57BL/6 * FVB/N)
|
increased insulinoma incidence
|
J:85042
|
Men1tm1.2Ctre/Men1+ Tg(Ins2-cre)25Mgn/0
(involves: 129S6/SvEvTac * C57BL/6 * FVB/N)
|
increased insulinoma incidence
|
J:85042
|
Men1tm1.2Ctre/Men1tm1.2Ctre Tg(Ins2-cre)1Dh/0
(involves: 129S6/SvEvTac * C57BL/6 * FVB/N)
|
increased insulinoma incidence
|
J:85042
|
Men1tm1.2Ctre/Men1tm1.2Ctre Tg(Ins2-cre)1Heed/0
(involves: 129S6/SvEvTac * C57BL/6 * FVB/N)
|
increased insulinoma incidence
|
J:85042
|
Men1tm1.2Ctre/Men1tm1.2Ctre Tg(Ins2-cre)25Mgn/0
(involves: 129S6/SvEvTac * C57BL/6 * FVB/N)
|
increased insulinoma incidence
|
J:85042
|
Men1tm1.2Zqw/Men1tm1.2Zqw Tg(Ins2-cre)23Herr/0
(involves: 129P2/OlaHsd * C57BL/6J * CBA/J)
|
increased insulinoma incidence
|
J:85133
|
Men1tm1Ctre/Men1+
(either: (involves: 129S6/SvEvTac * FVB/N) or (involves: 129S6/SvEvTac * Black Swiss * FVB/N))
|
increased adrenal gland tumor incidence
|
J:67128
|
increased lung adenocarcinoma incidence
|
J:67128
|
increased pancreas tumor incidence
|
J:67128
|
increased parathyroid adenoma incidence
|
J:67128
|
increased pheochromocytoma incidence
|
J:67128
|
increased pituitary adenoma incidence
|
J:67128
|
increased prolactinoma incidence
|
J:67128
|
increased stomach tumor incidence
|
J:67128
|
increased thyroid adenoma incidence
|
J:67128
|
Men1tm1Ctre/Men1tm1Ctre Tg(Pdx1-cre)89.1Dam/0
(involves: 129S6/SvEvTac * C57BL/6 * CBA * FVB/N)
|
increased insulinoma incidence
|
J:146440
|
Men1tm1Gfk/Men1tm1Gfk Tg(Ins2-cre)25Mgn/0
(involves: 129T2/SvEms * C57BL/6 * C57BL/6J * DBA)
|
increased insulinoma incidence
|
J:89898
|
increased pancreas tumor incidence
|
J:89898
|
increased prolactinoma incidence
|
J:89898
|
Men1tm1Rvt/Men1+
(involves: 129 * C57BL/6)
|
increased adrenal cortical tumor incidence
|
J:191261
|
increased ovary tumor incidence
|
J:191261
|
increased pancreatic islet cell adenoma incidence
|
J:191261
|
increased parathyroid adenoma incidence
|
J:191261
|
increased parathyroid gland tumor incidence
|
J:191261
|
increased pituitary adenohypophysis tumor incidence
|
J:191261
|
increased pituitary gland tumor incidence
|
J:191261
|
increased testis tumor incidence
|
J:191261
|
increased thyroid tumor incidence
|
J:191261
|
Men1tm1Zqw/Men1+
(involves: 129/Sv * 129P2/OlaHsd)
|
increased adrenal cortical tumor incidence
|
J:85302
|
increased adrenal gland adenoma incidence
|
J:85302
|
increased adrenal gland tumor incidence
|
J:85302
|
increased adrenocortical adenoma incidence
|
J:85302
|
increased gastrointestinal tumor incidence
|
J:85302
|
increased gland tumor incidence
|
J:85302
|
increased glucagonoma incidence
|
J:85302
|
increased gonad tumor incidence
|
J:85302
|
increased insulinoma incidence
|
J:85302
|
increased intestinal adenoma incidence
|
J:85302
|
increased Leydig cell tumor incidence
|
J:85302
|
increased mammary gland tumor incidence
|
J:85302
|
increased ovary tumor incidence
|
J:85302
|
increased pancreas tumor incidence
|
J:85302
|
increased pancreatic islet cell adenoma incidence
|
J:85302
|
increased pancreatic islet cell carcinoma incidence
|
J:85302
|
increased parathyroid adenoma incidence
|
J:85302
|
increased pituitary adenohypophysis tumor incidence
|
J:85302
|
increased prolactinoma incidence
|
J:85302
|
increased stomach tumor incidence
|
J:85302
|
increased testis tumor incidence
|
J:85302
|
increased thyroid carcinoma incidence
|
J:85302
|
increased thyroid tumor incidence
|
J:85302
|
Men1tm2.1Gfk/Men1+
(involves: 129T2/SvEms * C57BL/6)
|
increased insulinoma incidence
|
J:116086
|
increased Leydig cell tumor incidence
|
J:116086
|
increased ovary tumor incidence
|
J:116086
|
increased pancreas adenoma incidence
|
J:116086
|
increased parathyroid adenoma incidence
|
J:116086
|
increased pituitary adenoma incidence
|
J:116086
|
Men1tm2.1Mmey/Men1tm2.1Mmey Tg(Ins2-cre)23Herr/0
(involves: 129S6/SvEvTac * C57BL/6 * CBA/J * FVB/N)
|
increased insulinoma incidence
|
J:175625
|
Mettm1Gvw/Met+
(involves: 129 * C57BL/6J)
|
increased histiocytic sarcoma incidence
|
J:94722
|
increased lymphoma incidence
|
J:94722
|
Mettm2Gvw/Met+
(involves: 129 * C57BL/6J)
|
increased histiocytic sarcoma incidence
|
J:94722
|
increased lymphoma incidence
|
J:94722
|
Mettm4Gvw/Met+
(involves: 129 * C57BL/6J)
|
increased lymphoma incidence
|
J:94722
|
Mettm4Gvw/Met+
(involves: 129 * C57BL/6J * FVB/N)
|
increased mammary adenocarcinoma incidence
|
J:151890
|
increased mammary gland tumor incidence
|
J:151890
|
Mfsd1tm1a(KOMP)Wtsi/Mfsd1tm1a(KOMP)Wtsi
(involves: C57BL/6N)
|
increased liver tumor incidence
|
J:280713
|
Mgmttm1Mse/Mgmttm1Mse
(involves: 129S/SvEv)
|
increased T cell derived lymphoma incidence
|
J:47642
|
Mgmttm1Mse/Mgmttm1Mse Mlh1tm1Mse/Mlh1tm1Mse
(involves: 129S/SvEv)
|
increased lung adenoma incidence
|
J:47642
|
increased T cell derived lymphoma incidence
|
J:47642
|
Mir34atm1.2Arte/Mir34a+ Tg(Neurod2-Smo*A1)199Jols/0
(involves: C57BL/6 * C57BL/6N)
|
increased medulloblastoma incidence
|
J:221990
|
Mir34atm1.2Arte/Mir34atm1.2Arte Tg(Neurod2-Smo*A1)199Jols/0
(involves: C57BL/6 * C57BL/6N)
|
increased medulloblastoma incidence
|
J:221990
|
Mir122tm1.1Apts/Mir122tm1.1Apts
(involves: 129 * C57BL/6)
|
increased hepatocellular carcinoma incidence
|
J:190066
|
Mir122tm1.1Kgh/Mir122+
(involves: 129S1/Sv * 129X1/SvJ)
|
increased hepatocellular carcinoma incidence
|
J:190067
|
Mir122tm1.1Kgh/Mir122tm1.1Kgh
(involves: 129S1/Sv * 129X1/SvJ)
|
increased hepatocellular carcinoma incidence
|
J:190067
|
Mir122tm1.2Kgh/Mir122+ Speer6-ps1Tg(Alb-cre)21Mgn/Speer6-ps1+
(involves: 129S1/Sv * 129X1/SvJ * C57BL/6 * DBA)
|
increased hepatocellular carcinoma incidence
|
J:190067
|
Mir122tm1.2Kgh/Mir122tm1.2Kgh Speer6-ps1Tg(Alb-cre)21Mgn/Speer6-ps1+
(involves: 129S1/Sv * 129X1/SvJ * C57BL/6 * DBA)
|
increased hepatocellular carcinoma incidence
|
J:190067
|
increased liver tumor incidence
|
J:190067
|
Mir146tm1.1Bal/Mir146tm1.1Bal
(involves: C57BL/6)
|
increased B cell derived lymphoma incidence
|
J:173230
|
increased follicular lymphoma incidence
|
J:173230
|
increased myeloid sarcoma incidence
|
J:173230
|
increased spleen neoplasm incidence
|
J:173230
|
increased T cell derived lymphoma incidence
|
J:173230
|
Mir146tm2.1Bal/Mir146tm2.1Bal
(involves: 129S1/Sv * C57BL/6 * FVB/N)
|
increased follicular lymphoma incidence
|
J:173671
|
increased hemolymphoid system tumor incidence
|
J:173671
|
Mir216aem1Uf/Mir216aem1Uf Tg(Ela-KRAS*G12D)9Eps/0
(involves: C57BL/6N * FVB)
|
increased pancreas tumor incidence
|
J:278847
|
Mir216aem2Uf/Mir216aem2Uf Tg(Ela-KRAS*G12D)9Eps/0
(involves: C57BL/6N * FVB)
|
increased pancreas tumor incidence
|
J:278847
|
Mir216bem1Uf/Mir216bem1Uf Tg(Ela-KRAS*G12D)9Eps/0
(involves: C57BL/6N * FVB)
|
increased pancreas tumor incidence
|
J:278847
|
Mir217em1Uf/Mir217em1Uf Tg(Ela-KRAS*G12D)9Eps/0
(involves: C57BL/6N * FVB)
|
increased pancreas tumor incidence
|
J:278847
|
Mir217em2Uf/Mir217em2Uf Tg(Ela-KRAS*G12D)9Eps/0
(involves: C57BL/6N * FVB)
|
increased pancreas tumor incidence
|
J:278847
|
Mirc1tm2.1Aven/Mirc1tm2.1Aven Tg(ARR2/Pbsn-MYC)7Key/0
(involves: 129S4/SvJae * C57BL/6 * FVB/N * SJL/J)
|
increased prostate gland adenocarcinoma incidence
|
J:223213
|
Mirc1tm2.1Aven/Mirc1tm2.1Aven Tg(IghMyc)22Bri/?
(involves: 129S4/SvJae * C57BL/6 * SJL/J)
|
increased B cell derived lymphoma incidence
|
J:223213
|
Mirc30em1Hhzg/Mirc30em1Hhzg Tg(Vav1-cre)#Cgp/0
(involves: 129S4/SvJae * C57BL/6 * C57BL/6NRj)
|
increased chronic lymphocytic leukemia incidence
|
J:320883
|
Mirc30tm1.2Rdf/Mirc30tm1.2Rdf
(involves: 129S1/Sv * 129S4/SvJaeSor * C57BL/6)
|
increased B cell derived lymphoma incidence
|
J:156946
|
increased leukemia incidence
|
J:156946
|
Mldhrtm1Zhgn/Mldhrtm1Zhgn Tg(GFAP-cre)25Mes/0
(involves: FVB/N)
|
increased glioblastoma incidence
|
J:303725
|
Mleu1SWR/J/? Tg(CTSG-PML/RARA)135Ley/0
(involves: C3H/HeJ * C57BL/6J * SWR/J)
|
increased leukemia incidence
|
J:139159
|
Mleu2SWR/J/? Tg(CTSG-PML/RARA)135Ley/0
(involves: C3H/HeJ * C57BL/6J * SWR/J)
|
increased leukemia incidence
|
J:139159
|
Mleu3C57BL/6J/Mleu3SWR/J Tg(CTSG-PML/RARA)135Ley/0
(involves: C3H/HeJ * C57BL/6J * SWR/J)
|
increased leukemia incidence
|
J:139159
|
Mleu4SWR/J/? Tg(CTSG-PML/RARA)135Ley/0
(involves: C3H/HeJ * C57BL/6J * SWR/J)
|
increased leukemia incidence
|
J:139159
|
Mleu5SWR/J/? Tg(CTSG-PML/RARA)135Ley/0
(involves: C3H/HeJ * C57BL/6J * SWR/J)
|
increased leukemia incidence
|
J:139159
|
Mlh1tm1Lisk/Mlh1tm1Lisk
(involves: 129S7/SvEvBrd)
|
increased lymphoma incidence
|
J:34291
|
Mlh1tm1Lisk/Mlh1tm1Lisk
(involves: 129S4/SvJae * 129S7/SvEvBrd * C57BL/6)
|
increased intestinal adenocarcinoma incidence
|
J:75745
|
increased intestinal adenoma incidence
|
J:75745
|
increased lymphoma incidence
|
J:75745
|
increased skin tumor incidence
|
J:75745
|
increased uterus tumor incidence
|
J:75745
|
Mlh1tm1Mse/Mlh1tm1Mse
(involves: 129S/SvEv)
|
increased T cell derived lymphoma incidence
|
J:47642
|
Mlh1tm1Rak/Mlh1+
(involves: 129P2/OlaHsd * C57BL/6)
|
increased gastrointestinal tumor incidence
|
J:53451
|
increased lung carcinoma incidence
|
J:53451
|
increased lymphoma incidence
|
J:53451
|
increased T cell derived lymphoma incidence
|
J:53451
|
Mlh1tm1Rak/Mlh1tm1Rak
(involves: 129P2/OlaHsd * C57BL/6)
|
increased B cell derived lymphoma incidence
|
J:98929,
J:53451
|
increased gastrointestinal tumor incidence
|
J:53451
|
increased lymphoma incidence
|
J:53451
|
increased T cell derived lymphoma incidence
|
J:53451
|
Mlh1tm1Rak/Mlh1tm1Rak
(involves: 129P2/OlaHsd)
|
increased gastrointestinal tumor incidence
|
J:133352
|
increased lymphoma incidence
|
J:133352
|
increased skin tumor incidence
|
J:133352
|
increased small intestine adenocarcinoma incidence
|
J:133352
|
Mlh1tm1Rak/Mlh1tm1Rak
(involves: 129P2/OlaHsd * C57BL/6 * C57BL/6J)
|
increased intestinal adenocarcinoma incidence
|
J:153684
|
increased intestinal adenoma incidence
|
J:153684
|
increased lymphoma incidence
|
J:153684
|
increased T cell derived lymphoma incidence
|
J:153684
|
Mlh1tm1Wed/Mlh1tm1Wed
(involves: 129/Sv * C57BL/6J * SJL)
|
increased basal cell carcinoma incidence
|
J:133352
|
increased lymphoma incidence
|
J:133352
|
Mmp7tm1Lmm/Mmp7tm1Lmm Tg(MMTV-PyVT)634Mul/0
(involves: 129S1/Sv * 129X1/SvJ * C57BL/6 * FVB/N)
|
increased mammary gland tumor incidence
|
J:140033
|
Mmp9tm1Tvu/Mmp9tm1Tvu Tg(KRT14-HPV16)wt1Dh/0
(involves: 129S6/SvEvTac * C57BL/6 * DBA/2 * FVB/N)
|
increased skin squamous cell carcinoma incidence
|
J:65699
|
Mmp9tm1Tvu/Mmp9tm1Tvu Tg(MMTV-PyVT)634Mul/0
(involves: 129S6/SvEvTac * C57BL/6 * FVB/N)
|
increased mammary gland tumor incidence
|
J:140033
|
Mmp9tm1Tvu/Mmp9tm1Tvu Tg(MMTV-PyVT)634Mul/0
(involves: 129S6/SvEvTac * FVB/N)
|
increased mammary gland tumor incidence
|
J:140033
|
Mmp11tm1Mrio/Mmp11tm1Mrio Tg(MMTV-vHaras)SH1Led/Tg(MMTV-vHaras)SH1Led
(involves: 129S2/SvPas * 129X1/SvJ * C57BL/6J * CD-1 * FVB)
|
increased mammary gland tumor incidence
|
J:86074
|
Mnttm1Awb/Mnttm1.1Awb Tg(MMTV-cre)4Mam/?
(involves: 129S6/SvEvTac * FVB/N)
|
increased mammary adenocarcinoma incidence
|
J:110115
|
Mnttm1Phu/Mnttm1Phu Tg(MMTV-cre)4Mam/?
(involves: FVB)
|
increased mammary adenocarcinoma incidence
|
J:85481
|
Mob1atm1.1Asuz/Mob1atm1.1Asuz Mob1bGt(CC0690)Wtsi/Mob1bGt(CC0690)Wtsi Albtm1(cre/ERT2)Mtz/Alb+
(involves: 129P2/OlaHsd * 129S2/SvPas * C57BL/6)
|
increased hepatobiliary system tumor incidence
|
J:228499
|
Mob1atm1.1Asuz/Mob1atm1.1Asuz Mob1bGt(CC0690)Wtsi/Mob1bGt(CC0690)Wtsi Speer6-ps1Tg(Alb-cre)21Mgn/Speer6-ps1+
(B6.Cg-Mob1bGt(CC0690)Wtsi Mob1atm1.1Asuz Speer6-ps1Tg(Alb-cre)21Mgn)
|
increased cholangiocarcinoma incidence
|
J:228499
|
increased hepatobiliary system tumor incidence
|
J:228499
|
increased hepatocellular carcinoma incidence
|
J:228499
|
increased liver adenoma incidence
|
J:228499
|
Mob1atm1.2Asuz/Mob1a+ Mob1bGt(CC0690)Wtsi/Mob1bGt(CC0690)Wtsi
(involves: 129P2/OlaHsd * C57BL/6)
|
increased integument system tumor incidence
|
J:193981
|
increased mammary gland tumor incidence
|
J:193981
|
increased osteosarcoma incidence
|
J:193981
|
increased salivary gland tumor incidence
|
J:193981
|
increased skin tumor incidence
|
J:193981
|
Mob1atm1.2Asuz/Mob1atm1.2Asuz Mob1bGt(CC0690)Wtsi/Mob1b+
(involves: 129P2/OlaHsd * C57BL/6)
|
increased integument system tumor incidence
|
J:193981
|
increased liver tumor incidence
|
J:193981
|
increased lung tumor incidence
|
J:193981
|
increased mammary gland tumor incidence
|
J:193981
|
increased osteosarcoma incidence
|
J:193981
|
increased salivary gland tumor incidence
|
J:193981
|
increased skin tumor incidence
|
J:193981
|
Mom7AKR/Mom7AKR
(involves: AKR * C57BL/6)
|
increased gastrointestinal tumor incidence
|
J:123865
|
Mom21BTBR/Mom21BTBR
(involves: BTBR * C57BL/6)
|
increased gastrointestinal tumor incidence
|
J:123865
|
Morc2aem1(IMPC)Wtsi/Morc2aem1(IMPC)Wtsi
(C57BL/6N-Morc2aem1(IMPC)Wtsi/WtsiOulu)
|
increased trigeminal neuroma incidence
|
J:239583
|
Mp53d3BALB/c/Mp53d3MSM
(involves: BALB/c-Trp53tm1Brd * MSM)
|
increased skin tumor incidence
|
J:81940
|
Mre11atm1Jpt/Mre11a+ Rad50tm2Jpt/Rad50tm2Jpt
(involves: 129S7/SvEvBrd * C57BL/6)
|
increased lymphoma incidence
|
J:103922
|
Mre11atm1Jpt/Mre11atm1Jpt Rad50tm2Jpt/Rad50tm2Jpt
(involves: 129S7/SvEvBrd * C57BL/6)
|
increased lymphoma incidence
|
J:103922
|
Msh2tm1Htr/Msh2+
(involves: 129P2/OlaHsd)
|
increased liver tumor incidence
|
J:45433
|
increased lung tumor incidence
|
J:45433
|
increased mammary gland tumor incidence
|
J:45433
|
increased osteosarcoma incidence
|
J:45433
|
increased skin tumor incidence
|
J:45433
|
increased uterus tumor incidence
|
J:45433
|
Msh2tm1Htr/Msh2tm1Htr
(either: (involves: 129P2/OlaHsd) or (involves: 129P2/OlaHsd * FVB))
|
increased T cell derived lymphoma incidence
|
J:27469
|
Msh2tm1Htr/Msh2tm1Htr
(involves: 129P2/OlaHsd)
|
increased brain tumor incidence
|
J:45433
|
increased gastrointestinal tumor incidence
|
J:45433
|
increased lymphoma incidence
|
J:45433
|
increased skin tumor incidence
|
J:45433
|
increased T cell derived lymphoma incidence
|
J:45433
|
Msh2tm1Htr/Msh2tm1Htr
(involves: 129P2/OlaHsd * FVB)
|
increased gastrointestinal tumor incidence
|
J:45433
|
increased lung tumor incidence
|
J:45433
|
increased lymphoma incidence
|
J:45433
|
increased mammary gland tumor incidence
|
J:45433
|
increased skin tumor incidence
|
J:45433
|
increased T cell derived lymphoma incidence
|
J:45433
|
increased uterus tumor incidence
|
J:45433
|
Msh2tm1Htr/Msh2tm1Htr Smug1tm1a(EUCOMM)Hmgu/Smug1tm1a(EUCOMM)Hmgu Ungtm1Tld/Ungtm1Tld
(involves: 129P2/OlaHsd * C57BL/6 * C57BL/6N)
|
increased lymphoma incidence
|
J:197809
|
Msh2tm1Htr/Msh2tm1Htr Smug1tm1a(EUCOMM)Hmgu/Smug1tm1a(EUCOMM)Hmgu Ungtm1Tld/Ungtm1Tld
(involves: 129P2/OlaHsd * C57BL/6 * C57BL/6N)
|
increased lymphoma incidence
|
J:197809
|
Msh2tm1Htr/Msh2tm1Htr Tap1tm1Hpl/Tap1tm1Hpl
(involves: 129P2/OlaHsd * FVB)
|
increased gastrointestinal tumor incidence
|
J:45433
|
increased lung tumor incidence
|
J:45433
|
increased mammary gland tumor incidence
|
J:45433
|
increased skin tumor incidence
|
J:45433
|
increased uterus tumor incidence
|
J:45433
|
Msh2tm1Mak/Msh2+ Mutyhtm1Jhmi/Mutyhtm1Jhmi Ogg1tm1Tld/Ogg1tm1Tld
(involves: 129 * C57BL/6J)
|
increased lung adenocarcinoma incidence
|
J:89742
|
increased lung adenoma incidence
|
J:89742
|
increased lymphoma incidence
|
J:89742
|
increased ovary tumor incidence
|
J:89742
|
Msh2tm1Mak/Msh2tm1Mak
(involves: 129P2/OlaHsd * C57BL/6J)
|
increased lymphoma incidence
|
J:28397
|
Msh2tm1Mak/Msh2tm1Mak Mutyhtm1Jhmi/Mutyhtm1Jhmi Ogg1tm1Tld/Ogg1tm1Tld
(involves: 129 * C57BL/6J)
|
increased lung adenoma incidence
|
J:89742
|
increased lymphoma incidence
|
J:89742
|
Msh2tm1Rak/Msh2+
(involves: 129P2/OlaHsd)
|
increased liver adenoma incidence
|
J:64667
|
increased lymphoma incidence
|
J:64667
|
Msh2tm1Rak/Msh2tm1Rak
(involves: 129P2/OlaHsd)
|
increased gastrointestinal tumor incidence
|
J:64667
|
increased lymphoma incidence
|
J:64667
|
Msh2tm1Rak/Msh2tm1Rak
(involves: 129P2/OlaHsd * C57BL/6)
|
increased lymphoma incidence
|
J:98929
|
Msh2tm1Rak/Msh2tm2.1Rak Tg(Vil1-cre)20Syr/0
(involves: 129/Sv * 129P2/OlaHsd * C57BL/6 * DBA/2 * SJL)
|
increased gastrointestinal tumor incidence
|
J:161577
|
increased intestinal adenocarcinoma incidence
|
J:161577
|
increased intestinal adenoma incidence
|
J:161577
|
Msh2tm1Wed/Msh2tm1Wed
(involves: C57BL/6)
|
increased intestinal adenocarcinoma incidence
|
J:86278
|
increased lymphoma incidence
|
J:86278
|
Msh2tm1Wed/Msh2tm1Wed
(involves: 129 * C57BL/6 * SJL)
|
increased intestinal adenocarcinoma incidence
|
J:88092
|
increased lymphoma incidence
|
J:88092
|
Msh2tm1Whl/Msh2tm1Whl
(involves: 129P2/OlaHsd * C57BL/6J)
|
increased gastrointestinal tumor incidence
|
J:79016
|
increased lymphoblastic lymphoma incidence
|
J:79016
|
increased skin tumor incidence
|
J:79016
|
Msh2tm1Whl/Msh2tm1Whl Rb1tm1Brd/Rb1+
(involves: 129P2/OlaHsd * 129S7/SvEvBrd * C57BL/6J)
|
increased gastrointestinal tumor incidence
|
J:79016
|
increased lymphoblastic lymphoma incidence
|
J:79016
|
increased pheochromocytoma incidence
|
J:79016
|
increased pituitary adenohypophysis tumor incidence
|
J:79016
|
increased pituitary melanotroph tumor incidence
|
J:79016
|
increased skin tumor incidence
|
J:79016
|
increased thyroid C-cell carcinoma incidence
|
J:79016
|
Msh2tm2.1Rak/Msh2tm2.1Rak Tg(Vil1-cre)20Syr/0
(involves: 129/Sv * C57BL/6 * FVB/N * SJL)
|
increased gastrointestinal tumor incidence
|
J:161577
|
increased intestinal adenoma incidence
|
J:161577
|
increased lymphoma incidence
|
J:161577
|
increased small intestine adenocarcinoma incidence
|
J:161577
|
Msh2tm2.1Rak/Msh2tm3.1Rak Tg(Vil1-cre)20Syr/0
(involves: 129/Sv * C57BL/6 * DBA/2 * SJL)
|
increased gastrointestinal tumor incidence
|
J:161577
|
increased intestinal adenocarcinoma incidence
|
J:161577
|
increased intestinal adenoma incidence
|
J:161577
|
Msh2tm2.2Rak/Msh2tm2.2Rak
(involves: 129/Sv * C57BL/6 * FVB/N * SJL)
|
increased gastrointestinal tumor incidence
|
J:161577
|
increased lymphoma incidence
|
J:161577
|
Msh3tm1Htr/Msh3tm1Htr Msh6tm1Htr/Msh6tm1Htr
(involves: 129P2/OlaHsd * FVB/N)
|
increased gastrointestinal tumor incidence
|
J:59561
|
increased lymphoma incidence
|
J:59561
|
increased skin tumor incidence
|
J:59561
|
Msh3tm1Rak/Msh3tm1Rak
(involves: 129/Sv * C57BL/6J * SJL)
|
increased intestinal adenocarcinoma incidence
|
J:60604
|
Msh3tm1Rak/Msh3tm1Rak Msh6tm1Rak/Msh6tm1Rak
(involves: 129/Sv * C57BL/6J * SJL)
|
increased gastrointestinal tumor incidence
|
J:60604
|
increased intestinal adenocarcinoma incidence
|
J:60604
|
increased lymphoma incidence
|
J:60604
|
Msh5tm1Htr/Msh5tm1Htr
(involves: 129P2/OlaHsd * FVB)
|
increased granulosa cell tumor incidence
|
J:180025
|
Msh6tm1Htr/Msh6tm1Htr
(involves: 129P2/OlaHsd * FVB/N)
|
increased gastrointestinal tumor incidence
|
J:59561
|
increased hemolymphoid system tumor incidence
|
J:59561
|
increased lymphoma incidence
|
J:59561
|
increased skin tumor incidence
|
J:59561
|
increased uterus tumor incidence
|
J:59561
|
Msh6tm1Rak/Msh6tm1Rak
(involves: 129/Sv * C57BL/6J * SJL)
|
increased gastrointestinal tumor incidence
|
J:44428
|
increased lymphoma incidence
|
J:44428
|
Msh6tm1Wed/Msh6+
(involves: 129/Sv * C57BL/6J * SJL)
|
increased lymphoma incidence
|
J:92555
|
Msh6tm1Wed/Msh6tm1Wed
(involves: 129/Sv * C57BL/6J * SJL)
|
increased basal cell carcinoma incidence
|
J:92555
|
increased intestinal adenoma incidence
|
J:92555
|
increased lymphoma incidence
|
J:92555
|
Msmbtm1Xuan/Msmbtm1Xuan
(either: (involves: 129S1/Sv * 129X1/SvJ) or (involves: 129S1/Sv * 129X1/SvJ * CD-1))
|
increased prostate gland adenocarcinoma incidence
|
J:96884
|
increased prostate intraepithelial neoplasia incidence
|
J:96884
|
Msmr1SL/Kh/Msmr1SL/Kh
(involves: MSM/Ms * SL/Kh)
|
increased lymphoma incidence
|
J:34941
|
Msmr1SL/Kh/Msmr1SL/Kh Msmr2SL/Kh/Msmr2SL/Kh
(involves: MSM/Ms * SL/Kh)
|
increased B cell derived lymphoma incidence
|
J:34941
|
Msmr2SL/Kh/Msmr2SL/Kh
(involves: MSM/Ms * SL/Kh)
|
increased lymphoma incidence
|
J:34941
|
Mtbptm1Glo/Mtbp+ Trp53tm1Tyj/Trp53+
(involves: 129S2/SvPas * 129S7/SvEvBrd * C57BL/6J)
|
increased leukemia incidence
|
J:135509
|
increased lymphoma incidence
|
J:135509
|
Mtes1AKR/J/?
(involves: AKR/J * DBA/2J)
|
increased mammary gland tumor incidence
|
J:73358
|
Mtf1Thyls-BALB/c/Mtf1Thyls-BALB/c
(involves: BALB/c * MSM)
|
increased T cell derived lymphoma incidence
|
J:71358
|
Mtf1Thyls-BALB/c/Mtf1Thyls-MSM
(involves: BALB/c * MSM)
|
increased T cell derived lymphoma incidence
|
J:85264,
J:71358
|
Mtss1Gt(CSC156)Byg/Mtss1Gt(CSC156)Byg
(B6.129P2-Mtss1Gt(CSC156)Byg)
|
increased B cell derived lymphoma incidence
|
J:186118
|
Mtus1Gt(RRA048)Byg/Mtus1Gt(RRA048)Byg
(involves: 129P2/OlaHsd * C57BL/6)
|
increased B cell derived lymphoma incidence
|
J:212144
|
Mtv2a/Mtv2a
(DDD.GR-Mtv2a)
|
increased mammary adenocarcinoma incidence
|
J:109201
|
Muc1tm1Gend/Muc1tm1Gend Tg(WapTgfa)215Bri/0
(involves: 129P2/OlaHsd * C57BL/6 * SJL)
|
increased mammary gland tumor incidence
|
J:123146
|
Muc2tm1Avel/Muc2tm1Avel
(involves: 129P2/OlaHsd * C57BL/6)
|
increased intestinal adenocarcinoma incidence
|
J:75047
|
Mus81tm1Raz/Mus81+
(involves: 129P2/OlaHsd)
|
increased lymphoma incidence
|
J:91570
|
Mus81tm1Raz/Mus81tm1Raz
(involves: 129P2/OlaHsd)
|
increased B cell derived lymphoma incidence
|
J:91570
|
increased lymphoma incidence
|
J:91570
|
Mutyhtm1Jhmi/Mutyhtm1Jhmi Ogg1tm1Tld/Ogg1tm1Tld
(involves: 129 * C57BL/6J)
|
increased lung adenoma incidence
|
J:89742
|
increased lung tumor incidence
|
J:89742
|
increased lymphoma incidence
|
J:89742
|
increased ovary tumor incidence
|
J:89742
|
Mybl2tm1.1Jof/Mybl2+ Tg(Zp3-cre)3Mrt/0
(involves: 129S2/SvPas * C57BL/6 * FVB/N)
|
increased leukemia incidence
|
J:196804
|
Myctm1Lbox/Myc+
(involves: 129S1/Sv * 129X1/SvJ * FVB/N)
|
increased B cell derived lymphoma incidence
|
J:97900
|
Myctm1Lbox/Myctm1Lbox
(involves: 129S1/Sv * 129X1/SvJ * FVB/N)
|
increased B cell derived lymphoma incidence
|
J:97900
|
Myf6tm1(cre)Mrc/Myf6+ Pax3tm1Mrc/Pax3+
(involves: 129S1/Sv * 129X1/SvJ * C57BL/6 * SJL)
|
increased rhabdomyosarcoma incidence
|
J:93444
|
Myf6tm1(cre)Mrc/Myf6+ Pax3tm1Mrc/Pax3tm1Mrc Trp53tm1Brn/Trp53+
(involves: 129P2/OlaHsd * 129S1/Sv * 129X1/SvJ * C57BL/6 * SJL)
|
increased rhabdomyosarcoma incidence
|
J:93444
|
Myf6tm1(cre)Mrc/Myf6+ Pax3tm1Mrc/Pax3tm1Mrc Trp53tm1Brn/Trp53tm1Brn
(involves: 129P2/OlaHsd * 129S1/Sv * 129X1/SvJ * C57BL/6 * SJL)
|
increased rhabdomyosarcoma incidence
|
J:93444
|
Myh14tm2Rsad/Myh14+
(involves: 129S/SvEv * C57BL/6)
|
increased lymphoma incidence
|
J:171110
|
Myh14tm2Rsad/Myh14tm2Rsad
(involves: 129S/SvEv * C57BL/6)
|
increased lymphoma incidence
|
J:171110
|
Mzf1tm1Ppp/Mzf1tm1Ppp
(involves: 129)
|
increased hepatocellular carcinoma incidence
|
J:70407
|
increased spleen neoplasm incidence
|
J:70407
|
Nabp2tm1.1Kkha/Nabp2tm1.1Kkha Gt(ROSA)26Sortm9(cre/ESR1)Arte/Gt(ROSA)26Sor+
(involves: C57BL/6 * C57BL/6NTac)
|
increased B cell derived lymphoma incidence
|
J:195140
|
increased hepatocellular carcinoma incidence
|
J:195140
|
increased leukemia incidence
|
J:195140
|
increased T cell derived lymphoma incidence
|
J:195140
|
Nabp2tm1Schg/Nabp2tm1Schg Trp53tm1Brd/Trp53tm1Brd
(involves: 129S7/SvEvBrd * C57BL/6)
|
increased lymphoma incidence
|
J:228558
|
Nbnem3Jpt/Nbnem3Jpt Trp53tm1Tyj/Trp53tm1Tyj
(involves: 129S2/SvPas)
|
increased histiocytic sarcoma incidence
|
J:251434
|
increased leiomyosarcoma incidence
|
J:251434
|
increased rhabdomyosarcoma incidence
|
J:251434
|
Nbnem4Jpt/Nbnem4Jpt Trp53tm1Tyj/Trp53tm1Tyj
(involves: 129S2/SvPas)
|
increased histiocytic sarcoma incidence
|
J:251434
|
increased leiomyosarcoma incidence
|
J:251434
|
increased rhabdomyosarcoma incidence
|
J:251434
|
Nbnem7Jpt/Nbntm2Zqw Tg(VAV1-cre)1Graf/0
(involves: 129P2/OlaHsd)
|
increased T cell acute lymphoblastic leukemia incidence
|
J:277750
|
increased T cell derived lymphoma incidence
|
J:277750
|
Nbntm1Jpt/Nbntm1Jpt Trp53tm1Tyj/Trp53tm1Tyj
(involves: 129S2/SvPas * 129S7/SvEvBrd)
|
increased lymphoma incidence
|
J:75956
|
Nbntm1Xu/Nbntm1Xu
(Not Specified)
|
increased T cell derived lymphoma incidence
|
J:75272
|
Nbntm1Zqw/Nbn+
(involves: 129S2/SvPas * C57BL/6)
|
increased B cell derived lymphoma incidence
|
J:86563
|
increased gonad tumor incidence
|
J:86563
|
increased Leydig cell tumor incidence
|
J:86563
|
increased liver adenocarcinoma incidence
|
J:86563
|
increased liver adenoma incidence
|
J:86563
|
increased lung adenocarcinoma incidence
|
J:86563
|
increased lymphoma incidence
|
J:86563
|
increased mammary adenocarcinoma incidence
|
J:86563
|
increased prostate intraepithelial neoplasia incidence
|
J:86563
|
increased T cell derived lymphoma incidence
|
J:86563
|
increased thyroid adenoma incidence
|
J:86563
|
Nbntm2Zqw/Nbntm2Zqw Trp53tm1Brd/Trp53tm1Brd Tg(Nes-cre)1Wme/0
(involves: 129P2/OlaHsd * 129S7/SvEvBrd * C57BL/6 * CBA)
|
increased lymphoma incidence
|
J:98316
|
Ncoa3tm1Jxu/Ncoa3+ Tg(MMTV-vHaras)SH1Led/0
(involves: 129S6/SvEvTac * C57BL/6J * CD-1)
|
increased mammary adenocarcinoma incidence
|
J:88789
|
increased mammary gland tumor incidence
|
J:88789
|
Ncoa3tm1Jxu/Ncoa3tm1Jxu
(involves: 129S6/SvEvTac * C57BL/6J)
|
increased B cell derived lymphoma incidence
|
J:109522
|
increased lymphoma incidence
|
J:109522
|
Ncoa5tm1Hxia/Ncoa5+
(involves: 129 * C57BL/6)
|
increased hepatocellular carcinoma incidence
|
J:207622
|
Ncoa5tm1Hxia/Ncoa5+
(C.129(B6)-Ncoa5tm1Hxia)
|
increased hepatocellular carcinoma incidence
|
J:207622
|
Ncstntm1.1Akli/Ncstntm1.1Akli Tet2tm1.1Iaai/Tet2tm1.1Iaai Tg(VAV1-cre)1Graf/0
(involves: 129S/SvEv * C57BL/6)
|
increased leukemia incidence
|
J:196407
|
Ncstntm1.1Akli/Ncstntm1.1Akli Tg(Mx1-cre)1Cgn/0
(involves: 129 * C57BL/6 * CBA * SJL)
|
increased leukemia incidence
|
J:172442
|
Ncstntm1.1Akli/Ncstntm1.1Akli Tg(Upk2-cre,-EGFP)#Akli/0
(involves: 129)
|
increased urinary bladder carcinoma incidence
|
J:227748
|
Ncstntm1.1Akli/Ncstntm1.1Akli Tg(VAV1-cre)1Graf/0
(involves: 129 * C57BL/6 * SJL)
|
increased leukemia incidence
|
J:172442
|
Ndor1Tg(UBC-cre/ERT2)1Ejb/Ndor1+ Rragatm2Dmsa/Rragatm2Dmsa
(involves: 129S/SvEv * 129S4/SvJae * C57BL/6)
|
increased lymphoma incidence
|
J:213516
|
Ndrg2tm1Kmori/Ndrg2+
(involves: C57BL/6 * C57BL/6NCrlj * CBA/JNCrlj)
|
increased brain tumor incidence
|
J:210264
|
increased gastrointestinal tumor incidence
|
J:210264
|
increased hepatocellular carcinoma incidence
|
J:210264
|
increased lung carcinoma incidence
|
J:210264
|
increased pancreas tumor incidence
|
J:210264
|
increased skin tumor incidence
|
J:210264
|
increased T cell derived lymphoma incidence
|
J:210264
|
increased testis tumor incidence
|
J:210264
|
Ndrg2tm1Kmori/Ndrg2tm1Kmori
(involves: C57BL/6 * C57BL/6NCrlj * CBA/JNCrlj)
|
increased hepatocellular carcinoma incidence
|
J:210264
|
increased lung carcinoma incidence
|
J:210264
|
increased T cell derived lymphoma incidence
|
J:210264
|
Nf1tm1.1Kest/Nf1tm1c(KOMP)Wtsi Tg(Dhh-cre)1Mejr/0
(involves: 129S4/SvJaeSor * C57BL/6 * C57BL/6N * C57BL/6NTac * FVB/N)
|
increased neurofibroma incidence
|
J:234172
|
Nf1tm1c(KOMP)Wtsi/Nf1tm1c(KOMP)Wtsi Tg(Dhh-cre)1Mejr/0
(involves: 129S4/SvJaeSor * C57BL/6 * C57BL/6N * FVB/N)
|
increased neurofibroma incidence
|
J:234172
|
Nf1tm1Fcr/Nf1+ Ptentm1Hwu/Ptentm1Hwu Tg(Mx1-cre)1Cgn/0
(B6.Cg-Tg(Mx1-cre)1Cgn Nf1tm1Fcr Ptentm1Hwu)
|
increased T cell acute lymphoblastic leukemia incidence
|
J:232645
|
Nf1tm1Fcr/Nf1+ Tg(GFAP-cre)#Gtm/0
(involves: 129S/SvEv * 129S4/SvJae * C57BL/6 * CBA)
|
increased glioma incidence
|
J:176586
|
Nf1tm1Fcr/Nf1+ Trp53tm1Brd/Trp53+
(B6.129-Trp53tm1Brd Nf1tm1Fcr)
|
increased brain tumor incidence
|
J:95933
|
Nf1tm1Fcr/Nf1+ Trp53tm1Tyj/Trp53+
(involves: 129S/SvEv * 129S2/SvPas * C57BL/6)
|
increased fibrohistocytoma incidence
|
J:58877
|
increased leiomyosarcoma incidence
|
J:58877
|
increased lymphoma incidence
|
J:58877
|
increased neuroblastoma incidence
|
J:58877
|
increased neurofibrosarcoma incidence
|
J:58877
|
increased rhabdomyosarcoma incidence
|
J:58877
|
Nf1tm1Fcr/Nf1+ Trp53tm1Tyj/Trp53tm1Tyj
(involves: 129S/SvEv * 129S2/SvPas * C57BL/6)
|
increased lymphoma incidence
|
J:58877
|
Nf1tm1Fcr/Nf1tm1Fcr Trp53tm1Elee/Trp53tm1Elee Tg(GFAP-cre)25Mes/0
(involves: 129S/SvEv * 129S4/SvJae * FVB/N)
|
increased glioma incidence
|
J:149662
|
Nf1tm1Par/Nf1+ Ptentm1Hwu/Pten+ Trp53tm1Elee/Trp53+ Tg(GFAP-cre)25Mes/0
(involves: 129S1/Sv * 129S4/SvJae * 129X1/SvJ * FVB/N)
|
increased astrocytoma incidence
|
J:134611
|
increased brain tumor incidence
|
J:134611
|
Nf1tm1Par/Nf1+ Ptentm1Hwu/Pten+ Trp53tm1Tyj/Trp53+ Tg(GFAP-cre)25Mes/0
(involves: 129S1/Sv * 129S2/SvPas * 129S4/SvJae * 129X1/SvJ * FVB/N)
|
increased astrocytoma incidence
|
J:134611
|
increased brain tumor incidence
|
J:134611
|
Nf1tm1Par/Nf1+ Trp53tm1Elee/Trp53+ Tg(GFAP-cre)25Mes/0
(involves: 129S1/Sv * 129S4/SvJae * 129X1/SvJ * FVB/N)
|
increased astrocytoma incidence
|
J:134611
|
increased brain tumor incidence
|
J:134611
|
Nf1tm1Par/Nf1+ Trp53tm1Tyj/Trp53+ Tg(GFAP-cre)25Mes/0
(involves: 129S1/Sv * 129S2/SvPas * 129X1/SvJ * FVB/N)
|
increased astrocytoma incidence
|
J:134611
|
increased brain tumor incidence
|
J:134611
|
Nf1tm1Par/Nf1tm1Fcr Tg(GFAP-cre)#Gtm/0
(involves: 129S/SvEv * 129S1/Sv * 129X1/SvJ * C57BL/6 * CBA)
|
increased glioma incidence
|
J:165209
|
Nf1tm1Par/Nf1tm1Par H2az2Tg(Wnt1-cre)11Rth/H2az2+
(involves: 129S1/Sv * 129X1/SvJ * C57BL/6 * CBA)
|
increased ganglioneuroma incidence
|
J:80323
|
increased gangliosarcoma incidence
|
J:80323
|
increased pheochromocytoma incidence
|
J:80323
|
Nf1tm1Par/Nf1tm1Par Tg(Mpz-cre)94Imeg/0
(involves: 129S1/Sv * 129X1/SvJ)
|
increased ganglioneuroma incidence
|
J:80323
|
increased gangliosarcoma incidence
|
J:80323
|
increased pheochromocytoma incidence
|
J:80323
|
Nf1tm1Par/Nf1tm1Par Tg(Pax3-cre)1Joe/0
(involves: 129S1/Sv * 129X1/SvJ * C57BL/6 * SJL)
|
increased ganglioneuroma incidence
|
J:80323
|
increased gangliosarcoma incidence
|
J:80323
|
increased pheochromocytoma incidence
|
J:80323
|
Nf1tm1Par/Nf1tm1Tyj Tg(Mpz-cre)1Brn/0
(involves: 129/Sv * FVB/N)
|
increased neurofibroma incidence
|
J:131914
|
Nf1tm1Tyj/? Nstr1C57BL/6J/Nstr1C57BL/6J Trp53tm1Tyj/?
(involves: 129S2/SvPas * A/J * C57BL/6J)
|
increased neurofibrosarcoma incidence
|
J:105038
|
Nf1tm1Tyj/? Trp53tm1Tyj/? MastrC57BL/6J/?
(involves: 129S2/SvPas * 129S4/SvJae * C57BL/6J)
|
increased astrocytoma incidence
|
J:92444
|
Nf1tm1Tyj/Nf1+
(involves: 129S2/SvPas * C57BL/6)
|
increased adrenal gland tumor incidence
|
J:18542
|
increased hepatoma incidence
|
J:18542
|
increased leukemia incidence
|
J:18542
|
increased lung adenocarcinoma incidence
|
J:18542
|
increased lymphoma incidence
|
J:18542
|
increased neurofibrosarcoma incidence
|
J:18542
|
increased pheochromocytoma incidence
|
J:18542
|
Nf1tm1Tyj/Nf1+ Suz12Gt(Betageo)1Khe/Suz12+
(involves: 129P2/OlaHsd * 129S2/SvPas * C57BL/6)
|
increased hepatocellular carcinoma incidence
|
J:217077
|
increased histiocytic sarcoma incidence
|
J:217077
|
increased intestinal adenoma incidence
|
J:217077
|
increased lymphoma incidence
|
J:217077
|
increased neurofibroma incidence
|
J:217077
|
increased neurofibrosarcoma incidence
|
J:217077
|
increased Schwannoma incidence
|
J:217077
|
Nf1tm1Tyj/Nf1+ Suz12Gt(Betageo)1Khe/Suz12+ Trp53tm1Tyj/Trp53+
(involves: 129P2/OlaHsd * 129S2/SvPas * C57BL/6)
|
increased glioma incidence
|
J:217077
|
increased histiocytic sarcoma incidence
|
J:217077
|
increased lymphoma incidence
|
J:217077
|
increased neurofibrosarcoma incidence
|
J:217077
|
Nf1tm1Tyj/Nf1+ Tg(Th-MYCN)41Waw/0
(involves: 129S2/SvPas * BALB/c * C57BL/6J)
|
increased neuroblastoma incidence
|
J:41126
|
Nf1tm1Tyj/Nf1+ Trp53tm1Tyj/Trp53+
(involves: 129/Sv * C57BL/6)
|
increased neurofibrosarcoma incidence
|
J:58876
|
Nf1tm1Tyj/Nf1+ Trp53tm1Tyj/Trp53+
(involves: 129S2/SvPas)
|
increased neurofibrosarcoma incidence
|
J:131914
|
Nf1tm1Tyj/Nf1+ Trp53tm1Tyj/Trp53+
(B6.129S2-Trp53tm1Tyj Nf1tm1Tyj/+ +)
|
increased astrocytoma incidence
|
J:64364
|
increased brain tumor incidence
|
J:64364
|
increased glioblastoma incidence
|
J:64364
|
Nf1tm1Tyj/Nf1+ Trp53tm1Tyj/Trp53+
((C3H/HeJ x B6.129S2-Trp53tm1Tyj Nf1tm1Tyj/+ +)F1)
|
increased astrocytoma incidence
|
J:64364
|
increased brain tumor incidence
|
J:64364
|
increased glioblastoma incidence
|
J:64364
|
Nf1tm1Tyj/Nf1+ Trp53tm1Tyj/Trp53+
((CAST/EiJ x B6.129S2-Trp53tm1Tyj Nf1tm1Tyj/+ +)F1)
|
increased astrocytoma incidence
|
J:64364
|
increased brain tumor incidence
|
J:64364
|
increased glioblastoma incidence
|
J:64364
|
Nf1tm1Tyj/Nf1+ Trp53tm1Tyj/Trp53+
((CBA/J x B6.129S2-Trp53tm1Tyj Nf1tm1Tyj/+ +)F1)
|
increased brain tumor incidence
|
J:64364
|
Nf1tm1Tyj/Nf1+ Trp53tm1Tyj/Trp53+
((SJL/J x B6.129S2-Trp53tm1Tyj Nf1tm1Tyj/+ +)F1)
|
increased astrocytoma incidence
|
J:64364
|
increased brain tumor incidence
|
J:64364
|
increased glioblastoma incidence
|
J:64364
|
Nf1tm1Tyj/Nf1+ Trp53tm1Tyj/Trp53+
(involves: 129S2/SvPas * C57BL/6)
|
increased glioma incidence
|
J:217077
|
increased histiocytic sarcoma incidence
|
J:217077
|
increased lymphoma incidence
|
J:228258,
J:217077
|
increased neuroblastoma incidence
|
J:217077
|
increased neurofibrosarcoma incidence
|
J:217077
|
Nf1tm1Tyj/Nf1tm2Tyj
(chimera involves: 129S2/SvPas)
|
increased neurofibroma incidence
|
J:58876
|
Nf2tm1Gth/Nf2+
(involves: 129P2/OlaHsd * FVB/N)
|
increased fibroadenoma incidence
|
J:63264
|
increased lung adenocarcinoma incidence
|
J:63264
|
increased neurofibroma incidence
|
J:63264
|
increased neurofibrosarcoma incidence
|
J:63264
|
increased osteoma incidence
|
J:63264
|
increased osteosarcoma incidence
|
J:63264
|
increased renal carcinoma incidence
|
J:63264
|
Nf2tm1Gth/Nf2tm2Gth Tg(Mpz-cre)#Brn/0
(involves: 129P2/OlaHsd * FVB/N)
|
increased neurofibrosarcoma incidence
|
J:63264
|
increased Schwannoma incidence
|
J:63264
|
Nf2tm1Tyj/Nf2+
(either: (involves: 129S2/SvPas * 129S4/SvJae * C57BL/6) or (involves: 129S2/SvPas * C57BL/6J))
|
increased lung adenocarcinoma incidence
|
J:47282
|
increased lymphoma incidence
|
J:47282
|
increased osteosarcoma incidence
|
J:47282
|
Nf2tm2.1Gth/Nf2+
(involves: 129P2/OlaHsd * FVB/N)
|
increased lung adenocarcinoma incidence
|
J:63264
|
increased osteoma incidence
|
J:63264
|
increased osteosarcoma incidence
|
J:63264
|
Nf2tm2Gth/Nf2+ Tg(Mpz-cre)#Brn/0
(involves: 129P2/OlaHsd * FVB/N)
|
increased fibroadenoma incidence
|
J:63264
|
increased lung adenocarcinoma incidence
|
J:63264
|
increased osteoma incidence
|
J:63264
|
Nf2tm2Gth/Nf2+ Trp53tm1Brd/Trp53+ Tg(Mpz-cre)3Brn/0
(involves: 129P2/OlaHsd * 129S7/SvEvBrd * FVB/N)
|
increased neurofibrosarcoma incidence
|
J:92413
|
increased osteoma incidence
|
J:92413
|
increased osteosarcoma incidence
|
J:92413
|
increased skeletal tumor incidence
|
J:92413
|
Nf2tm2Gth/Nf2+ Trp53tm1Brn/Trp53tm1Brn
(involves: 129P2/OlaHsd * 129S7/SvEvBrd)
|
increased leukemia incidence
|
J:132943
|
increased Schwannoma incidence
|
J:132943
|
increased uterus leiomyoma incidence
|
J:132943
|
Nf2tm2Gth/Nf2tm2Gth
(involves: 129P2/OlaHsd * FVB/N)
|
increased meningioma incidence
|
J:173718
|
Nf2tm2Gth/Nf2tm2Gth Ptgdstm1.1(cre)Gvn/Ptgds+
(involves: 129P2/OlaHsd * FVB/N)
|
increased meningioma incidence
|
J:173718
|
increased osteoma incidence
|
J:173718
|
increased pituitary adenoma incidence
|
J:173718
|
Nf2tm2Gth/Nf2tm2Gth Ptgdstm1.1(cre)Gvn/Ptgds+ Trp53tm1Brn/Trp53tm1Brn
(involves: 129P2/OlaHsd * FVB/N)
|
increased nervous system tumor incidence
|
J:173718
|
increased osteosarcoma incidence
|
J:173718
|
Nf2tm2Gth/Nf2tm2Gth Speer6-ps1Tg(Alb-cre)21Mgn/Speer6-ps1+
(involves: 129P2/OlaHsd * C57BL/6 * DBA)
|
increased hepatobiliary system tumor incidence
|
J:162628
|
increased hepatocellular carcinoma incidence
|
J:162628
|
Nf2tm2Gth/Nf2tm2Gth Tg(Mpz-cre)2Brn/0
(involves: 129P2/OlaHsd * FVB/N)
|
increased lung adenocarcinoma incidence
|
J:92413
|
increased neurofibrosarcoma incidence
|
J:92413
|
increased renal carcinoma incidence
|
J:92413
|
increased Schwannoma incidence
|
J:63264,
J:92413
|
Nf2tm2Gth/Nf2tm2Gth Tg(Mpz-cre)3Brn/0
(involves: 129P2/OlaHsd * FVB/N)
|
increased fibroadenoma incidence
|
J:63264
|
increased lung adenocarcinoma incidence
|
J:63264
|
increased neurofibrosarcoma incidence
|
J:63264
|
increased osteoma incidence
|
J:63264
|
increased osteosarcoma incidence
|
J:63264
|
increased renal carcinoma incidence
|
J:63264
|
increased Schwannoma incidence
|
J:63264,
J:92413
|
Nf2tm2Gth/Nf2tm2Gth Tg(Mpz-cre)4Brn/0
(involves: 129P2/OlaHsd * FVB/N)
|
increased Schwannoma incidence
|
J:63264
|
Nf2tm2Gth/Nf2tm2Gth Tg(Mpz-cre)#Brn/0
(involves: 129P2/OlaHsd * FVB/N)
|
increased neurofibrosarcoma incidence
|
J:63264
|
increased osteoma incidence
|
J:63264
|
increased osteosarcoma incidence
|
J:63264
|
increased renal carcinoma incidence
|
J:63264
|
Nf2tm2Gth/Nf2tm2Gth Tg(Mx1-cre)1Cgn/0
(involves: 129P2/OlaHsd * C57BL/6 * CBA)
|
increased renal carcinoma incidence
|
J:150071
|
Nf2tm2Gth/Nf2tm2Gth Tg(Postn-cre)1Sjc/0
(involves: 129P2/OlaHsd * FVB/NTac)
|
increased neurofibrosarcoma incidence
|
J:216420
|
increased Schwannoma incidence
|
J:216420
|
Nf2tm2Gth/Nf2tm2Gth Tg(Vil1-cre)20Syr/0
(involves: 129P2/OlaHsd * C57BL/6 * DBA/2)
|
increased renal carcinoma incidence
|
J:150071
|
Nf2tm2Gth/Nf2tm2Gth Trp53tm1Brd/Trp53+ Tg(Mpz-cre)2Brn/0
(involves: 129P2/OlaHsd * 129S7/SvEvBrd * FVB/N)
|
increased leiomyosarcoma incidence
|
J:92413
|
increased nervous system tumor incidence
|
J:92413
|
increased neurofibroma incidence
|
J:92413
|
increased neurofibrosarcoma incidence
|
J:92413
|
increased Schwannoma incidence
|
J:92413
|
Nf2tm2Gth/Nf2tm2Gth Trp53tm1Brd/Trp53+ Tg(Mpz-cre)3Brn/0
(involves: 129P2/OlaHsd * 129S7/SvEvBrd * FVB/N)
|
increased neurofibrosarcoma incidence
|
J:92413
|
Nf2tm2Gth/Nf2tm2Gth Trp53tm1Brd/Trp53tm1Brd Tg(Mpz-cre)2Brn/0
(involves: 129P2/OlaHsd * 129S7/SvEvBrd * FVB/N)
|
increased neurofibrosarcoma incidence
|
J:92413
|
increased osteoma incidence
|
J:92413
|
increased osteosarcoma incidence
|
J:92413
|
increased rhabdomyosarcoma incidence
|
J:92413
|
Nf2tm2Gth/Nf2tm2Gth Trp53tm1Brn/Trp53+
(involves: 129P2/OlaHsd * 129S7/SvEvBrd)
|
increased leukemia incidence
|
J:132943
|
increased Schwannoma incidence
|
J:132943
|
increased uterus leiomyoma incidence
|
J:132943
|
Nf2tm2Gth/Nf2tm2Gth Trp53tm1Brn/Trp53tm1Brn
(involves: 129P2/OlaHsd * 129S7/SvEvBrd)
|
increased leukemia incidence
|
J:132943
|
increased rhabdomyosarcoma incidence
|
J:132943
|
increased Schwannoma incidence
|
J:132943
|
increased T cell derived lymphoma incidence
|
J:132943
|
increased uterus leiomyoma incidence
|
J:132943
|
Nfe2tm1.1Hlpa/?
(involves: 129 * C57BL/6)
|
increased acute myeloid leukemia incidence
|
J:275444
|
increased myeloid sarcoma incidence
|
J:275444
|
Nfe2l1tm1Jefc/Nfe2l1tm1Ywk Speer6-ps1Tg(Alb-cre)21Mgn/Speer6-ps1+
(involves: 129X1/SvJ * C57BL/6J)
|
increased hepatocellular carcinoma incidence
|
J:97188
|
increased liver adenoma incidence
|
J:97188
|
Nfe2l2tm1Mym/Nfe2l2tm1Mym
(involves: 129P2/OlaHsd * ICR)
|
increased stomach tumor incidence
|
J:68072
|
Nhej1tm1Fwa/Nhej1tm1Fwa Trp53tm1Tyj/Trp53tm1Tyj
(involves: 129)
|
increased B cell derived lymphoma incidence
|
J:138774
|
increased medulloblastoma incidence
|
J:138774
|
increased T cell derived lymphoma incidence
|
J:138774
|
Nkx2-9tm1Jlck/Nkx2-9tm1Jlck
(involves: 129/Sv * C57BL/6 * SJL)
|
increased lung adenoma incidence
|
J:115581
|
increased lung tumor incidence
|
J:115581
|
Nkx3-1tm1Mms/Nkx3-1+ Ptentm1Rps/Pten+
(involves: 129S1/Sv * 129S1/SvImJ * C57BL/6J)
|
increased prostate gland tumor incidence
|
J:75085
|
increased prostate intraepithelial neoplasia incidence
|
J:75085
|
Nkx3-1tm1Mms/Nkx3-1tm1Mms
(involves: 129S1/Sv)
|
increased prostate intraepithelial neoplasia incidence
|
J:131932
|
Nkx3-1tm1Mms/Nkx3-1tm1Mms Ptentm1Rps/Pten+
(involves: 129S1/Sv * 129S1/SvImJ * C57BL/6J)
|
increased prostate gland tumor incidence
|
J:75085
|
increased prostate intraepithelial neoplasia incidence
|
J:75085
|
Nkx3-1tm1Saa/Nkx3-1tm1Saa Tg(KLK3-cre)13Saa/?
(involves: C57BL/6)
|
increased prostate intraepithelial neoplasia incidence
|
J:74350
|
Nkx3-1tm4(cre/ERT2)Mms/Nkx3-1+ Ptentm1Hwu/Ptentm1Hwu
(involves: 129S4/SvJae * 129S6/SvEvTac * C57BL/6)
|
increased prostate gland adenocarcinoma incidence
|
J:153425
|
increased prostate intraepithelial neoplasia incidence
|
J:191327,
J:153425
|
Nlrp6tm1Macha/Nlrp6tm1Macha
(involves: 129S5/SvEvBrd * C57BL/6J)
|
increased gastrointestinal tumor incidence
|
J:173352
|
Nme1tm1Jyd/Nme1tm1Jyd
(involves: 129/Sv * C57BL/6)
|
increased lymphoma incidence
|
J:109190
|
Nmitm1.1Geno/Nmitm1.1Geno Tg(KRT14-cre)1Amc/0 Tg(MMTVneu)202Mul/0
(involves: 129S/SvEv * C57BL/6 * CBA * FVB/N)
|
increased mammary adenocarcinoma incidence
|
J:261035
|
Notch1tm2Rko/Notch1tm2Rko Notch2tm1Rko/Notch2tm1Rko Notch3Gt(PST033)Byg/Notch3Gt(PST033)Byg Tg(Mx1-cre)1Cgn/0
(involves: 129P2/OlaHsd * 129X1/SvJ * C57BL/6 * CBA)
|
increased leukemia incidence
|
J:172442
|
Npm1tm1Gsva/Npm1+ Tg(Mx1-cre)1Cgn/0
(involves: C57BL/6 * CBA)
|
increased acute promyelocytic leukemia incidence
|
J:172071
|
increased B cell derived lymphoma incidence
|
J:172071
|
Npm1tm1Ppp/Npm1+ Tg(IghMyc)22Bri/0
(involves: 129S1/Sv * C57BL/6 * SJL)
|
increased B cell derived lymphoma incidence
|
J:101494
|
Nqo1tm1Akj/Nqo1tm1Akj
(Not Specified)
|
increased skin tumor incidence
|
J:66196
|
Nqo2tm1Akj/Nqo2tm1Akj
(Not Specified)
|
increased skin tumor incidence
|
J:92400
|
Nr0b1tm1.1Lja/Y
(involves: 129S1/Sv * 129X1/SvJ)
|
increased testis tumor incidence
|
J:71710
|
Nr1h2tm1.1Gstr/Nr1h2tm1.1Gstr Nr1h3tm1.1Gstr/Nr1h3tm1.1Gstr
(involves: 129S1/Sv * 129X1/SvJ * C57BL/6)
|
increased lung squamous cell carcinoma incidence
|
J:234268
|
Nr1h4tm1Gonz/Nr1h4tm1Gonz
(involves: 129X1/SvJ * C57BL/6N)
|
increased hepatocellular carcinoma incidence
|
J:121075
|
increased liver adenoma incidence
|
J:121075
|
increased liver tumor incidence
|
J:121075
|
Nr1h4tm1Gonz/Nr1h4tm1Gonz
(involves: 129X1/SvJ * C57BL/6)
|
increased hepatocellular carcinoma incidence
|
J:118204
|
increased liver adenoma incidence
|
J:118204
|
increased liver tumor incidence
|
J:118204
|
Nr4a1tm1Jmi/Nr4a1tm1Jmi Nr4a3tm1Omc/Nr4a3tm1Omc
(involves: 129S/SvEv * 129S2/SvPas * C57BL/6)
|
increased leukemia incidence
|
J:121903
|
Nrastm1Tyj/Nrastm1Tyj Tg(Mx1-cre)1Cgn/0
(involves: C57BL/6 * CBA)
|
increased acute lymphoblastic leukemia incidence
|
J:204263
|
Nrbp1tm1.1Dja/Nrbp1tm1.1Dja Gt(ROSA)26Sortm1(cre/ERT)Brn/Gt(ROSA)26Sor+
(involves: 129P2/OlaHsd * 129S4/SvJaeSor * C57BL/6J)
|
increased gastrointestinal tumor incidence
|
J:184685
|
increased leukemia incidence
|
J:184685
|
increased lung carcinoma incidence
|
J:184685
|
increased lymphoma incidence
|
J:184685
|
Nrbp1tm1.1Dja/Nrbp1tm1.2Dja Gt(ROSA)26Sortm1(cre/ERT)Brn/Gt(ROSA)26Sor+
(involves: 129P2/OlaHsd * 129S4/SvJaeSor * 129S7/SvEvBrd * C57BL/6J)
|
increased gastrointestinal tumor incidence
|
J:184685
|
increased leukemia incidence
|
J:184685
|
increased lung carcinoma incidence
|
J:184685
|
increased lymphoma incidence
|
J:184685
|
Nsmce2Gt(AA0032)Wtsi/Nsmce2+
(involves: 129P2/OlaHsd * C57BL/6)
|
increased cardiovascular system tumor incidence
|
J:227197
|
increased histiocytic sarcoma incidence
|
J:227197
|
increased liver tumor incidence
|
J:227197
|
increased lymphoma incidence
|
J:227197
|
increased pancreas tumor incidence
|
J:227197
|
Nsun2tm1a(EUCOMM)Wtsi/Nsun2tm1a(EUCOMM)Wtsi
(B6JTyr;B6N-Nsun2tm1a(EUCOMM)Wtsi/Wtsi)
|
increased trigeminal neuroma incidence
|
J:239583
|
Nuak2tm1Esu/Nuak2+
(B6.129S4-Nuak2tm1Esu)
|
increased intestinal adenoma incidence
|
J:139603
|
Nudt1tm1Tts/Nudt1tm1Tts
(involves: 129S/SvEv * C57BL/6 * DBA/2)
|
increased liver tumor incidence
|
J:71836
|
increased lung adenocarcinoma incidence
|
J:71836
|
increased lung adenoma incidence
|
J:71836
|
increased stomach tumor incidence
|
J:71836
|
Ogg1tm1Yun/Ogg1tm1Yun
(involves: 129S/SvEv * C57BL/6J)
|
increased lung adenoma incidence
|
J:82287
|
increased lung carcinoma incidence
|
J:82287
|
Ossc3BALB/c/Ossc3CBA/Ca
(involves: BALB/c * CBA/Ca)
|
increased osteosarcoma incidence
|
J:107725
|
Otulintm1c(EUCOMM)Hmgu/Otulintm1c(EUCOMM)Hmgu Tg(KRT14-cre)1Cgn/0
(involves: C57BL/6 * C57BL/6N * DBA/2)
|
increased skin squamous cell carcinoma incidence
|
J:312394
|
Palb2tm1.1Dli/Palb2tm1.1Dli Trp53tm1Brn/Trp53+ Tg(KRT14-cre)1Amc/0
(involves: 129P2/OlaHsd * 129S4/SvJaeSor * C57BL/6 * CBA)
|
increased mammary gland tumor incidence
|
J:197442
|
Palb2tm1.1Dli/Palb2tm1.1Dli Trp53tm1Brn/Trp53tm1Brn Tg(KRT14-cre)1Amc/0
(involves: 129P2/OlaHsd * 129S4/SvJaeSor * C57BL/6 * CBA)
|
increased mammary gland tumor incidence
|
J:197442
|
increased mouth tumor incidence
|
J:197442
|
increased skin tumor incidence
|
J:197442
|
Paqr3tm1Ychn/Paqr3+
(involves: 129 * C57BL/6J)
|
increased skin papilloma incidence
|
J:139058
|
Paqr3tm1Ychn/Paqr3tm1Ychn
(involves: 129 * C57BL/6J)
|
increased skin papilloma incidence
|
J:139058
|
Par2A/JSlc/Par2BALB/cByJJcl
(involves: BALB/cByJJcl * A/JSlc)
|
increased lung adenoma incidence
|
J:70565
|
Par2BALB/cByJJcl/Par2BALB/cByJJcl
(involves: BALB/cByJJcl * A/JSlc)
|
increased lung adenoma incidence
|
J:70565
|
Parms1BALB/cByJ/Parms1C57BL/6NCrl Ptch1tm1Zim/Ptch1+
(involves: 129/Sv * BALB/cByJ * C57BL/6NCrl)
|
increased rhabdomyosarcoma incidence
|
J:93364
|
Parms1C57BL/6NCrl/Parms1C57BL/6NCrl Ptch1tm1Zim/Ptch1+
(involves: 129/Sv * BALB/cByJ * C57BL/6NCrl)
|
increased rhabdomyosarcoma incidence
|
J:93364
|
Pas1cBALB/cOlaHsd/Pas1cBALB/cOlaHsd
(involves: A/JOlaHsd * BALB/cOlaHsd)
|
increased lung adenoma incidence
|
J:50533
|
Pas5bA/JOlaHsd/Pas5bA/JOlaHsd
(involves: A/JOlaHsd * BALB/cOlaHsd)
|
increased lung adenoma incidence
|
J:50533
|
Pas7A/JOlaHsd/Pas7A/JOlaHsd
(involves: A/JOlaHsd * BALB/cOlaHsd)
|
increased lung adenoma incidence
|
J:50533
|
Pas8A/JOlaHsd/Pas8A/JOlaHsd
(involves: A/JOlaHsd * BALB/cOlaHsd)
|
increased lung adenoma incidence
|
J:50533
|
Pas8A/JOlaHsd/Pas8BALB/cOlaHsd
(involves: A/JOlaHsd * BALB/cOlaHsd)
|
increased lung adenoma incidence
|
J:50533
|
Pas9A/JOlaHsd/Pas9BALB/cOlaHsd
(involves: A/JOlaHsd * BALB/cOlaHsd)
|
increased lung adenoma incidence
|
J:50533
|
Pas9BALB/cOlaHsd/Pas9BALB/cOlaHsd
(involves: A/JOlaHsd * BALB/cOlaHsd)
|
increased lung adenoma incidence
|
J:50533
|
Pas14A/J/Pas14A/J
(involves: A/J * C57BL/6J)
|
increased lung adenoma incidence
|
J:21801
|
Pas19A/J/Pas19A/J
(involves: A/J * C57BL/6J)
|
increased lung adenoma incidence
|
J:21801
|
Pax5tm3Mbu/Pax5+ Tcf3tm1(PBX1)Mlc/Tcf3+ Cd19tm1(cre)Cgn/Cd19+
(involves: 129P2/OlaHsd * C57BL/6)
|
increased B cell acute lymphoblastic leukemia incidence
|
J:226241
|
Pax6Sey-4H/Pax6+
(involves: 101/H * C3H/HeCrj * C3H/HeH)
|
increased alimentary system tumor incidence
|
J:124276
|
increased intestinal adenoma incidence
|
J:124276
|
increased stomach tumor incidence
|
J:124276
|
Pcbp4Gt(D136D11)Wrst/Pcbp4+
(involves: 129S2/SvPas * C57BL/6)
|
increased B cell derived lymphoma incidence
|
J:231514
|
increased kidney tumor incidence
|
J:231514
|
increased lung adenocarcinoma incidence
|
J:231514
|
Pcbp4Gt(D136D11)Wrst/Pcbp4Gt(D136D11)Wrst
(involves: 129S2/SvPas * C57BL/6)
|
increased B cell derived lymphoma incidence
|
J:231514
|
increased kidney tumor incidence
|
J:231514
|
increased lung adenocarcinoma incidence
|
J:231514
|
Pcsk2tm1Dfs/Pcsk2tm1Dfs
(B6;129-Pcsk2tm1Dfs/J)
|
increased glucagonoma incidence
|
J:236511
|
increased pancreas tumor incidence
|
J:236905
|
increased pancreatic ductal adenocarcinoma incidence
|
J:236905
|
increased pancreatic islet cell adenoma incidence
|
J:236905
|
Pcsk6tm1Rob/Pcsk6tm1Rob
(involves: 129S1/Sv * 129X1/SvJ * C57BL/6)
|
increased ovary tumor incidence
|
J:180839
|
increased reproductive system tumor incidence
|
J:180839
|
Pdcd4tm1Yhcn/Pdcd4tm1Yhcn
(B6.129S6-Pdcd4tm1Yhcn)
|
increased B cell derived lymphoma incidence
|
J:120583
|
Per2tm1Brd/Per2tm1Brd
(involves: 129S7/SvEvBrd * C57BL/6)
|
increased lymphoma incidence
|
J:79456
|
Per2tm1Ccl/Per2tm1Ccl
(involves: 129 * C57BL/6)
|
increased salivary gland tumor incidence
|
J:79456
|
Perptm2Att/Perptm2Att Tg(KRT14-cre/ERT2)1Ipc/0
(involves: 129S4/SvJae)
|
increased skin squamous cell carcinoma incidence
|
J:167545
|
Pex1tm1.1Hrw/Pex1tm1.1Hrw
(involves: C57BL/6NTac)
|
increased liver adenoma incidence
|
J:278655
|
Pex5tm1Pec/Pex5tm1Pec Speer6-ps1Tg(Alb-cre)21Mgn/Speer6-ps1+
(involves: 129S1/Sv * 129X1/SvJ * C57BL/6 * DBA)
|
increased liver tumor incidence
|
J:112503
|
Pgbd5tm1.1Aken/Pgbd5tm1.2Aken Ptch1tm1Bjw/Ptch1tm1Bjw Ptf1atm1.1(cre)Cvw/Ptf1a+
(involves: 129 * C57BL/6J * C57BL/6NTac * FVB/N * SW)
|
increased medulloblastoma incidence
|
J:346387
|
Pgct1129S1/SvImJ/?
(involves: 129S1/SvImJ * C57BL/6J)
|
increased testis tumor incidence
|
J:63413
|
Pgrtm2(cre)Lyd/Pgr+ Ptentm1Hwu/Ptentm1Hwu
(involves: 129S1/Sv * 129S4/SvJae * 129X1/SvJ * C57BL/6)
|
increased endometrial carcinoma incidence
|
J:139053
|
Pgrtm2(cre)Lyd/Pgr+ Ptentm1Hwu/Ptentm1Hwu
(involves: 129S1/Sv * 129S4/SvJae * 129X1/SvJ)
|
increased endometrial carcinoma incidence
|
J:162027,
J:218222
|
Pgrtm2(cre)Lyd/Pgr+ Ptentm1Hwu/Ptentm1Hwu Trp53tm1Brn/Trp53tm1Brn
(involves: 129 * C57BL/6)
|
increased endometrial carcinoma incidence
|
J:139053
|
Phf6tm1.1Avo/Y Tg(Tek-cre)1Ywa/0
(involves: C57BL/6 * SJL)
|
increased leukemia incidence
|
J:276228
|
Phf6tm1.2Avo/Phf6+
(involves: BALB/cJ * C57BL/6)
|
increased leukemia incidence
|
J:276228
|
Pigatm1Bsl/Y Tg(FES-cre)31Bsl/0
(involves: 129S1/Sv * C57BL/6 * CBA/Ca)
|
increased B cell derived lymphoma incidence
|
J:71354
|
Pigatm1Bsl/Piga+ Tg(FES-cre)31Bsl/0
(involves: 129S1/Sv * C57BL/6 * CBA/Ca)
|
increased B cell derived lymphoma incidence
|
J:71354
|
Pik3catm1.1Waph/Pik3ca+ Ptentm1Hwu/Ptentm1Hwu
(involves: 129S1/Sv * 129S4/SvJae * BALB/c * C57BL/6)
|
increased granulosa cell tumor incidence
|
J:184382
|
increased ovary tumor incidence
|
J:184382
|
Pik3catm1.1Waph/Pik3ca+ Tg(MMTV-cre)#Mam/0
(involves: 129S1/Sv * C57BL/6 * FVB)
|
increased fibroadenoma incidence
|
J:187299
|
increased mammary adenoacanthoma incidence
|
J:187299
|
increased mammary gland tumor incidence
|
J:187299
|
increased osteosarcoma incidence
|
J:187299
|
Pik3catm1Gne/Pik3ca+ Tg(MMTV-cre)1Mam/0
(involves: C57BL/6N * FVB/N)
|
increased mammary gland tumor incidence
|
J:193377
|
Pik3catm1Jjz/Pik3catm1Jjz Ptentm1Hwu/Ptentm1Hwu Tg(KRT14-cre)#Smr/0
(FVB.Cg-Pik3catm1Jjz Ptentm1Hwu Tg(KRT14-cre)#Smr)
|
increased skin hamartoma incidence
|
J:199362
|
Pik3catm1Jjz/Pik3catm1Jjz Tg(Pbsn-cre)4Prb/0
(involves: 129 * C57BL/6 * DBA/2)
|
increased prostate intraepithelial neoplasia incidence
|
J:138565
|
Pik3cbtm1Jjz/Pik3cbtm1Jjz Ptentm1Hwu/Ptentm1Hwu Tg(KRT14-cre)#Smr/0
(FVB.Cg-Pik3cbtm1Jjz Ptentm1Hwu Tg(KRT14-cre)#Smr)
|
increased skin hamartoma incidence
|
J:199362
|
Pinx1tm1.1Kplu/Pinx1+
(involves: 129S7/SvEvBrd * C57BL/6 * FVB/N)
|
increased gastrointestinal tumor incidence
|
J:171997
|
increased Harderian gland adenoma incidence
|
J:171997
|
increased histiocytic sarcoma incidence
|
J:171997
|
increased liver tumor incidence
|
J:171997
|
increased lung tumor incidence
|
J:171997
|
increased lymphoma incidence
|
J:171997
|
increased mammary gland tumor incidence
|
J:171997
|
Pinx1tm1.1Kplu/Pinx1+ Trp53tm1Brd/Trp53+
(involves: 129S7/SvEvBrd * C57BL/6 * FVB/N)
|
increased hepatocellular carcinoma incidence
|
J:171997
|
increased liver tumor incidence
|
J:171997
|
increased lung carcinoma incidence
|
J:171997
|
increased lung tumor incidence
|
J:171997
|
increased lymphoma incidence
|
J:171997
|
increased mammary gland tumor incidence
|
J:171997
|
increased ovary tumor incidence
|
J:171997
|
Pinx1tm1.1Kplu/Pinx1+ Trp53tm1Brd/Trp53tm1Brd
(involves: 129S7/SvEvBrd * C57BL/6 * FVB/N)
|
increased gastrointestinal tumor incidence
|
J:171997
|
increased hepatocellular carcinoma incidence
|
J:171997
|
increased liver tumor incidence
|
J:171997
|
increased lung carcinoma incidence
|
J:171997
|
increased lymphoma incidence
|
J:171997
|
increased mammary gland tumor incidence
|
J:171997
|
Pkd1tm1.1Pcha/Pkd1tm1.1Pcha
(involves: 129S1/Sv * C57BL/6)
|
increased renal hamartoma incidence
|
J:193544
|
Pkn3tm1.1Mrl/Pkn3+ Ptentm1Hwu/Ptentm1Hwu Tg(Mx1-cre)1Cgn/0
(involves: 129S4/SvJae * C57BL/6 * CBA/J)
|
increased acute lymphoblastic leukemia incidence
|
J:216983
|
increased hemolymphoid system tumor incidence
|
J:216983
|
Pkn3tm1.1Mrl/Pkn3tm1.1Mrl Ptentm1Hwu/Ptentm1Hwu Tg(Mx1-cre)1Cgn/0
(involves: 129S4/SvJae * C57BL/6 * CBA/J)
|
increased acute lymphoblastic leukemia incidence
|
J:216983
|
increased hemolymphoid system tumor incidence
|
J:216983
|
Pknox1tm1Ngc/Pknox1+ Tg(IghMyc)22Bri/0
(involves: C57BL * SJL)
|
increased B cell derived lymphoma incidence
|
J:192251
|
Plbcq6M16i/?
(involves: FVB/NJ * M16i)
|
increased mammary gland tumor incidence
|
J:136011
|
Plcd1tm1Tta/Plcd1tm1Tta
(involves: 129P2/OlaHsd * C57BL/6J)
|
increased skin tumor incidence
|
J:83948
|
Plcg2tm1Jni/Plcg2tm1Jni Tg(IghMyc)22Bri/0
(involves: 129P2/OlaHsd * C57BL * C57BL/6 * SJL)
|
increased B cell derived lymphoma incidence
|
J:117023
|
increased lymphoma incidence
|
J:117023
|
Pldmq1FVB/NJ/?
(involves: FVB/NJ * M16i)
|
increased mammary gland tumor incidence
|
J:136011
|
Pldmq3FVB/NJ/?
(involves: FVB/NJ * M16i)
|
increased mammary gland tumor incidence
|
J:136011
|
Pldmq4FVB/NJ/?
(involves: FVB/NJ * M16i)
|
increased mammary gland tumor incidence
|
J:136011
|
Pldmq5FVB/NJ/?
(involves: FVB/NJ * M16i)
|
increased mammary gland tumor incidence
|
J:136011
|
Plgtm1Jld/Plgtm1Jld Tg(MMTV-PyVT)634Mul/0
(involves: 129P2/OlaHsd * Black Swiss * FVB/N)
|
increased mammary adenocarcinoma incidence
|
J:48285
|
Plk1Gt(RRR358)Byg/Plk1+
(involves: 129P2/OlaHsd * C57BL/6)
|
increased lung carcinoma incidence
|
J:142593
|
increased lymphoma incidence
|
J:142593
|
Plk3tm1Dai/Plk3tm1Dai
(involves: 129S4/SvJae * C57BL/6)
|
increased leiomyosarcoma incidence
|
J:136425
|
increased liver tumor incidence
|
J:136425
|
increased lung adenocarcinoma incidence
|
J:136425
|
increased lung tumor incidence
|
J:136425
|
Pmltm1(PML/RARA)Ley/Pml+ Lyz2tm1(cre)Ifo/Lyz2+
(involves: 129P2/OlaHsd * BALB/cJ * C57BL/6)
|
increased leukemia incidence
|
J:172024
|
Pmltm1.1Ews/Pmltm1.1Ews
(involves: 129 * 129P2/OlaHsd)
|
increased B cell derived lymphoma incidence
|
J:262172
|
increased T cell derived lymphoma incidence
|
J:262172
|
Pmltm1.1Ews/Pmltm1.1Ews Tg(PML-RARA)556Kog/0
(FVB.Cg-Pmltm1.1Ews Tg(PML-RARA)556Kog)
|
increased acute promyelocytic leukemia incidence
|
J:262172
|
Pmltm1Ppp/Pml+ Trp53tm3.1Glo/Trp53+
(B6.129S7(Cg)-Pmltm1Ppp Trp53tm3.1Glo)
|
increased B cell derived lymphoma incidence
|
J:317504
|
increased lymphoma incidence
|
J:317504
|
increased osteosarcoma incidence
|
J:317504
|
increased T cell derived lymphoma incidence
|
J:317504
|
Pmltm1Ppp/Pmltm1Ppp
(involves: 129S7/SvEvBrd)
|
increased lymphoma incidence
|
J:46381
|
Pmltm1Ppp/Pmltm1Ppp Trp53tm3.1Glo/Trp53+
(B6.129S7(Cg)-Pmltm1Ppp Trp53tm3.1Glo)
|
increased B cell derived lymphoma incidence
|
J:317504
|
increased lymphoma incidence
|
J:317504
|
increased osteosarcoma incidence
|
J:317504
|
increased T cell derived lymphoma incidence
|
J:317504
|
Pms2tm1.1Wed/Pms2tm1.1Wed
(involves: 129S6/SvEvTac * C57BL/6NCr)
|
increased B cell derived lymphoma incidence
|
J:162378
|
increased liver adenoma incidence
|
J:162378
|
increased lymphoma incidence
|
J:162378
|
increased T cell derived lymphoma incidence
|
J:162378
|
Pms2tm1Lisk/Pms2tm1Lisk
(involves: 129S2/SvPas * C57BL/6)
|
increased lymphoma incidence
|
J:27389
|
Pms2tm1Lisk/Pms2tm1Lisk
(involves: 129S2/SvPas)
|
increased B cell derived lymphoma incidence
|
J:162378
|
increased lymphoma incidence
|
J:125218
|
Pms2tm1Lisk/Pms2tm1Lisk Terctm1Rdp/Terctm1Rdp
(involves: 129/Sv * 129S2/SvPas * C57BL/6 * C57BL/6J * SJL)
|
increased lymphoma incidence
|
J:125218
|
Poats1C57BL/6JCrl/Poats1C57BL/6JCrl
(involves: C57BL/6JCrl * DBA/2JCrl)
|
increased adrenal gland tumor incidence
|
J:131752
|
Polbtm1a(KOMP)Wtsi/Polbtm1a(KOMP)Wtsi
(C57BL/6N-Polbtm1a(KOMP)Wtsi/Wtsi)
|
increased trigeminal neuroma incidence
|
J:239583
|
Pold1tm1.1Bdp/Pold1tm1.1Bdp
(B6.129-Pold1tm1.1Bdp)
|
increased intestinal adenocarcinoma incidence
|
J:153684
|
increased intestinal adenoma incidence
|
J:153684
|
increased lung tumor incidence
|
J:153684
|
increased lymphoma incidence
|
J:153684
|
increased skin tumor incidence
|
J:153684
|
increased T cell derived lymphoma incidence
|
J:153684
|
Pold1tm1.1Bdp/Pold1tm1.1Bdp Poletm1.1Bdp/Poletm1.1Bdp
(B6.129-Poletm1.1Bdp Pold1tm1.1Bdp)
|
increased skin tumor incidence
|
J:153684
|
increased T cell derived lymphoma incidence
|
J:153684
|
Pold1tm1Bdp/Pold1tm1Bdp
(involves: 129S1/Sv * 129X1/SvJ * C57BL/6)
|
increased lung adenocarcinoma incidence
|
J:100685
|
increased lymphoma incidence
|
J:80306,
J:100685
|
increased skin tumor incidence
|
J:80306
|
increased T cell derived lymphoma incidence
|
J:100685
|
Pole4tm1(KOMP)Vlcg/Pole4tm1(KOMP)Vlcg
(involves: 129S1/Sv * 129X1/SvJ * C57BL/6NTac * FVB/N)
|
increased lymphoma incidence
|
J:261973
|
increased T cell derived lymphoma incidence
|
J:261973
|
Pole4tm1(KOMP)Vlcg/Pole4tm1(KOMP)Vlcg Trp53tm1Brd/Trp53+
(involves: C57BL/6J * C57BL/6NTac)
|
increased T cell derived lymphoma incidence
|
J:261973
|
Poletm1.1Bdp/Poletm1.1Bdp
(B6.129-Poletm1.1Bdp)
|
increased colon adenocarcinoma incidence
|
J:153684
|
increased histiocytic sarcoma incidence
|
J:153684
|
increased intestinal adenocarcinoma incidence
|
J:153684
|
increased intestinal adenoma incidence
|
J:153684
|
increased lung tumor incidence
|
J:153684
|
increased lymphoma incidence
|
J:153684
|
increased small intestine adenocarcinoma incidence
|
J:153684
|
Polgtm1Jiha/Polg+
(involves: C57BL/6JJcl)
|
increased B cell derived lymphoma incidence
|
J:199416
|
Polhtm1.1Rak/Polh+
(involves: 129P2/OlaHsd * 129S4/SvJae * C57BL/6)
|
increased skin tumor incidence
|
J:105034
|
Polhtm1.1Rak/Polhtm1.1Rak
(involves: 129P2/OlaHsd * 129S4/SvJae * C57BL/6)
|
increased skin tumor incidence
|
J:105034
|
Pomctm1Low/Pomc+
(involves: 129S2/SvPas * 129X1/SvJ * C57BL/6 * DBA/2)
|
increased pituitary adenoma incidence
|
J:119240
|
Pomctm1Low/Pomc+ Tg(Pomc)#Low/0
(involves: 129 * C57BL/6 * CBA * DBA/2 * Swiss Webster)
|
increased pituitary adenoma incidence
|
J:119240
|
Pomctm1Low/Pomctm1Low
(involves: 129S2/SvPas * 129X1/SvJ * C57BL/6 * DBA/2)
|
increased pituitary adenoma incidence
|
J:119240
|
Pomctm1Low/Pomctm1Low Tg(Pomc)#Low/0
(involves: 129 * C57BL/6 * CBA * DBA/2 * Swiss Webster)
|
increased pituitary adenoma incidence
|
J:119240
|
Ppardtm1Jps/Ppardtm1Jps
(involves: 129/Sv * C57BL/6N)
|
increased intestinal adenocarcinoma incidence
|
J:90217
|
increased sebaceous gland adenoma incidence
|
J:90337
|
increased skin papilloma incidence
|
J:90337
|
increased skin tumor incidence
|
J:90337
|
Ppp2r1atm1.2Wltr/Ppp2r1a+
(FVB.129S1-Ppp2r1atm1.2Wltr)
|
increased lung tumor incidence
|
J:175748
|
Ppp2r1atm1.2Wltr/Ppp2r1atm2.1Wltr
(FVB.129-Ppp2r1atm1.2Wltr/Ppp2r1atm2.1Wltr)
|
increased lung adenocarcinoma incidence
|
J:175748
|
increased lung adenoma incidence
|
J:175748
|
increased lung tumor incidence
|
J:175748
|
Ppp2r1atm2.1Wltr/Ppp2r1a+
(FVB.129-Ppp2r1atm2.1Wltr)
|
increased lung tumor incidence
|
J:175748
|
Ppp5ctm1a(EUCOMM)Wtsi/Ppp5ctm1a(EUCOMM)Wtsi
(involves: C57BL/6 * C57BL/6N)
|
increased lymphoma incidence
|
J:213427
|
Prdm2tm1Shg/Prdm2+
(involves: 129S2/SvPas * C57BL/6)
|
increased B cell derived lymphoma incidence
|
J:71406
|
increased lung adenocarcinoma incidence
|
J:71406
|
increased lymphoma incidence
|
J:71406
|
increased pituitary adenoma incidence
|
J:71406
|
Prdm2tm1Shg/Prdm2tm1Shg
(involves: 129S2/SvPas * C57BL/6)
|
increased B cell derived lymphoma incidence
|
J:71406
|
increased lung adenocarcinoma incidence
|
J:71406
|
increased lymphoma incidence
|
J:71406
|
increased pituitary adenoma incidence
|
J:71406
|
Prdm11tm1.1Ahl/Prdm11tm1.1Ahl Tg(IghMyc)22Bri/0
(B6.Cg-Prdm11tm1.1Ahl Tg(IghMyc)22Bri)
|
increased B cell derived lymphoma incidence
|
J:221379
|
Prdx1tm1Rave/Prdx1+
(involves: 129S6/SvEvTac * C57BL/6)
|
increased hepatocellular carcinoma incidence
|
J:84677
|
increased histiocytic sarcoma incidence
|
J:84677
|
increased lung adenocarcinoma incidence
|
J:84677
|
increased lymphoma incidence
|
J:84677
|
increased mammary adenocarcinoma incidence
|
J:84677
|
increased osteosarcoma incidence
|
J:84677
|
Prdx1tm1Rave/Prdx1tm1Rave
(involves: 129S6/SvEvTac * C57BL/6)
|
increased B cell derived lymphoma incidence
|
J:84677
|
increased hepatocellular carcinoma incidence
|
J:84677
|
increased histiocytic sarcoma incidence
|
J:84677
|
increased lung adenocarcinoma incidence
|
J:84677
|
increased lymphoma incidence
|
J:84677
|
increased mammary adenocarcinoma incidence
|
J:84677
|
increased pancreatic islet cell adenoma incidence
|
J:84677
|
increased T cell derived lymphoma incidence
|
J:84677
|
Prf1tm1Sdz/Prf1tm1Sdz
(C57BL/6-Prf1tm1Sdz)
|
increased B cell derived lymphoma incidence
|
J:77491
|
increased lymphoma incidence
|
J:77491
|
Prf1tm1Sdz/Prf1tm1Sdz
(C.B6-Prf1tm1Sdz)
|
increased lung adenocarcinoma incidence
|
J:77491
|
increased lymphoma incidence
|
J:77491
|
increased T cell derived lymphoma incidence
|
J:77491
|
Prkacatm1Gsm/Prkaca+ Prkar1atm1.1Lsk/Prkar1a+
(involves: 129S1/Sv * 129X1/SvJ * C57BL/6)
|
increased osteochondroma incidence
|
J:160299
|
increased osteosarcoma incidence
|
J:160299
|
increased skeletal tumor incidence
|
J:160299,
J:166728
|
Prkar1atm1.1Lsk/Prkar1a+
(involves: 129S1/Sv * 129X1/SvJ)
|
increased thyroid tumor incidence
|
J:98799
|
Prkar1atm1.1Lsk/Prkar1a+
(involves: 129S1/Sv * 129X1/SvJ * C57BL/6)
|
increased osteosarcoma incidence
|
J:160299
|
increased Schwannoma incidence
|
J:160299
|
increased skeletal tumor incidence
|
J:160299
|
increased thyroid tumor incidence
|
J:160299
|
Prkar1atm1.2Lsk/Prkar1a+ Rb1tm2Brn/Rb1+ Tg(Col1a1-cre)1Kry/0 Trp53tm1Brn/Trp53tm1Brn
(involves: 129 * 129P2/OlaHsd * 129S1/Sv * 129X1/SvJ * FVB/N)
|
increased osteosarcoma incidence
|
J:234128
|
Prkar1atm1.2Lsk/Prkar1a+ Rb1tm2Brn/Rb1tm2Brn Trp53tm1Brn/Trp53tm1Brn Tg(Col1a1-cre)1Kry/0
(involves: 129 * 129P2/OlaHsd * 129S1/Sv * 129X1/SvJ * FVB/N)
|
increased osteosarcoma incidence
|
J:234128
|
Prkar1atm1.2Lsk/Prkar1a+ Tg(Bglap2-TAg)1Rkho/0 Tg(Col1a1-cre)1Kry/0
(involves: 129S1/Sv * 129X1/SvJ * FVB/N)
|
increased osteosarcoma incidence
|
J:165282
|
Prkar1atm1.2Lsk/Prkar1a+ Tg(Col1a1-cre)1Kry/0
(involves: 129S1/Sv * 129X1/SvJ * FVB/N)
|
increased skeletal tumor incidence
|
J:165282
|
Prkar1atm1.2Lsk/Prkar1a+ Tg(Col1a1-cre)1Kry/0 Trp53tm1Brn/Trp53tm1Brn
(involves: 129P2/OlaHsd * 129S1/Sv * 129X1/SvJ * FVB/N)
|
increased osteosarcoma incidence
|
J:234128
|
Prkar1atm1.2Lsk/Prkar1atm1.2Lsk Ptentm1.1Mwst/Ptentm1.1Mwst Tg(TPO-cre)1Shk/0
(involves: 129S1/Sv * 129X1/SvJ * FVB/NCr)
|
increased thyroid carcinoma incidence
|
J:225245
|
Prkar1atm1.2Lsk/Prkar1atm1.2Lsk Tg(Ghrhr-cre)3242Lsk/0
(involves: 129S1/Sv * 129X1/SvJ * FVB/N)
|
increased pituitary gland tumor incidence
|
J:130264
|
Prkar1atm1.2Lsk/Prkar1atm1.2Lsk Tg(TPO-cre)1Shk/0
(involves: 129S1/Sv * 129X1/SvJ * FVB/NCr)
|
increased thyroid carcinoma incidence
|
J:225245,
J:241066
|
Prkar1atm1.2Lsk/Prkar1atm1.2Lsk Tg(Tyr-cre)3Gfk/0
(either: (involves: 129S1/Sv * 129X1/SvJ * C57BL/6 * CBA) or (involves: 129S1/Sv * 129X1/SvJ * C57BL/6))
|
increased facial tumor incidence
|
J:98799
|
increased Schwannoma incidence
|
J:98799
|
Prkar1atm1Gsm/Prkar1a+
(involves: 129X1/SvJ)
|
increased hepatocellular carcinoma incidence
|
J:93393
|
Prkcatm1Cda/Prkcatm1Cda
(involves: 129S/SvEv * C57BL/6)
|
increased skin papilloma incidence
|
J:100793
|
Prkchtm1Cda/Prkchtm1Cda
(involves: 129S/SvEv * C57BL/6J)
|
increased skin papilloma incidence
|
J:83498
|
Prkdcscid/Prkdc+ Tg(LPV-TAg1135)11Tvd/0
(involves: C57BL/6J * DBA/2J)
|
increased thymoma incidence
|
J:47667
|
Prkdcscid/Prkdc+ Trp53tm1Tyj/Trp53tm1Tyj
(involves: 129S2/SvPas * C57BL/6J)
|
increased thymoma incidence
|
J:47667
|
Prkdcscid/Prkdcscid
(C.BKa-Prkdcscid)
|
increased T cell derived lymphoma incidence
|
J:6958
|
Prkdcscid/Prkdcscid
(NOD.Cg-Prkdcscid)
|
increased T cell derived lymphoma incidence
|
J:109833,
J:22026
|
Prkdcscid/Prkdcscid Tg(LPV-TAg1135)11Tvd/0
(involves: C57BL/6J * DBA/2J)
|
increased thymoma incidence
|
J:47667
|
Prkdctm1Gcl/Prkdctm1Gcl
(involves: 129S1/Sv * C57BL/6)
|
increased T cell derived lymphoma incidence
|
J:53765
|
Prltm1Hmn/Prltm1Hmn
(involves: 129S2/SvPas)
|
increased pituitary adenoma incidence
|
J:79661
|
Prlrtm1Cnp/Prlrtm1Cnp
(involves: 129/Sv * 129P2/OlaHsd)
|
increased thyroid carcinoma incidence
|
J:101609
|
Prlrtm1Cnp/Prlrtm1Cnp Tg(C3-1-TAg)cJeg/0
(involves: 129P2/OlaHsd * 129S2/SvPas * FVB/N)
|
increased prostate intraepithelial neoplasia incidence
|
J:84352
|
Prmt1tm1c(EUCOMM)Wtsi/Prmt1+ Rb1tm3Tyj/Rb1tm3Tyj Trp53tm1Brn/Trp53tm1Brn Tg(Sp7-tTA,tetO-EGFP/cre)1Amc/0
(involves: 129P2/OlaHsd * 129S4/SvJae * C57BL/6 * CD-1)
|
increased osteosarcoma incidence
|
J:245660
|
Prmt7tm1a(EUCOMM)Wtsi/Prmt7tm1a(EUCOMM)Wtsi
(B6JTyr;B6N-Prmt7tm1a(EUCOMM)Wtsi/Wtsi)
|
increased trigeminal neuroma incidence
|
J:239583
|
Pscatm1Witt/Psca+ Tg(TRAMP)8247Ng/0
(involves: 129/Sv * C57BL/6)
|
increased prostate gland adenocarcinoma incidence
|
J:133908
|
increased prostate gland tumor incidence
|
J:133908
|
increased prostate intraepithelial neoplasia incidence
|
J:133908
|
Pscatm1Witt/Pscatm1Witt Tg(TRAMP)8247Ng/0
(involves: 129/Sv * C57BL/6)
|
increased prostate gland adenocarcinoma incidence
|
J:133908
|
increased prostate gland tumor incidence
|
J:133908
|
increased prostate intraepithelial neoplasia incidence
|
J:133908
|
Psl1DBA/2/?
(involves: C57BL/6 * DBA/2)
|
increased skin tumor incidence
|
J:44548
|
Psl2C57BL/6/Psl2DBA/2
(involves: C57BL/6 * DBA/2)
|
increased skin tumor incidence
|
J:83608
|
Psl2DBA/2/Psl2DBA/2
(involves: C57BL/6 * DBA/2)
|
increased skin tumor incidence
|
J:83608
|
Psl3C57BL/6/Psl3C57BL/6
(involves: C57BL/6 * DBA/2)
|
increased skin tumor incidence
|
J:83608
|
Psl3C57BL/6/Psl3DBA/2
(involves: C57BL/6 * DBA/2)
|
increased skin tumor incidence
|
J:83608
|
Psl4DBA/2/Psl4DBA/2
(involves: C57BL/6 * DBA/2)
|
increased skin tumor incidence
|
J:83608
|
Psmb9tm1Stl/Psmb9tm1Stl
(involves: 129P2/OlaHsd * C57BL/6)
|
increased hepatocellular carcinoma incidence
|
J:73945
|
increased leiomyosarcoma incidence
|
J:73945
|
increased lung tumor incidence
|
J:73945
|
Psmb9tm1Stl/Psmb9tm1Stl Trp53tm1Brd/Trp53tm1Brd
(involves: 129P2/OlaHsd * C57BL/6)
|
increased lymphoma incidence
|
J:67509
|
Psphtm1a(EUCOMM)Hmgu/Psphtm1a(EUCOMM)Hmgu
(C57BL/6N-Psphtm1a(EUCOMM)Hmgu/Wtsi)
|
increased trigeminal neuroma incidence
|
J:239583
|
Ptch1tm1.1Hahn/Ptch1+
(involves: 129 * BALB/c * C57BL/6 * FVB/N)
|
increased medulloblastoma incidence
|
J:149148
|
increased rhabdomyosarcoma incidence
|
J:149148
|
Ptch1tm1Bjw/Ptch1tm1Bjw Tg(Atoh1-cre)1Bfri/0
(involves: 129T2/SvEms * C57BL/6 * CBA)
|
increased medulloblastoma incidence
|
J:139573
|
Ptch1tm1Bjw/Ptch1tm1Bjw Tg(Atoh1-cre/Esr1*)14Fsh/0
(involves: 129T2/SvEms * FVB/N)
|
increased medulloblastoma incidence
|
J:139573
|
Ptch1tm1Bjw/Ptch1tm1Bjw Tg(GFAP-cre)25Mes/0
(involves: 129T2/SvEms * FVB/N)
|
increased medulloblastoma incidence
|
J:139573
|
Ptch1tm1Bjw/Ptch1tm1Bjw Tg(KRT14-cre)8Brn/0
(involves: 129T2/SvEms * FVB/N)
|
increased basal cell carcinoma incidence
|
J:231264
|
Ptch1tm1Cklr/Ptch1+ Pax7tm1(cre)Mrc/Pax7+
(involves: 129S1/Sv * 129X1/SvJ * C57BL/6 * SJL)
|
increased medulloblastoma incidence
|
J:159972
|
Ptch1tm1Cklr/Ptch1+ Trp53tm1Brn/? Pax7tm1(cre)Mrc/Pax7+
(involves: 129P2/OlaHsd * 129S1/Sv * 129X1/SvJ * C57BL/6 * SJL)
|
increased medulloblastoma incidence
|
J:159972
|
Ptch1tm1Hahn/Ptch1tm1Hahn Gt(ROSA)26Sortm2(cre/ERT2)Brn/Gt(ROSA)26Sor+
(involves: 129P2/OlaHsd * 129S1/Sv * 129X1/SvJ * C57BL/6)
|
increased basal cell carcinoma incidence
|
J:149148
|
Ptch1tm1Hahn/Ptch1tm1Hahn Gt(ROSA)26Sortm2(cre/ERT2)Brn/Gt(ROSA)26Sor+
(involves: 129P2/OlaHsd * 129S1/Sv * 129X1/SvJ)
|
increased basal cell carcinoma incidence
|
J:158915
|
Ptch1tm1Hahn/Ptch1tm1Hahn Gt(ROSA)26Sortm2(cre/ERT2)Brn/Gt(ROSA)26Sor+
(involves: 129P2/OlaHsd * 129S1/Sv * 129X1/SvJ * BALB/c * C57BL/6)
|
increased basal cell carcinoma incidence
|
J:149148
|
Ptch1tm1Mps/Ptch1+
(involves: 129S1/Sv * 129X1/SvJ * C57BL/6)
|
increased gastrointestinal tumor incidence
|
J:205254
|
increased lymphoma incidence
|
J:205254
|
increased medulloblastoma incidence
|
J:205254
|
increased rhabdomyosarcoma incidence
|
J:205254
|
Ptch1tm1Mps/Ptch1+
(involves: 129S1/Sv * 129X1/SvJ * C57BL/6 * DBA/2)
|
increased medulloblastoma incidence
|
J:42441
|
Ptch1tm1Mps/Ptch1+
(involves: 129S1/Sv * 129X1/SvJ)
|
increased medulloblastoma incidence
|
J:144811,
J:114992,
J:102702
|
increased rhabdomyosarcoma incidence
|
J:114992
|
increased skin tumor incidence
|
J:82653
|
Ptch1tm1Mps/Ptch1+
(involves: 129S1/Sv * 129X1/SvJ * C57BL/6 * DBA/2J)
|
increased basal cell carcinoma incidence
|
J:58328
|
Ptch1tm1Mps/Ptch1+ Ptch2tm1Pmc/Ptch2+
(involves: 129S1/Sv * 129X1/SvJ * C57BL/6)
|
increased basal cell carcinoma incidence
|
J:112118
|
increased rhabdomyosarcoma incidence
|
J:112118
|
increased testicular teratoma incidence
|
J:112118
|
Ptch1tm1Mps/Ptch1+ Ptch2tm1Pmc/Ptch2tm1Pmc
(involves: 129S1/Sv * 129X1/SvJ * C57BL/6)
|
increased basal cell carcinoma incidence
|
J:112118
|
increased medulloblastoma incidence
|
J:112118
|
increased rhabdomyosarcoma incidence
|
J:112118
|
Ptch1tm1Mps/Ptch1+ Tg(Atoh1-GFP)1Jejo/?
(involves: 129S1/Sv * 129X1/SvJ * C57BL/6 * DBA/2)
|
increased medulloblastoma incidence
|
J:144811
|
Ptch1tm1Mps/Ptch1+ Tg(Atoh1-sb11)1Mtay/0 TgTn(sb-T2/Onc3)12740Njen/0
(involves: 129S1/Sv * 129X1/SvJ * C3H * C57BL/6J * ICR)
|
increased medulloblastoma incidence
|
J:181542
|
Ptch1tm1Mps/Ptch1+ Trp53tm1Tyj/Trp53tm1Tyj
(involves: 129 * 129S2/SvPas * C57BL/6)
|
increased medulloblastoma incidence
|
J:125534
|
increased rhabdomyosarcoma incidence
|
J:125534
|
Ptch1tm1Yy/Ptch1+ Trp53tm1Brd/Trp53+ Tg(BGLAP-cre)1Clem/0
(involves: 129S7/SvEvBrd * C57BL/6 * FVB/NJ)
|
increased osteosarcoma incidence
|
J:214349
|
Ptch1tm1Zim/Ptch1+
(either: (involves: 129 * C57BL/6) or (involves: 129 * CD-1))
|
increased medulloblastoma incidence
|
J:47421
|
increased rhabdomyosarcoma incidence
|
J:47421
|
Ptch1tm1Zim/Ptch1+
(involves: 129 * CD-1)
|
increased medulloblastoma incidence
|
J:79666,
J:165388
|
Ptentm1.1Gle/Pten+
(involves: 129S6/SvEvTac * Black Swiss * FVB/N)
|
increased adrenal gland tumor incidence
|
J:158751
|
increased lymphoma incidence
|
J:158751
|
increased mammary gland tumor incidence
|
J:158751
|
increased prostate gland tumor incidence
|
J:158751
|
increased stomach tumor incidence
|
J:158751
|
increased T cell derived lymphoma incidence
|
J:158751
|
increased thyroid tumor incidence
|
J:158751
|
Ptentm1.1Hwu/Pten+
(involves: 129S4/SvJae * BALB/c)
|
increased mammary adenocarcinoma incidence
|
J:110567
|
increased prostate gland tumor incidence
|
J:110567
|
Ptentm1.1Hwu/Pten+
(involves: 129S4/SvJae * C57BL/6NTac)
|
increased lymphoma incidence
|
J:170965
|
increased thyroid adenoma incidence
|
J:170965
|
Ptentm1.1Hwu/Pten+ Tmprss2tm1.1(ERG)Sho/Tmprss2tm1.1(ERG)Sho
(involves: 129S4/SvJae * C57BL/6 * DBA/2)
|
increased prostate intraepithelial neoplasia incidence
|
J:212219
|
Ptentm1.1Hwu/Pten+ Tmprss2tm2.1(ETV1)Sho/Tmprss2tm2.1(ETV1)Sho
(involves: 129S4/SvJae * C57BL/6 * DBA/2)
|
increased prostate intraepithelial neoplasia incidence
|
J:212219
|
Ptentm1.1Mro/Pten+
(Not Specified)
|
increased pheochromocytoma incidence
|
J:236514
|
Ptentm1.1Mro/Pten+ Sdhbtm1.2Ics/Sdhb+
(involves: 129S2/SvPas * BALB/c * C57BL/6)
|
increased pheochromocytoma incidence
|
J:236514
|
Ptentm1.1Mwst/Ptentm1.1Mwst Tg(MMTVneu)202Mul/0 Tg(S100a4-cre)1Gle/0
(involves: FVB/N)
|
increased mammary adenocarcinoma incidence
|
J:153747
|
increased mammary gland tumor incidence
|
J:153747
|
Ptentm1.1Mwst/Ptentm1.1Mwst Tg(S100a4-cre)1Gle/0
(involves: FVB/N)
|
increased mammary gland tumor incidence
|
J:153747
|
Ptentm1.2Mwst/Pten+
(involves: 129S6/SvEvTac * Black Swiss * FVB/N)
|
increased adrenal gland tumor incidence
|
J:158751
|
increased gastrointestinal tumor incidence
|
J:158751
|
increased lymphoma incidence
|
J:158751
|
increased mammary adenoacanthoma incidence
|
J:158751
|
increased mammary gland tumor incidence
|
J:158751
|
increased prostate gland tumor incidence
|
J:158751
|
increased stomach tumor incidence
|
J:158751
|
increased T cell derived lymphoma incidence
|
J:158751
|
increased thyroid tumor incidence
|
J:158751
|
increased uterus carcinoma incidence
|
J:158751
|
Ptentm1Hwu/Pten+ Tg(ARR2/Pbsn-FGF8)3Prb/0 Tg(Pbsn-cre)4Prb/0
(involves: 129S4/SvJae * BALB/c * C57BL/6 * DBA/2)
|
increased prostate gland adenocarcinoma incidence
|
J:106650
|
increased prostate intraepithelial neoplasia incidence
|
J:106650
|
Ptentm1Hwu/Pten+ Tg(KRT14-cre)#Smr/0
(involves: 129S4/SvJae * C57BL/6J * SJL/J)
|
increased mammary adenocarcinoma incidence
|
J:138927
|
increased mammary gland tumor incidence
|
J:138927
|
Ptentm1Hwu/Pten+ Tg(Nkx2-1-cre)2Sand/0
(B6.Cg-Ptentm1Hwu Tg(Nkx2-1-cre)2Sand)
|
increased thyroid tumor incidence
|
J:197590
|
Ptentm1Hwu/Pten+ Tg(Pbsn-cre)4Prb/0
(involves: 129S4/SvJae * BALB/c * C57BL/6 * DBA/2)
|
increased prostate intraepithelial neoplasia incidence
|
J:93902
|
Ptentm1Hwu/Pten+ Tmprss2tm2.1(ETV1)Sho/Tmprss2tm2.1(ETV1)Sho Tg(Pbsn-cre)4Prb/0
(involves: 129S4/SvJae * C57BL/6 * DBA/2)
|
increased prostate gland adenocarcinoma incidence
|
J:212219
|
Ptentm1Hwu/Ptentm1Hwu
(involves: 129S4/SvJae)
|
increased prostate gland adenocarcinoma incidence
|
J:144810
|
increased prostate intraepithelial neoplasia incidence
|
J:144810
|
Ptentm1Hwu/Ptentm1Hwu Amhr2tm3(cre)Bhr/Amhr2+
(involves: 129S4/SvJae * 129S7/SvEvBrd)
|
increased granulosa cell tumor incidence
|
J:142150,
J:222579
|
Ptentm1Hwu/Ptentm1Hwu Cop1tm2.1Vmd/Cop1tm2.1Vmd Tg(Pbsn-cre)4Prb/0
(B6N.CgCop1tm2.1Vmd Ptentm1Hwu Tg(Pbsn-cre)4Prb)
|
increased prostate gland adenocarcinoma incidence
|
J:172653
|
increased prostate intraepithelial neoplasia incidence
|
J:172653
|
Ptentm1Hwu/Ptentm1Hwu Ptpn1tm1Bpk/Ptpn1tm1Bpk Tg(Pbsn-cre)4Prb/0
(involves: 129S4/SvJae * C57BL/6 * DBA/2)
|
increased prostate gland adenocarcinoma incidence
|
J:231906
|
increased prostate intraepithelial neoplasia incidence
|
J:231906
|
Ptentm1Hwu/Ptentm1Hwu Rps6kb1tm1Gtho/Rps6kb1tm1Gtho Tg(Mx1-cre)1Cgn/0
(involves: 129P2/OlaHsd * 129S4/SvJae * C57BL/6 * CBA)
|
increased acute lymphoblastic leukemia incidence
|
J:169097
|
Ptentm1Hwu/Ptentm1Hwu Smad4tm2.1Cxd/Smad4tm2.1Cxd Tg(Alb1-cre)1Dlr/0
(involves: 129S4/SvJae * 129S6/SvEvTac * FVB/N)
|
increased cholangiocarcinoma incidence
|
J:111718
|
Ptentm1Hwu/Ptentm1Hwu Speer6-ps1Tg(Alb-cre)21Mgn/Speer6-ps1+
(involves: 129S4/SvJae * C57BL/6 * DBA)
|
increased cholangiocarcinoma incidence
|
J:218587
|
increased hepatocellular carcinoma incidence
|
J:218587
|
increased liver tumor incidence
|
J:218587
|
Ptentm1Hwu/Ptentm1Hwu Tg(Alb1-cre)1Dlr/0
(involves: 129S4/SvJae * FVB/N)
|
increased cholangiocarcinoma incidence
|
J:111718
|
increased hepatocellular carcinoma incidence
|
J:111718
|
Ptentm1Hwu/Ptentm1Hwu Tg(CAG-EGFP,-PAX8/PPARG)1Rkoe/0 Tg(TPO-cre)1Shk/0
(involves: 129S4/SvJae * FVB/NCr * FVB/NJ)
|
increased thyroid carcinoma incidence
|
J:177181
|
Ptentm1Hwu/Ptentm1Hwu Tg(CAG-MYC,-GFP*)#Rugg/0 Tg(Pbsn-cre)4Prb/0
(involves: 129S4/SvJae * C57BL/6 * C57BL/6J * DBA/2)
|
increased prostate gland adenocarcinoma incidence
|
J:261540
|
increased prostate intraepithelial neoplasia incidence
|
J:261540
|
Ptentm1Hwu/Ptentm1Hwu Tg(Cdh5-cre)7Mlia/0
(involves: 129S4/SvJae * BALB/c * C57BL/6 * FVB/N)
|
increased acute lymphoblastic leukemia incidence
|
J:135172
|
increased acute promyelocytic leukemia incidence
|
J:135172
|
Ptentm1Hwu/Ptentm1Hwu Tg(Fabp1-cre)1Jig/0
(involves: 129S4/SvJae * FVB/N)
|
increased colon adenocarcinoma incidence
|
J:106662
|
increased prostate gland tumor incidence
|
J:106662
|
increased renal carcinoma incidence
|
J:106662
|
increased urethra carcinoma incidence
|
J:106662
|
increased urinary bladder carcinoma incidence
|
J:106662
|
Ptentm1Hwu/Ptentm1Hwu Tg(KRT14-cre)#Smr/0
(involves: 129S4/SvJae * C57BL/6J * SJL/J)
|
increased mammary adenocarcinoma incidence
|
J:138927
|
increased mammary gland tumor incidence
|
J:138927
|
increased skin papilloma incidence
|
J:138927
|
increased skin tumor incidence
|
J:138927
|
increased thyroid tumor incidence
|
J:138927
|
Ptentm1Hwu/Ptentm1Hwu Tg(KRT14-cre)#Smr/0
(FVB.Cg-Ptentm1Hwu Tg(KRT14-cre)#Smr)
|
increased skin hamartoma incidence
|
J:199362
|
increased skin papilloma incidence
|
J:199362
|
Ptentm1Hwu/Ptentm1Hwu Tg(MMTV-cre)#Tfln/0
(involves: 129S4/SvJae)
|
increased fibroadenoma incidence
|
J:78415
|
increased mammary adenocarcinoma incidence
|
J:78415
|
increased mammary gland tumor incidence
|
J:78415
|
Ptentm1Hwu/Ptentm1Hwu Tg(Mx1-cre)1Cgn/0
(involves: 129S4/SvJae * C57BL/6 * CBA)
|
increased acute lymphoblastic leukemia incidence
|
J:169097
|
Ptentm1Hwu/Ptentm1Hwu Tg(Mx1-cre)1Cgn/0
(BKS.Cg-Ptprcb Thy1a Tg(Mx1-cre)1Cgn Ptentm1Hwu)
|
increased acute lymphoblastic leukemia incidence
|
J:109085
|
increased acute promyelocytic leukemia incidence
|
J:109085
|
increased leukemia incidence
|
J:109085
|
Ptentm1Hwu/Ptentm1Hwu Tg(Mx1-cre)1Cgn/0
(B6.Cg-Tg(Mx1-cre)1Cgn Ptentm1Hwu)
|
increased T cell acute lymphoblastic leukemia incidence
|
J:232645
|
Ptentm1Hwu/Ptentm1Hwu Tg(Nkx2-1-cre)2Sand/0
(B6.Cg-Ptentm1Hwu Tg(Nkx2-1-cre)2Sand)
|
increased thyroid adenoma incidence
|
J:197590
|
Ptentm1Hwu/Ptentm1Hwu Tg(Pbsn-cre)4Prb/0
(involves: 129 * 129S4/SvJae * C57BL/6 * DBA/2)
|
increased prostate gland adenocarcinoma incidence
|
J:142106
|
increased prostate gland tumor incidence
|
J:142106
|
increased prostate intraepithelial neoplasia incidence
|
J:138565
|
Ptentm1Hwu/Ptentm1Hwu Tg(Pbsn-cre)4Prb/0
(involves: 129S4/SvJae * C57BL/6 * DBA/2)
|
increased prostate gland adenocarcinoma incidence
|
J:268934,
J:184935,
J:212219
|
increased prostate gland tumor incidence
|
J:268934,
J:172730,
J:170965
|
increased prostate intraepithelial neoplasia incidence
|
J:268934,
J:131932,
J:212219
|
Ptentm1Hwu/Ptentm1Hwu Tg(Pbsn-cre)4Prb/0
(involves: 129S4/SvJae * BALB/c * C57BL/6 * DBA/2)
|
increased prostate gland adenocarcinoma incidence
|
J:93902,
J:124208
|
increased prostate gland tumor incidence
|
J:124208
|
increased prostate intraepithelial neoplasia incidence
|
J:93902,
J:106650
|
Ptentm1Hwu/Ptentm1Hwu Tg(Pbsn-cre)20Fwan/?
(involves: 129S4/SvJae * C57BL/6 * FVB/NCrl)
|
increased prostate gland adenocarcinoma incidence
|
J:238768
|
increased prostate intraepithelial neoplasia incidence
|
J:238768
|
Ptentm1Hwu/Ptentm1Hwu Tg(Pdx1-cre)89.1Dam/0
(involves: 129S4/SvJae * C57BL/6 * CBA)
|
increased pancreatic ductal adenocarcinoma incidence
|
J:102226
|
increased pancreatic intraepithelial neoplasia incidence
|
J:102226
|
Ptentm1Hwu/Ptentm1Hwu Tg(Pdx1-cre)89.1Dam/0 Trp53tm1Tyj/Trp53tm1Tyj
(involves: 129S2/SvPas * 129S4/SvJae * C57BL/6 * CBA)
|
increased pancreatic acinar cell carcinoma incidence
|
J:102226
|
increased pancreatic ductal adenocarcinoma incidence
|
J:102226
|
Ptentm1Hwu/Ptentm1Hwu Tg(Pgc-cre,-secNluc)#Hcz/0
(involves: 129S4/SvJae)
|
increased mammary adenocarcinoma incidence
|
J:338079
|
Ptentm1Hwu/Ptentm1Hwu Tgfbr1tm1.1Karl/Tgfbr1tm1.1Karl Tg(KRT14-cre/ERT)20Efu/0
(involves: 129 * 129S4/SvJae * C57BL/6 * CD-1 * FVB/N)
|
increased oral papilloma incidence
|
J:194652
|
increased organ/body region tumor incidence
|
J:209026
|
Ptentm1Hwu/Ptentm1Hwu Trp53tm1Brn/Trp53tm1Brn
(involves: 129P2/OlaHsd * 129S4/SvJae * C57BL/6 * FVB)
|
increased urinary bladder carcinoma incidence
|
J:146760
|
Ptentm1Hwu/Ptentm1Hwu Trp53tm2Tyj/Trp53+ Amhr2tm3(cre)Bhr/Amhr2+
(involves: 129P2/OlaHsd * 129S4/SvJae * 129S7/SvEvBrd)
|
increased granulosa cell tumor incidence
|
J:222579
|
increased ovarian carcinoma incidence
|
J:222579
|
Ptentm1Hwu/Ptentm1Hwu Vhltm1Jae/Vhltm1Jae Tg(Cdh16-cre)91Igr/0
(involves: 129S4/SvJae * ICR)
|
increased epididymal cystadenoma incidence
|
J:137442
|
Ptentm1Mak/Pten+
(involves: 129P2/OlaHsd * C57BL/6J)
|
increased adrenal gland tumor incidence
|
J:63478
|
increased endometrial carcinoma incidence
|
J:63478
|
increased fibroadenoma incidence
|
J:63478
|
increased leukemia incidence
|
J:50437
|
increased lymphoma incidence
|
J:63478
|
increased mammary adenocarcinoma incidence
|
J:63478
|
increased mammary gland tumor incidence
|
J:63478
|
increased prostate gland tumor incidence
|
J:63478
|
increased T cell derived lymphoma incidence
|
J:50437
|
Ptentm1Mak/Pten+
(B6.129P2-Ptentm1Mak)
|
increased adrenal gland tumor incidence
|
J:93530
|
increased endometrial carcinoma incidence
|
J:93530
|
increased lymphoma incidence
|
J:93530
|
Ptentm1Mro/Pten+ Sdhbtm1.1Ics/Sdhb+ Tg(KLK3-cre)D4Trp/0
(involves: 129S2/SvPas * FVB)
|
increased pheochromocytoma incidence
|
J:236514
|
Ptentm1Mro/Pten+ Tg(KLK3-cre)D4Trp/0
(involves: 129P2/OlaHsd * FVB)
|
increased prostate gland adenocarcinoma incidence
|
J:99524
|
increased prostate gland tumor incidence
|
J:99524
|
increased prostate intraepithelial neoplasia incidence
|
J:99524
|
Ptentm1Mro/Pten+ Tg(Pbsn-cre)4Prb/0
(involves: C57BL/6 * DBA/2)
|
increased prostate intraepithelial neoplasia incidence
|
J:184533
|
Ptentm1Mro/Ptentm1Mro Sdhbtm1.1Ics/Sdhb+ Tg(KLK3-cre)D4Trp/0
(involves: 129S2/SvPas * FVB)
|
increased pheochromocytoma incidence
|
J:236514
|
Ptentm1Mro/Ptentm1Mro Sdhbtm1.1Ics/Sdhbtm1.2Ics Tg(KLK3-cre)D4Trp/0
(involves: 129S2/SvPas * BALB/c * C57BL/6 * FVB)
|
increased pheochromocytoma incidence
|
J:236514
|
Ptentm1Ppp/Pten+ Tg(Pbsn-TAg)15Tvd/0
(involves: 129S1/Sv * C57BL/6 * DBA/2)
|
increased prostate gland adenocarcinoma incidence
|
J:103408
|
increased prostate gland tumor incidence
|
J:103408
|
increased prostate intraepithelial neoplasia incidence
|
J:103408
|
Ptentm1Ppp/Ptentm2Ppp
(involves: 129S1/Sv * C57BL/6)
|
increased prostate gland tumor incidence
|
J:86212
|
Ptentm1Rdp/Pten+ Trp53tm1Brn/Trp53tm1Brn Tg(GFAP-cre)25Mes/0
(involves: 129P2/OlaHsd * 129S6/SvEvTac * C57BL/6 * FVB/N)
|
increased astrocytoma incidence
|
J:140704
|
increased glioblastoma incidence
|
J:140704
|
increased glioma incidence
|
J:140704
|
Ptentm1Rdp/Ptentm1Rdp Smad4tm1Rdp/Smad4tm1Rdp Trp53tm1Brn/Trp53tm1Brn Tg(Pbsn-cre)4Prb/0
(involves: 129 * C57BL/6 * DBA/2)
|
increased prostate gland adenocarcinoma incidence
|
J:186105
|
Ptentm1Rdp/Ptentm1Rdp Terttm1Rdp/Tert+ Trp53tm1Brn/Trp53tm1Brn Tg(Pbsn-cre)4Prb/0
(involves: 129P2/OlaHsd * 129S6/SvEvTac * C57BL/6 * DBA/2)
|
increased prostate gland adenocarcinoma incidence
|
J:186105
|
increased prostate intraepithelial neoplasia incidence
|
J:186105
|
Ptentm1Rdp/Ptentm1Rdp Terttm1Rdp/Terttm1Rdp Trp53tm1Brn/Trp53tm1Brn Tg(Pbsn-cre)4Prb/0
(involves: 129P2/OlaHsd * 129S6/SvEvTac * C57BL/6 * DBA/2)
|
increased prostate intraepithelial neoplasia incidence
|
J:186105
|
Ptentm1Rdp/Ptentm1Rdp Terttm3Rdp/Terttm3Rdp Trp53tm1Brn/Trp53tm1Brn Tg(Pbsn-cre)4Prb/0
(involves: 129P2/OlaHsd * 129S6/SvEvTac * C57BL/6 * DBA/2)
|
increased prostate gland adenocarcinoma incidence
|
J:186105
|
increased prostate intraepithelial neoplasia incidence
|
J:186105
|
Ptentm1Rdp/Ptentm1Rdp Trp53tm1Brn/Trp53tm1Brn Tg(Pbsn-cre)4Prb/0
(involves: 129P2/OlaHsd * 129S6/SvEvTac * C57BL/6 * DBA/2)
|
increased prostate gland adenocarcinoma incidence
|
J:186105
|
increased prostate intraepithelial neoplasia incidence
|
J:186105
|
Ptentm1Rps/Pten+
(involves: 129S1/Sv * C57BL/6J)
|
increased leukemia incidence
|
J:53065
|
increased liver adenoma incidence
|
J:53065
|
increased lymphoma incidence
|
J:53065
|
increased prostate intraepithelial neoplasia incidence
|
J:53065
|
increased thyroid carcinoma incidence
|
J:53065
|
Ptentm1Rps/Pten+
(involves: 129S1/Sv * 129S1/SvImJ * C57BL/6J)
|
increased prostate intraepithelial neoplasia incidence
|
J:75085
|
Ptentm1Rps/Pten+ Tg(Wnt1)1Hev/0
(involves: 129S1/Sv * C57BL/6 * FVB/N * SJL)
|
increased mammary adenocarcinoma incidence
|
J:67497
|
increased mammary gland ductal carcinoma incidence
|
J:67497
|
increased salivary adenocarcinoma incidence
|
J:67497
|
Ptentm2.1Gle/Pten+
(involves: 129S6/SvEvTac * Black Swiss * FVB/N)
|
increased adrenal gland tumor incidence
|
J:158751
|
increased lymphoma incidence
|
J:158751
|
increased mammary adenoacanthoma incidence
|
J:158751
|
increased mammary gland tumor incidence
|
J:158751
|
increased prostate gland tumor incidence
|
J:158751
|
increased T cell derived lymphoma incidence
|
J:158751
|
increased thyroid tumor incidence
|
J:158751
|
Ptentm2.1Ppp/Pten+ Spry1tm1Jdli/Spry1tm1.1Jdli Spry2tm1Mrt/Spry2tm1.1Mrt Tg(Osr1-cre)4Mrt/0
(involves: 129P2/OlaHsd * 129S1/Sv * 129X1/SvJ * FVB/N)
|
increased prostate gland tumor incidence
|
J:192348
|
increased prostate intraepithelial neoplasia incidence
|
J:192348
|
Ptentm2.1Ppp/Pten+ Tg(Cnp-EGFR)10Nrat/0 Tg(Dhh-cre)1Mejr/0
(involves: 129S1/Sv * C57BL/6 * FVB/N * SJL)
|
increased neurofibrosarcoma incidence
|
J:195067
|
Ptentm2.1Ppp/Ptentm2.1Ppp Rb1tm2Brn/Rb1tm2Brn Tg(Pbsn-cre)4Prb/0
(involves: 129 * 129S1/Sv * 129S6/SvEvTac * C57BL/6 * DBA/2)
|
increased prostate intraepithelial neoplasia incidence
|
J:307910
|
Ptentm2.1Ppp/Ptentm2.1Ppp Tg(CAG-Bgeo,-Spry2,-ALPP)1Mrt/0 Tg(Osr1-cre)4Mrt/0
(involves: 129P2/OlaHsd * 129S1/Sv * FVB/N)
|
increased prostate intraepithelial neoplasia incidence
|
J:192348
|
Ptentm2.1Ppp/Ptentm2.1Ppp Tg(Cnp-EGFR)10Nrat/0 Tg(Dhh-cre)1Mejr/0
(involves: 129S1/Sv * C57BL/6 * FVB/N * SJL)
|
increased neurofibrosarcoma incidence
|
J:195067
|
Ptentm2.1Ppp/Ptentm2.1Ppp Tg(Dhh-cre)1Mejr/0
(involves: 129S1/Sv * C57BL/6 * FVB/N * SJL)
|
increased neurofibrosarcoma incidence
|
J:195067
|
Ptentm2.1Ppp/Ptentm2.1Ppp Tg(GFAP-TAg121)1Tvd/0
(involves: 129S1/Sv * C57BL/6 * C57BL/6J * DBA/2 * FVB/N)
|
increased astrocytoma incidence
|
J:99385
|
Ptentm2.1Ppp/Ptentm2.1Ppp Tg(Osr1-cre)4Mrt/0
(involves: 129S1/Sv * 129X1/SvJ)
|
increased prostate intraepithelial neoplasia incidence
|
J:192348
|
Ptentm2.1Ppp/Ptentm2.1Ppp Tg(Pbsn-cre)4Prb/0
(involves: 129S1/Sv * C57BL/6 * DBA/2)
|
increased prostate gland adenocarcinoma incidence
|
J:163589,
J:100683
|
increased prostate gland tumor incidence
|
J:86212,
J:100683
|
increased prostate intraepithelial neoplasia incidence
|
J:239660,
J:163589,
J:100683,
J:200002
|
Ptentm2.1Ppp/Ptentm2.1Ppp Tg(Pbsn-cre)8113ANg/0
(involves: 129S1/Sv * C57BL/6)
|
increased prostate gland tumor incidence
|
J:86212
|
Ptentm2.1Ppp/Ptentm2.1Ppp Tg(TPO-cre)1Shk/0
(129S1.Cg-Ptentm2.1Ppp Tg(TPO-cre)1Shk)
|
increased thyroid adenoma incidence
|
J:165293
|
increased thyroid carcinoma incidence
|
J:165293
|
Ptentm2.1Ppp/Ptentm2.1Ppp Trp53tm1Brn/Trp53tm1Brn Tg(TPO-cre)1Shk/0
(129.Cg-Tg(TPO-cre)1Shk Trp53tm1Brn Ptentm2.1Ppp)
|
increased thyroid carcinoma incidence
|
J:211100
|
Ptentm2.1Ppp/Ptentm2.1Ppp Trp53tm1Thl/Trp53tm1Thl Tg(Pbsn-cre)4Prb/0
(involves: 129S1/Sv * C57BL/6 * DBA/2)
|
increased prostate gland tumor incidence
|
J:100683
|
Ptentm2Mak/Ptentm2Mak Smad4tm2.1Cxd/Smad4tm2.1Cxd Tg(KRT5-cre)1Xya/0
(involves: 129P2/OlaHsd * 129S6/SvEvTac)
|
increased skin papilloma incidence
|
J:101602
|
increased skin tumor incidence
|
J:101602
|
increased stomach tumor incidence
|
J:101602
|
Ptentm2Mak/Ptentm2Mak Speer6-ps1Tg(Alb-cre)21Mgn/Speer6-ps1+
(involves: 129P2/OlaHsd * C57BL/6 * DBA)
|
increased hepatocellular carcinoma incidence
|
J:138099
|
increased liver adenoma incidence
|
J:138099
|
Ptentm2Mak/Ptentm2Mak Speer6-ps1Tg(Alb-cre)21Mgn/Speer6-ps1+
(involves: 129P2/OlaHsd * C57BL/6 * C57BL/6J * DBA)
|
increased hepatocellular carcinoma incidence
|
J:90905
|
increased liver adenoma incidence
|
J:90905
|
Ptentm2Mak/Ptentm2Mak Stk11tm1Keis/Stk11tm1Keis Tg(Cyp1a1-cre/ERT)1Dwi/0
(involves: 129P2/OlaHsd * C57BL/6 * C57BL/6J * CBA)
|
increased urinary bladder carcinoma incidence
|
J:169565
|
Ptentm2Mak/Ptentm2Mak Tg(Cyp1a1-cre)1Dwi/0
(involves: 129P2/OlaHsd * C57BL/6 * CBA)
|
increased hepatocellular carcinoma incidence
|
J:143082
|
increased lymphoma incidence
|
J:143082
|
Ptentm2Mak/Ptentm2Mak Tg(Fabp1-cre)1Jig/0
(involves: 129P2/OlaHsd * C57BL/6 * FVB/N)
|
increased urinary bladder transitional cell carcinoma incidence
|
J:113388
|
Ptentm2Mak/Ptentm2Mak Tg(GFAP-cre/Esr1*,-lacZ)ASbk/0 Trp53tm1Brn/Trp53tm1Brn
(involves: 129P2/OlaHsd * FVB/NJ)
|
increased glioblastoma incidence
|
J:290447
|
Ptentm2Mak/Ptentm2Mak Tg(KLK3-cre)13Saa/0
(involves: 129P2/OlaHsd * C57BL/6)
|
increased prostate gland adenocarcinoma incidence
|
J:214242
|
increased prostate gland tumor incidence
|
J:214242
|
increased prostate intraepithelial neoplasia incidence
|
J:214242
|
Ptentm2Mak/Ptentm2Mak Tg(MMTV-cre)#Tfln/0
(involves: 129P2/OlaHsd * C57BL/6 * FVB/N)
|
increased mammary adenocarcinoma incidence
|
J:224955
|
increased mammary gland tumor incidence
|
J:224955
|
increased mammary gland tumor incidence in breeding females
|
J:224955
|
Ptentm2Mak/Ptentm2Mak Tg(SFTPC-rtTA)5Jaw/0 Tg(tetO-cre)1Jaw/0
(involves: 129 * 129P2/OlaHsd * C57BL/6 * C57BL/6J)
|
increased lung adenocarcinoma incidence
|
J:127405
|
increased lung squamous cell carcinoma incidence
|
J:127405
|
Ptentm2Mak/Ptentm2Mak Tg(Wap-cre)11738Mam/0
(involves: 129P2/OlaHsd * C57BL/6 * FVB/N * SJL)
|
increased mammary adenocarcinoma incidence
|
J:224955
|
increased mammary gland tumor incidence
|
J:224955
|
increased mammary gland tumor incidence in breeding females
|
J:224955
|
Ptentm2Mak/Ptentm2Mak Trp53tm1Brn/Trp53tm1Brn Tg(MMTV-cre)#Tfln/0
(involves: 129P2/OlaHsd * C57BL/6 * FVB/N)
|
increased mammary adenocarcinoma incidence
|
J:224955
|
increased mammary gland tumor incidence
|
J:224955
|
Ptentm2Mak/Ptentm2Mak Trp53tm1Brn/Trp53tm1Brn Tg(Nes-cre/ERT2,-ALPP)1Sbk/0
(involves: 129P2/OlaHsd)
|
increased glioma incidence
|
J:237990
|
increased medulloblastoma incidence
|
J:237990
|
Ptentm2Mak/Ptentm2Mak Trp53tm1Brn/Trp53tm1Brn Tg(Wap-cre)11738Mam/0
(involves: 129P2/OlaHsd * C57BL/6 * FVB/N * SJL)
|
increased mammary adenocarcinoma incidence
|
J:224955
|
increased mammary gland tumor incidence
|
J:224955
|
Ptpn11tm1Ckq/Ptpn11+ Lyz2tm1(cre)Ifo/Lyz2+
(involves: 129P2/OlaHsd * 129S6/SvEvTac * C57BL/6J)
|
increased acute promyelocytic leukemia incidence
|
J:177285
|
Ptpn11tm1Ckq/Ptpn11+ Tg(Lck-cre)1Cwi/0
(involves: 129S6/SvEvTac * C57BL/6J)
|
increased acute lymphoblastic leukemia incidence
|
J:177285
|
increased lymphoblastic lymphoma incidence
|
J:177285
|
Ptpn11tm1Ckq/Ptpn11+ Tg(Mx1-cre)1Cgn/0
(involves: 129S6/SvEvTac * C57BL/6 * C57BL/6J * CBA)
|
increased acute lymphoblastic leukemia incidence
|
J:177285
|
increased acute promyelocytic leukemia incidence
|
J:177285
|
increased B cell derived lymphoma incidence
|
J:177285
|
increased leukemia incidence
|
J:177285
|
increased lymphoblastic lymphoma incidence
|
J:177285
|
Ptpn11tm1Gsf/Ptpn11tm1Gsf Speer6-ps1Tg(Alb-cre)21Mgn/Speer6-ps1+
(involves: 129S1/Sv * 129X1/SvJ * C57BL/6 * DBA)
|
increased liver adenoma incidence
|
J:172422
|
Ptprctm1Holm/Ptprctm1Holm Tg(Lck*F505)2964Rmp/?
(involves: 129/Sv * C57BL/6 * DBA/2)
|
increased T cell derived lymphoma incidence
|
J:64671
|
Ptprctm1Holm/Ptprctm1Holm Tg(Lck*F505)3073Rmp/?
(involves: 129/Sv * C57BL/6 * DBA/2)
|
increased T cell derived lymphoma incidence
|
J:64671
|
Ptprttm1Sata/Ptprttm1Sata
(B6.129P2-Ptprttm1Sata)
|
increased colon adenoma incidence
|
J:157542
|
Ptprz1tm1Schl/Ptprz1+ Trp53tm1Tyj/Trp53+
(involves: 129 * 129S2/SvPas * C57BL/6J)
|
increased osteosarcoma incidence
|
J:243104
|
Ptprz1tm1Schl/Ptprz1tm1Schl
(involves: 129)
|
increased osteosarcoma incidence
|
J:243104
|
Ptprz1tm1Schl/Ptprz1tm1Schl Trp53tm1Tyj/Trp53+
(involves: 129 * 129S2/SvPas * C57BL/6J)
|
increased osteosarcoma incidence
|
J:243104
|
Puf60tm1.1Kmtsu/Puf60+ Trp53tm1Sia/Trp53tm1Sia
(involves: C57BL/6NCrlj * C57BL/6NCrSlc * CBA/JNCrlj)
|
increased T cell derived lymphoma incidence
|
J:233347
|
Rab11atm1.1Ngao/Rab11atm1.1Ngao Tg(Vil1-cre)997Gum/0
(involves: 129S4/SvJae * C57BL/6J * SJL)
|
increased intestinal adenoma incidence
|
J:278932
|
Rab25tm1Jrgo/Rab25tm1Jrgo Smad3tm1Par/Smad3+
(129-Rab25tm1Jrgo Smad3tm1Par)
|
increased colon adenocarcinoma incidence
|
J:158733
|
Rac3tm1Hkp/Rac3tm1Hkp Tg(BCR/ABL)623Hkp/0
(involves: C57BL/6 * C57BL/6J * CBA)
|
increased leukemia incidence
|
J:99168
|
Rad9atm2Lieb/Rad9a+ Tg(KRT5-cre)1Xya/?
(involves: 129S/SvEv * C57BL/6)
|
increased skin papilloma incidence
|
J:138845
|
Rad9atm2Lieb/Rad9atm2Lieb Tg(KRT5-cre)1Xya/?
(involves: 129S/SvEv * C57BL/6)
|
increased skin papilloma incidence
|
J:138845
|
Rad50tm1Jpt/Rad50tm2Jpt
(involves: 129S7/SvEvBrd * C57BL/6)
|
increased lymphoma incidence
|
J:103922
|
Rad50tm2Jpt/Rad50tm2Jpt
(either: (involves: 129S6/SvEvTac * 129S7/SvEvBrd) or (involves: 129S7/SvEvBrd * C57BL/6))
|
increased leukemia incidence
|
J:78820
|
increased T cell derived lymphoma incidence
|
J:78820
|
Rad50tm2Jpt/Rad50tm2Jpt
(involves: 129S7/SvEvBrd * C57BL/6)
|
increased lymphoma incidence
|
J:103922
|
Rad50tm2Jpt/Rad50tm2Jpt Trp53tm1Tyj/Trp53tm1Tyj
(involves: 129S2/SvPas * 129S6/SvEvTac * 129S7/SvEvBrd * C57BL/6)
|
increased T cell derived lymphoma incidence
|
J:78820
|
Rad50tm4.1Jpt/Rad50+
(involves: 129/Sv * C57BL/6)
|
increased hepatoblastoma incidence
|
J:209141
|
increased liver adenoma incidence
|
J:209141
|
increased liver tumor incidence
|
J:209141
|
Rad50tm4Jpt/Rad50+
(involves: 129/Sv * C57BL/6)
|
increased liver adenoma incidence
|
J:209141
|
increased liver tumor incidence
|
J:209141
|
Rag1tm1Jsek/Rag1tm1Jsek Trp53tm1Tyj/Trp53tm1Tyj
(involves: 129S2/SvPas * 129S6/SvEvTac)
|
increased T cell derived lymphoma incidence
|
J:146912
|
Rag1tm1Mom/Rag1+ Tg(LPV-TAg1135)11Tvd/0
(involves: 129/Sv * C57BL/6 * DBA/2)
|
increased T cell derived lymphoma incidence
|
J:47667
|
Rag1tm1Mom/Rag1+ Tg(LPV-TAg1135)11Tvd/0 Tg(TcrLCMV)327Sdz/0
(involves: 129S7/SvEvBrd * C57BL/6 * DBA/2)
|
increased T cell derived lymphoma incidence
|
J:47667
|
Rag1tm1Mom/Rag1tm1Mom Prf1tm1Sdz/Prf1tm1Sdz
(NOD.Cg-Rag1tm1Mom Prf1tm1Sdz/Sz)
|
increased T cell derived lymphoma incidence
|
J:109843
|
Rag1tm1Mom/Rag1tm1Mom Tg(LPV-TAg1135)11Tvd/0
(involves: 129/Sv * C57BL/6 * DBA/2)
|
increased T cell derived lymphoma incidence
|
J:47667
|
Rag1tm1Mom/Rag1tm1Mom Tg(LPV-TAg1135)11Tvd/0 Tg(TcrLCMV)327Sdz/0
(involves: 129S7/SvEvBrd * C57BL/6 * DBA/2)
|
increased T cell derived lymphoma incidence
|
J:47667
|
Rag1tm1Mom/Rag1tm1Mom Trp53tm1Brd/Trp53tm1Brd
(involves: 129S7/SvEvBrd * C57BL)
|
increased hepatocellular carcinoma incidence
|
J:141515
|
increased medulloblastoma incidence
|
J:141515
|
increased pituitary adenoma incidence
|
J:141515
|
increased T cell derived lymphoma incidence
|
J:141515
|
Rag1tm1Mom/Rag1tm1Mom Trp53tm1Brd/Trp53tm1Brd Xrcc5tm1Dbr/Xrcc5tm1Dbr
(involves: 129S7/SvEvBrd * C57BL)
|
increased medulloblastoma incidence
|
J:141515
|
increased stomach tumor incidence
|
J:141515
|
increased T cell derived lymphoma incidence
|
J:141515
|
Rag2tm1.1Desi/Rag2tm1.1Desi Trp53tm1Tyj/Trp53tm1Tyj
(involves: 129S2/SvPas * 129X1/SvJ * C57BL/6)
|
increased B cell derived lymphoma incidence
|
J:168974
|
increased T cell derived lymphoma incidence
|
J:168974
|
Rag2tm1.1Mss/Rag2tm1.1Mss Trp53tm1Tyj/Trp53tm1Tyj
(involves: 129S2/SvPas * 129S6/SvEvTac)
|
increased lymphoma incidence
|
J:170462
|
increased T cell derived lymphoma incidence
|
J:170462
|
Rag2tm1Fwa/Rag2+ Tg(LPV-TAg1135)11Tvd/0
(involves: 129S/SvEv * C57BL/6 * DBA/2)
|
increased T cell derived lymphoma incidence
|
J:47667
|
Rag2tm1Fwa/Rag2+ Trp53tm1Tyj/Trp53tm1Tyj
(involves: 129S/SvEv * 129S2/SvPas * C57BL/6J)
|
increased T cell derived lymphoma incidence
|
J:47667
|
Rag2tm1Fwa/Rag2tm1Fwa Stat1tm1Rds/Stat1tm1Rds
(involves: 129S/SvEv * 129S6/SvEvTac)
|
increased gastrointestinal tumor incidence
|
J:216040
|
increased mammary adenocarcinoma incidence
|
J:216040
|
Rag2tm1Fwa/Rag2tm1Fwa Tg(Cd4-NPM/ALK)N1Ingh/0
(involves: 129S/SvEv * C57BL/6 * Swiss Webster)
|
increased T cell derived lymphoma incidence
|
J:235890
|
increased thymus tumor incidence
|
J:235890
|
Rag2tm1Fwa/Rag2tm1Fwa Tg(Cd4-NPM/ALK)N1Ingh/0 Tg(TcraTcrb)1100Mjb/0
(involves: 129S/SvEv * C57BL/6 * Swiss Webster)
|
increased gastrointestinal stromal tumor incidence
|
J:235890
|
increased hepatocellular carcinoma incidence
|
J:235890
|
Rag2tm1Fwa/Rag2tm1Fwa Tg(LPV-TAg1135)11Tvd/0
(involves: 129S/SvEv * C57BL/6 * DBA/2)
|
increased T cell derived lymphoma incidence
|
J:47667
|
Rag2tm1Fwa/Rag2tm1Fwa Trp53tm1Tyj/Trp53tm1Tyj
(involves: 129S/SvEv * 129S2/SvPas * C57BL/6J)
|
increased T cell derived lymphoma incidence
|
J:47667
|
Rag2tm2.1Desi/Rag2tm2.1Desi Trp53tm1Tyj/Trp53tm1Tyj
(involves: 129S2/SvPas * 129X1/SvJ * C57BL/6)
|
increased T cell derived lymphoma incidence
|
J:168974
|
Ralgapa2tm1Hhor/Ralgapa2tm1Hhor
(C57BL/6J-Ralgapa2tm1Hhor)
|
increased urinary system tumor incidence
|
J:193368
|
Ranbp2tm1Jvd/Ranbp2tm1.1Jvd
(involves: 129/Sv * C57BL/6)
|
increased hepatocellular carcinoma incidence
|
J:137482
|
increased lung carcinoma incidence
|
J:137482
|
Ranbp2tm1Jvd/Ranbp2tm1Jvd
(involves: 129/Sv * C57BL/6)
|
increased hepatocellular carcinoma incidence
|
J:137482
|
increased lung carcinoma incidence
|
J:137482
|
Rarres1tm1.2Mhl/Rarres1+
(involves: 129S1/SvImJ * C57BL/6 * FVB/N * NIH Black Swiss)
|
increased follicular lymphoma incidence
|
J:324270
|
Rarres1tm1.2Mhl/Rarres1tm1.2Mhl
(involves: 129S1/SvImJ * C57BL/6 * FVB/N * NIH Black Swiss)
|
increased follicular lymphoma incidence
|
J:324270
|
Rarres1tm1d(KOMP)Wtsi/Rarres1+
(involves: C57BL/6N)
|
increased follicular lymphoma incidence
|
J:324270
|
Rasal2Gt(463C12)Cmhd/Rasal2Gt(463C12)Cmhd Tg(MMTVneu)202Mul/0
(involves: 129S1/Sv * 129X1/SvJ * C57BL/6NCrl * FVB/N)
|
increased mammary adenocarcinoma incidence
|
J:202603
|
Rasal2Gt(463C12)Cmhd/Rasal2Gt(463C12)Cmhd Trp53tm1Tyj/Trp53tm1Tyj
(involves: 129S * 129X1/SvJ * C57BL/6 * C57BL/6NCrl)
|
increased colon adenoma incidence
|
J:202603
|
increased hepatocellular carcinoma incidence
|
J:202603
|
increased liver tumor incidence
|
J:202603
|
increased lymphoma incidence
|
J:202603
|
increased mouth tumor incidence
|
J:202603
|
increased stomach tumor incidence
|
J:202603
|
Rassf1tm1.2Brd/Rassf1tm1.2Brd
(involves: 129S7/SvEvBrd * C57BL/6)
|
increased intestinal adenocarcinoma incidence
|
J:101369
|
increased lymphoma incidence
|
J:101369
|
Rassf1tm1Gpp/Rassf1+
(involves: 129S1/SvImJ * C57BL/6)
|
increased lung adenoma incidence
|
J:95683
|
Rassf1tm1Gpp/Rassf1tm1Gpp
(involves: 129S1/SvImJ * C57BL/6)
|
increased B cell derived lymphoma incidence
|
J:95683
|
increased lung adenoma incidence
|
J:95683
|
Rassf1tm1Gpp/Rassf1tm1Gpp
(involves: 129S1/SvImJ)
|
increased hepatocellular carcinoma incidence
|
J:231761
|
increased liver adenoma incidence
|
J:231761
|
increased liver tumor incidence
|
J:231761
|
Rassf1tm1Gpp/Rassf1tm1Gpp Sav1tm1.1Gpp/Sav1+
(involves: 129S1/Sv * 129S1/SvImJ)
|
increased hepatoblastoma incidence
|
J:231761
|
increased hepatocellular carcinoma incidence
|
J:231761
|
increased liver adenoma incidence
|
J:231761
|
increased liver tumor incidence
|
J:231761
|
Rassf5tm1Kina/Rassf5tm1Kina
(B6.Cg-Rassf5tm1Kina)
|
increased B cell derived lymphoma incidence
|
J:168749
|
increased hepatocellular carcinoma incidence
|
J:168749
|
increased lung adenocarcinoma incidence
|
J:168749
|
Rb1tm1.1Jyjw/Rb1tm1.1Jyjw Trp53tm1Tyj/Trp53tm1Tyj
(129S6.129-Trp53tm1Tyj Rb1tm1.1Jyjw)
|
increased colon adenoma incidence
|
J:102483
|
increased intestinal adenocarcinoma incidence
|
J:102483
|
increased lymphoma incidence
|
J:102483
|
increased testicular teratoma incidence
|
J:102483
|
Rb1tm1Brd/Rb1+
(involves: 129S7/SvEvBrd * C57BL/6)
|
increased brain tumor incidence
|
J:2516
|
increased pituitary adenoma incidence
|
J:17434
|
Rb1tm1Brd/Rb1+
(involves: 129P2/OlaHsd * 129S7/SvEvBrd * C57BL/6J)
|
increased pheochromocytoma incidence
|
J:79016
|
increased pituitary adenohypophysis tumor incidence
|
J:79016
|
increased pituitary melanotroph tumor incidence
|
J:79016
|
increased thyroid C-cell carcinoma incidence
|
J:79016
|
Rb1tm1Brn/Rb1+ Tg(Pomc-FLP)1aBrn/0
(involves: 129P2/OlaHsd * FVB/N)
|
increased pituitary adenoma incidence
|
J:48860
|
Rb1tm1Brn/Rb1tm1Brn Tg(Pomc-FLP)1aBrn/0
(involves: 129P2/OlaHsd * FVB/N)
|
increased pituitary adenoma incidence
|
J:48860
|
Rb1tm1Brn/Rb1tm1Brn X/Tg(Pomc-FLP)1bBrn
(involves: 129P2/OlaHsd * FVB/N)
|
increased pituitary adenoma incidence
|
J:48860
|
Rb1tm1Mlh/Rb1+
(either: 129P2/OlaHsd-Rb1tm1Mlh or (involves: 129P2/OlaHsd * BALB/c) or (involves: 129P2/OlaHsd * FVB/N))
|
increased pituitary melanotroph tumor incidence
|
J:20542
|
Rb1tm1Tyj/Rb1+
(involves: 129S2/SvPas * C57BL/6)
|
increased pituitary gland tumor incidence
|
J:81082,
J:2511
|
increased thyroid tumor incidence
|
J:81082
|
Rb1tm1Tyj/Rb1+
(involves: 129S2/SvPas * C57BL/6J)
|
increased lung tumor incidence
|
J:133299
|
increased pheochromocytoma incidence
|
J:133299
|
increased pituitary adenohypophysis tumor incidence
|
J:133299
|
increased pituitary melanotroph tumor incidence
|
J:133299
|
increased thyroid C-cell carcinoma incidence
|
J:133299
|
Rb1tm1Tyj/Rb1+
(involves: 129S2/SvPas * 129S6/SvEvTac * FVB/N)
|
increased pituitary gland tumor incidence
|
J:175625
|
increased thyroid tumor incidence
|
J:175625
|
Rb1tm1Tyj/Rb1+
(involves: 129S2/SvPas)
|
increased pituitary gland tumor incidence
|
J:215358
|
Rb1tm1Tyj/Rb1+ Rbl1tm1Tyj/Rbl1+
(involves: 129S2/SvPas * C57BL/6)
|
increased pituitary gland tumor incidence
|
J:34058
|
Rb1tm1Tyj/Rb1+ Rbl1tm1Tyj/Rbl1tm1Tyj
(involves: 129S2/SvPas * C57BL/6)
|
increased pituitary gland tumor incidence
|
J:34058
|
Rb1tm1Tyj/Rb1+ Smarca4tm1Mag/Smarca4+
(involves: 129S/Sv * 129S2/SvPas * C57BL/6J * CD-1)
|
increased pituitary gland tumor incidence
|
J:132091
|
Rb1tm1Tyj/Rb1+ Tg(S100b-v-erbB)4496Waw/0
(involves: 129S2/SvPas * C57BL/6J * DBA/2J * FVB/N)
|
increased glioma incidence
|
J:82649
|
Rb1tm1Tyj/Rb1+ Tg(Th-MYCN)41Waw/0
(involves: 129S2/SvPas * BALB/c * C57BL/6J)
|
increased neuroblastoma incidence
|
J:41126
|
Rb1tm1Tyj/Rb1+ Trim27Gt(XP0484)Wtsi/Trim27Gt(XP0484)Wtsi
(involves: 129P2/OlaHsd * C57BL/6)
|
increased pituitary gland tumor incidence
|
J:189317
|
increased thyroid tumor incidence
|
J:189317
|
Rb1tm1Tyj/Rb1+ Trp53tm1Tyj/Trp53+
(involves: 129S2/SvPas * C57BL/6)
|
increased leiomyosarcoma incidence
|
J:19542
|
increased pancreatic islet cell carcinoma incidence
|
J:19542
|
increased pituitary melanotroph tumor incidence
|
J:19542
|
increased thyroid tumor incidence
|
J:19542
|
Rb1tm1Tyj/Rb1tm2Brn Rbl1tm1Tyj/Rbl1+ Tg(Chx10-EGFP/cre,-ALPP)2Clc/0
(involves: 129P2/OlaHsd * 129S2/SvPas * C57BL/6 * SJL)
|
increased retinoblastoma incidence
|
J:120315
|
Rb1tm1Tyj/Rb1tm2Brn Rbl1tm1Tyj/Rbl1+ Trp53tm1Brn/Trp53tm1Brn Tg(Chx10-EGFP/cre,-ALPP)2Clc/0
(involves: 129P2/OlaHsd * 129S2/SvPas * C57BL/6 * SJL)
|
increased retinoblastoma incidence
|
J:120315
|
Rb1tm1Tyj/Rb1tm2Brn Rbl1tm1Tyj/Rbl1tm1Tyj Trp53tm1Brn/Trp53tm1Brn Tg(Chx10-EGFP/cre,-ALPP)2Clc/0
(involves: 129P2/OlaHsd * 129S2/SvPas * C57BL/6 * SJL)
|
increased retinoblastoma incidence
|
J:120315
|
Rb1tm1Tyj/Rb1tm2Brn Rbl1tm1Tyj/Rbl1tm1Tyj Trp53tm1Brn/Trp53tm1Tyj Tg(Chx10-EGFP/cre,-ALPP)2Clc/0
(involves: 129P2/OlaHsd * 129S2/SvPas * C57BL/6 * SJL)
|
increased retinoblastoma incidence
|
J:120315
|
Rb1tm1Tyj/Rb1tm2Tyj
(chimera involves: 129S2/SvPas * C57BL/6)
|
increased pituitary adenoma incidence
|
J:59268
|
Rb1tm2Brn/Rb1+ Trp53tm1Brn/Trp53tm1Brn
(involves: 129P2/OlaHsd)
|
increased lung adenocarcinoma incidence
|
J:86077
|
increased lung small cell carcinoma incidence
|
J:86077
|
Rb1tm2Brn/Rb1+ Trp53tm1Brn/Trp53tm1Brn Tg(Col1a1-cre)1Kry/0
(involves: 129 * 129P2/OlaHsd * FVB/N)
|
increased osteosarcoma incidence
|
J:234128
|
Rb1tm2Brn/Rb1tm2Brn Rbl1tm1Tyj/Rbl1tm1Tyj Rbl2tm2Tyj/Rbl2tm2Tyj
(involves: 129 * 129S2/SvPas * 129S4/SvJae)
|
increased urinary bladder carcinoma incidence
|
J:217195
|
Rb1tm2Brn/Rb1tm2Brn Tg(Gfap-cre)2Brn/0
(involves: 129 * FVB/N)
|
increased pituitary gland tumor incidence
|
J:187257
|
Rb1tm2Brn/Rb1tm2Brn Tg(Rbp3-cre)1Brn/0
(involves: 129 * FVB/N)
|
increased pituitary adenohypophysis tumor incidence
|
J:77982
|
increased pituitary melanotroph tumor incidence
|
J:77982
|
Rb1tm2Brn/Rb1tm2Brn Trp53tm1Brd/Trp53tm1Brd Tg(Gfap-cre)2Brn/0
(involves: 129 * 129S7/SvEvBrd * FVB/N)
|
increased medulloblastoma incidence
|
J:61961
|
Rb1tm2Brn/Rb1tm2Brn Trp53tm1Brn/Trp53+
(involves: 129P2/OlaHsd)
|
increased lung adenocarcinoma incidence
|
J:86077,
J:157319
|
increased lung small cell carcinoma incidence
|
J:86077,
J:157319
|
increased lung tumor incidence
|
J:157319
|
increased thyroid carcinoma incidence
|
J:86077,
J:157319
|
Rb1tm2Brn/Rb1tm2Brn Trp53tm1Brn/Trp53tm1Brn
(involves: 129P2/OlaHsd)
|
increased lung carcinoma incidence
|
J:86077
|
increased lung small cell carcinoma incidence
|
J:86077,
J:157319
|
increased lung tumor incidence
|
J:157319
|
increased ovarian carcinoma incidence
|
J:84345
|
increased ovary tumor incidence
|
J:84345
|
increased thyroid carcinoma incidence
|
J:86077,
J:157319
|
Rb1tm2Brn/Rb1tm2Brn Trp53tm1Brn/Trp53tm1Brn Tg(BGLAP-cre)1Clem/0
(involves: 129 * 129P2/OlaHsd * FVB/NJ)
|
increased osteosarcoma incidence
|
J:326989
|
Rb1tm2Brn/Rb1tm2Brn Trp53tm1Brn/Trp53tm1Brn Tg(Col1a1-cre)1Kry/0
(involves: 129 * 129P2/OlaHsd * FVB/N)
|
increased osteosarcoma incidence
|
J:234128
|
Rb1tm2Brn/Rb1tm2Brn Trp53tm1Brn/Trp53tm1Brn Tg(Gfap-cre)2Brn/0
(involves: 129P2/OlaHsd * FVB/N)
|
increased medulloblastoma incidence
|
J:61961
|
Rb1tm2Brn/Rb1tm2Brn Trp53tm1Brn/Trp53tm1Brn Tg(Gfap-cre)2Brn/0
(involves: 129 * 129P2/OlaHsd * FVB/N)
|
increased medulloblastoma incidence
|
J:187257
|
increased pituitary gland tumor incidence
|
J:187257
|
Rb1tm2Brn/Rb1tm2Brn Trp53tm1Brn/Trp53tm1Brn Tg(MMTV-cre)105Ayn/0
(FVB.Cg-Trp53tm1Brn Rb1tm2Brn Tg(MMTV-cre)105Ayn)
|
increased lung tumor incidence
|
J:165292
|
increased mammary gland tumor incidence
|
J:165292
|
Rb1tm2Brn/Rb1tm2Brn Trp53tm1Brn/Trp53tm1Brn Tg(Ren-cre)#Kwg/0
(involves: 129 * 129P2/OlaHsd)
|
increased glucagonoma incidence
|
J:216559
|
increased pancreatic islet cell carcinoma incidence
|
J:216559
|
Rb1tm2Brn/Rb1tm2Brn Trp53tm1Lejo/Trp53tm1Lejo
(involves: 129)
|
increased lung small cell carcinoma incidence
|
J:187012
|
Rb1tm2Mlh/Rb1+
(either: 129P2/OlaHsd-Rb1tm2Mlh or (involves: 129P2/OlaHsd * BALB/c) or (involves: 129P2/OlaHsd * FVB/N))
|
increased pituitary melanotroph tumor incidence
|
J:20542
|
Rb1tm3Fad/Rb1tm3Fad
(involves: 129S1/Sv * 129X1/SvJ)
|
increased lymphoma incidence
|
J:249124
|
Rb1tm3Tyj/Rb1+ Trp53tm1Brn/Trp53+ Tg(Sp7-tTA,tetO-EGFP/cre)1Amc/0
(involves: 129P2/OlaHsd * 129S4/SvJae * C57BL/6J * CD-1 * FVB/N)
|
increased osteosarcoma incidence
|
J:136693
|
Rb1tm3Tyj/Rb1+ Trp53tm1Brn/Trp53tm1Brn Tg(Sp7-tTA,tetO-EGFP/cre)1Amc/0
(involves: 129P2/OlaHsd * 129S4/SvJae * C57BL/6J * CD-1 * FVB/N)
|
increased osteosarcoma incidence
|
J:136693
|
Rb1tm3Tyj/Rb1+ Trp53tm1Brn/Trp53tm1Brn Tg(Sp7-tTA,tetO-EGFP/cre)1Amc/0
(involves: 129 * C57BL/6 * CD-1)
|
increased osteosarcoma incidence
|
J:318885
|
Rb1tm3Tyj/Rb1tm3Tyj Rbl1tm1Tyj/Rbl1tm1Tyj Rbl2tm2.1Tyj/Rbl2tm2.1Tyj
(involves: 129S2/SvPas * 129S4/SvJae * C57BL/6)
|
increased hepatocellular carcinoma incidence
|
J:177573
|
Rb1tm3Tyj/Rb1tm3Tyj Rbl1tm1Tyj/Rbl1tm1Tyj Tg(Pax6-cre,GFP)2Pgr/0
(involves: 129S2/SvPas * 129S4/SvJae * 129X1/SvJ * C57BL/6 * FVB/N)
|
increased retinoblastoma incidence
|
J:119919
|
Rb1tm3Tyj/Rb1tm3Tyj Rbl2tm1Tyj/Rbl2tm1Tyj Tg(Nes-cre)1Atp/0
(involves: 129S2/SvPas * 129S4/SvJae * FVB/N)
|
increased retinoblastoma incidence
|
J:91406
|
Rb1tm3Tyj/Rb1tm3Tyj Rbl2tm2.1Tyj/Rbl2tm2.1Tyj Tg(Pax6-cre,GFP)2Pgr/0
(involves: 129S4/SvJae * 129X1/SvJ * C57BL/6 * FVB/N)
|
increased retinoblastoma incidence
|
J:119919
|
Rb1tm3Tyj/Rb1tm3Tyj Rbl2tm2Tyj/Rbl2tm2Tyj Trp53tm1Brn/Trp53tm1Brn
(involves: 129P2/OlaHsd * 129S4/SvJae)
|
increased lung small cell carcinoma incidence
|
J:160148
|
increased lung tumor incidence
|
J:160148
|
Rb1tm3Tyj/Rb1tm3Tyj Tg(Nes-cre)1Atp/0
(involves: 129S4/SvJae * FVB/N)
|
increased pituitary gland tumor incidence
|
J:91406
|
Rb1tm3Tyj/Rb1tm3Tyj Tg(Sp7-tTA,tetO-EGFP/cre)1Amc/0 Tg(tetO-RNAi:Trp53)ASlowe/0
(involves: 129S4/SvJae * C57BL/6 * CD-1)
|
increased osteosarcoma incidence
|
J:199542
|
Rb1tm3Tyj/Rb1tm3Tyj Tg(tetO-MYC)36aBop/0 Tg(Cebpb-tTA)5Bjd/0
(involves: FVB/N * NMRI)
|
increased hepatocellular carcinoma incidence
|
J:172430
|
increased liver tumor incidence
|
J:172430
|
Rb1tm3Tyj/Rb1tm3Tyj Trp53tm1Brn/Trp53+ Tg(Sp7-tTA,tetO-EGFP/cre)1Amc/0
(involves: 129P2/OlaHsd * 129S4/SvJae * C57BL/6J * CD-1 * FVB/N)
|
increased osteosarcoma incidence
|
J:136693
|
Rb1tm3Tyj/Rb1tm3Tyj Trp53tm1Brn/Trp53tm1Brn
(involves: 129P2/OlaHsd * 129S4/SvJae)
|
increased lung small cell carcinoma incidence
|
J:160148
|
increased lung tumor incidence
|
J:160148
|
Rb1tm3Tyj/Rb1tm3Tyj Trp53tm1Brn/Trp53tm1Brn Tg(Sp7-tTA,tetO-EGFP/cre)1Amc/0
(involves: 129P2/OlaHsd * 129S4/SvJae * C57BL/6J * CD-1 * FVB/N)
|
increased osteosarcoma incidence
|
J:136693,
J:318035
|
Rb1tm3Tyj/Rb1tm3Tyj Trp53tm1Brn/Trp53tm1Brn Tg(Sp7-tTA,tetO-EGFP/cre)1Amc/0
(involves: 129P2/OlaHsd * 129S4/SvJae * C57BL/6 * CD-1)
|
increased osteosarcoma incidence
|
J:199542
|
Rb1tm3Tyj/Rb1tm3Tyj Trp53tm1Brn/Trp53tm1Brn Tg(Sp7-tTA,tetO-EGFP/cre)1Amc/0
(involves: 129P2/OlaHsd * 129S4/SvJae * CD-1)
|
increased osteosarcoma incidence
|
J:329449
|
Rb1tm3Tyj/Rb1tm3Tyj Trp53tm1Tyj/Trp53tm1Tyj Tg(Nes-cre)1Atp/0
(involves: 129S2/SvPas * 129S4/SvJae * FVB/N)
|
increased pituitary gland tumor incidence
|
J:91406
|
Rbbp8tm1Whl/Rbbp8+
(Not Specified)
|
increased lymphoma incidence
|
J:97648
|
Rbm15tm1.1(MAL)Dgg/Rbm15tm1.1(MAL)Dgg
(B6.129-Rbm15tm1.1(MAL)Dgg)
|
increased leukemia incidence
|
J:149622
|
Rbm38tm1.1Xch/Rbm38tm1.1Xch
(involves: C57BL/6 * FVB/N)
|
increased hepatoma incidence
|
J:216929
|
increased lymphoma incidence
|
J:216929
|
Rbm38tm1.1Xch/Rbm38tm1.1Xch Trp53tm1Tyj/Trp53tm1Tyj
(involves: 129S2/SvPas * C57BL/6 * FVB/N)
|
increased lymphoma incidence
|
J:216929
|
Rc3h1san/Rc3h1+
(involves: C57BL/6JSfdAnu)
|
increased T cell derived lymphoma incidence
|
J:189087
|
Rcbtb2tm1.1Xyw/Rcbtb2+
(involves: C57BL/6 * CBA)
|
increased gastrointestinal tumor incidence
|
J:282928
|
increased histiocytic sarcoma incidence
|
J:282928
|
increased liver tumor incidence
|
J:282928
|
increased lymphoma incidence
|
J:282928
|
Rcbtb2tm1.1Xyw/Rcbtb2tm1.1Xyw
(involves: C57BL/6 * CBA)
|
increased gastrointestinal tumor incidence
|
J:282928
|
increased histiocytic sarcoma incidence
|
J:282928
|
increased liver tumor incidence
|
J:282928
|
increased lymphoma incidence
|
J:282928
|
Recql4tm1Glu/Recql4tm1Glu
(involves: 129S7/SvEvBrd * C57BL/6J)
|
increased lymphoma incidence
|
J:97101
|
Rettm1Giro/Ret+
(129.129P2-Rettm1Giro)
|
increased thyroid adenoma incidence
|
J:141658
|
Rettm2.1Cos/? Tg(Th-MYCN)41Waw/0
(involves: 129S1/Sv * BALB/c * C57BL/6J)
|
increased neuroblastoma incidence
|
J:261033
|
Rettm2.1Cos/Rettm2.1Cos
(involves: 129S1/Sv * C57BL/6J * FVB/N)
|
increased ganglioneuroma incidence
|
J:60659
|
increased pheochromocytoma incidence
|
J:60659
|
Rettm2.1Cos/Rettm2.1Cos
(involves: 129S1/Sv * C57BL/6J)
|
increased pheochromocytoma incidence
|
J:148708
|
Rev3ltm1Rwd/Rev3ltm2.1Rwd Tg(MMTV-cre)1Mam/0
(involves: 129P2/OlaHsd * C57BL/6 * FVB)
|
increased mammary gland tumor incidence
|
J:158922
|
Rev3ltm1Rwd/Rev3ltm2.1Rwd Trp53tm1Brd/Trp53+ Tg(MMTV-cre)1Mam/0
(involves: 129P2/OlaHsd * 129S7/SvEvBrd * C57BL/6 * FVB/N)
|
increased mammary gland tumor incidence
|
J:158922
|
increased osteosarcoma incidence
|
J:158922
|
Rev3ltm1Rwd/Rev3ltm2.1Rwd Trp53tm1Brd/Trp53tm1Brd Tg(MMTV-cre)1Mam/0
(involves: 129P2/OlaHsd * 129S7/SvEvBrd * C57BL/6 * FVB/N)
|
increased T cell derived lymphoma incidence
|
J:158922
|
Rgs5tm1.1Rgan/Rgs5tm1.1Rgan Tg(RIP1-Tag)5Dh/0
(C3.Cg-Rgs5tm1.1Rgan Tg(RIP1-Tag)5Dh)
|
increased insulinoma incidence
|
J:136259
|
Rgsc142/Rgsc142+
(involves: C57BL/6JJcl * DBA/2JJcl)
|
increased leukemia incidence
|
J:133634
|
increased T cell derived lymphoma incidence
|
J:133634
|
Rgsc1033/Rgsc1033+
(involves: C57BL/6JJcl * DBA/2JJcl)
|
increased pituitary adenoma incidence
|
J:133634
|
increased thyroid carcinoma incidence
|
J:133634
|
Rgsc1050/Rgsc1050+
(involves: C57BL/6JJcl * DBA/2JJcl)
|
increased renal carcinoma incidence
|
J:133634
|
Rgsc1324/Rgsc1324+
(involves: C57BL/6JJcl * DBA/2JJcl)
|
increased pheochromocytoma incidence
|
J:133634
|
Rgsc1328/Rgsc1328+
(involves: C57BL/6JJcl * DBA/2JJcl)
|
increased pheochromocytoma incidence
|
J:133634
|
Rgv1C57BL/6/Rgv1C57BL/6
(involves: C3Hf/Bi * C57BL/6)
|
increased leukemia incidence
|
J:5011
|
Rhoctm1Mak/Rhoctm1Mak Tg(MMTV-PyVT)634Mul/0
(involves: 129P2/OlaHsd * FVB/N)
|
increased mammary adenocarcinoma incidence
|
J:100482
|
Rigitm1Zgwg/Rigitm1Zgwg
(involves: 129S1/Sv)
|
increased chronic myelocytic leukemia incidence
|
J:139016
|
Ril1A/J/Ril1A/J
(involves: A/J * C57BL/10ScSn)
|
increased leukemia incidence
|
J:6610
|
Ril1A/J/Ril1C57BL/10ScSn
(involves: A/J * C57BL/10ScSn)
|
increased leukemia incidence
|
J:6610
|
Ril2A/J/Ril2C57BL/10ScSn
(involves: A/J * C57BL/10ScSn)
|
increased leukemia incidence
|
J:6610
|
Ril2C57BL/10ScSn/Ril2C57BL/10ScSn
(involves: A/J * C57BL/10ScSn)
|
increased leukemia incidence
|
J:6610
|
Ril3A/J/Ril3C57BL/10ScSn
(involves: A/J * C57BL/10ScSn)
|
increased leukemia incidence
|
J:6610
|
Ril3C57BL/10ScSn/Ril3C57BL/10ScSn
(involves: A/J * C57BL/10ScSn)
|
increased leukemia incidence
|
J:6610
|
Ril4BALB/c/Ril4BALB/c
(B6.C-H30c/(HW105)ByJ)
|
increased leukemia incidence
|
J:7027
|
Rint1tm1Whl/Rint1+
(Not Specified)
|
increased hepatocellular carcinoma incidence
|
J:122805
|
increased keratoacanthoma incidence
|
J:122805
|
increased lung adenocarcinoma incidence
|
J:122805
|
increased lymphoma incidence
|
J:122805
|
increased mammary adenocarcinoma incidence
|
J:122805
|
increased mammary gland tumor incidence
|
J:122805
|
increased ovary tumor incidence
|
J:122805
|
increased pituitary adenoma incidence
|
J:122805
|
increased skin squamous cell carcinoma incidence
|
J:122805
|
increased uterus leiomyoma incidence
|
J:122805
|
Rnf8Gt(AS0574)Wtsi/Rnf8Gt(AS0574)Wtsi
(involves: 129P2/OlaHsd * C57BL/6)
|
increased lymphoma incidence
|
J:161240
|
increased mammary adenocarcinoma incidence
|
J:161240
|
increased skin tumor incidence
|
J:161240
|
increased T cell derived lymphoma incidence
|
J:161240
|
Rnf8Gt(RRR260)Byg/Rnf8Gt(RRR260)Byg
(involves: 129P2/OlaHsd * C57BL/6)
|
increased lymphoma incidence
|
J:161240
|
increased mammary adenocarcinoma incidence
|
J:161240
|
increased skin tumor incidence
|
J:161240
|
increased T cell derived lymphoma incidence
|
J:161240
|
Rnf20Gt(RRJ249)Byg/Rnf20+
(involves: 129P2/OlaHsd)
|
increased colon adenocarcinoma incidence
|
J:268221
|
increased large intestine adenocarcinoma incidence
|
J:268221
|
Rnf43tm1Cle/Rnf43tm1Cle Znrf3tm1Cle/Znrf3tm1Cle Lgr5tm1(cre/ERT2)Cle/Lgr5+
(involves: 129P2/OlaHsd)
|
increased intestinal adenoma incidence
|
J:186765
|
Rnf43tm1Cle/Rnf43tm1Cle Znrf3tm1Cle/Znrf3tm1Cle Tg(Vil1-cre/ERT2)23Syr/0
(involves: C57BL/6 * DBA/2)
|
increased intestinal adenoma incidence
|
J:186765
|
Rnf168Gt(156B6)Cmhd/Rnf168Gt(156B6)Cmhd Trp53tm1Brd/Trp53tm1Brd
(involves: 129S1/Sv * 129S7/SvEvBrd * 129X1/SvJ * C57BL/6)
|
increased B cell derived lymphoma incidence
|
J:198260
|
increased thymoma incidence
|
J:198260
|
Rnf168Gt(405F11)Cmhd/Rnf168Gt(405F11)Cmhd Trp53tm1Brd/Trp53tm1Brd
(involves: 129S1/Sv * 129S7/SvEvBrd * 129X1/SvJ * C57BL/6)
|
increased B cell derived lymphoma incidence
|
J:198260
|
increased thymoma incidence
|
J:198260
|
Robo1tm1Phr/Robo1+
(involves: 129P2/OlaHsd * C57BL/6)
|
increased lung adenocarcinoma incidence
|
J:93666
|
increased lymphoma incidence
|
J:93666
|
Rpa1tm1Wed/Rpa1+
(involves: 129/Sv * C57BL/6J * SJL)
|
increased lymphoma incidence
|
J:99303
|
Rps6kb2tm1Gtho/Rps6kb2tm1Gtho Tg(Ins2-Akt1*)3Mbb/0
(B6.Cg-Rps6kb2tm1Gtho Tg(Ins2-Akt1*)3Mbb)
|
increased insulinoma incidence
|
J:144599
|
Rps27lGt(IST11658B7)Tigm/Rps27lGt(IST11658B7)Tigm Trp53tm1Tyj/Trp53+
(involves: 129S2/SvPas * C57BL/6N)
|
increased B cell derived lymphoma incidence
|
J:223276
|
increased T cell derived lymphoma incidence
|
J:223276
|
Rps27lGt(IST11658B7)Tigm/Rps27lGt(IST11658B7)Tigm Trp53tm1Tyj/Trp53tm1Tyj
(involves: 129S2/SvPas * C57BL/6N)
|
increased lymphoma incidence
|
J:223276
|
Rr28tm1Tilg/Rr28+ Tg(CRP-TAg)60-3Urt/0
(involves: 129S1/Sv * C57BL/6 * SJL)
|
increased liver tumor incidence
|
J:138826
|
Rr149356tm1Che/Rr149356tm1Che Tcrdtm1Mom/Tcrdtm1Mom Trp53tm1Tyj/Trp53tm1Tyj
(involves: 129P2/OlaHsd * 129S2/SvPas * 129S4/SvJae * C57BL/6)
|
increased T cell derived lymphoma incidence
|
J:106246
|
Rr149356tm1Che/Rr149356tm1Che Trp53tm1Tyj/Trp53tm1Tyj
(involves: 129S2/SvPas * 129S4/SvJae * C57BL/6)
|
increased T cell derived lymphoma incidence
|
J:106246
|
Rtel1tm2.1Hdin/Rtel1tm2.1Hdin Trp53tm1Tyj/Trp53tm1Tyj
(involves: 129S1/Sv * 129S2/SvPas * 129X1/SvJ * C57BL/6)
|
increased lymphoma incidence
|
J:202812
|
increased medulloblastoma incidence
|
J:202812
|
Runx1tm1(RUNX1)Gcg/Runx1tm1(RUNX1)Gcg Tg(Mx1-cre)1Cgn/0
(involves: 129S1/Sv * C57BL/6 * CBA)
|
increased T cell derived lymphoma incidence
|
J:106800
|
Runx1tm1Spe/Runx1+
(either: (involves: 129S4/SvJae * BALB/c * C57BL/6 * CBA/Ca) or (involves: 129S4/SvJae * C57BL/6 * CBA/Ca))
|
increased T cell derived lymphoma incidence
|
J:80829
|
Runx1tm2Buch/Runx1tm2Buch Tg(Mx1-cre)1Cgn/?
(involves: 129P2/OlaHsd * C57BL/6 * CBA)
|
increased lymphoma incidence
|
J:105709
|
increased T cell derived lymphoma incidence
|
J:105709
|
Runx1tm3Dow/Runx1+ Tg(Mx1-cre)1Cgn/0
(involves: C57BL/6 * CBA)
|
increased acute promyelocytic leukemia incidence
|
J:77129
|
increased T cell derived lymphoma incidence
|
J:77129
|
Rv2BALB/cJ/Rv2BALB/cJ
(B6.C-H7b/By)
|
increased leukemia incidence
|
J:7613
|
Rv2BALB/cJ/Rv2BALB/cJ
(B10.C-H7b/(47N)SnJ)
|
increased leukemia incidence
|
J:7613
|
Rv3C57BL/6J/Rv3C57BL/6J
(involves: C57BL/6J * CBA/Lac)
|
increased leukemia incidence
|
J:7613
|
Rv3C57BL/6J/Rv3CBA/Lac
(involves: C57BL/6J * CBA/Lac)
|
increased leukemia incidence
|
J:7613
|
Rv3CBA/Lac/Rv3CBA/Lac
(involves: C57BL/6J * CBA/Lac)
|
increased leukemia incidence
|
J:7613
|
Rvil1CE/J/Rvil1CE/J
(B10.CE-H3bb/(30NX)SnDcr)
|
increased leukemia incidence
|
J:7027
|
Rxratm1Krc/Rxra+ Tg(Pbsn-cre)4Prb/0
(involves: 129S4/SvJae * C57BL/6 * DBA/2)
|
increased prostate intraepithelial neoplasia incidence
|
J:78553
|
Rxratm1Krc/Rxratm1Krc Tg(Pbsn-cre)4Prb/0
(involves: 129S4/SvJae * C57BL/6 * DBA/2)
|
increased prostate intraepithelial neoplasia incidence
|
J:78553
|
Ryr2tm1(CAG-KRAS*G12V,-lacZ)Nobs/Ryr2tm1(CAG-KRAS*G12V,-lacZ)Nobs Trp53tm1Sia/Trp53+
(involves: 129X1/SvJ * C57BL/6 * CBA)
|
increased rhabdomyosarcoma incidence
|
J:117828
|
Ryr2tm1(CAG-KRAS*G12V,-lacZ)Nobs/Ryr2tm1(CAG-KRAS*G12V,-lacZ)Nobs Trp53tm1Sia/Trp53tm1Sia
(involves: 129X1/SvJ * C57BL/6 * CBA)
|
increased rhabdomyosarcoma incidence
|
J:117828
|
S1pr2tm1Ajml/S1pr2tm1Ajml
(involves: 129S5/SvEvBrd * C57BL/6)
|
increased B cell derived lymphoma incidence
|
J:154439
|
increased lung tumor incidence
|
J:154439
|
S1pr2tm1Ajml/S1pr2tm1Ajml
(129S5/SvEvBrd-S1pr2tm1Ajml)
|
increased B cell derived lymphoma incidence
|
J:154439
|
S100a4tm1Amba/S100a4tm1Amba
(involves: 129S1/Sv * 129X1/SvJ * NMRI)
|
increased hepatocellular carcinoma incidence
|
J:89563
|
increased lung carcinoma incidence
|
J:89563
|
increased lymphoma incidence
|
J:89563
|
increased mammary adenocarcinoma incidence
|
J:89563
|
Samd9ltm1Homy/Samd9l+
(involves: 129P2/OlaHsd)
|
increased leukemia incidence
|
J:180923,
J:202604
|
Samd9ltm1Homy/Samd9ltm1Homy
(involves: 129P2/OlaHsd)
|
increased leukemia incidence
|
J:180923,
J:202604
|
Samd9ltm1Homy/Samd9ltm1Homy
(B6N.129P2-Samd9ltm1Homy)
|
increased leukemia incidence
|
J:225110
|
Sav1tm1.1Gpp/Sav1+
(involves: 129S1/Sv)
|
increased hepatocellular carcinoma incidence
|
J:231761
|
increased liver adenoma incidence
|
J:231761
|
increased liver tumor incidence
|
J:231761
|
Sav1tm1.1Rjo/Sav1tm1.1Rjo Speer6-ps1Tg(Alb-cre)21Mgn/Speer6-ps1+
(involves: 129S6/SvEvTac * C57BL/6 * CD-1 * DBA * SJL)
|
increased hepatocellular carcinoma incidence
|
J:156531
|
Sav1tm1.1Rjo/Sav1tm1.1Rjo Tg(CAG-cre/Esr1*)5Amc/0
(involves: 129S6/SvEvTac * C57BL/6 * CBA * CD-1 * SJL)
|
increased liver tumor incidence
|
J:156531
|
Sav1tm1.1Rjo/Sav1tm1.1Rjo Tg(MMTV-cre)4Mam/0
(involves: 129S6/SvEvTac * C57BL/6 * CD-1 * FVB/N * SJL)
|
increased liver tumor incidence
|
J:156531
|
Sav1tm1Dlim/Sav1+
(involves: 129S1/Sv * 129X1/SvJ)
|
increased hepatoma incidence
|
J:160325
|
increased liver tumor incidence
|
J:160325
|
increased lymphoma incidence
|
J:160325
|
increased osteosarcoma incidence
|
J:160325
|
increased ovary tumor incidence
|
J:160325
|
Sav1tm1Dlim/Sav1tm1Dlim
(involves: 129S1/Sv * 129X1/SvJ)
|
increased liver tumor incidence
|
J:160325
|
Sav1tm2.1Dlim/Sav1tm2.1Dlim Speer6-ps1Tg(Alb-cre)21Mgn/Speer6-ps1+
(involves: C57BL/6 * DBA)
|
increased hepatocellular carcinoma incidence
|
J:238319
|
increased hepatoma incidence
|
J:160325
|
Scc4BALB/cHeA/? Scc5STS/A/Scc5STS/A
(involves: BALB/cHeA * STS/A)
|
increased colon adenoma incidence
|
J:36996
|
Scc4STS/A/Scc4STS/A Scc5BALB/cHeA/?
(involves: BALB/cHeA * STS/A)
|
increased colon adenoma incidence
|
J:36996
|
Scc6STS/A/?
(involves: BALB/cHeA * STS/A)
|
increased colon adenoma incidence
|
J:57235
|
Scc7STS/A/? Scc8STS/A/?
(involves: BALB/cHeA * STS/A)
|
increased colon adenoma incidence
|
J:57235
|
Scc8STS/A/?
(involves: BALB/cHeA * STS/A)
|
increased colon adenoma incidence
|
J:57235
|
Scc9STS/A/?
(involves: BALB/cHeA * CcS-5)
|
increased colon adenoma incidence
|
J:57235
|
Scribtm1.1Phum/Scribtm1.1Phum Tg(Pbsn-cre)20Fwan/0
(involves: FVB/NCrl)
|
increased prostate intraepithelial neoplasia incidence
|
J:178461
|
Scribtm1.2Phum/Scrib+
(involves: FVB/N)
|
increased lung adenocarcinoma incidence
|
J:178461
|
increased lung adenoma incidence
|
J:216266
|
increased lung non-small cell carcinoma incidence
|
J:216266
|
seb/seb
(Him:OF1)
|
increased skin tumor incidence
|
J:20987
|
Sf1Gt(XD130)Byg/Sf1+
(involves: 129P2/OlaHsd * 129S1/SvImJ * MOLF/Ei)
|
increased testis tumor incidence
|
J:164224
|
SfnEr/Sfn+
(involves: 129/Sv * C57BL/6)
|
increased skin papilloma incidence
|
J:12025
|
Sgo1Gt(neo-btk)1Dai/Sgo1+
(involves: 129S4/SvJae * C57BL/6)
|
increased colon tumor incidence
|
J:204809
|
Shc1tm5Paw/Shc1+ Tg(MMTV-PyVT)634Mul/0
(involves: 129S1/Sv * 129X1/SvJ * FVB/N)
|
increased mammary gland tumor incidence
|
J:133325
|
Shc1tm5Paw/Shc1tm5Paw Tg(MMTV-PyVT)634Mul/0
(involves: 129S1/Sv * 129X1/SvJ * FVB/N)
|
increased mammary gland tumor incidence
|
J:133325
|
Shc1tm6Paw/Shc1+ Tg(MMTV-PyVT)634Mul/0
(involves: 129S1/Sv * 129X1/SvJ * FVB/N)
|
increased mammary gland tumor incidence
|
J:133325
|
Shc1tm6Paw/Shc1tm6Paw Tg(MMTV-PyVT)634Mul/0
(involves: 129S1/Sv * 129X1/SvJ * FVB/N)
|
increased mammary gland tumor incidence
|
J:133325
|
Shc1tm7Paw/Shc1+ Tg(MMTV-PyVT)634Mul/0
(involves: 129S1/Sv * 129X1/SvJ * FVB/N)
|
increased mammary gland tumor incidence
|
J:133325
|
Sipa1tm1Nm/Sipa1+
(involves: 129P2/OlaHsd * C57BL/6)
|
increased chronic myelocytic leukemia incidence
|
J:97239
|
Sipa1tm1Nm/Sipa1tm1Nm
(involves: 129P2/OlaHsd * C57BL/6)
|
increased chronic myelocytic leukemia incidence
|
J:97239
|
Sirt1tm1.1Cxd/Sirt1+ Trp53tm1Brd/Trp53+
(either: (involves: 129S6/SvEvTac * 129S7/SvEvBrd * Black Swiss * FVB/N) or (involves: 129S6/SvEvTac * 129S7/SvEvBrd * C57BL/6 * FVB/N))
|
increased lymphoma incidence
|
J:140089
|
Sirt2tm1.1Cxd/Sirt2tm1.1Cxd
(either: (involves: C57BL/6 * FVB/N) or (involves: FVB/N * NIH Black Swiss))
|
increased B cell derived lymphoma incidence
|
J:177486
|
increased gastrointestinal tumor incidence
|
J:177486
|
increased hepatocellular carcinoma incidence
|
J:177486
|
increased lung tumor incidence
|
J:177486
|
increased mammary gland tumor incidence
|
J:177486
|
increased pancreas tumor incidence
|
J:177486
|
increased prostate gland tumor incidence
|
J:177486
|
increased stomach tumor incidence
|
J:177486
|
Skitm1Cco/Ski+
(involves: 129P2/OlaHsd * C57BL/6)
|
increased lymphoma incidence
|
J:73349
|
Skiltm1Sis/Skil+
(involves: C57BL/6 * CBA)
|
increased B cell derived lymphoma incidence
|
J:62174
|
increased T cell derived lymphoma incidence
|
J:62174
|
Skts1M. spretus/?
(involves: M. spretus * NIH)
|
increased skin tumor incidence
|
J:27733
|
Skts2M. spretus/?
(involves: M. spretus * NIH)
|
increased skin tumor incidence
|
J:27733
|
Skts4SENCARA/Pt/?
(involves: BALB/cAnPt * SENCARA/Pt)
|
increased skin tumor incidence
|
J:48305
|
Skts5NIH/Ola/?
(involves: M. spretus * NIH/Ola)
|
increased skin tumor incidence
|
J:59049
|
Skts6NIH/Ola/?
(involves: M. spretus * NIH/Ola)
|
increased skin tumor incidence
|
J:59049
|
Skts7NIH/Ola/?
(involves: M. spretus * NIH/Ola)
|
increased skin tumor incidence
|
J:59049
|
Skts8NIH/Ola/?
(involves: M. spretus * NIH/Ola)
|
increased skin tumor incidence
|
J:59049
|
Skts9NIH/Ola/?
(involves: M. spretus * NIH/Ola)
|
increased skin tumor incidence
|
J:59049
|
Skts10M. spretus/?
(involves: M. spretus * NIH/Ola)
|
increased skin tumor incidence
|
J:59049
|
Skts11M. spretus/Skts11M. spretus
(involves: M. spretus * NIH/Ola)
|
increased skin tumor incidence
|
J:59049
|
Skts12M. spretus/Skts12M. spretus
(involves: M. spretus * NIH/Ola)
|
increased skin tumor incidence
|
J:27733
|
Skts12M. spretus/Skts12NIH/Ola
(involves: M. spretus * NIH/Ola)
|
increased skin tumor incidence
|
J:27733
|
Skts13M. spretus/?
(involves: M. spretus * NIH/Ola)
|
increased skin papilloma incidence
|
J:84842
|
Skts16Car-S/Skts16Car-S
(involves: Car-R * Car-S)
|
increased skin tumor incidence
|
J:68404
|
Skts-fp2FVB/NTac/Skts-fp2FVB/NTac Skts-fp3FVB/NTac/Skts-fp3FVB/NTac
(involves: FVB/NTac * PWK/Rbrc)
|
increased skin papilloma incidence
|
J:125337
|
Slc29a3tm1Lex/Slc29a3tm1Lex
(involves: 129S5/SvEvBrd * C57BL/6)
|
increased histiocytic sarcoma incidence
|
J:179286
|
Slc33a1tm1.1Lpu/Slc33a1+
(involves: 129S7/SvEvBrd * C57BL/6)
|
increased lung adenoma incidence
|
J:211266
|
increased lymphoma incidence
|
J:211266
|
Sluc10B10.O20/Dem/Sluc10B10.O20/Dem Sluc25O20/A/Sluc25O20/A
(involves: B10.O20/Dem * O20/A)
|
increased lung adenocarcinoma incidence
|
J:71973
|
Sluc10O20/A/Sluc10O20/A Sluc25O20/A/Sluc25O20/A
(involves: B10.O20/Dem * O20/A)
|
increased lung adenocarcinoma incidence
|
J:71973
|
Sluc18B10.O20/Dem/Sluc18B10.O20/Dem Sluc26B10.O20/Dem/Sluc26B10.O20/Dem
(involves: B10.O20/Dem * O20/A)
|
increased lung adenocarcinoma incidence
|
J:71973
|
Sluc25O20/A/Sluc25O20/A Sluc5B10.O20/Dem/Sluc5B10.O20/Dem
(involves: B10.O20/Dem * O20/A)
|
increased lung adenocarcinoma incidence
|
J:71973
|
Sluc25O20/A/Sluc25O20/A Sluc9B10.O20/Dem/Sluc9O20/A
(involves: B10.O20/Dem * O20/A)
|
increased lung adenocarcinoma incidence
|
J:71973
|
Sluc25O20/A/Sluc25O20/A Sluc9O20/A/Sluc9O20/A
(involves: B10.O20/Dem * O20/A)
|
increased lung adenocarcinoma incidence
|
J:71973
|
Smad3tm1Cxd/Smad3tm1Cxd
(either: (involves: 129S6/SvEvTac * C57BL/6) or (involves: 129S6/SvEvTac * NIH Black Swiss))
|
increased intestinal adenocarcinoma incidence
|
J:53510
|
Smad3tm1Par/Smad3tm1Par
(either: (involves: 129S1/Sv * 129X1/SvJ) or (involves: 129S1/Sv * 129X1/SvJ * C57BL/6))
|
increased intestinal adenocarcinoma incidence
|
J:49839
|
Smad3tm1Par/Smad3tm1Par
(129-Smad3tm1Par/J)
|
increased intestinal adenocarcinoma incidence
|
J:106572
|
Smad4E6sad/Smad4+
(involves: 129P2/OlaHsd * C57BL/6)
|
increased intestinal adenoma incidence
|
J:81488
|
increased stomach tumor incidence
|
J:81488
|
Smad4m4Mag/Smad4+
(involves: 129S/Sv * Black Swiss * C57BL/6)
|
increased lung tumor incidence
|
J:106440
|
increased ovary tumor incidence
|
J:106440
|
increased stomach tumor incidence
|
J:106440
|
Smad4tm1.1Gsu/Smad4tm1.1Gsu Ptf1atm1.1(cre)Cvw/Ptf1a+ Tg(MtTGFA)Lmb/0
(involves: 129S1/Sv * 129X1/SvJ * CD-1)
|
increased pancreatic intraepithelial neoplasia incidence
|
J:229184
|
Smad4tm1.1Rob/Smad4+
(involves: 129S/SvEv * CD-1)
|
increased stomach tumor incidence
|
J:92066
|
Smad4tm2.1Cxd/Smad4tm2.1Cxd Tg(KRT5-cre)1Xya/0
(involves: 129S6/SvEvTac)
|
increased skin papilloma incidence
|
J:101602
|
increased skin tumor incidence
|
J:101602
|
Smad4tm2.1Cxd/Smad4tm2.1Cxd Trp53tm1Brn/Trp53tm1Brn Tg(MMTV-cre)7Mul/0
(involves: 129P2/OlaHsd * 129S6/SvEvTac * FVB/N)
|
increased mammary adenocarcinoma incidence
|
J:212549
|
Smad4tm2.1Cxd/Smad4tm2.1Cxd Trp53tm1Brn/Trp53tm1Brn Tg(Vil1-cre)20Syr/0
(involves: 129P2/OlaHsd * 129S6/SvEvTac * C57BL/6 * DBA/2)
|
increased intestinal adenocarcinoma incidence
|
J:212549
|
Smad9tm3Jfm/Smad9tm3Jfm
(involves: 129S4/SvJaeSor)
|
increased lung adenoma incidence
|
J:150213
|
Smap1tm1.1Sata/Smap1tm1.1Sata
(B6.Cg-Smap1tm1.1Sata)
|
increased leukemia incidence
|
J:196385
|
Smarca2tm1Mya/Smarca2tm1Mya Smarca4tm1Mag/Smarca4+
(involves: 129S/Sv * 129S2/SvPas * C57BL/6J * CD-1)
|
increased mammary gland tumor incidence
|
J:132091
|
Smarca4tm1Mag/Smarca4+
(involves: 129S/Sv * C57BL/6J * CD-1)
|
increased mammary adenocarcinoma incidence
|
J:132091
|
increased osteosarcoma incidence
|
J:132091
|
Smarcb1tm1Gvk/Smarcb1+
(involves: 129/Sv * C57BL/6J * SJL/J)
|
increased brain tumor incidence
|
J:101185
|
increased facial tumor incidence
|
J:101185
|
Smarcb1tm1Sho/Smarcb1tm3Sho Tg(Mx1-cre)1Cgn/?
(involves: 129S1/Sv * 129S6/SvEvTac * C57BL/6 * CBA)
|
increased lymphoma incidence
|
J:80224
|
increased rhabdomyoma incidence
|
J:80224
|
increased T cell derived lymphoma incidence
|
J:80224
|
Smarcb1tm2Sho/Smarcb1tm2Sho Trp53tm1Brn/Trp53tm1Brn Tg(GFAP-cre)#Gtm/0
(involves: 129P2/OlaHsd * 129S1/Sv * C57BL/6 * CBA)
|
increased brain tumor incidence
|
J:226786
|
Smg1Gt(AG0297)Wtsi/Smg1+
(involves: 129P2/OlaHsd * C57BL/6)
|
increased B cell derived lymphoma incidence
|
J:193626
|
increased lung adenocarcinoma incidence
|
J:193626
|
increased lymphoma incidence
|
J:193626
|
Smurf2Gt(RRA098)Byg/Smurf2+
(involves: 129P2/OlaHsd * C57BL/6)
|
increased lymphoma incidence
|
J:189320
|
Smurf2Gt(RRA098)Byg/Smurf2Gt(RRA098)Byg
(involves: 129P2/OlaHsd * C57BL/6)
|
increased B cell derived lymphoma incidence
|
J:189320,
J:245679
|
increased hepatocellular carcinoma incidence
|
J:189320
|
increased lymphoma incidence
|
J:189320
|
increased small intestine adenocarcinoma incidence
|
J:189320
|
Soat1ald/Soat1ald
(AKR/O)
|
increased leukemia incidence
|
J:12157
|
Socs1tm1Jni/Socs1+
(Not Specified)
|
increased hepatoma incidence
|
J:91651
|
Sod1m1H/Sod1m1H
(involves: C3H/HeH * C57BL/6J)
|
increased hepatocellular carcinoma incidence
|
J:219360
|
increased liver tumor incidence
|
J:219360
|
Sod2tm1Cje/Sod2+
(B6.Cg-Sod2tm1Cje/Mmmh)
|
increased lymphoma incidence
|
J:87514
|
Spi1tm1.1Dgt/Spi1tm1.1Dgt
(involves: 129S1/Sv * 129X1/SvJ)
|
increased leukemia incidence
|
J:90331
|
increased T cell derived lymphoma incidence
|
J:90331
|
Spi1tm1.3Dgt/Spi1tm1.3Dgt
(involves: 129S1/Sv * 129X1/SvJ * BALB/c * C57BL/6)
|
increased leukemia incidence
|
J:106040
|
increased T cell derived lymphoma incidence
|
J:106040
|
Spi1tm1.3Dgt/Spi1tm1.3Dgt
(involves: 129 * BALB/c * C57BL/6)
|
increased leukemia incidence
|
J:90331
|
increased T cell derived lymphoma incidence
|
J:90331
|
Spry1tm1Jdli/Spry1tm1.1Jdli Spry2tm1Mrt/Spry2tm1.1Mrt Tg(Osr1-cre)4Mrt/0
(involves: 129P2/OlaHsd * 129S1/Sv * 129X1/SvJ * FVB/N)
|
increased prostate intraepithelial neoplasia incidence
|
J:192348
|
Spry2tm1.1Mrt/Spry2+ Spry4tm1.2Mrt/Spry4tm1.2Mrt
(involves: 129P2/OlaHsd)
|
increased enchondroma incidence
|
J:315670
|
increased osteochondroma incidence
|
J:315670
|
Spry2tm1.1Mrt/Spry2tm1.1Mrt Spry4tm1.2Mrt/Spry4+
(involves: 129P2/OlaHsd)
|
increased enchondroma incidence
|
J:315670
|
increased osteochondroma incidence
|
J:315670
|
Spry2tm1Mrt/Spry2tm1Mrt
(involves: 129P2/OlaHsd)
|
increased lung tumor incidence
|
J:119477
|
Sptbn1tm1Mish/Sptbn1+
(involves: 129S6/SvEvTac * C57BL/6)
|
increased hepatocellular carcinoma incidence
|
J:132133
|
Sptbn1tm1Mish/Sptbn1+
(involves: 129S6/SvEvTac)
|
increased adrenal cortical tumor incidence
|
J:166879
|
increased glioma incidence
|
J:166879
|
increased hepatocellular carcinoma incidence
|
J:166879
|
increased liver tumor incidence
|
J:166879
|
increased lung adenocarcinoma incidence
|
J:166879
|
increased lymphoma incidence
|
J:166879
|
increased ovary tumor incidence
|
J:166879
|
increased renal carcinoma incidence
|
J:166879
|
increased testis tumor incidence
|
J:166879
|
increased thyroid carcinoma incidence
|
J:166879
|
Srctm1Mul/Src+ Tg(MMTV-cre)7Mul/0 Tg(MMTV-PyVT)#Mul/0
(involves: 129S1/Sv * 129X1/SvJ * FVB/N)
|
increased mammary gland tumor incidence
|
J:181822
|
Srctm1Mul/Srctm1Mul Tg(MMTV-cre)7Mul/0 Tg(MMTV-PyVT)#Mul/0
(involves: 129S1/Sv * 129X1/SvJ * FVB/N)
|
increased mammary gland tumor incidence
|
J:181822
|
Srpxtm1Hzi/Srpx+
(involves: 129S1/Sv * 129X1/SvJ * C57BL/6)
|
increased lymphoma incidence
|
J:119999
|
Srpxtm1Hzi/Srpxtm1Hzi
(involves: 129S1/Sv * 129X1/SvJ * C57BL/6)
|
increased hepatoma incidence
|
J:119999
|
increased lung adenocarcinoma incidence
|
J:119999
|
increased lymphoma incidence
|
J:119999
|
increased T cell derived lymphoma incidence
|
J:119999
|
Ssbp2tm1Lana/Ssbp2tm1Lana
(involves: 129S/SvEv * C57BL/6)
|
increased B cell derived lymphoma incidence
|
J:162035
|
increased jejunum adenocarcinoma incidence
|
J:162035
|
increased lung adenoma incidence
|
J:162035
|
increased lymphoma incidence
|
J:162035
|
Ssbp2tm1Lana/Ssbp2tm1Lana Trp53tm1Tyj/Trp53tm1Tyj
(involves: 129S/SvEv * 129S2/SvPas * BALB/c * C57BL/6)
|
increased T cell derived lymphoma incidence
|
J:162035
|
Ssic1C57BL/10J/Ssic1C57BL/10J
(involves: C57BL/10 * O20/A)
|
increased small intestine adenocarcinoma incidence
|
J:26873
|
Ssr2tm1b(EUCOMM)Wtsi/Ssr2tm1b(EUCOMM)Wtsi
(C57BL/6N-Ssr2tm1b(EUCOMM)Wtsi/Wtsi)
|
increased trigeminal neuroma incidence
|
J:239583
|
Stag1Gt(P099A04)Wrst/Stag1+
(involves: 129S2/SvPas)
|
increased hepatocellular carcinoma incidence
|
J:184720
|
increased histiocytic sarcoma incidence
|
J:184720
|
increased lymphoma incidence
|
J:184720
|
Stat1tm1Dlv/Stat1tm1Dlv
(B6.129S-Stat1tm1Dlv)
|
increased mammary adenocarcinoma incidence
|
J:216040
|
Stat1tm1Rds/Stat1tm1Rds
(129S6/SvEv-Stat1tm1Rds/Tac)
|
increased mammary adenocarcinoma incidence
|
J:216040
|
Stat3tm1Dlv/Stat3tm1Dlv Tg(Csf1r-icre)1Jwp/0
(involves: 129P2/OlaHsd * C57BL/6 * FVB)
|
increased gastrointestinal tumor incidence
|
J:156593
|
Stat3tm4Vpo/Stat3tm4Vpo Tg(MMTV-Erbb2)1Pv/0
(involves: 129P2/OlaHsd * BALB/cAn * C57BL/6 * CD-1 * DBA)
|
increased mammary adenocarcinoma incidence
|
J:157976
|
increased mammary gland tumor incidence
|
J:157976
|
Stk3tm1.1Jav/Stk3+ Stk4Gt(AJ0315)Wtsi/Stk4Gt(AJ0315)Wtsi
(involves: 129 * C57BL/6)
|
increased hepatocellular carcinoma incidence
|
J:153945
|
Stk3tm1.1Jav/Stk3tm1.1Jav
(involves: 129 * C57BL/6)
|
increased mammary gland tumor incidence
|
J:153945
|
Stk3tm1.1Jav/Stk3tm1.1Jav Stk4Gt(AJ0315)Wtsi/Stk4+
(involves: 129 * C57BL/6)
|
increased hepatocellular carcinoma incidence
|
J:153945
|
Stk3tm1.1Jav/Stk3tm1Jav Stk4Gt(AJ0315)Wtsi/Stk4Gt(AJ0315)Wtsi
(involves: 129 * C57BL/6)
|
increased hepatocellular carcinoma incidence
|
J:153945
|
Stk3tm1.1Rjo/Stk3tm1.1Rjo Stk4tm1.1Rjo/Stk4tm1.1Rjo Speer6-ps1Tg(Alb-cre)21Mgn/Speer6-ps1+
(involves: 129S6/SvEvTac * C57BL/6 * CD-1 * DBA * SJL)
|
increased hepatocellular carcinoma incidence
|
J:156531
|
increased liver tumor incidence
|
J:156531
|
Stk3tm1.1Yy/Stk3tm1Yy Stk4tm1.1Yy/Stk4tm1.1Yy
(involves: C57BL/6 * CBA)
|
increased liver tumor incidence
|
J:156541
|
Stk3tm1.1Yy/Stk3tm1Yy Stk4tm1.1Yy/Stk4tm1.1Yy Tg(CAG-cre/Esr1*)5Amc/0
(involves: C57BL/6 * CBA)
|
increased hepatocellular carcinoma incidence
|
J:156541
|
increased liver tumor incidence
|
J:156541
|
Stk3tm1Jav/Stk3tm1Jav Stk4Gt(AJ0315)Wtsi/Stk4Gt(AJ0315)Wtsi
(involves: 129 * C57BL/6)
|
increased hepatocellular carcinoma incidence
|
J:153945
|
Stk3tm1Jav/Stk3tm1Jav Stk4Gt(AJ0315)Wtsi/Stk4Gt(AJ0315)Wtsi Speer6-ps1Tg(Alb-cre)21Mgn/Speer6-ps1+
(involves: 129 * C57BL/6)
|
increased hepatocellular carcinoma incidence
|
J:153945
|
Stk3tm1Jav/Stk3tm1Jav Stk4Gt(AJ0315)Wtsi/Stk4Gt(AJ0315)Wtsi Speer6-ps1Tg(Alb-cre)21Mgn/Speer6-ps1+
(involves: 129 * 129P2/OlaHsd * C57BL/6 * DBA)
|
increased hepatocellular carcinoma incidence
|
J:238319
|
Stk4Gt(AJ0315)Wtsi/Stk4Gt(AJ0315)Wtsi
(involves: 129 * C57BL/6)
|
increased histiocytic sarcoma incidence
|
J:153945
|
Stk11tm1.1Jish/Stk11+
(involves: 129S7/SvEvBrd * C57BL/6J)
|
increased intestinal adenoma incidence
|
J:77213
|
Stk11tm1.1Mlfr/Stk11+ Trp53tm1Tyj/Trp53+
(involves: 129S2/SvPas * 129S7/SvEvBrd * C57BL/6J)
|
increased lymphoma incidence
|
J:104347
|
increased osteosarcoma incidence
|
J:104347
|
Stk11tm1.1Rdp/Stk11+ Taglntm1(cre/ERT2)Feil/Tagln+
(involves: 129S/Sv * 129X1/SvJ * C57BL/6 * CD-1 * SJL)
|
increased gastrointestinal tumor incidence
|
J:134476
|
Stk11tm1.1Rdp/Stk11tm1.1Rdp
(involves: 129S6/SvEvTac * FVB/N)
|
increased endometrial carcinoma incidence
|
J:131865
|
Stk11tm1.1Rdp/Stk11tm1.1Rdp Isl1tm1(cre)Tmj/Isl1+
(involves: 129S6/SvEvTac * 129X1/SvJ)
|
increased gastrointestinal tumor incidence
|
J:201695
|
Stk11tm1.1Rdp/Stk11tm1.1Rdp Taglntm1(cre/ERT2)Feil/Tagln+
(involves: 129S/Sv * 129X1/SvJ * C57BL/6 * CD-1 * SJL)
|
increased gastrointestinal tumor incidence
|
J:134476
|
Stk11tm1.1Rdp/Stk11tm1.1Rdp Tg(Sprr2f-cre)1Dcas/0
(involves: 129S6/SvEvTac * FVB/N)
|
increased endometrial carcinoma incidence
|
J:158190
|
Stk11tm1.2Rdp/Stk11+
(involves: 129S6/SvEvTac * FVB/N)
|
increased endometrial carcinoma incidence
|
J:131865
|
Stk11tm1.2Rdp/Stk11+
(involves: 129S6/SvEvTac * C57BL/6 * CD-1 * FVB/N * SJL)
|
increased gastrointestinal tumor incidence
|
J:134476
|
Stk11tm1Mmt/Stk11+
(involves: 129X1/SvJ)
|
increased hepatocellular carcinoma incidence
|
J:76202
|
Stk11tm1Mmt/Stk11+ Trp53tm1Brd/Trp53tm1Brd
(involves: 129S7/SvEvBrd * 129X1/SvJ)
|
increased hepatocellular carcinoma incidence
|
J:107275
|
increased liver tumor incidence
|
J:107275
|
increased ovary tumor incidence
|
J:107275
|
Stk11tm1Rdp/Stk11tm1Rdp Tg(MMTV-Erbb2*,-cre)1Mul/0
(involves: 129S6/SvEvTac * C57BL/6)
|
increased mammary gland tumor incidence
|
J:198481
|
Stk11tm1Tpm/Stk11+
(Not Specified)
|
increased endometrial carcinoma incidence
|
J:79074
|
increased hepatocellular carcinoma incidence
|
J:79074
|
increased liver adenoma incidence
|
J:79074
|
Stk38tm1Hem/Stk38+
(involves: 129P2/Ola * C57BL/6)
|
increased T cell derived lymphoma incidence
|
J:185408
|
Stk38tm1Hem/Stk38tm1Hem
(involves: 129P2/Ola * C57BL/6)
|
increased T cell derived lymphoma incidence
|
J:185408
|
SufuGt(XB699)Byg/Sufu+ Trp53tm1Tyj/Trp53tm1Tyj
(involves: 129P2/OlaHsd * 129S2/SvPas * C57BL/6)
|
increased lymphoma incidence
|
J:125534
|
increased medulloblastoma incidence
|
J:125534
|
increased rhabdomyosarcoma incidence
|
J:125534
|
Suprmam1BALB/cMed/Suprmam1BALB/cMed Trp53tm1Tyj/Trp53+
(involves: 129S2/SvPas * BALB/cMed * C57BL/6 * C57BL/6J)
|
increased mammary gland tumor incidence
|
J:122161
|
Suv39h1tm1Jnw/Suv39h1+
(involves: 129 * C57BL/6J)
|
increased B cell derived lymphoma incidence
|
J:72503
|
Suv39h1tm1Jnw/Suv39h1+ Suv39h2tm1Jnw/Suv39h2+
(involves: 129 * C57BL/6J)
|
increased B cell derived lymphoma incidence
|
J:72503
|
Suv39h1tm1Jnw/Suv39h1+ Suv39h2tm1Jnw/Suv39h2tm1Jnw
(involves: 129 * C57BL/6J)
|
increased B cell derived lymphoma incidence
|
J:72503
|
Suv39h1tm1Jnw/Suv39h1tm1Jnw
(involves: 129 * C57BL/6J)
|
increased B cell derived lymphoma incidence
|
J:72503
|
Suv39h1tm1Jnw/Suv39h1tm1Jnw Suv39h2tm1Jnw/Suv39h2+
(involves: 129 * C57BL/6J)
|
increased B cell derived lymphoma incidence
|
J:72503
|
Suv39h2tm1Jnw/Suv39h2+
(involves: 129 * C57BL/6J)
|
increased B cell derived lymphoma incidence
|
J:72503
|
Suv39h2tm1Jnw/Suv39h2tm1Jnw
(involves: 129 * C57BL/6J)
|
increased B cell derived lymphoma incidence
|
J:72503
|
Suz12Gt(Betageo)1Khe/Suz12+
(involves: 129P2/OlaHsd)
|
increased histiocytic sarcoma incidence
|
J:217077
|
T(9;17)138Ca/T(9;17)138Ca
(Not Specified)
|
increased mammary gland tumor incidence
|
J:169366
|
Tbrg1tm1a(KOMP)Wtsi/Tbrg1tm1a(KOMP)Wtsi
(C57BL/6N-Tbrg1tm1a(KOMP)Wtsi)
|
increased B cell derived lymphoma incidence
|
J:225146
|
increased Harderian gland adenoma incidence
|
J:225146
|
increased lung adenoma incidence
|
J:225146
|
Tbx21tm1Glm/Tbx21tm1Glm Tg(TRAMP)8247Ng/0
(involves: 129S6/SvEvTac * C57BL/6)
|
increased prostate gland adenocarcinoma incidence
|
J:88093
|
increased prostate gland tumor incidence
|
J:88093
|
increased prostate intraepithelial neoplasia incidence
|
J:88093
|
Tcf3tm1(PBX1)Mlc/Tcf3+ Cd19tm1(cre)Cgn/Cd19+
(involves: 129P2/OlaHsd * C57BL/6)
|
increased B cell acute lymphoblastic leukemia incidence
|
J:226241
|
Tcf3tm1(PBX1)Mlc/Tcf3+ Cd79atm1(cre)Reth/Cd79a+
(involves: BALB/c * C57BL/6)
|
increased B cell acute lymphoblastic leukemia incidence
|
J:226241
|
Tcf3tm1(PBX1)Mlc/Tcf3+ Tg(Mx1-cre)1Cgn/0
(involves: C57BL/6 * C57BL/6J * CBA/J)
|
increased B cell acute lymphoblastic leukemia incidence
|
J:226241
|
Tcf3tm1(TCF3/HLF)Homy/Tcf3+ Tg(Emu-Zfp521)1Homy/0 Tg(Mx1-cre)1Cgn/0
(involves: 129P2/OlaHsd * C57BL/6 * CBA)
|
increased leukemia incidence
|
J:160392
|
Tcf3tm1Wein/Tcf3tm1Wein
(involves: 129S4/SvJaeSor * C57BL/6)
|
increased T cell derived lymphoma incidence
|
J:44278
|
Tcf3tm2Wein/Tcf3tm2Wein
(Not Specified)
|
increased T cell derived lymphoma incidence
|
J:47671
|
Tcf7tm1Cle/Tcf7tm1Cle
(involves: 129P2/OlaHsd)
|
increased intestinal adenoma incidence
|
J:57721
|
increased mammary adenoacanthoma incidence
|
J:57721
|
Tcra-Jtm1Tgi/Tcra-Jtm1Tgi Tg(Pklr-Myc)73Ak/0
(B6.Cg-Tcra-Jtm1Tgi Tg(Pklr-Myc)73Ak)
|
increased hepatocellular carcinoma incidence
|
J:184496
|
Terctm1Rdp/Terctm1Rdp
(involves: 129/Sv * C57BL/6 * C57BL/6J * SJL)
|
increased lymphoma incidence
|
J:125218
|
Terctm1Rdp/Terctm1Rdp Wrntm1Lgu/Wrntm1Lgu
(involves: 129/Sv * BALB/c * C57BL/6 * SLJ)
|
increased osteosarcoma incidence
|
J:91715
|
Terf1tm1.1Blas/Terf1tm1.1Blas Tg(KRT5-cre)1Tak/0 Trp53tm1Tyj/Trp53tm1Tyj
(involves: 129 * C3H * C57BL/6 * SJL)
|
increased skin squamous cell carcinoma incidence
|
J:152077
|
Testm1Cro/Tes+
(involves: 129X1/SvJ * C57BL/6J)
|
increased stomach tumor incidence
|
J:100181
|
Testm1Cro/Testm1Cro
(involves: 129X1/SvJ * C57BL/6J)
|
increased stomach tumor incidence
|
J:100181
|
Tet2tm1.1Iaai/Tet2tm1.1Iaai Tg(VAV1-cre)1Graf/0
(involves: 129S/SvEv * C57BL/6)
|
increased chronic myelocytic leukemia incidence
|
J:174053
|
Tet2tm1.1Mjxu/Tet2+
(involves: 129 * C57BL/6)
|
increased chronic myelocytic leukemia incidence
|
J:178415
|
increased leukemia incidence
|
J:178415
|
Tet2tm1.1Mjxu/Tet2tm1.1Mjxu
(involves: 129 * C57BL/6)
|
increased chronic myelocytic leukemia incidence
|
J:178415
|
increased leukemia incidence
|
J:178415
|
Tff1tm1Mrio/Tff1tm1Mrio
(involves: 129S2/SvPas)
|
increased stomach tumor incidence
|
J:84201
|
Tg(ACTB-Artn)1Wss/0
(involves: C57BL/6Crl * DBA/2Crl)
|
increased adrenal gland tumor incidence
|
J:90843
|
Tg(ACTB-Eif4e)#Ppp/?
(Not Specified)
|
increased B cell derived lymphoma incidence
|
J:89878
|
increased liver adenoma incidence
|
J:89878
|
increased lung adenocarcinoma incidence
|
J:89878
|
Tg(ACTB-Eif4e)#Ppp/0 Tg(IghMyc)22Bri/0
(involves: C57BL * SJL)
|
increased lymphoma incidence
|
J:89878
|
Tg(ACTB-KRAS*G12V,-luc)#Lche/0
(involves: C57BL/6 * FVB/N)
|
increased lung adenocarcinoma incidence
|
J:199528
|
increased lung adenoma incidence
|
J:199528
|
increased lung tumor incidence
|
J:199528
|
Tg(Alb1-Myc)#Sst/0
(involves: C57BL/6 * CBA)
|
increased hepatocellular carcinoma incidence
|
J:34434
|
increased liver adenoma incidence
|
J:34434
|
Tg(Alb1-Myc)#Sst/0 Tg(MtTGFA)42Lmb/0
(involves: C57BL/6 * CBA * CD-1)
|
increased hepatocellular carcinoma incidence
|
J:34434
|
increased liver adenoma incidence
|
J:34434
|
Tg(Alb1-Myc)#Sst/0 Tg(MtTGFA)Lmb/0
(involves: C57BL/6 * CBA * CD-1)
|
increased hepatocellular carcinoma incidence
|
J:176432
|
Tg(Alb1HBV)43Bri/0
(involves: C57BL/6J)
|
increased liver tumor incidence
|
J:86165
|
Tg(Alb1HBV)44Bri/0
(involves: C57BL/6J * SJL/J)
|
increased hepatocellular carcinoma incidence
|
J:86165
|
increased liver adenoma incidence
|
J:86165
|
increased liver tumor incidence
|
J:86165
|
Tg(Alb1HBV)44Bri/0
(C57BL/6J-Tg(Alb1HBV)44Bri/J)
|
increased hepatocellular carcinoma incidence
|
J:223921
|
increased liver adenoma incidence
|
J:223921
|
increased liver tumor incidence
|
J:223921
|
Tg(Alb-E2F1)8Sst/0
(involves: C57BL/6J * CBA/J)
|
increased hepatocellular carcinoma incidence
|
J:65354,
J:101128
|
increased liver adenoma incidence
|
J:65354
|
increased liver tumor incidence
|
J:65354,
J:101128
|
Tg(Alb-HBx)A112Tfts/0
(involves: C57BL/6)
|
increased hepatocellular carcinoma incidence
|
J:104728
|
Tg(Alb-HRAS*G12V)28Yu/0
(involves: C57BL/6J * CBA/J)
|
increased hepatocellular carcinoma incidence
|
J:107083,
J:238319
|
increased liver adenoma incidence
|
J:107083,
J:238319
|
increased liver tumor incidence
|
J:107083,
J:238319
|
Tg(Alb-PDGFC)#Jcam/0
(involves: C57BL/6)
|
increased hepatocellular carcinoma incidence
|
J:96979,
J:211984
|
Tg(Alb-SND1)3aDsar/0
(involves: C57BL/6 * CBA)
|
increased hepatocellular carcinoma incidence
|
J:242582
|
Tg(Alb-TAg)1Gjh/0
(C3.Cg-Tg(Alb-TAg)1Gjh)
|
increased hepatocellular carcinoma incidence
|
J:105110
|
Tg(Alb-TAg)#Arnd/0
(C3Fe.Cg-Tg(Alb-TAg)#Arnd)
|
increased hepatocellular carcinoma incidence
|
J:171880
|
Tg(AMH-Fshr)27Hht/0
(involves: FVB/N)
|
increased ovarian teratoma incidence
|
J:160015
|
Tg(AMH-Fshr*D580H)#Hht/0
(involves: FVB/N)
|
increased ovarian carcinoma incidence
|
J:160015
|
increased ovarian teratoma incidence
|
J:160015
|
increased prolactinoma incidence
|
J:160015
|
Tg(AMH-Fshr*D580Y)#Hht/0
(involves: FVB/N)
|
increased ovarian teratoma incidence
|
J:160015
|
Tg(Amh-SMAD2*)#Jebu/0
(FVB/N-Tg(Amh-SMAD2*)#Jebu)
|
increased ovarian teratoma incidence
|
J:200783
|
increased ovary tumor incidence
|
J:200783
|
Tg(Amh-SMAD2*)#Jebu/0 Trp53tm1Brn/Trp53tm1Brn
(involves: 129P2/OlaHsd * FVB/N)
|
increased ovarian teratoma incidence
|
J:200783
|
Tg(Amhr2-SV40TAg)1Dcco/0
((C57BL/6 x C3H)F1)
|
increased ovarian carcinoma incidence
|
J:82550
|
increased ovary tumor incidence
|
J:82550
|
increased testis tumor incidence
|
J:82550
|
Tg(Amy1TAg)354Knw/0
(C57BL/6J-Tg(Amy1TAg)354Knw)
|
increased hepatoma incidence
|
J:90326
|
Tg(Amy1TAg)501Knw/?
(C57BL/6-Tg(Amy1TAg)501Knw)
|
increased osteosarcoma incidence
|
J:90730
|
Tg(APOE-Artn)1Wss/0
(involves: C57BL/6Crl * DBA/2Crl)
|
increased adrenal gland tumor incidence
|
J:90843
|
Tg(ARR2/Pbsn-FGF8)3Prb/0
(involves: C57BL/6 * DBA/2)
|
increased prostate intraepithelial neoplasia incidence
|
J:106650,
J:78918
|
Tg(Arr2/Pbsn-FGFR1K656E)1Wmck/0
(involves: FVB)
|
increased prostate intraepithelial neoplasia incidence
|
J:87067
|
Tg(Arr2/Pbsn-FGFR1K656E)1Wmck/0 Tg(Pbsn-FGFR2_iiib*)#Ng/0
(involves: FVB)
|
increased prostate intraepithelial neoplasia incidence
|
J:87067
|
Tg(ARR2/Pbsn-MYC)7Key/?
(involves: FVB/N)
|
increased prostate gland adenocarcinoma incidence
|
J:223213,
J:85480
|
increased prostate gland tumor incidence
|
J:85480
|
increased prostate intraepithelial neoplasia incidence
|
J:223213,
J:85480
|
Tg(Atoh1-sb11)1Mtay/0 TgTn(sb-T2/Onc3)12740Njen/0 Trp53tm1Tyj/Trp53tm1Tyj
(involves: 129S2/SvPas * C3H * C57BL/6J * ICR)
|
increased medulloblastoma incidence
|
J:181542
|
Tg(Atp4b-TAg)#Jig/0
(involves: FVB/N)
|
increased stomach tumor incidence
|
J:89240
|
Tg(BCL2)22Wehi/0 Tg(IghMyc)22Bri/0
(involves: C57BL/6 * C57BL/6JWehi * SJL/J * SJL/JWehi)
|
increased lymphoma incidence
|
J:69571
|
Tg(BCL2)36Wehi/0
(involves: C57BL/6JWehi * SJL/JWehi)
|
increased T cell derived lymphoma incidence
|
J:93111
|
Tg(BCL2/IGH)#Jcre/0 Tg(H2-K/Igh-Traf2*)#Ywc/0
(involves: BALB/c * C57BL/6 * CBA/J * FVB/N * SJL/J * SWR/J)
|
increased chronic lymphocytic leukemia incidence
|
J:94116
|
increased small lymphocytic lymphoma incidence
|
J:94116
|
Tg(BCL2OVARY)1Ah/0
(involves: FVB)
|
increased ovarian teratoma incidence
|
J:55158
|
Tg(BCR/ABL)623Hkp/0
(involves: C57BL/6 * CBA)
|
increased acute lymphoblastic leukemia incidence
|
J:160846
|
increased B cell derived lymphoma incidence
|
J:89786
|
increased leukemia incidence
|
J:89786
|
Tg(BCR/ABL)623Hkp/0
(involves: C57BL/6 * C57BL/6J * CBA)
|
increased leukemia incidence
|
J:99168
|
Tg(BCR/ABL)623Hkp/?
(involves: 129S1/Sv * 129X1/SvJ * Black Swiss * C57BL/6 * CBA)
|
increased B cell derived lymphoma incidence
|
J:76680
|
increased leukemia incidence
|
J:76680
|
Tg(Bglap2-TAg)1Rkho/0
(FVB/N-Tg(Bglap2-TAg)1Rkho)
|
increased osteosarcoma incidence
|
J:165282
|
increased skeletal tumor incidence
|
J:165282
|
Tg(Bglap2-TAg)1Rkho/0
(involves: FVB/N)
|
increased osteosarcoma incidence
|
J:234128
|
Tg(Bglap2-TAg)1Rkho/0 Tg(Col1a1-cre)1Kry/0 Tnfrsf11atm1.1Pngr/Tnfrsf11atm1.1Pngr
(involves: 129P2/OlaHsd * C57BL/6 * FVB/N)
|
increased osteosarcoma incidence
|
J:234128
|
Tg(Bglap2-TAg)1Rkho/0 Tnfsf11tm1Pngr/Tnfsf11+
(involves: 129P2/OlaHsd * FVB/N)
|
increased osteosarcoma incidence
|
J:234128
|
Tg(BLG-STAT5A)6Itb/0
(involves: FVB/N)
|
increased mammary gland tumor incidence
|
J:80588
|
Tg(BLG-STAT5A)15Itb/0
(involves: FVB/N)
|
increased mammary gland tumor incidence
|
J:80588
|
Tg(C3-1-TAg)cJeg/0
(involves: FVB/N)
|
increased bulbourethral gland adenocarcinoma incidence
|
J:46513
|
increased mammary adenocarcinoma incidence
|
J:52786,
J:46513
|
increased prostate gland adenocarcinoma incidence
|
J:52786,
J:46513,
J:72324
|
increased prostate intraepithelial neoplasia incidence
|
J:46513,
J:72324
|
increased urethral gland adenocarcinoma incidence
|
J:46513
|
Tg(C3-1-TAg)cJeg/0
(FVB/N-Tg(C3-1-TAg)cJeg)
|
increased prostate gland tumor incidence
|
J:84352
|
increased prostate intraepithelial neoplasia incidence
|
J:84352
|
Tg(CAG-Alk*F1174L,-luc)60Jhsc/0 Tg(Dbh-icre)1Gsc/0
(involves: C57BL/6 * FVB/N)
|
increased neuroblastoma incidence
|
J:186696
|
Tg(CAG-Alk*F1174L,-luc)60Jhsc/0 Tg(Dbh-icre)1Gsc/0 Tg(Th-MYCN)41Waw/0
(involves: 129X1/SvJ * BALB/c * C57BL/6 * C57BL/6J * FVB/N)
|
increased neuroblastoma incidence
|
J:186696
|
Tg(CAG-Alk*F1174L,-luc)60Jhsc/0 Thtm1(cre)Te/Th+
(involves: 129X1/SvJ * C57BL/6 * FVB/N)
|
increased neuroblastoma incidence
|
J:186696
|
Tg(CAG-Bgeo,-Tle1,-ALPP)1Lbe/0 Tg(CAG-cre)1Nagy/0
(involves: 129S1/Sv * 129X1/SvJ * CD-1)
|
increased lung adenocarcinoma incidence
|
J:106684
|
Tg(CAG-Bgeo,-tTA,-EGFP)2A11Kuw/0 Tg(Pdx1-cre)6Tuv/0 Tg(tetO-MYC)36Bop/0
(involves: 129P2/OlaHsd * FVB/N)
|
increased pancreas tumor incidence
|
J:197052
|
increased pancreatic ductal adenocarcinoma incidence
|
J:197052
|
increased pancreatic intraepithelial neoplasia incidence
|
J:197052
|
Tg(CAG-cat,-ALOX15)1868Klv/0 Tg(Pbsn-cre)4Prb/0
(involves: C57BL/6 * DBA/2)
|
increased prostate intraepithelial neoplasia incidence
|
J:114903
|
Tg(CAG-cat,-ALOX15)1868Klv/Tg(CAG-cat,-ALOX15)1868Klv Tg(Pbsn-cre)4Prb/?
(involves: C57BL/6 * DBA/2)
|
increased prostate intraepithelial neoplasia incidence
|
J:114903
|
Tg(CAG-Has2)99Nita/0 Tg(MMTV-cre)4Mam/0 Tg(MMTVneu)202Mul/0
(FVB.Cg-Tg(CAG-Has2)99Nita Tg(MMTV-cre)4Mam Tg(MMTVneu)202Mul)
|
increased mammary adenocarcinoma incidence
|
J:130531,
J:164205
|
increased mammary gland tumor incidence
|
J:164205
|
Tg(CAG-Has2)99Nita/0 Tg(MMTVneu)202Mul/0
(FVB.Cg-Tg(CAG-Has2)99Nita Tg(MMTVneu)202Mul)
|
increased mammary adenocarcinoma incidence
|
J:130531
|
Tg(CAG-lacZ,-SV40)#Bcv/0
(involves: FVB/N)
|
increased liver tumor incidence
|
J:158388
|
increased ovarian carcinoma incidence
|
J:158388
|
increased ovary tumor incidence
|
J:158388
|
increased pancreas tumor incidence
|
J:158388
|
increased spleen neoplasm incidence
|
J:158388
|
Tg(CAG-Ptafr)1Tksh/0
(B6;D2-Tg(CAG-Ptafr)1Tksh/TkshRbrc)
|
increased cutaneous melanoma incidence
|
J:38639
|
Tg(CAG-Tle1,-ALPP)1Lbe/0
(involves: 129S1/Sv * 129X1/SvJ * CD-1)
|
increased lung adenocarcinoma incidence
|
J:106684
|
Tg(CAG-TRIM29)ADims/0
(FVB/NJ-Tg(CAG-TRIM29)ADims)
|
increased urinary bladder carcinoma incidence
|
J:226764
|
Tg(CD2-Lmo2)#Thr/0
(involves: C57BL/6 * CBA)
|
increased acute lymphoblastic leukemia incidence
|
J:102058
|
Tg(CD2-NPM/ALK)4Sudt/0
(involves: C57BL/6J * CBA)
|
increased B cell derived lymphoma incidence
|
J:181238
|
increased hemolymphoid system tumor incidence
|
J:181238
|
increased liver tumor incidence
|
J:181238
|
Tg(CD2-Tgfbr2)1Grs/?
(C57BL/6-Tg(CD2-Tgfbr2)1Grs/Nci)
|
increased leukemia incidence
|
J:93665
|
increased T cell derived lymphoma incidence
|
J:93665
|
Tg(Cd4-NPM/ALK)N1Ingh/0
(either: (involves: BALB/c * Swiss Webster) or (involves: C57BL/6 * Swiss Webster))
|
increased hemolymphoid system tumor incidence
|
J:82127
|
increased lymphoblastic lymphoma incidence
|
J:82127
|
increased myeloma incidence
|
J:82127
|
Tg(Cd4-NPM/ALK)N1Ingh/0
(involves: C57BL/6 * Swiss Webster)
|
increased thymus tumor incidence
|
J:235890
|
Tg(Cd4-NPM/ALK)N1Ingh/0 Tg(TcraTcrb)1100Mjb/0
(involves: C57BL/6 * Swiss Webster)
|
increased gastrointestinal stromal tumor incidence
|
J:235890
|
increased hepatocellular carcinoma incidence
|
J:235890
|
increased T cell derived lymphoma incidence
|
J:235890
|
Tg(Cd79b-TCL1A)BKTeit/0
(involves: C3H * C57BL/6)
|
increased B cell derived lymphoma incidence
|
J:79703
|
Tg(CEACAM5-Tag)L5496Wzm/0
(involves: C57BL/6 * CBA)
|
increased gastric adenocarcinoma incidence
|
J:62581
|
Tg(Cebpb-tTA)5Bjd/0 Tg(tetO-MYC,-OVAL)#Gtgm/0
(B6J.Cg-Tg(Cebpb-tTA)5Bjd Tg(tetO-MYC,-OVAL)#Gtgm)
|
increased hepatocellular carcinoma incidence
|
J:186226
|
Tg(Cela1-luc,Cela1-TAg)#Nzh/0
(involves: FVB/N)
|
increased ovary tumor incidence
|
J:207960
|
increased pancreatic acinar cell carcinoma incidence
|
J:207960
|
Tg(Cga-LHB/CGB)94Jhn/?
(involves: C57BL/6 * SJL)
|
increased ovary tumor incidence
|
J:55157
|
Tg(Cma1-cre)ARoer/0 Tg(Kit*D814V)1Roer/0
(involves: C57BL/6)
|
increased skin tumor incidence
|
J:169611
|
Tg(Cma1-cre)ARoer/0 Tg(Kit*D814V)3Roer/0
(involves: C57BL/6)
|
increased skin tumor incidence
|
J:169611
|
Tg(CMV-SALL4_iB)#Chai/?
(Not Specified)
|
increased leukemia incidence
|
J:115037
|
Tg(CMV-Tsc2*)1Arbi/0
(involves: C57BL/6)
|
increased skin hamartoma incidence
|
J:96943
|
Tg(CMV-tTA)3Bjd/0 Tg(tetO-Prkar1a*x2as)1Stra/0
(involves: C57BL/6 * NMRI * SJL)
|
increased histiocytic sarcoma incidence
|
J:94953
|
increased liver adenoma incidence
|
J:94953
|
increased liver tumor incidence
|
J:94953
|
increased lymphoma incidence
|
J:94953
|
increased Schwannoma incidence
|
J:95465
|
increased skin papilloma incidence
|
J:95465
|
increased thyroid adenoma incidence
|
J:95465,
J:94953
|
Tg(Cnp-EGFR)10Nrat/0
(involves: C57BL/6 * SJL)
|
increased neurofibroma incidence
|
J:95933
|
increased rhabdomyosarcoma incidence
|
J:95933
|
Tg(Cryaa-TAg)7488Lmgd/?
(Not Specified)
|
increased eye tumor incidence
|
J:127709
|
Tg(CSTG-NPM1/RARA)#Sjch/0
(involves: C57BL/6)
|
increased acute promyelocytic leukemia incidence
|
J:55196
|
increased chronic myelocytic leukemia incidence
|
J:55196
|
increased leukemia incidence
|
J:55196
|
Tg(CTNNB1)1Efu/0
(involves: CD-1)
|
increased pilomatricoma incidence
|
J:51296
|
increased trichofolliculoma incidence
|
J:51296
|
Tg(CTSG-NUMA1/RARA)#Skr/0
(involves: C57BL/6)
|
increased acute promyelocytic leukemia incidence
|
J:88103
|
Tg(CTSG-PML/RARA)135Ley/?
(Not Specified)
|
increased acute promyelocytic leukemia incidence
|
J:77881
|
Tg(CTSG-PML/RARA)135Ley/?
(involves: C3H * C57BL/6)
|
increased acute promyelocytic leukemia incidence
|
J:59080
|
Tg(CTSG-PML/RARA)135Ley/0 Tg(CTSG-RARA/PML)2544Ley/0
(involves: C3H * C57BL/6)
|
increased acute promyelocytic leukemia incidence
|
J:59080
|
Tg(CTSG-PML/RARA)135Ley/0 Tg(CTSG-RARA/PML)#Ley/0
(involves: C3H * C57BL/6)
|
increased acute promyelocytic leukemia incidence
|
J:59080
|
Tg(CTSG-PML/RARA)6179Ppp/0
(Not Specified)
|
increased acute promyelocytic leukemia incidence
|
J:40373
|
increased leukemia incidence
|
J:40373
|
Tg(CTSG-PML/RARA)#Ppp/0
(Not Specified)
|
increased acute promyelocytic leukemia incidence
|
J:78201,
J:40373
|
increased leukemia incidence
|
J:78201,
J:40373
|
Tg(CTSG-RARA/ZBTB16)#Ppp/0 Tg(CTSG-ZBTB16/RARA)#Ppp/0
(Not Specified)
|
increased acute promyelocytic leukemia incidence
|
J:65878
|
increased leukemia incidence
|
J:65878
|
Tg(CTSG-RARA/ZBTB16)#Sjch/0 Tg(CTSG-ZBTB16/RARA)#Sjch/0
(Not Specified)
|
increased acute promyelocytic leukemia incidence
|
J:194312
|
Tg(CTSG-ZBTB16/RARA)#Ppp/0
(Not Specified)
|
increased chronic myelocytic leukemia incidence
|
J:65878,
J:78201
|
increased leukemia incidence
|
J:78201
|
Tg(CTSG-ZBTB16/RARA)#Ppp/0 Zbtb16tm1Ppp/Zbtb16tm1Ppp
(involves: 129S1/Sv)
|
increased acute promyelocytic leukemia incidence
|
J:65878
|
Tg(CTSG-ZBTB16/RARA)#Sjch/0
(involves: C57BL/6)
|
increased chronic myelocytic leukemia incidence
|
J:55196
|
increased leukemia incidence
|
J:55196
|
Tg(Cyp19)C2-3Rrte/0
(involves: BALB/c * C57BL/6)
|
increased fibroadenoma incidence
|
J:34063
|
increased mammary gland tumor incidence
|
J:78693
|
Tg(Dct-Birc5)21Gros/0 Tg(Mt1-Hgf)19Lmb/0
(involves: C57BL/6 * CBA * FVB/N)
|
increased skin tumor incidence
|
J:122181
|
Tg(Dct-Grm1)ESzc/0
(involves: C57BL/6J)
|
increased cutaneous melanoma incidence
|
J:83183
|
Tg(Dct-Grm1)ESzc/0
(C57BL/6J-Tg(Dct-Grm1)ESzc)
|
increased intraocular melanoma incidence
|
J:230115
|
Tg(Ddx4-cre)1Dcas/0 Tg(EIF1AX-Lin28a)#Gqda/0
(involves: 129S4/SvJae * C57BL/6 * CD-1 * FVB/N)
|
increased kidney tumor incidence
|
J:211179
|
Tg(Ela1-Myc)158Bri/0
(involves: C57BL/6 * SJL)
|
increased pancreas tumor incidence
|
J:76992
|
increased pancreatic acinar cell carcinoma incidence
|
J:76992
|
Tg(Ela1-Myc)159Bri/0
(involves: C57BL/6 * SJL)
|
increased pancreas tumor incidence
|
J:76992
|
increased pancreatic acinar cell carcinoma incidence
|
J:76992
|
Tg(Ela1-Myc)160Bri/0
(involves: C57BL/6 * SJL)
|
increased pancreas tumor incidence
|
J:76992
|
increased pancreatic acinar cell carcinoma incidence
|
J:76992
|
Tg(Ela1-TAg)18Bri/0
(involves: C57BL/6 * SJL)
|
increased insulinoma incidence
|
J:76995
|
increased pancreas tumor incidence
|
J:76995
|
increased pancreatic acinar cell carcinoma incidence
|
J:76995
|
increased pancreatic islet cell adenoma incidence
|
J:76995
|
Tg(Ela1-TAg)19Bri/0
(involves: C57BL/6 * SJL)
|
increased insulinoma incidence
|
J:76995
|
increased pancreas tumor incidence
|
J:76995
|
increased pancreatic acinar cell carcinoma incidence
|
J:76995
|
Tg(Ela1-TAg*)79Mjt/0
(involves: C57BL/6 * DBA/2)
|
increased pancreas adenoma incidence
|
J:78026
|
increased pancreas tumor incidence
|
J:78026
|
increased pancreatic acinar cell carcinoma incidence
|
J:78026
|
Tg(Ela1-TAg*)79Mjt/0 Tg(MUC1)79.24Gend/0
(involves: C57BL/6 * DBA/2)
|
increased pancreas adenoma incidence
|
J:64570
|
increased pancreas tumor incidence
|
J:64570
|
increased pancreatic acinar cell carcinoma incidence
|
J:64570
|
Tg(Ela1-TAg*)289Mjt/0
(involves: C57BL/6 * DBA/2)
|
increased pancreas adenoma incidence
|
J:78026
|
increased pancreas tumor incidence
|
J:78026
|
increased pancreatic acinar cell carcinoma incidence
|
J:78026
|
Tg(Ela1-Tgfa)150Bri/0
(involves: C57BL/6 * SJL)
|
increased pancreas tumor incidence
|
J:52757,
J:67389
|
Tg(Ela1-Tgfa)150Bri/0 Trp53tm1Tyj/Trp53+
(involves: 129S2/SvPas * BALB/c * C57BL/6 * SJL)
|
increased pancreas tumor incidence
|
J:67389
|
Tg(Ela1-Tgfa)150Bri/0 Trp53tm1Tyj/Trp53tm1Tyj
(involves: 129S2/SvPas * BALB/c * C57BL/6 * SJL)
|
increased pancreas tumor incidence
|
J:67389
|
increased pancreatic ductal adenocarcinoma incidence
|
J:67389
|
Tg(Ela-KRAS*G12D)9Eps/0
(involves: C57BL/6 * FVB)
|
increased pancreas tumor incidence
|
J:231759
|
Tg(Ela-KRAS*G12D)9Eps/0 Tg(Mt1-TGFBR2*)AM3Epb/0
(involves: C57BL/6 * FVB)
|
increased pancreas tumor incidence
|
J:231759
|
Tg(Ela-KRAS*G12D)9Eps/0 Tgfbr1tm1Bopa/Tgfbr1+
(involves: 129S1/SvImJ * C57BL/6 * FVB)
|
increased pancreas tumor incidence
|
J:231759
|
Tg(Emu-Pim1)64aBrn/0
(involves: C57BL/6LiA * CBA)
|
increased lymphoma incidence
|
J:79624
|
increased T cell derived lymphoma incidence
|
J:79624
|
Tg(Emu-TXLNA)1Amjr/0
(B6.Cg-Tg(Emu-TXLNA)1Amjr)
|
increased B cell derived lymphoma incidence
|
J:117018
|
Tg(EmuSR-HDAC9)1468Kpet/0
(involves: C57BL/6 * CBA)
|
increased B cell derived lymphoma incidence
|
J:237420
|
increased histiocytic sarcoma incidence
|
J:237420
|
increased leukemia incidence
|
J:237420
|
increased splenic marginal zone lymphoma incidence
|
J:237420
|
Tg(EmuSR-tTa)83Bop/0 Tg(IghMyc)22Bri/0 Tg(tetO-RNAi:Trp53)ASlowe/0
(involves: C57BL * C57BL/6 * FVB/N * SJL)
|
increased lymphoma incidence
|
J:123006
|
Tg(EmuSR-tTa)83Bop/Tg(EmuSR-tTa)83Bop Tg(tetO-NPM1/ALK,-luc)2Gde/0
(involves: FVB/N)
|
increased B cell derived lymphoma incidence
|
J:160236
|
increased leukemia incidence
|
J:160236
|
Tg(EmuSR-tTa)83Bop/Tg(EmuSR-tTa)83Bop Tg(tetO-TPM3/ALK,-luc)2Gde/0
(involves: FVB/N)
|
increased B cell derived lymphoma incidence
|
J:160236
|
increased leukemia incidence
|
J:160236
|
Tg(Erbb2*)#Maed/0 Tg(Foxa3-cre)1Khk/0
(involves: C57BL/6 * C57BL/6J * DBA)
|
increased pancreas tumor incidence
|
J:262746
|
Tg(Erbb2-Erbb2)NN60Led/0
(involves: FVB/N)
|
increased keratoacanthoma incidence
|
J:62441
|
Tg(Erbb2-Erbb2*V664E)#Led/0
(involves: FVB/N)
|
increased mammary adenocarcinoma incidence
|
J:62441
|
increased mammary gland tumor incidence in breeding females
|
J:62441
|
Tg(Fabp1-Ccnd1)2Rdb/0
(C57BL/6-Tg(Fabp1-Ccnd1)2Rdb)
|
increased liver adenoma incidence
|
J:70394
|
Tg(Fabp1-Ccnd1)4Rdb/0
(C57BL/6-Tg(Fabp1-Ccnd1)4Rdb/J)
|
increased hepatocellular carcinoma incidence
|
J:70394
|
increased liver adenoma incidence
|
J:70394
|
Tg(Gcg-TAg)25Ddr/?
(involves: CD-1)
|
increased colon tumor incidence
|
J:101537
|
increased large intestine adenocarcinoma incidence
|
J:91490,
J:101537
|
increased pancreas tumor incidence
|
J:91490,
J:101537
|
Tg(GFAP-Hras1)2Agu/0
(involves: 129S1/Sv * 129X1/SvJ * ICR)
|
increased astrocytoma incidence
|
J:69129
|
Tg(GFAP-Hras1)2Agu/Tg(GFAP-Hras1)2Agu
(involves: 129S1/Sv * 129X1/SvJ * ICR)
|
increased astrocytoma incidence
|
J:69129
|
Tg(GFAP-SRC)1Aag/0
(involves: C3H * C57BL/6)
|
increased astrocytoma incidence
|
J:40335
|
Tg(GFAP-SRC)2Aag/0
(involves: C3H * C57BL/6)
|
increased astrocytoma incidence
|
J:40335
|
increased Schwannoma incidence
|
J:40335
|
Tg(GFAP-TAg121)1Tvd/0
(involves: C57BL/6 * DBA/2 * FVB/N)
|
increased astrocytoma incidence
|
J:77132
|
Tg(GFAP-tTA)67Pop/0 Tg(tetO-Ifng)184Pop/0
(B6.Cg-Tg(GFAP-tTA)67Pop Tg(tetO-Ifng)184Pop)
|
increased medulloblastoma incidence
|
J:94092
|
Tg(GFAP-tTA)67Pop/0 Tg(tetO-Ifng)184Pop/0
(involves: 129S/SvEv * C57BL/6 * DBA/2)
|
increased medulloblastoma incidence
|
J:94092
|
Tg(GFAP-TVA)5Hev/0
(involves: BALB/c * C57BL/6 * FVB/N)
|
increased glioma incidence
|
J:125535
|
increased oligodendroglioma incidence
|
J:125535
|
Tg(Ggamma-T)15Cps/0
(involves: C57BL/6J * CBA/J)
|
increased adrenal gland tumor incidence
|
J:38778
|
increased prostate gland tumor incidence
|
J:38778
|
increased prostate intraepithelial neoplasia incidence
|
J:38778
|
increased testis tumor incidence
|
J:38778
|
Tg(Ggamma-T)15Cps/Tg(Ggamma-T)15Cps
(involves: C57BL/6J * CBA/J)
|
increased adrenal gland tumor incidence
|
J:38778
|
increased prostate gland tumor incidence
|
J:38778
|
increased prostate intraepithelial neoplasia incidence
|
J:38778
|
increased testis tumor incidence
|
J:38778
|
Tg(Ggt1-Hif1a*)43Log/0
(involves: C57BL/6)
|
increased renal carcinoma incidence
|
J:177381
|
Tg(Ggt1-tTA)#Agoc/0 Tg(tetO-MYC)36aBop/0
(involves: FVB/N)
|
increased renal carcinoma incidence
|
J:222943
|
Tg(Gh-Gal)4599Vron/?
(involves: C57BL/6 * CD-1 * SJL)
|
increased pituitary adenoma incidence
|
J:86486
|
Tg(GHRL-TAg)1-5Hiwa/0
(C57BL/6-Tg(GHRL-TAg)1-5Hiwa)
|
increased pancreas tumor incidence
|
J:152492
|
increased stomach tumor incidence
|
J:152492
|
increased thyroid tumor incidence
|
J:152492
|
Tg(GHRL-TAg)3-1Hiwa/0
(C57BL/6-Tg(GHRL-TAg)3-1Hiwa)
|
increased stomach tumor incidence
|
J:152492
|
Tg(GZMB-Tax)#Lera/0
(involves: C57BL/6)
|
increased skeletal tumor incidence
|
J:147601
|
Tg(H2-D-Il15)3304Clgr/?
(FVB/N-Tg(H2-D-Il15)3304Clgr)
|
increased leukemia incidence
|
J:97873,
J:67478
|
Tg(H2-K-BCL2)1Josd/0 Tg(SFTPC-RAF1-BxB)1Urr/0
(involves: 129S2/SvPas * C3H * C57BL/6 * DBA/2)
|
increased lung adenoma incidence
|
J:79696
|
Tg(H2-K-Hmga1)#Lmsr/0
(involves: C57BL/6 * SJL)
|
increased leukemia incidence
|
J:121308
|
increased lymphoma incidence
|
J:90252,
J:121308
|
increased T cell acute lymphoblastic leukemia incidence
|
J:90252
|
increased uterus leiomyoma incidence
|
J:121308
|
increased uterus tumor incidence
|
J:121308
|
Tg(H2-L-IL6)46Kish/Tg(H2-L-IL6)46Kish
(C.B6-Tg(H2-L-IL6)46Kish)
|
increased B cell derived lymphoma incidence
|
J:74377
|
increased follicular lymphoma incidence
|
J:74377
|
Tg(H-2K1-Lrp5/Fkbp1a,-luc*)#Dmps/0
(involves: FVB/N)
|
increased prostate gland adenocarcinoma incidence
|
J:206727,
J:184212
|
Tg(H-2K1-Lrp5/Fkbp1a,-luc*)#Dmps/0 Tg(Pbsn-Fgfr1/Fkbp1a)#aDmsp/0
(involves: FVB/N)
|
increased prostate gland adenocarcinoma incidence
|
J:206727
|
Tg(HBV-HCV)21Kko/0
(C57BL/6N-Tg(HBV-HCV)21Kko)
|
increased hepatocellular carcinoma incidence
|
J:52686
|
increased liver adenoma incidence
|
J:52686
|
Tg(HBV-HCV)49Kko/0
(C57BL/6N-Tg(HBV-HCV)49Kko)
|
increased hepatocellular carcinoma incidence
|
J:52686
|
increased liver adenoma incidence
|
J:52686
|
Tg(HBV-HCV)Kko/0
(C57BL/6N-Tg(HBV-HCV)Kko)
|
increased hepatocellular carcinoma incidence
|
J:52686
|
increased liver adenoma incidence
|
J:52686
|
Tg(HBVX*,-Myc)#Skp/0
(Not Specified)
|
increased hepatocellular carcinoma incidence
|
J:81098
|
Tg(HBVX*,-Myc)#Skp/Tg(HBVX*,-Myc)#Skp
(Not Specified)
|
increased hepatocellular carcinoma incidence
|
J:81098
|
Tg(HBx)3Yu/0
(involves: C57BL/6 * DBA)
|
increased hepatocellular carcinoma incidence
|
J:56196
|
Tg(HIV)26Aln/0
(involves: FVB/N)
|
increased skin papilloma incidence
|
J:90297
|
Tg(Hnf1a-RB1*)XMiu/?
(Not Specified)
|
increased liver adenoma incidence
|
J:180294
|
Tg(HRAS)2Jic/?
(involves: BALB/c * C57BL/6)
|
increased lung adenocarcinoma incidence
|
J:64968
|
increased lymphoma incidence
|
J:64968
|
increased skin papilloma incidence
|
J:64968
|
Tg(HRAS)7Mok/?
(involves: C57BL/6)
|
increased lung adenocarcinoma incidence
|
J:64968
|
increased lymphoma incidence
|
J:64968
|
Tg(IGF1)1Jdg/0
(involves: FVB * ICR)
|
increased skin papilloma incidence
|
J:39752
|
Tg(Igh*-Mir125b-1)5Toki/0
(Not Specified)
|
increased B cell derived lymphoma incidence
|
J:178816
|
increased lymphoma incidence
|
J:178816
|
Tg(Igh*-Mir125b-1)116Toki/0
(Not Specified)
|
increased B cell derived lymphoma incidence
|
J:178816
|
increased lymphoma incidence
|
J:178816
|
increased T cell derived lymphoma incidence
|
J:178816
|
Tg(Igh-HMGA2)#Cro/0
(FVB/N-Tg(Igh-HMGA2)#Cro)
|
increased T cell acute lymphoblastic leukemia incidence
|
J:233225
|
Tg(Igh-HOX11)11Idd/0
(CD-1)
|
increased B cell derived lymphoma incidence
|
J:52782
|
Tg(Igh-Maf)68Staka/0
(C57BL/6-Tg(Igh-Maf)68Staka)
|
increased lymphoma incidence
|
J:168074
|
Tg(Igh-Maf)524Staka/0
(involves: C57BL/6 * C57BL/6J * DBA/2)
|
increased lymphoma incidence
|
J:168074
|
Tg(Igh-Mir29a,-Mir29b-1,-hrGFP)#Cro/0
(FVB/N-Tg(Igh-Mir29a,-Mir29b-1,-hrGFP)#Cro)
|
increased chronic lymphocytic leukemia incidence
|
J:162077
|
Tg(Igh-Mir29a,-Mir29b-1,-hrGFP)#Cro/0 Tg(Igh-V186.2-TCL1A)3Cro/0
(involves: C3H * C57BL/6 * FVB/N)
|
increased chronic lymphocytic leukemia incidence
|
J:162077
|
Tg(Igh-Mir155)8Cro/0
(involves: FVB/N)
|
increased B cell derived lymphoma incidence
|
J:109591
|
increased lymphoblastic lymphoma incidence
|
J:109591
|
Tg(Igh-Pim1)1Brn/0
(involves: C57BL/6LiA * CBA)
|
increased lymphoma incidence
|
J:79624
|
increased T cell derived lymphoma incidence
|
J:79624
|
Tg(Igh-ROR1)1Kip/0
(C57BL/6-Tg(Igh-ROR1)1Kip)
|
increased chronic lymphocytic leukemia incidence
|
J:206368
|
Tg(Igh-ROR1)1Kip/0 Tg(Igh-V186.2-TCL1A)3Cro/0
(B6.Cg-Tg(Igh-ROR1)1Kip Tg(Igh-V186.2-TCL1A)3Cro)
|
increased chronic lymphocytic leukemia incidence
|
J:206368
|
Tg(Igh-TCL1A)1Ypek/0
(FVB/N-Tg(Igh-TCL1A)1Ypek)
|
increased chronic lymphocytic leukemia incidence
|
J:160184
|
Tg(Igh-V186.2-TCL1A)3Cro/0
(involves: C3H * C57BL/6)
|
increased leukemia incidence
|
J:76574
|
Tg(Igh-V186.2-TCL1A)3Cro/0
(B6.Cg-Tg(Igh-V186.2-TCL1A)3Cro)
|
increased chronic lymphocytic leukemia incidence
|
J:206368
|
Tg(IghMyc)22Bri/?
(involves: C57BL * C57BL/6 * SJL)
|
increased lymphoma incidence
|
J:121564
|
Tg(IghMyc)22Bri/0
(involves: C57BL/6 * SJL)
|
increased B cell derived lymphoma incidence
|
J:186117,
J:78177
|
increased leukemia incidence
|
J:78177
|
increased lymphoma incidence
|
J:78177,
J:223213
|
Tg(IghMyc)22Bri/0
(B6.Cg-Tg(IghMyc)22Bri/J)
|
increased lymphoma incidence
|
J:164200
|
Tg(IghMyc)22Bri/0
(involves: C57BL * C57BL/6 * SJL)
|
increased lymphoma incidence
|
J:117023
|
Tg(IghMyc)22Bri/0
(involves: C57BL/6N * SJL)
|
increased lymphoma incidence
|
J:214383
|
Tg(IghMyc)22Bri/0 Tg(Igk-V21-Bax)1967Bvn/0
(involves: C57BL/6 * FVB/N)
|
increased B cell derived lymphoma incidence
|
J:89049
|
Tg(IghMyc)22Bri/0 Tg(Lck/Emu-Eif4e)#Ppp/0
(involves: C57BL * SJL)
|
increased lymphoma incidence
|
J:89878
|
Tg(IghMyc)22Bri/0 Trp53tm1Tyj/Trp53+
(involves: 129/Sv * 129X1/SvJ * C57BL * C57BL/6 * SJL)
|
increased B cell derived lymphoma incidence
|
J:125164
|
Tg(Igkv3-5*-MYC)24Plbe/0
(C57BL/6J-Tg(Igkv3-5*-MYC)DLoxP4Plbe/PlbeMmmh)
|
increased B cell derived lymphoma incidence
|
J:131912
|
increased myeloma incidence
|
J:131912
|
Tg(Igkv3-5-MYC)#Plbe/0
(involves: C57BL/6)
|
increased B cell derived lymphoma incidence
|
J:131912
|
Tg(IGL-MYC)3Hm/0
(C57BL/6N-Tg(IGL-MYC)3Hm/Nci)
|
increased B cell derived lymphoma incidence
|
J:65245
|
Tg(Ins1-Tag,-luc)1Gcr/0
(FVB/N-Tg(Ins1-Tag,-luc)1Gcr)
|
increased insulinoma incidence
|
J:162648
|
Tg(Ins1-Tag,-luc)1Gcr/0
(involves: C57BL/6 * FVB/N)
|
increased insulinoma incidence
|
J:162648
|
Tg(Ins2-Akt1*)3Mbb/0
(B6.Cg-Tg(Ins2-Akt1*)3Mbb)
|
increased insulinoma incidence
|
J:144599
|
increased pancreas tumor incidence
|
J:144599
|
increased pancreatic islet cell carcinoma incidence
|
J:144599
|
Tg(Ins2-IGF1R)1Dh/0 Tg(RIP1-Tag)2Dh/0
(involves: C3H * C57BL/6 * C57BL/6J * DBA/2J)
|
increased insulinoma incidence
|
J:205389
|
increased pancreatic islet cell carcinoma incidence
|
J:205389
|
Tg(Ins2-rtTA)2Efr/0 Tg(tetO-TAg)1Efr/0
(involves: C3HeB/FeJ * C57BL/6 * CBA)
|
increased insulinoma incidence
|
J:130049
|
Tg(Ins2-TAg)1Lt/0
(NOD/ShiLt-Tg(Ins2-TAg)1Lt)
|
increased insulinoma incidence
|
J:92449
|
Tg(Ins2-Tag*,-flpe)#Gne/0
(involves: C57BL/6J)
|
increased insulinoma incidence
|
J:187012
|
increased pancreas tumor incidence
|
J:187012
|
increased pancreatic islet cell carcinoma incidence
|
J:187012
|
Tg(Ins2-Tag*,-flpe)#Gne/0
(Not Specified)
|
increased pancreatic islet cell carcinoma incidence
|
J:188693
|
Tg(IRS1)1Mhep/0 Tg(SERPINA1-HBVX)1655Jtsb/0
(involves: C3H * C57BL/6 * FVB * ICR)
|
increased hepatocellular carcinoma incidence
|
J:227278
|
Tg(K5-Ptgs2)19Kmd/0
(involves: NMRI)
|
increased sebaceous gland adenoma incidence
|
J:79071
|
increased skin papilloma incidence
|
J:79071
|
Tg(K5-Ptgs2)667Kmd/0
(involves: NMRI)
|
increased sebaceous gland adenoma incidence
|
J:79071
|
increased skin papilloma incidence
|
J:79071
|
Tg(K6ODCtr)55Tgo/0
(involves: C3H * C57BL/6)
|
increased keratoacanthoma incidence
|
J:29098
|
increased skin papilloma incidence
|
J:29098
|
increased skin tumor incidence
|
J:29098
|
Tg(Kit*D814V)1Roer/0 Tg(Mx1-cre)1Cgn/0
(involves: C57BL/6 * CBA)
|
increased chronic myelocytic leukemia incidence
|
J:169611
|
increased leukemia incidence
|
J:169611
|
increased skin tumor incidence
|
J:169611
|
Tg(Kit*D814V)2Roer/0 Tg(Mx1-cre)1Cgn/0
(involves: C57BL/6 * CBA)
|
increased skin tumor incidence
|
J:169611
|
Tg(Kit*D814V)3Roer/0 Tg(Mx1-cre)1Cgn/0
(involves: C57BL/6 * CBA)
|
increased leukemia incidence
|
J:169611
|
increased skin tumor incidence
|
J:169611
|
Tg(Krt1-14-GLI)1Oro/0
(involves: C57BL/6 * CBA)
|
increased trichofolliculoma incidence
|
J:82653
|
Tg(KRT5-Akt1*)Jmpa/0
(involves: C57BL/6 * DBA/2 * DBA/2J * FVB/N)
|
increased trichoepithelioma incidence
|
J:144831
|
Tg(KRT5-Terf2)PMBlas/Y
(involves: C57BL/6 * CBA)
|
increased keratoacanthoma incidence
|
J:102653
|
increased skin squamous cell carcinoma incidence
|
J:102653
|
increased skin tumor incidence
|
J:102653
|
Tg(KRT5-Terf2)POBlas/0
(involves: C57BL/6 * CBA)
|
increased keratoacanthoma incidence
|
J:102653
|
increased skin squamous cell carcinoma incidence
|
J:102653
|
increased skin tumor incidence
|
J:102653
|
Tg(Krt14-dnLef1)LFmw/?
(involves: C57BL/6 * CBA)
|
increased skin tumor incidence
|
J:73649
|
Tg(KRT14-Edn3)1Takk/?
(B6.Cg-Tg(KRT14-Edn3)1Takk)
|
increased thyroid tumor incidence
|
J:104881
|
Tg(KRT14-Fyn*)aJsey/0
(involves: C57BL/6 * CBA)
|
increased skin squamous cell carcinoma incidence
|
J:155536
|
Tg(KRT14-Fyn*)aJsey/0
(involves: C57BL/6 * CBA * FVB/N)
|
increased skin squamous cell carcinoma incidence
|
J:155536
|
Tg(KRT14-HPV8)9Vuc/0
(FVB.Cg-Tg(KRT14-HPV8)9Vuc)
|
increased skin papilloma incidence
|
J:96784
|
increased skin squamous cell carcinoma incidence
|
J:96784
|
Tg(KRT14-HPV8)9Vuc/0
(involves: C57BL/6 * DBA * FVB/N)
|
increased skin papilloma incidence
|
J:96784
|
Tg(KRT14-HPV8)61Vuc/0
(involves: C57BL/6 * DBA)
|
increased skin papilloma incidence
|
J:96784
|
Tg(KRT14-HPV8)85Vuc/0
(FVB.Cg-Tg(KRT14-HPV8)85Vuc)
|
increased skin papilloma incidence
|
J:96784
|
increased skin squamous cell carcinoma incidence
|
J:96784
|
Tg(KRT14-HPV8)85Vuc/0
(B6.Cg-Tg(KRT14-HPV8)85Vuc)
|
increased skin papilloma incidence
|
J:96784
|
Tg(KRT14-HPV8)#Vuc/0
(involves: C57BL/6 * DBA * FVB/N)
|
increased skin papilloma incidence
|
J:96784
|
increased skin squamous cell carcinoma incidence
|
J:96784
|
increased skin tumor incidence
|
J:96784
|
Tg(KRT14-HPV16)wt1Dh/0
(FVB.Cg-Tg(KRT14-HPV16)wt1Dh/Nci)
|
increased skin squamous cell carcinoma incidence
|
J:65699
|
Tg(KRT14-HPV16)wt1Dh/0
(either: FVB.Cg-Tg(KRT14-HPV16)wt1Dh or (involves: C57BL/6 * DBA/2 * FVB/N))
|
increased skin squamous cell carcinoma incidence
|
J:20130
|
Tg(KRT14-HPV16E7)2304Plam/0
(involves: FVB/N)
|
increased skin squamous cell carcinoma incidence
|
J:86018
|
Tg(KRT14-HPV16E7)2326Plam/0
(involves: FVB/N)
|
increased sebaceous gland tumor incidence
|
J:86018
|
increased skin squamous cell carcinoma incidence
|
J:86018
|
Tg(KRT14-Shh)#Cobm/0
(involves: C57BL/6 * CBA)
|
increased basal cell carcinoma incidence
|
J:150375
|
Tg(KRT14-Snai1)1Efu/0
(involves: CD-1)
|
increased basal cell carcinoma incidence
|
J:229072
|
increased sebaceous gland tumor incidence
|
J:229072
|
increased skin squamous cell carcinoma incidence
|
J:229072
|
increased skin tumor incidence
|
J:229072
|
Tg(Krt18-EGFP,-TAg121)36Ysng/0
(involves: C57BL/6 * DBA/2)
|
increased ovarian carcinoma incidence
|
J:189304
|
increased ovary tumor incidence
|
J:189304
|
Tg(Krt18-EGFP,-TAg121)36Ysng/0 Trp53tm1Brn/Trp53tm1Brn
(involves: 129P2/OlaHsd * C57BL/6 * DBA/2 * FVB/N)
|
increased ovary tumor incidence
|
J:189304
|
Tg(Krt18-EGFP,-TAg121)36Ysng/0 Trp53tm1Brn/Trp53tm2Tyj
(involves: 129P2/OlaHsd * 129S4/SvJae * C57BL/6 * DBA/2 * FVB/N)
|
increased ovary tumor incidence
|
J:189304
|
Tg(Krt19-Ptgs2,Krt19-Ptges)8Tko/0 Tg(Krt19-Wnt1)2Maos/0
(involves: C3H * C57BL/6)
|
increased gastric adenocarcinoma incidence
|
J:116782
|
increased stomach tumor incidence
|
J:116782,
J:153058
|
Tg(KRT19-TAg)7Eps/0
(involves: FVB/N)
|
increased adrenal gland tumor incidence
|
J:64395
|
increased prostate gland tumor incidence
|
J:64395
|
increased urinary bladder transitional cell carcinoma incidence
|
J:64395
|
Tg(LANA,vFLIP,vCYC)801Dtmr/?
(involves: C57BL/6)
|
increased lymphoma incidence
|
J:196403
|
Tg(Lck)4220Rmp/0
(involves: C57BL/6J * DBA/2)
|
increased T cell derived lymphoma incidence
|
J:88120
|
Tg(Lck-Akt1*)M-1Pnt/0
(involves: C3H/He * C57BL/6)
|
increased T cell derived lymphoma incidence
|
J:73487
|
Tg(Lck-Akt1*E40K)E-3Pnt/0
(involves: C3H/He * C57BL/6)
|
increased T cell derived lymphoma incidence
|
J:73487
|
Tg(Lck-Akt1*E40K)E-3Pnt/0
(Not Specified)
|
increased T cell derived lymphoma incidence
|
J:144975
|
Tg(Lck-Akt2*)#Test/0
(Not Specified)
|
increased lymphoma incidence
|
J:154583
|
increased T cell derived lymphoma incidence
|
J:153923
|
Tg(Lck-Id1)28Xhsu/0
(Not Specified)
|
increased T cell derived lymphoma incidence
|
J:58607
|
Tg(Lck-LMO1)11Sjk/0 Tg(STIL-TAL1)A5(3)Alpa/0
(involves: C3H * C3H/HeRos * C57BL/6 * C57BL/10Ros)
|
increased leukemia incidence
|
J:40868
|
increased T cell derived lymphoma incidence
|
J:40868
|
Tg(Lck-Map3k8)3456Ngc/?
(involves: C3H/HeJ * C57BL/6J)
|
increased T cell derived lymphoma incidence
|
J:39450
|
Tg(Lck-Notch3)#Issc/0
(involves: C57BL/6 * DBA/2)
|
increased acute lymphoblastic leukemia incidence
|
J:63300
|
increased lymphoblastic lymphoma incidence
|
J:63300
|
increased T cell derived lymphoma incidence
|
J:96010
|
Tg(Lck-Tal1)4709Led/0
(FVB/N-Tg(Lck-Tal1)4709Led)
|
increased leukemia incidence
|
J:36076
|
increased lymphoblastic lymphoma incidence
|
J:36076
|
Tg(Lck-Tax)53Hall/0
(involves: C57BL/6)
|
increased leukemia incidence
|
J:129531
|
increased T cell derived lymphoma incidence
|
J:129531
|
Tg(Lck-TNFSF13)3919Mhah/0
(B6.Cg-Tg(Lck-TNFSF13)3919Mhah)
|
increased chronic lymphocytic leukemia incidence
|
J:94628
|
Tg(LckNotch1)9Erob/?
(involves: C57BL/6 * CBA/J)
|
increased T cell derived lymphoma incidence
|
J:93005
|
Tg(LCKprBCL2)36Sjk/?
(involves: C3H * C57BL/6)
|
increased T cell derived lymphoma incidence
|
J:28635
|
Tg(Ly6a-BCR/ABL1)IS1AIsg/0
(involves: C57BL/6J * CBA)
|
increased chronic myelocytic leukemia incidence
|
J:144382
|
increased hepatoma incidence
|
J:144382
|
increased lung adenocarcinoma incidence
|
J:144382
|
increased osteosarcoma incidence
|
J:144382
|
increased testis tumor incidence
|
J:144382
|
Tg(Ly6a-BCR/ABL1)IS1AIsg/0 Tg(Ly6a-BCR/ABL1)IS1BIsg/0
(involves: C57BL/6J * CBA)
|
increased leukemia incidence
|
J:144382
|
Tg(Ly6a-BCR/ABL1)IS1BIsg/0
(involves: C57BL/6J * CBA)
|
increased chronic myelocytic leukemia incidence
|
J:144382
|
increased hepatoma incidence
|
J:144382
|
increased lung adenocarcinoma incidence
|
J:144382
|
increased osteosarcoma incidence
|
J:144382
|
increased testis tumor incidence
|
J:144382
|
Tg(Ly6a-TK,-BCR/ABL1)IS9AIsg/0
(involves: C57BL/6J * CBA)
|
increased chronic myelocytic leukemia incidence
|
J:144382
|
Tg(Ly6e-MALT1)#Isg/0
(involves: C57BL/6 * CBA)
|
increased B cell derived lymphoma incidence
|
J:185590
|
Tg(MCL1)8Caig/0
(involves: C57BL/6 * SJL)
|
increased follicular lymphoma incidence
|
J:69755
|
increased lymphoma incidence
|
J:69755
|
increased T cell derived lymphoma incidence
|
J:69755
|
Tg(Mdm2)1Snj/0
(involves: 129S7/SvEvBrd * C57BL/6)
|
increased lymphoma incidence
|
J:51661
|
increased pituitary adenoma incidence
|
J:51661
|
increased rhabdomyosarcoma incidence
|
J:51661
|
Tg(Mdm2)1Snj/0 Trp53tm1Brd/Trp53tm1Brd
(involves: 129S7/SvEvBrd * C57BL/6)
|
increased lymphoma incidence
|
J:51661
|
increased medulloblastoma incidence
|
J:51661
|
increased osteosarcoma incidence
|
J:51661
|
Tg(MGMT)3Bec/Tg(MGMT)3Bec
(involves: NMRI)
|
increased skin papilloma incidence
|
J:92925
|
Tg(MMTV-AURKA)#Cxd/?
(involves: FVB/N)
|
increased kidney tumor incidence
|
J:145680
|
increased mammary adenocarcinoma incidence
|
J:145680
|
increased ovary tumor incidence
|
J:145680
|
Tg(MMTV-AURKA)#Cxd/? Trp53tm1Tyj/Trp53+
(involves: 129S2/SvPas * FVB/N)
|
increased mammary adenocarcinoma incidence
|
J:145680
|
Tg(MMTV-CCND1)1Esmp/0
(Not Specified)
|
increased mammary adenoacanthoma incidence
|
J:70571
|
increased mammary adenocarcinoma incidence
|
J:70571
|
increased mammary gland tumor incidence
|
J:70571
|
increased testis tumor incidence
|
J:70571
|
Tg(MMTV-CCND1)1Esmp/0 Tg(MMTV-Cdc37)1Stp/0
(involves: C57BL/6 * DBA/2 * FVB/N)
|
increased mammary adenocarcinoma incidence
|
J:62465
|
increased mammary gland tumor incidence
|
J:62465
|
Tg(MMTV-Cdc37)1Stp/0
(involves: C57BL/6 * DBA/2 * FVB/N)
|
increased lymphoma incidence
|
J:62465
|
increased mammary adenoacanthoma incidence
|
J:62465
|
increased mammary adenocarcinoma incidence
|
J:62465
|
Tg(MMTV-Cdc37)1Stp/0 Tg(MMTV-Myc)141-3Led/0
(involves: C57BL/6 * CD-1 * DBA/2 * FVB/N)
|
increased Leydig cell tumor incidence
|
J:62465
|
increased lymphoma incidence
|
J:62465
|
increased mammary adenocarcinoma incidence
|
J:62465
|
increased mammary gland tumor incidence
|
J:62465
|
increased salivary adenocarcinoma incidence
|
J:62465
|
Tg(MMTV-Cdc37)2Stp/0
(involves: C57BL/6 * DBA/2 * FVB/N)
|
increased lymphoma incidence
|
J:62465
|
increased mammary adenoacanthoma incidence
|
J:62465
|
Tg(MMTV-DMTF1_i2)7Kai/0
(FVB/NJ-Tg(MMTV-DMTF1_i2)7Kai)
|
increased mammary gland tumor incidence in breeding females
|
J:220608
|
Tg(MMTV-ENPP2)20Gbm/0
(FVB/N-Tg(MMTV-ENPP2)20Gbm)
|
increased mammary adenocarcinoma incidence
|
J:149661
|
increased mammary gland tumor incidence in breeding females
|
J:149661
|
Tg(MMTV-ENPP2)21Gbm/0
(FVB/N-Tg(MMTV-ENPP2)21Gbm)
|
increased mammary adenocarcinoma incidence
|
J:149661
|
increased mammary gland tumor incidence in breeding females
|
J:149661
|
Tg(MMTV-ENPP2)#Gbm/0
(FVB/N-Tg(MMTV-ENPP2)#Gbm)
|
increased mammary adenocarcinoma incidence
|
J:149661
|
increased mammary gland tumor incidence in breeding females
|
J:149661
|
Tg(MMTV-Erbb2)1Pv/0
(involves: BALB/c * C57BL/6 * CD-1 * DBA)
|
increased mammary adenocarcinoma incidence
|
J:234420
|
Tg(MMTV-ERBB2)5Erick/?
(FVB/N-Tg(MMTV-ERBB2)5Erick)
|
increased Harderian gland adenoma incidence
|
J:90202
|
increased mammary adenocarcinoma incidence
|
J:90202
|
increased mammary gland tumor incidence
|
J:90202
|
Tg(MMTV-Erbb2)9Pjo/0
(involves: BALB/c * C3H * C57BL/6)
|
increased mammary adenocarcinoma incidence
|
J:72129
|
Tg(MMTV-Erbb2)10Pjo/0
(involves: BALB/c * C3H * C57BL/6)
|
increased Harderian gland tumor incidence
|
J:72129
|
increased mammary adenocarcinoma incidence
|
J:72129
|
increased salivary gland tumor incidence
|
J:72129
|
Tg(MMTV-Erbb2)12Pjo/0
(involves: BALB/c * C3H * C57BL/6)
|
increased mammary adenocarcinoma incidence
|
J:72129
|
increased salivary gland tumor incidence
|
J:72129
|
Tg(MMTV-Erbb2)17Pjo/0
(involves: BALB/c * C3H * C57BL/6)
|
increased mammary adenocarcinoma incidence
|
J:72129
|
Tg(MMTV-Erbb2)NA1Mul/0
(involves: FVB/N)
|
increased mammary adenocarcinoma incidence
|
J:48632
|
Tg(MMTV-Erbb2)NF1Mul/0
(involves: FVB/N)
|
increased mammary adenocarcinoma incidence
|
J:48632
|
Tg(MMTV-Erbb2)NF1Mul/0
(involves: CD-1 * FVB/N)
|
increased mammary adenocarcinoma incidence
|
J:48632
|
Tg(MMTV-Erbb2)NF1Mul/0
(FVB/N-Tg(MMTV-Erbb2)NF1Mul)
|
increased mammary adenocarcinoma incidence
|
J:48632
|
Tg(MMTV-Erbb2)NK1Mul/0
(involves: FVB/N)
|
increased mammary adenocarcinoma incidence
|
J:48632
|
Tg(MMTV-Erbb2)NK1Mul/0
(involves: 129P2/OlaHsd * C57BL/6 * FVB/N)
|
increased mammary gland tumor incidence
|
J:76653
|
Tg(MMTV-Erbb2)NK1Mul/0
(FVB/N-Tg(MMTV-Erbb2)NK1Mul)
|
increased mammary gland tumor incidence
|
J:67457
|
Tg(MMTV-Erbb2)NK1Mul/Tg(MMTV-Erbb2)NK1Mul
(involves: 129 * C57BL/6 * FVB/N)
|
increased mammary adenocarcinoma incidence
|
J:117336
|
Tg(MMTV-Erbb2*)NDL2-5Mul/0
(involves: C57BL/6)
|
increased mammary gland tumor incidence
|
J:189292
|
Tg(MMTV-Erbb2*,-cre)1Mul/0
(involves: 129S1/Sv * 129X1/SvJ * FVB/N)
|
increased mammary gland tumor incidence
|
J:133325
|
Tg(MMTV-Erbb2*,-cre)1Mul/0
(involves: FVB)
|
increased mammary gland tumor incidence
|
J:198481
|
Tg(MMTV-ERBB2*,-luc)6157Aami/0
(FVB-Tg(MMTV-ERBB2*,-luc)6157Aami)
|
increased mammary adenocarcinoma incidence
|
J:172352
|
increased mammary gland tumor incidence
|
J:172352
|
Tg(MMTV-ERBB2*,-luc)6177Aami/0
(FVB-Tg(MMTV-ERBB2*,-luc)6177Aami)
|
increased mammary gland tumor incidence
|
J:172352
|
Tg(MMTV-ERBB2*,-luc)6180Aami/0
(FVB-Tg(MMTV-ERBB2*,-luc)6180Aami)
|
increased mammary gland tumor incidence
|
J:172352
|
Tg(MMTV-ERBB3)1Slg/0
(involves: FVB)
|
increased lung adenocarcinoma incidence
|
J:80974
|
Tg(MMTV-ERBB3)1Slg/0 Tg(MMTVneu)202Mul/0
(involves: FVB)
|
increased lung adenocarcinoma incidence
|
J:80974
|
increased mammary gland tumor incidence
|
J:80974
|
Tg(MMTV-Espl1)1Pati/0
(involves: C57BL/6)
|
increased mammary adenocarcinoma incidence
|
J:216267
|
increased mammary gland tumor incidence in breeding females
|
J:216267
|
Tg(MMTV-KRAS*G12V)3025Mrl/0
(involves: C57BL/6 * FVB * SJL)
|
increased mammary adenocarcinoma incidence
|
J:77272
|
Tg(MMTV-KRAS*G12V)3025Mrl/0 Tg(MMTV-rtTA)1Lach/0 Tg(tetO-MYC)1Lach/0
(involves: C57BL/6 * FVB/N * SJL)
|
increased mammary gland tumor incidence
|
J:133578
|
Tg(MMTV-LPAR1)2Gbm/Tg(MMTV-LPAR1)2Gbm
(FVB/N-Tg(MMTV-LPAR1)2Gbm)
|
increased mammary adenocarcinoma incidence
|
J:149661
|
increased mammary gland tumor incidence in breeding females
|
J:149661
|
Tg(MMTV-LPAR1)7Gbm/Tg(MMTV-LPAR1)7Gbm
(FVB/N-Tg(MMTV-LPAR1)7Gbm)
|
increased mammary adenocarcinoma incidence
|
J:149661
|
increased mammary gland tumor incidence in breeding females
|
J:149661
|
Tg(MMTV-LPAR1)27Gbm/Tg(MMTV-LPAR1)27Gbm
(FVB/N-Tg(MMTV-LPAR1)27Gbm)
|
increased mammary adenocarcinoma incidence
|
J:149661
|
increased mammary gland tumor incidence in breeding females
|
J:149661
|
Tg(MMTV-LPAR1)#Gbm/Tg(MMTV-LPAR1)#Gbm
(FVB/N-Tg(MMTV-LPAR1)#Gbm)
|
increased mammary adenocarcinoma incidence
|
J:149661
|
increased mammary gland tumor incidence in breeding females
|
J:149661
|
Tg(MMTV-LPAR2)3Gbm/Tg(MMTV-LPAR2)3Gbm
(FVB/N-Tg(MMTV-LPAR2)3Gbm)
|
increased mammary adenocarcinoma incidence
|
J:149661
|
increased mammary gland tumor incidence in breeding females
|
J:149661
|
Tg(MMTV-LPAR2)6Gbm/Tg(MMTV-LPAR2)6Gbm
(FVB/N-Tg(MMTV-LPAR2)6Gbm)
|
increased mammary adenocarcinoma incidence
|
J:149661
|
increased mammary gland tumor incidence in breeding females
|
J:149661
|
Tg(MMTV-LPAR2)#Gbm/Tg(MMTV-LPAR2)#Gbm
(FVB/N-Tg(MMTV-LPAR2)#Gbm)
|
increased mammary adenocarcinoma incidence
|
J:149661
|
increased mammary gland tumor incidence in breeding females
|
J:149661
|
Tg(MMTV-LPAR3)3Gbm/Tg(MMTV-LPAR3)3Gbm
(FVB/N-Tg(MMTV-LPAR3)3Gbm)
|
increased mammary adenocarcinoma incidence
|
J:149661
|
increased mammary gland tumor incidence in breeding females
|
J:149661
|
Tg(MMTV-LPAR3)22Gbm/Tg(MMTV-LPAR3)22Gbm
(FVB/N-Tg(MMTV-LPAR3)22Gbm)
|
increased mammary adenocarcinoma incidence
|
J:149661
|
increased mammary gland tumor incidence in breeding females
|
J:149661
|
Tg(MMTV-LPAR3)#Gbm/Tg(MMTV-LPAR3)#Gbm
(FVB/N-Tg(MMTV-LPAR3)#Gbm)
|
increased mammary adenocarcinoma incidence
|
J:149661
|
increased mammary gland tumor incidence in breeding females
|
J:149661
|
Tg(MMTV-Myc)141-3Led/0
(involves: C57BL/6J * CD-1)
|
increased B cell derived lymphoma incidence
|
J:62465
|
Tg(MMTV-Myc)141-3Led/0 Tg(MMTV-rtTA)1Lach/0 Tg(tetO-Kras2)12Hev/0
(involves: C57BL/6J * CD-1 * FVB/N)
|
increased mammary gland tumor incidence
|
J:133578
|
Tg(MMTV-Myc)WT13Jrn/0
(involves: FVB/N)
|
increased mammary adenocarcinoma incidence
|
J:153233
|
increased mammary gland tumor incidence
|
J:153233,
J:193362
|
Tg(MMTV-Myc)WT21Jrn/0
(involves: FVB/N)
|
increased mammary adenocarcinoma incidence
|
J:153233
|
increased mammary gland tumor incidence
|
J:153233,
J:193362
|
Tg(MMTV-Myc*T58A)TA14Jrn/0
(involves: FVB/N)
|
increased mammary adenocarcinoma incidence
|
J:153233
|
increased mammary gland tumor incidence
|
J:153233,
J:193362
|
Tg(MMTV-Myc*T58A)TA39Jrn/0
(involves: FVB)
|
increased mammary gland tumor incidence
|
J:193362
|
Tg(MMTV-Myc*T58A)TA41Jrn/0
(involves: FVB/N)
|
increased mammary adenocarcinoma incidence
|
J:153233
|
increased mammary gland tumor incidence
|
J:153233,
J:193362
|
Tg(MMTV-NCOA3)#Mybr/0
(FVB/N-Tg(MMTV-NCOA3)#Mybr)
|
increased leiomyosarcoma incidence
|
J:93548
|
increased lung adenocarcinoma incidence
|
J:93548
|
increased mammary adenocarcinoma incidence
|
J:93548
|
increased mammary gland tumor incidence
|
J:93548
|
increased pituitary adenoma incidence
|
J:93548
|
Tg(MMTV-neu/OT-I/OT-II)CBnel/?
(involves: C57BL/6)
|
increased lung tumor incidence
|
J:122846
|
increased mammary gland tumor incidence
|
J:122846
|
Tg(MMTV-neu/OT-I/OT-II)CBnel/? Tg(Trp53R172H)8512Jmr/?
(involves: C57BL/6 * FVB)
|
increased mammary adenocarcinoma incidence
|
J:122846
|
Tg(MMTV-Notch4)3Rnc/0
(involves: FVB/N)
|
increased mammary adenocarcinoma incidence
|
J:11644
|
increased salivary adenocarcinoma incidence
|
J:11644
|
Tg(MMTV-PTGS2)#Thla/0
(involves: CD-1)
|
increased mammary adenocarcinoma incidence
|
J:68565
|
increased mammary gland ductal carcinoma incidence
|
J:68565
|
Tg(MMTV-PyVT)634Mul/0
(FVB/N-Tg(MMTV-PyVT)634Mul/Nci)
|
increased mammary adenocarcinoma incidence
|
J:46460,
J:51424,
J:87544,
J:48285
|
Tg(MMTV-PyVT)634Mul/0
(multiple strains)
|
increased mammary adenocarcinoma incidence
|
J:48854
|
Tg(MMTV-PyVT)634Mul/0
(involves: 129 * C57BL/6 * FVB/N)
|
increased mammary adenocarcinoma incidence
|
J:117336
|
Tg(MMTV-PyVT)634Mul/0
(FVB/N-Tg(MMTV-PyVT)634Mul/J)
|
increased mammary gland tumor incidence
|
J:140033,
J:147458
|
Tg(MMTV-PyVT)634Mul/0
(involves: C57BL/6 * FVB/N)
|
increased mammary gland tumor incidence
|
J:147458
|
Tg(MMTV-PyVT)634Mul/0
(involves: FVB/N)
|
increased mammary gland tumor incidence
|
J:133325,
J:236031
|
Tg(MMTV-PyVT)#Mul/0
(B6.FVB-Tg(MMTV-PyVT)#Mul)
|
increased mammary adenocarcinoma incidence
|
J:147923
|
Tg(MMTV-PyVT*Y250F)250-2Mul/?
(FVB/N-Tg(MMTV-PyVT*Y250F)250-2Mul)
|
increased mammary adenocarcinoma incidence
|
J:56327
|
Tg(MMTV-PyVT*Y315F*Y322F)Db-1Mul/?
(FVB/N-Tg(MMTV-PyVT*Y315F*Y322F)Db-1Mul)
|
increased mammary adenocarcinoma incidence
|
J:56327
|
Tg(MMTV-rtTA)1Lach/0 Tg(TetO-Erbb2)1Lach/0
(involves: FVB)
|
increased mammary adenocarcinoma incidence
|
J:81083
|
Tg(MMTV-rtTA)1Lach/0 Tg(tetO-ERBB2)#Jjz/0
(involves: FVB/N)
|
increased mammary adenocarcinoma incidence
|
J:231766
|
Tg(MMTV-rtTA)1Lach/0 Tg(tetO-Esr1)#Paf/0
(involves: FVB/N)
|
increased mammary gland ductal carcinoma incidence
|
J:96383
|
Tg(MMTV-rtTA)1Lach/0 Tg(tetO-IGF1R)1Ramo/0
(involves: FVB)
|
increased mammary adenocarcinoma incidence
|
J:121069
|
increased mammary gland tumor incidence
|
J:121069
|
Tg(MMTV-rtTA)1Lach/0 Tg(tetO-Kras2)12Hev/0
(involves: FVB/N)
|
increased mammary gland tumor incidence
|
J:133578
|
Tg(MMTV-rtTA)1Lach/0 Tg(tetO-Kras2)12Hev/0 Tg(tetO-MYC)1Lach/0
(involves: FVB/N)
|
increased mammary gland tumor incidence
|
J:133578
|
Tg(MMTV-rtTA)1Lach/0 Tg(tetO-MYC)1Lach/0
(involves: FVB)
|
increased mammary adenocarcinoma incidence
|
J:67498
|
increased mammary gland tumor incidence
|
J:133578,
J:67498
|
Tg(MMTV-rtTA)1Lach/0 Tg(tetO-PIK3CA*H1047R,-luc)2239Jjz/0
(involves: FVB/N)
|
increased mammary adenocarcinoma incidence
|
J:175839
|
increased mammary gland tumor incidence
|
J:175839
|
Tg(MMTV-rtTA)1Lach/0 Tg(tetO-PyVT,-cre)1Mul/0
(FVB/N-Tg(MMTV-rtTA)1Lach Tg(tetO-PyVT,-cre)#Mul)
|
increased mammary adenocarcinoma incidence
|
J:231983
|
increased mammary gland tumor incidence in virgin females
|
J:231983
|
Tg(MMTV-TGFBR2)7Hlm/? Tg(MMTVTGFA)29Rjc/?
(involves: C57BL/6 * DBA)
|
increased mammary adenocarcinoma incidence
|
J:85799
|
Tg(MMTV-TGFBR2)7Hlm/Tg(MMTV-TGFBR2)7Hlm
(involves: C57BL/6 * DBA)
|
increased mammary adenocarcinoma incidence
|
J:85799
|
Tg(MMTV-vHaras)SH1Led/0
(involves: C57BL/6J * CD-1)
|
increased mammary gland tumor incidence
|
J:88789
|
Tg(MMTV-vHaras)SH1Led/Tg(MMTV-vHaras)SH1Led
(involves: 129X1/SvJ * C57BL/6J * CD-1 * FVB)
|
increased mammary adenocarcinoma incidence
|
J:86074
|
Tg(MMTVneu)202Mul/0
(involves: FVB/N)
|
increased mammary gland tumor incidence
|
J:35344,
J:80974
|
Tg(MMTVneu)202Mul/0
(FVB/N-Tg(MMTVneu)202Mul)
|
increased mammary adenocarcinoma incidence
|
J:56332
|
Tg(MMTVneu)202Mul/0 Tg(MMTVTGFA)29Rjc/0
(involves: C57BL/6 * DBA/2 * FVB/N)
|
increased mammary gland tumor incidence
|
J:35344
|
Tg(MMTVneu)202Mul/0 Tg(Trp53R172H)8512Jmr/0
(C.FVB-Tg(MMTVneu)202Mul Tg(Trp53R172H)8512Jmr)
|
increased lung tumor incidence
|
J:115041
|
increased mammary adenocarcinoma incidence
|
J:115041
|
increased parotid gland tumor incidence
|
J:115041
|
Tg(MMTVneu)202Mul/0 Tg(Trp53R172H)8512Jmr/0
(involves: FVB)
|
increased mammary gland tumor incidence
|
J:40336
|
Tg(MMTVTGFA)29Rjc/0
(involves: C57BL/6 * DBA/2)
|
increased mammary adenocarcinoma incidence
|
J:72085,
J:72080,
J:28453,
J:71696
|
increased mammary gland tumor incidence
|
J:28453,
J:71696
|
Tg(MMTVTGFA)64Rjc/0
(involves: C57BL/6 * DBA/2)
|
increased mammary gland tumor incidence
|
J:72085
|
Tg(MMTVTGFA)254Rjc/0
(involves: C57BL/6 * DBA/2)
|
increased mammary adenocarcinoma incidence
|
J:72085
|
Tg(Msmb-TAg)183-2Xuan/0
(involves: C57BL/6 * CBA)
|
increased prostate gland adenocarcinoma incidence
|
J:80313
|
increased prostate intraepithelial neoplasia incidence
|
J:80313
|
Tg(Mt1-Hgf)19Lmb/0
(involves: C57BL/6 * CBA * FVB/N)
|
increased skin tumor incidence
|
J:122181
|
Tg(Mt1-Hgf)19Lmb/0
(involves: FVB/N)
|
increased cutaneous melanoma incidence
|
J:50947
|
Tg(Mt1-RET)304Ina/0
(B6.C-Tg(Mt1-RET)304Ina)
|
increased cutaneous melanoma incidence
|
J:50392
|
Tg(Mt1-RET)304Ina/0
(involves: BALB/c * C57BL/6)
|
increased cutaneous melanoma incidence
|
J:88074,
J:155735
|
Tg(Mt1-Tgfa)147Bri/0
(involves: C57BL/6 * SJL)
|
increased mammary adenocarcinoma incidence
|
J:56318
|
increased mammary gland tumor incidence
|
J:56318
|
Tg(Mt1-Tgfa)149Bri/0
(involves: C57BL/6 * SJL)
|
increased pancreatic intraepithelial neoplasia incidence
|
J:162125
|
Tg(MtTGFA)42Lmb/0
(involves: C57BL/6 * CD-1)
|
increased liver tumor incidence
|
J:2578
|
Tg(MtTGFA)42Lmb/0
(involves: CD-1 * FVB/N)
|
increased liver tumor incidence
|
J:2578
|
Tg(MtTGFA)42Lmb/Tg(MtTGFA)42Lmb
(involves: CD-1)
|
increased hepatocellular carcinoma incidence
|
J:28452
|
Tg(MtTGFA)100Lmb/0
(involves: FVB/N)
|
increased mammary adenocarcinoma incidence
|
J:72083
|
increased mammary gland tumor incidence
|
J:72083
|
Tg(MtTGFA)Lmb/0
(involves: CD-1)
|
increased pancreatic intraepithelial neoplasia incidence
|
J:229184
|
Tg(MtTPRMET)243Lng/0
(FVB/N-Tg(MtTPRMET)243Lng)
|
increased lymphoma incidence
|
J:71573
|
increased mammary gland tumor incidence
|
J:71573
|
increased osteosarcoma incidence
|
J:71573
|
Tg(MtTPRMET)773Lng/0
(FVB/N-Tg(MtTPRMET)773Lng)
|
increased mammary gland tumor incidence
|
J:71573
|
Tg(Mup3-Plau)350-2Eps/0
(involves: C57BL/6)
|
increased liver tumor incidence
|
J:66132
|
Tg(Mup3-Plau)350-2Eps/?
(C57BL/6-Tg(Mup3-Plau)350-2Eps)
|
increased hepatocellular carcinoma incidence
|
J:233146
|
increased liver adenoma incidence
|
J:233146
|
increased liver tumor incidence
|
J:233146
|
Tg(Mx1-cre)1Cgn/0 Tg(Tal1-tTA)19Dgt/0 Tg(tetO-BCR/ABL1)2Dgt/0 TgTn(pb-sb-GrOnc)#aGsva/0
(involves: C57BL/6 * CBA/J * DBA/2 * FVB/N)
|
increased chronic myelocytic leukemia incidence
|
J:227558
|
Tg(Myl2-FGF19)1Dfre/?
(involves: FVB)
|
increased hepatocellular carcinoma incidence
|
J:187236,
J:77160
|
increased liver tumor incidence
|
J:77160
|
Tg(NES-TVA)J12Ech/0
(involves: FVB/N)
|
increased glioma incidence
|
J:125535
|
increased oligodendroglioma incidence
|
J:125535
|
Tg(NES-TVA)J12Ech/0 Trp53tm1Brd/Trp53+
(involves: 129 * C57BL/6 * FVB/N)
|
increased glioma incidence
|
J:52161
|
Tg(Neurod2-Smo*A1)199Jols/0
(C57BL/6-Tg(Neurod2-Smo*A1)199Jols)
|
increased medulloblastoma incidence
|
J:93861
|
Tg(Neurod2-Smo*A1)199Jols/0
(involves: C57BL/6)
|
increased medulloblastoma incidence
|
J:221990
|
Tg(Neurod2-Smo*A1)199Jols/Tg(Neurod2-Smo*A1)199Jols
(C57BL/6-Tg(Neurod2-Smo*A1)199Jols)
|
increased medulloblastoma incidence
|
J:133312,
J:189258
|
Tg(Neurod2-Smo*A2)#Jols/0
(C57BL/6-Tg(Neurod2-Smo*A2)#Jols)
|
increased medulloblastoma incidence
|
J:189258
|
Tg(OMP-SV40T)13Bse/0
(involves: C57BL/6 * SJL)
|
increased adrenal gland tumor incidence
|
J:54269
|
increased neuroblastoma incidence
|
J:54269
|
Tg(Pax6-TAg)1796Hur/0
(involves: FVB)
|
increased eye tumor incidence
|
J:196814
|
increased retinoblastoma incidence
|
J:196814
|
Tg(Pax8-rtTA2S*M2)1Koes/0 Tg(tetO-MYC)36aBop/0
(involves: C57BL/6 * DBA * FVB/N)
|
increased renal carcinoma incidence
|
J:140925
|
Tg(Pbsn-Ar*E231G)7353Ng/0
(involves: FVB/N)
|
increased prostate gland adenocarcinoma incidence
|
J:96117
|
increased prostate gland tumor incidence
|
J:96117
|
Tg(Pbsn-ERG*)1Vv/0
(involves: 129/Sv * C57BL/6J * CBA)
|
increased prostate intraepithelial neoplasia incidence
|
J:131932
|
Tg(Pbsn-ERG*)1Vv/0
(involves: 129S1/SvImJ * C57BL/6J * CBA)
|
increased prostate gland adenocarcinoma incidence
|
J:222916
|
increased prostate gland tumor incidence
|
J:222916
|
Tg(Pbsn-FGF7)3293Ng/0
(Not Specified)
|
increased prostate intraepithelial neoplasia incidence
|
J:80821
|
Tg(Pbsn-FGFR1*K656E)#Wmck/0
(involves: FVB)
|
increased prostate intraepithelial neoplasia incidence
|
J:87519
|
Tg(Pbsn-FGFR1*K656E)#Wmck/0 Tg(Pbsn-FGFR2_iiib*)#Ng/0
(involves: FVB)
|
increased prostate intraepithelial neoplasia incidence
|
J:87067
|
Tg(Pbsn-Fgfr1/Fkbp1a)#aDmsp/0
(FVB-Tg(Pbsn-Fgfr1/Fkbp1a)#aDmsp)
|
increased prostate gland adenocarcinoma incidence
|
J:130340
|
increased prostate gland tumor incidence
|
J:130340
|
increased prostate intraepithelial neoplasia incidence
|
J:130340,
J:87092
|
Tg(Pbsn-Fgfr1/Fkbp1a)#aDmsp/0 Tg(Pbsn-Lrp5/Fkbp1a,-luc*)#Dmps/0
(involves: FVB/N)
|
increased prostate gland adenocarcinoma incidence
|
J:206727
|
Tg(Pbsn-Hpn,-GFP)DVv/0 Tg(Pbsn-Tag)12T7fRjm/0
(involves: C57BL/6J * CBA * CD-1)
|
increased prostate gland adenocarcinoma incidence
|
J:92562
|
increased prostate intraepithelial neoplasia incidence
|
J:92562
|
Tg(Pbsn-IGF1*)5305Ng/0
(involves: FVB/N)
|
increased prostate intraepithelial neoplasia incidence
|
J:144539
|
Tg(Pbsn-IGF1*)5305Ng/0 Tg(TRAMP)8247Ng/0
(involves: C57BL/6 * FVB/N)
|
increased prostate gland tumor incidence
|
J:144539
|
Tg(Pbsn-MYC)6Key/?
(involves: FVB)
|
increased prostate gland adenocarcinoma incidence
|
J:85480
|
increased prostate gland tumor incidence
|
J:85480
|
increased prostate intraepithelial neoplasia incidence
|
J:85480
|
Tg(Pbsn-MYC)#Tt/?
(involves: C57BL/6J)
|
increased prostate gland adenocarcinoma incidence
|
J:205395
|
increased prostate intraepithelial neoplasia incidence
|
J:205395
|
Tg(Pbsn-Tag)12T7fRjm/0
(involves: CD-1)
|
increased prostate gland adenocarcinoma incidence
|
J:48623
|
increased prostate gland tumor incidence
|
J:48623
|
increased prostate intraepithelial neoplasia incidence
|
J:92562,
J:48623
|
Tg(Pbsn-Tag)12T10Rjm/0
(involves: CD-1)
|
increased prostate gland adenocarcinoma incidence
|
J:68483,
J:48623
|
increased prostate gland tumor incidence
|
J:48623
|
increased prostate intraepithelial neoplasia incidence
|
J:68483
|
Tg(Pbsn-TAg)15Tvd/0
(involves: C57BL/6 * DBA/2)
|
increased prostate gland adenocarcinoma incidence
|
J:103408
|
increased prostate intraepithelial neoplasia incidence
|
J:103408
|
Tg(Pim1-Il9)5Jcrd/0
(involves: FVB/N)
|
increased T cell derived lymphoma incidence
|
J:17848
|
Tg(Pklr-HRAS*G12V)23Ak/0
(involves: C57BL/6 * DBA/2)
|
increased hepatocellular carcinoma incidence
|
J:44803
|
increased hepatoma incidence
|
J:44803
|
increased kidney tumor incidence
|
J:44803
|
Tg(Pklr-Myc)73Ak/0
(involves: C57BL/6 * DBA)
|
increased hepatocellular carcinoma incidence
|
J:185488
|
increased hepatoma incidence
|
J:185488
|
Tg(Pklr-Myc)73Ak/0
(B6.Cg-Tg(Pklr-Myc)73Ak)
|
increased hepatocellular carcinoma incidence
|
J:184496
|
Tg(Pklr-SV40)1Ak/0
(involves: C57BL/6 * DBA)
|
increased hepatocellular carcinoma incidence
|
J:185488
|
increased hepatoma incidence
|
J:185488
|
increased insulinoma incidence
|
J:185488
|
increased osteosarcoma incidence
|
J:185488
|
increased pancreas tumor incidence
|
J:185488
|
Tg(Pklr-SV40)1Ak/Tg(Pklr-SV40)1Ak
(involves: C57BL/6 * DBA)
|
increased pancreas tumor incidence
|
J:185488
|
Tg(PML-RARA)556Kog/?
(involves: FVB/N)
|
increased acute promyelocytic leukemia incidence
|
J:39327
|
increased skin papilloma incidence
|
J:39327
|
Tg(PML-RARA)556Kog/0
(FVB/N-Tg(PML-RARA)556Kog)
|
increased acute promyelocytic leukemia incidence
|
J:262172
|
Tg(Prl-EGFR)#Sme/0
(Not Specified)
|
increased prolactinoma incidence
|
J:219654
|
Tg(PTH-CCND1)PC2Anar/0
(FVB/N-Tg(PTH-CCND1)PC2Anar)
|
increased parathyroid adenoma incidence
|
J:69423
|
Tg(PyLT)1Vb/0
(Not Specified)
|
increased pituitary adenoma incidence
|
J:55528
|
increased pituitary gland tumor incidence
|
J:55528
|
Tg(RasE)290Biat/0
(involves: C57BL/6 * DBA/2)
|
increased lung adenocarcinoma incidence
|
J:226601
|
Tg(Rbp3-SV40)IT-2Jjw/?
(involves: BALB/c * C57BL/6)
|
increased pineal gland tumor incidence
|
J:60231
|
increased retinoblastoma incidence
|
J:60231
|
Tg(RBP3-TAg)#Ove/0
(involves: C57BL/6 * FVB/N)
|
increased brain tumor incidence
|
J:59267
|
increased retina tumor incidence
|
J:59267
|
Tg(RIP1-Tag)2Dh/?
(C3.Cg-Tg(RIP1-Tag)2Dh/Nci)
|
increased insulinoma incidence
|
J:80168
|
Tg(RIP1-Tag)2Dh/0
(involves: C57BL/6)
|
increased insulinoma incidence
|
J:162648
|
Tg(RIP1-Tag)2Dh/0
(involves: C57BL/6J * DBA/2J)
|
increased insulinoma incidence
|
J:205389
|
increased pancreas tumor incidence
|
J:50695
|
increased pancreatic islet cell carcinoma incidence
|
J:205389
|
Tg(RIP1-Tag)5Dh/?
(C3HeB/FeJ-Tg(RIP1-Tag)5Dh)
|
increased insulinoma incidence
|
J:80168
|
Tg(RIP1-Tag)5Dh/0
(C3.Cg-Rgs5tm1.1Rgan Tg(RIP1-Tag)5Dh)
|
increased insulinoma incidence
|
J:136259
|
Tg(RIR-Tag)87Dh/0
(involves: C57BL/6J * DBA/2J)
|
increased pancreas tumor incidence
|
J:50695
|
Tg(rTH-Tag)20Dmc/0
(involves: C57BL/6NTac * DBA/2NTac)
|
increased adrenal gland tumor incidence
|
J:90323
|
increased brain tumor incidence
|
J:90323
|
increased neuroblastoma incidence
|
J:90323
|
Tg(S100b-v-erbB)4496Waw/0
(involves: C57BL/6J * DBA/2J * FVB/N)
|
increased oligodendroglioma incidence
|
J:82649
|
Tg(S100b-v-erbB)4496Waw/0 Trp53tm1Brd/Trp53+
(involves: 129S7/SvEvBrd * C57BL/6J * DBA/2J * FVB/N)
|
increased glioma incidence
|
J:82649
|
increased oligodendroglioma incidence
|
J:82649
|
Tg(S100b-v-erbB)4496Waw/0 Trp53tm1Brd/Trp53tm1Brd
(involves: 129S7/SvEvBrd * C57BL/6J * DBA/2J)
|
increased glioma incidence
|
J:225862
|
increased oligodendroglioma incidence
|
J:225862
|
Tg(Scgb1a1-rtTA)1Jaw/0 Tg(tetO-EGFR*)#Kkw/0
(involves: 129 * C57BL/6 * FVB/N)
|
increased lung tumor incidence
|
J:156440,
J:235747
|
Tg(Scgb1a1-rtTA)1Jaw/0 Tg(tetO-EGFR*delta19)11Hev/0
(involves: C57BL/6 * CBA)
|
increased lung adenocarcinoma incidence
|
J:109092
|
Tg(Scgb1a1-rtTA)1Jaw/0 Tg(tetO-EGFR*L858R)56Hev/0
(involves: C57BL/6 * CBA)
|
increased lung adenocarcinoma incidence
|
J:109092
|
Tg(Scgb1a1-rtTA)1Jaw/0 Tg(tetO-EGFR*L858R)57Hev/0
(involves: C57BL/6 * CBA)
|
increased lung adenocarcinoma incidence
|
J:109092
|
Tg(Scgb1a1-rtTA)1Jaw/0 Tg(tetO-EGFR*L858R)#Hev/0
(involves: 129 * C57BL/6 * CBA)
|
increased lung adenocarcinoma incidence
|
J:128700,
J:213447
|
Tg(Scgb1a1-rtTA)1Jaw/0 Tg(tetO-EGFR*T790M)8Paow/0
(involves: 129 * C57BL/6 * FVB/N)
|
increased lung adenocarcinoma incidence
|
J:128700
|
Tg(Scgb1a1-rtTA)1Jaw/0 Tg(tetO-EGFR*T790M*L858R)19Kkw/0
(involves: 129 * C57BL/6 * FVB/N)
|
increased lung adenocarcinoma incidence
|
J:122849
|
increased lung carcinoma incidence
|
J:122849
|
increased lung tumor incidence
|
J:122849,
J:156440,
J:235747
|
Tg(Scgb1a1-rtTA)1Jaw/0 Tg(tetO-EGFR*T790M*L858R)51Paow/0
(involves: 129 * C57BL/6 * FVB/N)
|
increased lung adenocarcinoma incidence
|
J:128700
|
Tg(Scgb1a1-rtTA)1Jaw/0 Tg(tetO-ERBB2*)5BKkw/0
(involves: FVB/N)
|
increased lung carcinoma incidence
|
J:143874
|
increased lung non-small cell carcinoma incidence
|
J:143874
|
increased lung tumor incidence
|
J:143874
|
Tg(Scgb1a1-rtTA)1Jaw/0 Tg(tetO-ERBB2*)26Kkw/0
(involves: FVB/N)
|
increased lung carcinoma incidence
|
J:143874
|
increased lung non-small cell carcinoma incidence
|
J:143874
|
increased lung tumor incidence
|
J:143874
|
Tg(Scgb1a1-rtTA)1Jaw/0 Tg(tetO-IGF1R)1Ramo/0
(involves: 129 * C57BL/6 * FVB)
|
increased lung adenoma incidence
|
J:271820
|
increased lung tumor incidence
|
J:271820
|
Tg(Scgb1a1-rtTA)1Jaw/0 Tg(tetO-Kras2)12Hev/0
(involves: 129 * C57BL/6 * FVB/N)
|
increased lung adenocarcinoma incidence
|
J:73468
|
increased lung adenoma incidence
|
J:73468
|
increased lung tumor incidence
|
J:73468
|
Tg(Scgb1a1-rtTA)1Jaw/0 Tg(tetO-Kras2)12Hev/0 Trp53tm1Tyj/Trp53+
(involves: 129S2/SvPas * C57BL/6 * FVB/N)
|
increased lung adenocarcinoma incidence
|
J:73468
|
increased lung tumor incidence
|
J:73468
|
Tg(Scgb1a1-rtTA)1Jaw/0 Tg(tetO-MYC)36Bop/0
(involves: 129 * C57BL/6)
|
increased lung adenocarcinoma incidence
|
J:169920
|
increased lung adenoma incidence
|
J:169920
|
increased lung tumor incidence
|
J:169920
|
Tg(Scgb1a1-rtTA)1Jaw/0 Tg(tetO-PIK3CA*H1047R)13Lca/0
(involves: 129 * C57BL/6 * FVB/N)
|
increased lung adenocarcinoma incidence
|
J:142254
|
Tg(Scgb1a1-rtTA)1Jaw/0 Tg(tetO-PTPN11*E76K)#Jiwu/0
(involves: 129 * C57BL/6 * FVB/N)
|
increased lung adenoma incidence
|
J:212505
|
increased lung non-small cell carcinoma incidence
|
J:212505
|
Tg(Scgb1a1-rtTA)1Jaw/0 Tg(tetO/CMV-KRAS*G12C)9.1Msmi/0
(involves: FVB/N)
|
increased lung adenocarcinoma incidence
|
J:102839
|
increased lung adenoma incidence
|
J:102839
|
Tg(SERPINA1-TAg)1812Jtsb/0
(involves: C3H * C57BL/6 * ICR)
|
increased hepatocellular carcinoma incidence
|
J:101633
|
Tg(SERPINC1-SV40)A1Pbr/0
(involves: C57BL/6 * DBA/2)
|
increased hepatocellular carcinoma incidence
|
J:101541
|
Tg(SERPINC1-SV40)A1Pbr/Tg(SERPINC1-SV40)A1Pbr
(involves: C57BL/6 * DBA/2)
|
increased hepatocellular carcinoma incidence
|
J:101541
|
X/Tg(SERPINC1-SV40)BPbr
(involves: C57BL/6 * DBA/2)
|
increased hepatocellular carcinoma incidence
|
J:84204,
J:101541
|
increased liver adenoma incidence
|
J:84204
|
Tg(SFTPC-CCNE1)1Edm/?
(involves: FVB/N)
|
increased lung adenocarcinoma incidence
|
J:122698
|
Tg(SFTPC-CCNE1*T62A*T380A)3Edm/?
(involves: FVB/N)
|
increased lung adenocarcinoma incidence
|
J:122698
|
Tg(SFTPC-CCNE1*T62A*T380A)4Edm/?
(involves: FVB/N)
|
increased lung adenocarcinoma incidence
|
J:122698
|
Tg(SFTPC-CD74/ROS1)125Tno/0
(C57BL/6J-Tg(SFTPC-CD74/ROS1)125Tno)
|
increased lung adenocarcinoma incidence
|
J:231770
|
increased lung adenoma incidence
|
J:231770
|
increased lung non-small cell carcinoma incidence
|
J:231770
|
increased lung tumor incidence
|
J:231770
|
Tg(SFTPC-EGFR*L858R)4-3Kkiu/0
(involves: C57BL/6Cr)
|
increased lung adenocarcinoma incidence
|
J:152157
|
increased lung carcinoma incidence
|
J:152157
|
increased lung tumor incidence
|
J:152157
|
Tg(SFTPC-EML4/ALK)502-4Hima/0
(involves: C57BL/6J)
|
increased lung adenocarcinoma incidence
|
J:142679
|
Tg(SFTPC-env)1Yhch/0
(FVB/N-Tg(SFTPC-env)1Yhch)
|
increased lung adenocarcinoma incidence
|
J:153538,
J:247986
|
increased lung tumor incidence
|
J:153538
|
Tg(SFTPC-EZR/ROS1)AShiba/0
(C57BL/6-Tg(SFTPC-EZR/ROS1)AShiba)
|
increased lung adenocarcinoma incidence
|
J:199415
|
Tg(SFTPC-KIF5B/RET)1Tkoh/0
(involves: C57BL/6J)
|
increased lung adenocarcinoma incidence
|
J:215989
|
increased lung adenoma incidence
|
J:215989
|
increased lung tumor incidence
|
J:215989
|
Tg(SFTPC-MST1R)71Mhw/0
(involves: C3H * C57BL/6)
|
increased lung adenocarcinoma incidence
|
J:79080
|
increased lung adenoma incidence
|
J:79080
|
Tg(SFTPC-RAF1)87Urr/0
(involves: C57BL/6 * DBA/2)
|
increased lung adenoma incidence
|
J:80895
|
Tg(SFTPC-RAF1-BxB)1Urr/0
(involves: 129S2/SvPas * C57BL/6 * DBA/2)
|
increased lung adenoma incidence
|
J:79696
|
Tg(SFTPC-RAF1-BxB)1Urr/0
(involves: C57BL/6 * DBA/2)
|
increased lung adenoma incidence
|
J:80895
|
Tg(SFTPC-rtTA)5Jaw/0 Tg(tetO-Fgf9,-EGFP)#Dor/0
(involves: FVB)
|
increased lung adenocarcinoma incidence
|
J:204282
|
increased lung adenoma incidence
|
J:204282
|
increased lung tumor incidence
|
J:204282
|
Tg(SFTPC-rtTA)5Jaw/0 Tg(tetO-IGF1R)1Ramo/0
(involves: FVB)
|
increased lung adenoma incidence
|
J:271820
|
increased lung tumor incidence
|
J:271820
|
Tg(SFTPC-rtTA)5Jaw/0 Tg(tetO-MYC)36Bop/0
(Not Specified)
|
increased lung adenocarcinoma incidence
|
J:169920
|
increased lung adenoma incidence
|
J:169920
|
increased lung tumor incidence
|
J:169920
|
Tg(SFTPC-rtTA)5Jaw/0 Tg(tetO/CMV-KRAS*G12C)9.1Msmi/0
(involves: FVB/N)
|
increased lung adenoma incidence
|
J:102839
|
Tg(SFTPC-SDC4/ROS1)141Tno/0
(C57BL/6J-Tg(SFTPC-SDC4/ROS1)141Tno)
|
increased lung adenocarcinoma incidence
|
J:231770
|
increased lung adenoma incidence
|
J:231770
|
increased lung non-small cell carcinoma incidence
|
J:231770
|
increased lung tumor incidence
|
J:231770
|
Tg(Slc1a2-tTA)#Waw/0 Tg(tetO-MYCN,-luc)#Waw/0
(involves: FVB/NJ)
|
increased medulloblastoma incidence
|
J:160518
|
Tg(Slc1a2-tTA)#Waw/0 Tg(tetO-MYCN,-luc)#Waw/Tg(tetO-MYCN,-luc)#Waw
(involves: FVB/NJ)
|
increased medulloblastoma incidence
|
J:160518
|
Tg(Smgb-TAg)8Mir/Tg(Smgb-TAg)8Mir
(involves: BALB/cJ * C57BL/6J)
|
increased salivary adenocarcinoma incidence
|
J:66189
|
Tg(Sp7-tTA,tetO-EGFP/cre)1Amc/0 Tg(tetO-RNAi:Trp53)ASlowe/0
(involves: C57BL/6 * CD-1)
|
increased osteosarcoma incidence
|
J:199542
|
Tg(Sp7-tTA,tetO-EGFP/cre)1Amc/0 Trp53tm1Brn/Trp53tm1Brn
(involves: 129 * 129P2/OlaHsd * C57BL/6J * CD-1 * FVB/N)
|
increased osteosarcoma incidence
|
J:136693
|
Tg(SV40-Ahr)1Poe/0
(involves: C57BL/6 * CBA)
|
increased stomach tumor incidence
|
J:77977
|
Tg(SV40-NRAS*G12D)1Sco/?
(Not Specified)
|
increased T cell derived lymphoma incidence
|
J:125150
|
Tg(SV)7Bri/0
(C57BL/6J-Tg(SV)7Bri/J)
|
increased brain tumor incidence
|
J:94307
|
Tg(SV)419Bri/Tg(SV)419Bri
(C57BL/6J-Tg(SV)419Bri)
|
increased brain tumor incidence
|
J:147031
|
increased kidney tumor incidence
|
J:147031
|
increased T cell derived lymphoma incidence
|
J:147031
|
Tg(SV)427Bri/0
(C57BL/6J-Tg(SV)427Bri)
|
increased brain tumor incidence
|
J:79096,
J:147031
|
Tg(TagRb)1Plm/?
(involves: BALB/cJ * C57BL/6J)
|
increased retinoblastoma incidence
|
J:10320
|
Tg(Tal1-cre/ERT)1Jrg/0 Tsc1tm1Djk/Tsc1tm1Djk
(involves: 129S4/SvJae * C57BL/6)
|
increased liver tumor incidence
|
J:231316
|
Tg(TCF3/HLF)1Mlc/0
(involves: FVB/N)
|
increased B cell derived lymphoma incidence
|
J:55022
|
increased T cell derived lymphoma incidence
|
J:55022
|
Tg(Tcra2B4)1Mmd/?
(involves: C3H/HeJ * C57BL/6)
|
increased lymphoma incidence
|
J:92992
|
Tg(Tcra,Tcrb)HRVAll/0 Tg(TRAMP)8247Ng/0
(B6.Cg-Tg(TRAMP)8247Ng Tg(Tcra,Tcrb)HRVAll)
|
increased prostate gland tumor incidence
|
J:131347
|
Tg(Tcrb-TCF3/PBX1)19Gusa/0
(involves: C3H * C57BL/6 * C57BL/6J)
|
increased acute lymphoblastic leukemia incidence
|
J:95693
|
increased leukemia incidence
|
J:95693
|
Tg(Tcrb-TCF3/PBX1)23Gusa/0
(involves: C3H * C57BL/6 * C57BL/6J)
|
increased acute lymphoblastic leukemia incidence
|
J:95693
|
increased leukemia incidence
|
J:95693
|
Tg(Tek-cre)1Ywa/0 Trp53tm1Brn/Trp53tm1Brn
(involves: 129P2/OlaHsd * C57BL/6 * CD-1 * SJL)
|
increased T cell derived lymphoma incidence
|
J:263520
|
Tg(tetO-BCR/ABL1)2Dgt/0 Tg(MMTVtTA)1Mam/0
(involves: C57BL/6 * FVB/N * SJL)
|
increased leukemia incidence
|
J:72377
|
Tg(tetO-BCR/ABL1)2Dgt/0 Tg(Tal1-tTA)19Dgt/0
(involves: C57BL/6 * DBA/2 * FVB/N)
|
increased lymphoma incidence
|
J:96511
|
Tg(tetO-BCR/ABL1)27Dgt/0 Tg(MMTVtTA)1Mam/0
(involves: C57BL/6 * FVB/N * SJL)
|
increased leukemia incidence
|
J:72377
|
Tg(tetO-BRAF*V600E)26Jaf/0 Tg(TG-rtTA)30Jaf/0
(involves: FVB/N)
|
increased thyroid carcinoma incidence
|
J:184420
|
increased thyroid tumor incidence
|
J:184420
|
Tg(tetO-MET)23Rwng/0 Tg(Cebpb-tTA)5Bjd/0
(involves: FVB/N * NMRI)
|
increased hepatocellular carcinoma incidence
|
J:69731
|
Tg(tetO-MYC)36aBop/0 Tg(Cebpb-tTA)5Bjd/0
(involves: FVB/N * NMRI)
|
increased hepatoblastoma incidence
|
J:93899
|
increased hepatocellular carcinoma incidence
|
J:172430,
J:186226,
J:190067,
J:93899
|
increased liver tumor incidence
|
J:172430,
J:93899
|
Tg(tetO-TAg)2-5Hiwa/0
(involves: C57BL/6)
|
increased adrenal gland tumor incidence
|
J:175962
|
increased neuroblastoma incidence
|
J:156984,
J:175962
|
Tg(tetO-TAg,CMV-rtTA)123Yihu/0
(involves: FVB/N)
|
increased medulloblastoma incidence
|
J:141623
|
Tg(TetOp-Polb/tTA)2Sbl/0
(B6.Cg-Tg(TetOp-Polb/tTA)2Sbl)
|
increased intestinal adenoma incidence
|
J:152481
|
increased osteoma incidence
|
J:152481
|
increased osteosarcoma incidence
|
J:152481
|
increased skeletal tumor incidence
|
J:152481
|
Tg(Tff3-Tmem207)1Tamo/0
(C57BL/6-Tg(Tff3-Tmem207)1Tamo)
|
increased skin tumor incidence
|
J:217436
|
increased trichoepithelioma incidence
|
J:217436
|
Tg(TG-BRAF*V600E)2Jaf/0
(FVB/N-Tg(TG-BRAF*V600E)2Jaf)
|
increased thyroid carcinoma incidence
|
J:98550
|
increased thyroid tumor incidence
|
J:98550
|
Tg(TG-BRAF*V600E)3Jaf/0
(FVB/N-Tg(TG-BRAF*V600E)3Jaf)
|
increased thyroid carcinoma incidence
|
J:98550
|
Tg(TG-NRAS*Q61K)#Msnt/0
(Not Specified)
|
increased thyroid adenoma incidence
|
J:210016
|
increased thyroid carcinoma incidence
|
J:210016
|
Tg(TG-RET/CCDC6)1Cled/0
(involves: FVB/N)
|
increased thyroid carcinoma incidence
|
J:55883,
J:93679
|
Tg(TG-RET/CCDC6)42Cled/0
(involves: FVB/N)
|
increased thyroid carcinoma incidence
|
J:55883,
J:93679
|
Tg(TG-RET/NCOA4)3209Rstn/0
(involves: C57BL/6)
|
increased thyroid carcinoma incidence
|
J:51366
|
Tg(TG-SV40)#Cled/0
(involves: C57BL/6J * DBA/2J)
|
increased thyroid carcinoma incidence
|
J:209788
|
Tg(TG-TPR/NTRK1)5215Rstn/0
(involves: C3H * C57BL/6)
|
increased thyroid carcinoma incidence
|
J:67120
|
Tg(TG-TPR/NTRK1)#Rstn/0
(involves: 129S4/SvJaeSor * C3H * C57BL/6 * C57BL/6J)
|
increased thyroid carcinoma incidence
|
J:210015
|
Tg(Tgfa)1Efu/0
(Not Specified)
|
increased skin papilloma incidence
|
J:65045
|
Tg(Th-ALK*F1174L)2Loch/0 Tg(Th-MYCN)41Waw/0
(involves: 129X1/SvJ * BALB/c * C57BL/6J * CBA)
|
increased neuroblastoma incidence
|
J:191012
|
Tg(Th-MYCN)41Waw/0
(involves: BALB/c * C57BL/6J)
|
increased neuroblastoma incidence
|
J:41126
|
Tg(Th-MYCN)41Waw/0
(involves: BALB/c * C57BL/6J * FVB/N)
|
increased neuroblastoma incidence
|
J:41126
|
Tg(Th-MYCN)41Waw/0
(involves: 129X1/SvJ * BALB/c * C57BL/6J)
|
increased neuroblastoma incidence
|
J:172448
|
Tg(Th-MYCN)41Waw/0 Trp53tm1Brd/Trp53+
(involves: 129S7/SvEvBrd * BALB/c * C57BL/6J * FVB/N)
|
increased neuroblastoma incidence
|
J:41126
|
Tg(Th-MYCN)41Waw/Tg(Th-MYCN)41Waw
(involves: BALB/c * C57BL/6J)
|
increased neuroblastoma incidence
|
J:41126
|
Tg(Th-TAg)17Dmc/0
((C57BL/6NTac x DBA/2NTac)F2)
|
increased adrenal gland tumor incidence
|
J:90323
|
Tg(Thy1-cmyc)6Kio/0
(Not Specified)
|
increased T cell derived lymphoma incidence
|
J:129440
|
Tg(Thy1-cmyc)6LKio/0
(Not Specified)
|
increased T cell derived lymphoma incidence
|
J:129440
|
Tg(Thy1/THY1)hT10Gsv/0
(involves: C57BL/10 * CBA)
|
increased kidney tumor incidence
|
J:133943
|
Tg(Thy1/THY1)hT13Gsv/0
(involves: C57BL/10 * CBA)
|
increased kidney tumor incidence
|
J:133943
|
Tg(Tnfsf13b)1Fma/0
(B6.Cg-Tg(Tnfsf13b)1Fma)
|
increased submandibular gland tumor incidence
|
J:73711
|
Tg(TRAMP)8247Ng/0
(involves: 129S1/Sv * C57BL/6)
|
increased prostate gland tumor incidence
|
J:108849
|
Tg(TRAMP)8247Ng/0
(involves: C57BL/6)
|
increased prostate gland adenocarcinoma incidence
|
J:217920,
J:65303
|
Tg(TRAMP)8247Ng/0
(involves: C3H * C57BL/6)
|
increased prostate gland adenocarcinoma incidence
|
J:125633
|
increased prostate gland tumor incidence
|
J:125633
|
increased prostate intraepithelial neoplasia incidence
|
J:125633
|
Tg(TRAMP)8247Ng/0
(involves: 129/Sv * C57BL/6)
|
increased prostate gland adenocarcinoma incidence
|
J:133908
|
increased prostate gland tumor incidence
|
J:133908
|
increased prostate intraepithelial neoplasia incidence
|
J:133908,
J:131932
|
Tg(TRAMP)8247Ng/0 Usp11tm1Tac/Y
(involves: 129 * C57BL/6)
|
increased prostate gland adenocarcinoma incidence
|
J:270214
|
increased prostate intraepithelial neoplasia incidence
|
J:270214
|
Tg(TRP53)4Dgj/0 Trp53tm1Tyj/Trp53tm1Tyj
(involves: 129S2/SvPas * FVB)
|
increased osteosarcoma incidence
|
J:162466
|
Tg(Trp53A135V)L3Ber/0
(involves: C57BL/6 * CD-1)
|
increased lung adenocarcinoma incidence
|
J:73757
|
Tg(Trp53R172H)8512Jmr/0
(involves: FVB)
|
increased mammary adenocarcinoma incidence
|
J:46426
|
Tg(Tyr-TAg)BJjw/0
(involves: BALB/cAnNHsd * C57BL/6NHsd)
|
increased choroid tumor incidence
|
J:52122
|
increased iris tumor incidence
|
J:52122
|
increased retina tumor incidence
|
J:52122
|
Tg(Tyrp1-TAg)3434Bee/?
(involves: BALB/c * C57BL/6J)
|
increased eye tumor incidence
|
J:75629
|
Tg(UPII-SV40T)2Xrw/0
(involves: FVB/N)
|
increased urinary bladder carcinoma incidence
|
J:56305
|
increased urinary bladder transitional cell carcinoma incidence
|
J:56305
|
Tg(UPII-SV40T)9Xrw/0
(involves: FVB/N)
|
increased urinary bladder carcinoma incidence
|
J:56305
|
Tg(UPII-SV40T)29Xrw/0
(involves: FVB/N)
|
increased urinary bladder carcinoma incidence
|
J:56305
|
increased urinary bladder transitional cell carcinoma incidence
|
J:56305
|
Tg(Upk2-HRAS*Q61L)5Xrw/?
(involves: FVB/N)
|
increased urinary system tumor incidence
|
J:69251
|
Tg(Upk2-HRAS*Q61L)12Xrw/?
(involves: FVB/N)
|
increased urinary system tumor incidence
|
J:69251
|
Tg(Upk2-TAg)1Rkl/0
(involves: C57BL/6)
|
increased urinary bladder carcinoma incidence
|
J:173505
|
increased urinary bladder transitional cell carcinoma incidence
|
J:173505
|
Tg(Utg-TAg)7593Fjd/?
(involves: FVB)
|
increased lung adenocarcinoma incidence
|
J:70785
|
Tg(Utg-TAg)7736Fjd/?
(involves: FVB)
|
increased lung adenocarcinoma incidence
|
J:70785
|
Tg(Utg-TAg)#Fjd/?
(involves: FVB)
|
increased lung adenocarcinoma incidence
|
J:70785
|
Tg(Vav1-Asxl1*Y588X)#Fcy/0
(C57BL/6-Tg(Vav1-Asxl1*Y588X)#Fcy)
|
increased acute myeloid leukemia incidence
|
J:257690
|
increased myeloid sarcoma incidence
|
J:257690
|
Tg(Vav1-ERG)#Jpim/0
(involves: C57BL/6)
|
increased acute lymphoblastic leukemia incidence
|
J:203438,
J:174808
|
increased leukemia incidence
|
J:203438,
J:174808
|
Tg(Vav1-Lin28b)C3Apla/0
(involves: C57BL/6)
|
increased T cell derived lymphoma incidence
|
J:189197
|
Tg(Vav1-NUP98/HOXD13)C1Apla/0
(FVB/N-Tg(Vav1-NUP98/HOXD13)C1Apla)
|
increased leukemia incidence
|
J:107446
|
Tg(Vav1-NUP98/HOXD13)G2Apla/0
(C57BL/6-Tg(Vav1-NUP98/HOXD13)G2Apla)
|
increased leukemia incidence
|
J:107446
|
Tg(Vav1-STAT5B*N642H)726Biat/0
(C57BL/6NCrl-Tg(Vav1-STAT5B*N642H)726Biat)
|
increased leukemia incidence
|
J:257519
|
increased lymphoma incidence
|
J:257519
|
Tg(Vav-BCL2)69Jad/0
(involves: C57BL/6J)
|
increased B cell derived lymphoma incidence
|
J:88565,
J:228913
|
increased follicular lymphoma incidence
|
J:88565,
J:228913
|
increased histiocytic sarcoma incidence
|
J:88565
|
increased lymphoma incidence
|
J:88565
|
increased T cell derived lymphoma incidence
|
J:88565
|
Tg(Vil1-Lin28b,-tdTomato)HiAru/0
(involves: C57BL/6J * SJL)
|
increased intestinal adenoma incidence
|
J:202923
|
increased small intestine adenocarcinoma incidence
|
J:202923
|
Tg(Vil1-Lin28b,-tdTomato)MedAru/0
(involves: C57BL/6J * SJL)
|
increased intestinal adenoma incidence
|
J:202923
|
increased small intestine adenocarcinoma incidence
|
J:202923
|
Tg(Vil-SLC3A2)HEMerl/0
(involves: FVB/N)
|
increased colon adenoma incidence
|
J:173946
|
Tg(Wap-Hgf)402Mig/0
(involves: FVB/N)
|
increased mammary adenocarcinoma incidence
|
J:86776
|
increased mammary gland tumor incidence in breeding females
|
J:86776
|
increased mammary gland tumor incidence in virgin females
|
J:86776
|
Tg(Wap-Hgf)402Mig/0
(FVB/N-Tg(Wap-Hgf)402Mig)
|
increased mammary adenocarcinoma incidence
|
J:206839
|
increased mammary gland tumor incidence in breeding females
|
J:206839
|
X/Tg(Wap-HRAS)69Lln
(involves: C57BL/6 * SJL)
|
increased mammary gland tumor incidence
|
J:46458
|
increased salivary adenocarcinoma incidence
|
J:46458
|
X/Tg(Wap-HRAS)69Lln
(FVB.Cg-Tg(Wap-HRAS)69Lln Chr YSJL/J)
|
increased mammary gland tumor incidence
|
J:101113
|
Tg(Wap-TAg)1Depp/0
(involves: BALB/c * C57BL/6)
|
increased mammary gland ductal carcinoma incidence
|
J:61012
|
Tg(Wap-tAg)1Gmn/?
(involves: NMRI)
|
increased mammary adenocarcinoma incidence
|
J:69711
|
Tg(Wap-TAg)12Gmn/?
(involves: NMRI)
|
increased mammary gland tumor incidence
|
J:69711
|
Tg(Wap-TAg)NP8Depp/0
(involves: BALB/c * C57BL/6)
|
increased mammary gland ductal carcinoma incidence
|
J:61012
|
Tg(Wap-Tsg101)4389Kuw/0
(FVB/N-Tg(Wap-Tsg101)4389Kuw)
|
increased mammary adenocarcinoma incidence
|
J:121475
|
Tg(WapMyc)212Bri/0
(FVB.Cg-Tg(WapMyc)212Bri)
|
increased mammary gland tumor incidence
|
J:114568
|
Tg(WapMyc)212Bri/0
(involves: C57BL/6 * SJL)
|
increased mammary adenocarcinoma incidence
|
J:56318
|
increased mammary gland tumor incidence
|
J:56318
|
Tg(WapMyc)212Bri/0 Tg(WapTgfa)215Bri/0
(involves: C57BL/6 * SJL)
|
increased mammary gland tumor incidence
|
J:56318
|
Tg(WapNotch4)10Rnc/0
(involves: FVB/N)
|
increased lung tumor incidence
|
J:33193
|
increased mammary adenocarcinoma incidence
|
J:33193
|
Tg(WapTAg)1Knw/0
(C57BL/6J-Tg(WapTAg)1Knw/J)
|
increased mammary adenocarcinoma incidence
|
J:53175
|
Tg(WapTAg)3Knw/0
(C57BL/6J-Tg(WapTAg)3Knw)
|
increased mammary adenocarcinoma incidence
|
J:53175
|
increased osteosarcoma incidence
|
J:53175
|
Tg(WapTgfa)215Bri/0
(FVB.Cg-Tg(WapTgfa)215Bri)
|
increased mammary gland tumor incidence
|
J:114568
|
Tg(WapTgfa)215Bri/0
(involves: C57BL/6 * SJL)
|
increased mammary adenocarcinoma incidence
|
J:56318
|
increased mammary gland tumor incidence
|
J:56318
|
Tg(WapTgfa)215Bri/0
(B6.Cg-Tg(WapTgfa)215Bri)
|
increased lymphoma incidence
|
J:123146
|
increased mammary gland tumor incidence
|
J:123146
|
Tg(Wnt1)1Hev/0
(involves: C57BL/6 * FVB * SJL)
|
increased mammary gland tumor incidence
|
J:96305
|
Tg(Wnt1)1Hev/0
(involves: 129P2/OlaHsd * C57BL/6 * SJL)
|
increased mammary adenocarcinoma incidence
|
J:54215
|
Tg(Wnt1)1Hev/0
(involves: C57BL/6 * SJL)
|
increased mammary adenocarcinoma incidence
|
J:61009
|
Tgct1MOLF/Ei/Tgct1MOLF/Ei
(involves: 129S1/SvImJ * MOLF/Ei)
|
increased testis tumor incidence
|
J:81573
|
Tgct2MOLF/Ei/Tgct2MOLF/Ei
(involves: 129S1/SvImJ * MOLF/Ei)
|
increased testis tumor incidence
|
J:81573
|
Tgct3MOLF/Ei/Tgct3MOLF/Ei
(involves: 129S1/SvImJ * MOLF/Ei)
|
increased testis tumor incidence
|
J:81573
|
Tgct5MOLF/Ei/Tgct5MOLF/Ei
(involves: 129S1/SvImJ * MOLF/Ei)
|
increased testis tumor incidence
|
J:81573
|
Tgfb1tm1Rif/Tgfb1tm1Rif
(either: (involves: 129) or (involves: 129S/SvEv * C57BL/6))
|
increased anal adenocarcinoma incidence
|
J:142353
|
increased colon adenocarcinoma incidence
|
J:142353
|
increased gastric adenocarcinoma incidence
|
J:142353
|
increased large intestine adenocarcinoma incidence
|
J:142353
|
increased rectum adenocarcinoma incidence
|
J:142353
|
increased stomach tumor incidence
|
J:142353
|
Tgfbitm1Zhao/Tgfbitm1Zhao
(involves: 129 * C57BL/6J)
|
increased lung adenocarcinoma incidence
|
J:143036
|
increased lymphoma incidence
|
J:143036
|
Tgfbr2tm1.2Hlm/Tgfbr2tm1.2Hlm Tg(Col1a2-cre/ERT,-ALPP)7Cpd/0
(involves: 129S6/SvEvTac * C57BL/6 * DBA/2)
|
increased prostate gland adenocarcinoma incidence
|
J:204736
|
increased prostate intraepithelial neoplasia incidence
|
J:204736
|
Thbs1tm1Hyn/Thbs1tm1Hyn Trp53tm1Tyj/Trp53+
(involves: 129S2/SvPas * C57BL/6)
|
increased histiocytic sarcoma incidence
|
J:72391
|
increased liver adenocarcinoma incidence
|
J:72391
|
increased lung adenocarcinoma incidence
|
J:72391
|
increased lymphoma incidence
|
J:72391
|
increased mammary adenocarcinoma incidence
|
J:72391
|
increased osteosarcoma incidence
|
J:72391
|
increased pancreas tumor incidence
|
J:72391
|
Thbs1tm1Hyn/Thbs1tm1Hyn Trp53tm1Tyj/Trp53tm1Tyj
(involves: 129S2/SvPas * C57BL/6)
|
increased histiocytic sarcoma incidence
|
J:72391
|
increased lymphoma incidence
|
J:72391
|
increased pancreas tumor incidence
|
J:72391
|
increased small intestine adenocarcinoma incidence
|
J:72391
|
ThimTg(Myh6-TGFB1)1Ljf/Thim+
(involves: C3HeB/FeJ)
|
increased T cell derived lymphoma incidence
|
J:59903
|
Thrbtm1.1Syc/Thrbtm1.1Syc
(involves: 129S6/SvEvTac * 129X1/SvJ * C57BL/6)
|
increased pituitary adenoma incidence
|
J:95391
|
Thrbtm1.1Syc/Thrbtm1.1Syc
(involves: 129S1/Sv * 129S6/SvEvTac * C57BL/6 * C57BL/6J)
|
increased thyroid carcinoma incidence
|
J:92629
|
Thrbtm1Df/Thrbtm1.1Syc
(involves: 129S1/Sv * 129S6/SvEvTac * C57BL/6 * C57BL/6J)
|
increased thyroid carcinoma incidence
|
J:92629
|
Thyls2MSM/Thyls2MSM
(involves: BALB/c * MSM)
|
increased T cell derived lymphoma incidence
|
J:87704
|
Tlag2AKR/J/Tlag2C57L/J
(involves: AKR/J * C57L/J)
|
increased T cell derived lymphoma incidence
|
J:74369
|
Tlag2AKR/J/Tlag2C57L/J Tlag1AKR/J/Tlag1AKR/J
(involves: AKR/J * C57L/J)
|
increased T cell derived lymphoma incidence
|
J:74369
|
Tle5tm1.1Mmt/Tle5tm1.1Mmt Apctm1Mmt/Apc+ Tg(Vil1-cre/ERT2)23Syr/0
(involves: 129S2/SvPas * C57BL/6 * DBA * SJL)
|
increased colon adenocarcinoma incidence
|
J:168065
|
increased small intestine adenocarcinoma incidence
|
J:168065
|
Tlr2tm1Kir/Tlr2tm1Kir
(B6.129-Tlr2tm1Kir)
|
increased colon adenoma incidence
|
J:165105
|
increased gastrointestinal tumor incidence
|
J:165105
|
Tlr7em2Anu/Y
(C57BL/6NCrl-Tlr7em2Anu)
|
increased splenic marginal zone lymphoma incidence
|
J:324448
|
Tlr7em2Anu/Tlr7em2Anu
(C57BL/6NCrl-Tlr7em2Anu)
|
increased splenic marginal zone lymphoma incidence
|
J:324448
|
Tlsm1AKR/JMs/Tlsm1AKR/JMs
(involves: AKR/JMs * SL/Kh)
|
increased T cell derived lymphoma incidence
|
J:21741,
J:41197,
J:33016
|
Tlsm1AKR/JMs/Tlsm1SL/Kh
(involves: AKR/JMs * SL/Kh)
|
increased T cell derived lymphoma incidence
|
J:21741,
J:41197,
J:33016
|
Tmigd1em1Gpt/Tmigd1em1Gpt
(C57BL/6NGpt-Tmigd1em1Gpt/Gpt)
|
increased intestinal adenoma incidence
|
J:300338
|
Tmprss11dtm1Bug/Tmprss11dtm1Bug
(involves: 129S1/Sv * 129X1/SvJ * NIH Black Swiss)
|
increased lymphoma incidence
|
J:175364
|
Tnfrsf1atm1Imx/Tnfrsf1atm1Imx
(C57BL/6-Tnfrsf1atm1Imx)
|
increased skin papilloma incidence
|
J:89088
|
Tnfrsf1btm1Imx/Tnfrsf1btm1Imx
(involves: 129S7/SvEvBrd * C57BL/6)
|
increased skin papilloma incidence
|
J:89088
|
Tnfrsf13btm1Vmd/Tnfrsf13btm1Vmd
(involves: C57BL/6)
|
increased leukemia incidence
|
J:82331
|
Tnk1tm1Sksuf/Tnk1+
(involves: 129X1/SvJ * C57BL/6)
|
increased hepatocellular carcinoma incidence
|
J:140639
|
increased hepatoma incidence
|
J:140639
|
increased intestinal adenocarcinoma incidence
|
J:140639
|
increased intestinal adenoma incidence
|
J:140639
|
increased lung adenoma incidence
|
J:140639
|
increased lymphoma incidence
|
J:140639
|
increased pancreas tumor incidence
|
J:140639
|
increased skin tumor incidence
|
J:140639
|
increased trichoepithelioma incidence
|
J:140639
|
Tnk1tm1Sksuf/Tnk1tm1Sksuf
(involves: 129X1/SvJ * C57BL/6)
|
increased B cell derived lymphoma incidence
|
J:140639
|
increased gastrointestinal tumor incidence
|
J:140639
|
increased hepatocellular carcinoma incidence
|
J:140639
|
increased lung adenocarcinoma incidence
|
J:140639
|
increased lymphoma incidence
|
J:140639
|
increased skin tumor incidence
|
J:140639
|
increased trichoepithelioma incidence
|
J:140639
|
Tom1l2Gt(XG909)Byg/Tom1l2+
(involves: 129P2/OlaHsd * C57BL/6J)
|
increased lung tumor incidence
|
J:133892
|
increased prostate gland tumor incidence
|
J:133892
|
increased skin tumor incidence
|
J:133892
|
Tom1l2Gt(XG909)Byg/Tom1l2Gt(XG909)Byg
(involves: 129P2/OlaHsd * C57BL/6J)
|
increased basal cell carcinoma incidence
|
J:133892
|
increased lung tumor incidence
|
J:133892
|
increased mammary gland tumor incidence
|
J:133892
|
increased ovary tumor incidence
|
J:133892
|
increased prostate gland tumor incidence
|
J:133892
|
increased skin tumor incidence
|
J:133892
|
Tpx2Gt(D028B03)Wrst/Tpx2+
(involves: 129S2/SvPas * C57BL/6J)
|
increased hepatocellular carcinoma incidence
|
J:184948
|
increased intestinal adenoma incidence
|
J:184948
|
increased lung adenocarcinoma incidence
|
J:184948
|
increased lung adenoma incidence
|
J:184948
|
increased lymphoma incidence
|
J:184948
|
increased stomach tumor incidence
|
J:184948
|
Trim24tm1.1Los/Trim24tm1.1Los
(involves: 129/Sv * C57BL/6 * SJL)
|
increased hepatocellular carcinoma incidence
|
J:130210
|
increased liver adenoma incidence
|
J:130210
|
increased liver tumor incidence
|
J:130210
|
Trim37Gt(RRO307)Byg/Trim37Gt(RRO307)Byg
(B6J.129P2-Trim37Gt(RRO307)Byg)
|
increased lymphoma incidence
|
J:232482
|
increased medulloblastoma incidence
|
J:232482
|
increased ovary tumor incidence
|
J:232482
|
Trim62tm1Akil/Trim62+
(involves: 129S/SvEv * C57BL/6)
|
increased hepatocellular carcinoma incidence
|
J:204336
|
increased liver adenocarcinoma incidence
|
J:204336
|
increased lung adenocarcinoma incidence
|
J:204336
|
increased lymphoma incidence
|
J:204336
|
increased mammary adenocarcinoma incidence
|
J:204336
|
Trim62tm1Akil/Trim62tm1Akil
(involves: 129S/SvEv * C57BL/6)
|
increased liver adenocarcinoma incidence
|
J:204336
|
increased lung adenocarcinoma incidence
|
J:204336
|
increased lymphoma incidence
|
J:204336
|
increased mammary adenocarcinoma incidence
|
J:204336
|
Trp53Bbl/Trp53+
(C57BL/6JSfdAnu-Trp53Bbl/Anu)
|
increased brain tumor incidence
|
J:104190
|
increased lymphoma incidence
|
J:104190
|
increased osteosarcoma incidence
|
J:104190
|
increased T cell derived lymphoma incidence
|
J:104190
|
Trp53Bbl/Trp53Bbl
(C57BL/6JSfdAnu-Trp53Bbl/Anu)
|
increased B cell derived lymphoma incidence
|
J:104190
|
increased leukemia incidence
|
J:104190
|
Trp53bhy/Trp53+
(C57BL/6JSfdAnu-Trp53bhy/Anu)
|
increased brain tumor incidence
|
J:104190
|
increased lymphoma incidence
|
J:104190
|
increased osteosarcoma incidence
|
J:104190
|
increased T cell derived lymphoma incidence
|
J:104190
|
Trp53bhy/Trp53bhy
(C57BL/6JSfdAnu-Trp53bhy/Anu)
|
increased leukemia incidence
|
J:104190
|
Trp53tm1.1Awbr/Trp53tm1.1Awbr
(involves: C57BL/6)
|
increased B cell derived lymphoma incidence
|
J:173271
|
increased follicular lymphoma incidence
|
J:169434
|
increased histiocytic sarcoma incidence
|
J:173271
|
increased osteosarcoma incidence
|
J:173271
|
increased T cell derived lymphoma incidence
|
J:173271
|
Trp53tm1.1Brn/Trp53+ Tg(KRT14-cre)8Brn/?
(involves: 129P2/OlaHsd * FVB/N * SKH1)
|
increased skin tumor incidence
|
J:121734
|
Trp53tm1.1Brn/Trp53tm1.1Brn Tg(KRT14-cre)8Brn/?
(involves: 129P2/OlaHsd * FVB/N * SKH1)
|
increased skin tumor incidence
|
J:121734
|
Trp53tm1.1Brn/Trp53tm3Tyj Tg(KRT14-cre)8Brn/?
(involves: 129P2/OlaHsd * 129S4/SvJae * FVB/N * SKH1)
|
increased lymphoma incidence
|
J:121734
|
increased skin tumor incidence
|
J:121734
|
Trp53tm1.1Thst/Trp53+ Tg(IghMyc)22Bri/0
(involves: 129S1/Sv * 129S4/SvJae * 129X1/SvJ * C57BL * SJL)
|
increased lymphoma incidence
|
J:198482
|
Trp53tm1.1Thst/Trp53tm1.1Thst
(involves: 129S1/Sv * 129S4/SvJae * 129X1/SvJ)
|
increased leiomyosarcoma incidence
|
J:198482
|
increased T cell derived lymphoma incidence
|
J:198482
|
Trp53tm1.1Umol/Trp53tm1.1Umol
(involves: 129S6/SvEvTac * C57BL/6 * C57BL/6NTac)
|
increased B cell derived lymphoma incidence
|
J:228632
|
increased T cell derived lymphoma incidence
|
J:228632
|
Trp53tm1.1Xlu/Trp53tm1.1Xlu
(involves: 129S6/SvEvTac * C57BL/6 * C57BL/6J * FVB/N)
|
increased liver tumor incidence
|
J:166152
|
increased lymphoma incidence
|
J:166152
|
Trp53tm1.2Awbr/Trp53+
(involves: C57BL/6)
|
increased B cell derived lymphoma incidence
|
J:173271
|
increased intestinal adenoma incidence
|
J:173271
|
increased lung adenoma incidence
|
J:173271
|
increased osteosarcoma incidence
|
J:173271
|
increased ovary tumor incidence
|
J:173271
|
Trp53tm1.2Awbr/Trp53tm1.2Awbr
(involves: C57BL/6)
|
increased B cell derived lymphoma incidence
|
J:173271
|
increased histiocytic sarcoma incidence
|
J:173271
|
increased intestinal adenoma incidence
|
J:173271
|
increased lung adenoma incidence
|
J:173271
|
increased osteosarcoma incidence
|
J:173271
|
increased ovary tumor incidence
|
J:173271
|
increased T cell derived lymphoma incidence
|
J:173271
|
Trp53tm1Adv/Trp53+
(involves: 129S4/SvJae * C57BL/6)
|
increased skin papilloma incidence
|
J:93328
|
increased skin tumor incidence
|
J:93328
|
Trp53tm1Adv/Trp53tm1Adv
(involves: 129S4/SvJae * C57BL/6)
|
increased skin papilloma incidence
|
J:93328
|
increased skin tumor incidence
|
J:93328
|
Trp53tm1Brd/Trp53+
(involves: 129S7/SvEvBrd * C57BL/6)
|
increased lymphoma incidence
|
J:73757
|
increased osteosarcoma incidence
|
J:73757
|
Trp53tm1Brd/Trp53tm1Brd
(involves: 129S7/SvEvBrd)
|
increased lymphoma incidence
|
J:51661
|
increased osteosarcoma incidence
|
J:51661
|
increased rhabdomyosarcoma incidence
|
J:51661
|
Trp53tm1Brd/Trp53tm1Brd
(involves: 129S7/SvEvBrd * C57BL/6)
|
increased lymphoma incidence
|
J:1999
|
increased osteosarcoma incidence
|
J:1999
|
increased T cell derived lymphoma incidence
|
J:126497
|
Trp53tm1Brd/Trp53tm1Brd Tg(Lck-cre)1Cwi/0
(involves: 129S7/SvEvBrd)
|
increased T cell derived lymphoma incidence
|
J:157041
|
Trp53tm1Brd/Trp53tm1Brd Tg(Nes-cre)1Kln/0
(involves: 129S6/SvEvTac * 129S7/SvEvBrd * C57BL/6 * SJL)
|
increased T cell derived lymphoma incidence
|
J:109585
|
Trp53tm1Brd/Trp53tm1Brd Xrcc4tm2.1Fwa/Xrcc4tm2Fwa Tg(Nes-cre)1Kln/0
(involves: 129S6/SvEvTac * 129S7/SvEvBrd * C57BL/6 * SJL)
|
increased medulloblastoma incidence
|
J:109585
|
Trp53tm1Brd/Trp53tm1Brd Xrcc5tm1Dbr/Xrcc5tm1Dbr
(involves: 129S7/SvEvBrd * C57BL)
|
increased lymphoma incidence
|
J:141515
|
increased medulloblastoma incidence
|
J:141515
|
Trp53tm1Brd/Trp53tm1Ldo
(involves: 129S7/SvEvBrd * C57BL/6)
|
increased T cell derived lymphoma incidence
|
J:73757
|
Trp53tm1Brn/Trp53+ Tg(MMTV-cre)#Tfln/0
(involves: 129P2/OlaHsd)
|
increased mammary adenocarcinoma incidence
|
J:170898
|
increased mammary gland tumor incidence
|
J:170898
|
Trp53tm1Brn/Trp53+ Tg(Sp7-tTA,tetO-EGFP/cre)1Amc/0
(involves: 129 * 129P2/OlaHsd * C57BL/6J * CD-1 * FVB/N)
|
increased osteosarcoma incidence
|
J:136693
|
Trp53tm1Brn/Trp53tm1.1Brn
(involves: 129P2/OlaHsd)
|
increased lung adenocarcinoma incidence
|
J:86077,
J:157319
|
Trp53tm1Brn/Trp53tm1Brn
(involves: 129P2/OlaHsd)
|
increased lung adenocarcinoma incidence
|
J:86077,
J:157319
|
Trp53tm1Brn/Trp53tm1Brn Tg(Cdh16-cre)91Igr/0
(involves: 129P2/OlaHsd * C57BL/6J * FVB/N * ICR)
|
increased endometrial carcinoma incidence
|
J:214850,
J:215149
|
Trp53tm1Brn/Trp53tm1Brn Tg(GFAP-cre)25Mes/0
(involves: 129P2/OlaHsd * C57BL/6 * FVB/N)
|
increased astrocytoma incidence
|
J:140704
|
Trp53tm1Brn/Trp53tm1Brn Tg(KRT5-cre/PGR)1Der/0
(involves: 129P2/OlaHsd * C57BL/6N * FVB/N * ICR)
|
increased skin squamous cell carcinoma incidence
|
J:216813
|
Trp53tm1Brn/Trp53tm1Brn Tg(KRT14-cre)8Brn/0
(involves: 129P2/OlaHsd * FVB/N)
|
increased mammary adenocarcinoma incidence
|
J:116152
|
increased mammary gland tumor incidence
|
J:126551
|
increased pilomatricoma incidence
|
J:116152
|
increased skin tumor incidence
|
J:116152,
J:126551
|
Trp53tm1Brn/Trp53tm1Brn Tg(MMTV-cre)105Ayn/0
(FVB.Cg-Trp53tm1Brn Tg(MMTV-cre)105Ayn)
|
increased lung tumor incidence
|
J:165292
|
increased mammary gland tumor incidence
|
J:165292
|
Trp53tm1Brn/Trp53tm1Brn Tg(MMTV-cre)#Mam/0
(involves: 129P2/OlaHsd * FVB)
|
increased lymphoma incidence
|
J:162126
|
increased mammary gland tumor incidence
|
J:162126
|
Trp53tm1Brn/Trp53tm1Brn Tg(MMTV-cre)#Tfln/0
(involves: 129P2/OlaHsd * C57BL/6 * FVB/N)
|
increased mammary adenocarcinoma incidence
|
J:224955
|
increased mammary gland tumor incidence
|
J:224955
|
Trp53tm1Brn/Trp53tm1Brn Tg(Nes-cre/ERT2,-ALPP)1Sbk/0
(involves: 129P2/OlaHsd)
|
increased brain tumor incidence
|
J:237990
|
increased medulloblastoma incidence
|
J:237990
|
Trp53tm1Brn/Trp53tm1Brn Tg(Sp7-tTA,tetO-EGFP/cre)1Amc/0
(involves: 129P2/OlaHsd * C57BL/6 * CD-1)
|
increased osteosarcoma incidence
|
J:199542
|
Trp53tm1Brn/Trp53tm1Brn Tg(Tyr-cre/ERT2)13Bos/0 Tg(Tyr-NRAS*Q61K)1Bee/0
(FVB.Cg-Tg(Tyr-cre/ERT2)13Bos Trp53tm1Brn Tg(Tyr-NRAS*Q61K)1Bee)
|
increased cutaneous melanoma incidence
|
J:222847
|
Trp53tm1Brn/Trp53tm1Brn Tg(Wap-cre)51Nki/0
(involves: 129P2/OlaHsd * FVB/N)
|
increased mammary adenocarcinoma incidence
|
J:171765
|
increased mammary gland tumor incidence
|
J:171765
|
Trp53tm1Brn/Trp53tm1Tyj Tg(Nes-cre)1Kln/0
(involves: 129P2/OlaHsd * 129S2/SvPas * C57BL/6 * SJL)
|
increased medulloblastoma incidence
|
J:102702
|
Trp53tm1Elee/Trp53tm1Elee Tg(GFAP-cre)25Mes/0
(involves: 129S4/SvJae * FVB/N)
|
increased glioma incidence
|
J:149662
|
increased medulloblastoma incidence
|
J:149662
|
Trp53tm1Elee/Trp53tm1Elee Tg(MMTV-cre)AElee/0
(involves: 129S4/SvJae * C57BL/6)
|
increased lymphoma incidence
|
J:90247
|
increased mammary adenocarcinoma incidence
|
J:90247
|
increased mammary gland tumor incidence
|
J:90247
|
Trp53tm1Elee/Trp53tm1Elee Tg(MMTV-cre)BElee/0
(involves: 129S4/SvJae * C57BL/6)
|
increased mammary adenocarcinoma incidence
|
J:90247
|
Trp53tm1Elee/Trp53tm1Elee Tg(Wap-rtTA-cre)10Whl/0
(involves: 129S4/SvJae * C57BL/6)
|
increased mammary adenocarcinoma incidence
|
J:90247
|
Trp53tm1Elee/Trp53tm1Tyj Tg(GFAP-cre)25Mes/0
(involves: 129S2/SvPas * 129S4/SvJae * FVB/N)
|
increased glioma incidence
|
J:149662
|
increased medulloblastoma incidence
|
J:149662
|
Trp53tm1Gev/Trp53tm1Gev
(involves: 129P2/OlaHsd * C57BL/6)
|
increased T cell derived lymphoma incidence
|
J:99305
|
Trp53tm1Glo/Trp53+
(involves: 129S7/SvEvBrd * C57BL/6)
|
increased lymphoma incidence
|
J:61683
|
increased osteosarcoma incidence
|
J:61683
|
Trp53tm1Glo/Trp53+
(involves: 129S7/SvEvBrd)
|
increased lymphoma incidence
|
J:129627
|
increased osteosarcoma incidence
|
J:129627
|
Trp53tm1Glo/Trp53tm1Glo
(involves: 129S7/SvEvBrd * C57BL/6)
|
increased T cell derived lymphoma incidence
|
J:61683
|
Trp53tm1Glo/Trp53tm4Glo
(involves: 129S7/SvEvBrd * C57BL/6)
|
increased lymphoma incidence
|
J:171821
|
increased T cell derived lymphoma incidence
|
J:171821
|
Trp53tm1Ldo/Trp53+
(involves: 129S7/SvEvBrd * C57BL/6)
|
increased lung adenoma incidence
|
J:73757
|
Trp53tm1Sia/Trp53tm1Sia
(involves: C57BL/6 * CBA)
|
increased T cell derived lymphoma incidence
|
J:36762
|
Trp53tm1Sia/Trp53tm1Sia
(involves: C57BL/6NCrlj * CBA/JNCrlj)
|
increased T cell derived lymphoma incidence
|
J:233347
|
Trp53tm1Thst/Trp53+ Tg(IghMyc)22Bri/0
(involves: 129S1/Sv * 129X1/SvJ * C57BL * SJL)
|
increased lymphoma incidence
|
J:198482
|
Trp53tm1Thst/Trp53tm1Thst
(involves: 129S1/Sv * 129X1/SvJ)
|
increased T cell derived lymphoma incidence
|
J:198482
|
Trp53tm1Tyj/Trp53+
(involves: 129S2/SvPas * C57BL/6)
|
increased histiocytic sarcoma incidence
|
J:72391
|
increased leiomyosarcoma incidence
|
J:17728
|
increased leukemia incidence
|
J:135509
|
increased lung adenocarcinoma incidence
|
J:72391
|
increased lymphoma incidence
|
J:72391,
J:17728
|
increased mammary adenocarcinoma incidence
|
J:72391
|
increased osteosarcoma incidence
|
J:72391,
J:17728
|
increased pancreas tumor incidence
|
J:72391
|
increased rhabdomyosarcoma incidence
|
J:17728
|
Trp53tm1Tyj/Trp53+
(involves: 129S2/SvPas)
|
increased urinary system tumor incidence
|
J:170769
|
Trp53tm1Tyj/Trp53+ Trp53bp2tm1Xlu/Trp53bp2+
(involves: 129S2/SvPas * 129S6/SvEvTac * C57BL/6J)
|
increased lymphoma incidence
|
J:108701
|
Trp53tm1Tyj/Trp53+ Trp63tm1Fmc/Trp63+
(involves: 129S2/SvPas * 129S4/SvJae * C57BL/6)
|
increased chronic myelocytic leukemia incidence
|
J:98958
|
increased mammary adenocarcinoma incidence
|
J:98958
|
increased osteosarcoma incidence
|
J:98958
|
increased rhabdomyosarcoma incidence
|
J:98958
|
increased T cell derived lymphoma incidence
|
J:98958
|
increased urinary bladder transitional cell carcinoma incidence
|
J:98958
|
Trp53tm1Tyj/Trp53+ Trp73tm1Fmc/Trp73+
(involves: 129S2/SvPas * 129S4/SvJae * C57BL/6)
|
increased hepatocellular carcinoma incidence
|
J:98958
|
increased lung adenocarcinoma incidence
|
J:98958
|
increased pancreatic acinar cell carcinoma incidence
|
J:98958
|
increased T cell derived lymphoma incidence
|
J:98958
|
Trp53tm1Tyj/Trp53+ Uimc1tm1.2Amj/Uimc1tm1.2Amj
(involves: 129S2/SvPas * BALB/cJ * C57BL/6)
|
increased lymphoma incidence
|
J:191827
|
Trp53tm1Tyj/Trp53+ Xpatm1Hvs/Xpatm1Hvs
(involves: 129P2/OlaHsd * 129S2/SvPas)
|
increased urinary system tumor incidence
|
J:170769
|
Trp53tm1Tyj/Trp53+ Xrcc2tm1Pmc/Xrcc2tm1Pmc
(involves: 129S1/Sv * 129S2/SvPas * C57BL/6)
|
increased T cell derived lymphoma incidence
|
J:111068
|
Trp53tm1Tyj/Trp53tm1.1Umol
(involves: 129S2/SvPas * 129S6/SvEvTac * C57BL/6 * C57BL/6NTac)
|
increased B cell derived lymphoma incidence
|
J:228632
|
increased leukemia incidence
|
J:228632
|
increased lymphoma incidence
|
J:228632
|
increased reproductive system tumor incidence
|
J:228632
|
increased T cell derived lymphoma incidence
|
J:228632
|
Trp53tm1Tyj/Trp53tm1Tyj
(involves: 129S2/SvPas * C57BL/6)
|
increased lymphoma incidence
|
J:72391,
J:17728,
J:95318
|
increased osteosarcoma incidence
|
J:72391,
J:17728
|
increased rhabdomyosarcoma incidence
|
J:17728
|
increased T cell derived lymphoma incidence
|
J:87501,
J:17728
|
Trp53tm1Tyj/Trp53tm1Tyj
(involves: 129S2/SvPas)
|
increased lymphoma incidence
|
J:221224
|
increased medulloblastoma incidence
|
J:102702
|
increased T cell derived lymphoma incidence
|
J:251434,
J:221224,
J:88120,
J:95316
|
Trp53tm1Tyj/Trp53tm1Tyj
(129S6.129-Trp53tm1Tyj Rb1tm1.1Jyjw)
|
increased lymphoma incidence
|
J:102483
|
increased testicular teratoma incidence
|
J:102483
|
Trp53tm1Tyj/Trp53tm1Tyj Tg(Ly6e-MALT1)#Isg/0
(involves: 129S2/SvPas * C57BL/6 * CBA)
|
increased B cell derived lymphoma incidence
|
J:185590
|
Trp53tm1Tyj/Trp53tm1Tyj Xrcc2tm1Pmc/Xrcc2tm1Pmc
(involves: 129S1/Sv * 129S2/SvPas * C57BL/6)
|
increased lymphoma incidence
|
J:111068
|
increased medulloblastoma incidence
|
J:111068
|
increased skin tumor incidence
|
J:111068
|
increased T cell derived lymphoma incidence
|
J:111068
|
Trp53tm1Tyj/Trp53tm1Tyj Xrcc2tm2Pmc/Xrcc2tm2Pmc Tg(Nes-cre)1Kln/0
(involves: 129S1/Sv * 129S2/SvPas * C57BL/6 * SJL)
|
increased medulloblastoma incidence
|
J:144617
|
Trp53tm1Tyj/Trp53tm1Tyj Xrcc4tm1Fwa/Xrcc4tm1Fwa
(involves: 129P2/OlaHsd * 129S2/SvPas)
|
increased B cell derived lymphoma incidence
|
J:61973
|
Trp53tm1Tyj/Trp53tm2.1Tyj
(involves: 129S2/SvPas * 129S4/SvJae)
|
increased T cell derived lymphoma incidence
|
J:95316
|
Trp53tm1Tyj/Trp53tm2.1Umol
(involves: 129S2/SvPas * 129S6/SvEvTac * C57BL/6 * C57BL/6NTac)
|
increased B cell derived lymphoma incidence
|
J:228632
|
increased lymphoma incidence
|
J:228632
|
increased reproductive system tumor incidence
|
J:228632
|
increased T cell derived lymphoma incidence
|
J:228632
|
Trp53tm1Tyj/Trp53tm3.1Tyj
(involves: 129S2/SvPas * 129S4/SvJae)
|
increased T cell derived lymphoma incidence
|
J:95316
|
Trp53tm1Yjc/Trp53tm1Yjc
(B6.129S1-Trp53tm1Yjc)
|
increased splenic marginal zone lymphoma incidence
|
J:195018
|
Trp53tm2.1Thst/Trp53tm2.1Thst
(involves: 129S1/Sv * 129S4/SvJae * 129X1/SvJ)
|
increased B cell derived lymphoma incidence
|
J:282255
|
increased T cell derived lymphoma incidence
|
J:282255
|
increased testis tumor incidence
|
J:282255
|
Trp53tm2.1Umol/Trp53tm2.1Umol
(involves: 129S6/SvEvTac * C57BL/6 * C57BL/6NTac)
|
increased B cell derived lymphoma incidence
|
J:228632
|
increased T cell derived lymphoma incidence
|
J:228632
|
Trp53tm2Glo/Trp53tm2Glo
(involves: 129/Sv * C57BL/6)
|
increased lymphoma incidence
|
J:87501
|
Trp53tm2Thst/Trp53tm2.1Thst
(involves: 129S1/Sv * 129S4/SvJae * 129X1/SvJ)
|
increased B cell derived lymphoma incidence
|
J:282255
|
increased T cell derived lymphoma incidence
|
J:282255
|
increased testis tumor incidence
|
J:282255
|
Trp53tm3.1Glo/Trp53+
(B6.129S7-Trp53tm3.1Glo)
|
increased B cell derived lymphoma incidence
|
J:317504
|
increased lymphoma incidence
|
J:317504,
J:95318
|
increased osteosarcoma incidence
|
J:317504
|
increased T cell derived lymphoma incidence
|
J:317504
|
Trp53tm3.1Glo/Trp53tm3.1Glo
(B6.129S7-Trp53tm3.1Glo)
|
increased lymphoma incidence
|
J:95318
|
Trp53tm3.1Glo/Trp53tm4Glo
(involves: 129S7/SvEvBrd * C57BL/6)
|
increased lymphoma incidence
|
J:171821
|
Trp53tm3.1Tyj/Trp53+
(involves: 129S4/SvJae)
|
increased B cell derived lymphoma incidence
|
J:95316
|
increased hepatocellular carcinoma incidence
|
J:95316
|
increased lung adenocarcinoma incidence
|
J:95316
|
Trp53tm3.1Tyj/Trp53+
(involves: 129S4/SvJae * SKH1)
|
increased mammary adenocarcinoma incidence
|
J:121734
|
increased skin tumor incidence
|
J:121734
|
Trp53tm3Tyj/Trp53+ Tg(KRT14-cre)8Brn/?
(involves: 129S4/SvJae * FVB/N * SKH1)
|
increased lymphoma incidence
|
J:121734
|
increased skin tumor incidence
|
J:121734
|
Trp53tm3Tyj/Trp53+ Tg(Wap-cre)11738Mam/0
(involves: 129S4/SvJae * C57BL/6 * SJL)
|
increased lung tumor incidence
|
J:101617
|
increased lymphoma incidence
|
J:101617
|
increased mammary adenocarcinoma incidence
|
J:101617
|
increased mammary gland tumor incidence
|
J:101617
|
Trp53tm4Glo/Trp53tm4Glo
(involves: 129S7/SvEvBrd * C57BL/6)
|
increased lymphoma incidence
|
J:171821
|
increased T cell derived lymphoma incidence
|
J:171821
|
Trp53tm4Tyj/Trp53tm4Tyj
(involves: 129S4/SvJae * C57BL/6)
|
increased B cell derived lymphoma incidence
|
J:92917
|
Trp53tm4Xu/Trp53tm4Xu
(Not Specified)
|
increased lymphoma incidence
|
J:126497
|
increased T cell derived lymphoma incidence
|
J:126497
|
Trp53tm6Xu/Trp53tm6Xu Tg(Lck-cre)1Cwi/0
(involves: 129S4/SvJae)
|
increased lymphoma incidence
|
J:157041
|
increased T cell derived lymphoma incidence
|
J:157041
|
Trp53tm7.1Xu/Trp53tm7.1Xu
(Not Specified)
|
increased lymphoma incidence
|
J:160414
|
Trp53bp1tm1Jc/Trp53bp1tm1Jc
(involves: 129 * C57BL/6)
|
increased lymphoma incidence
|
J:82512
|
increased T cell derived lymphoma incidence
|
J:82512
|
Trp53bp2tm1Cdlo/Trp53bp2+ Tg(EmuSR-tTa)83Bop/0 Tg(tetO-MYC)36aBop/0
(involves: 129S1/Sv * 129X1/SvJ * C57BL/6 * FVB/N)
|
increased T cell derived lymphoma incidence
|
J:146764
|
Trp53bp2tm1Xlu/Trp53bp2+
(involves: 129S6/SvEvTac * C57BL/6J)
|
increased lymphoma incidence
|
J:108701
|
increased rhabdomyosarcoma incidence
|
J:108701
|
increased T cell derived lymphoma incidence
|
J:108701
|
Trp53inp1tm1Acar/Trp53inp1tm1Acar
(involves: 129/Sv * C57BL/6)
|
increased colon adenoma incidence
|
J:118867
|
Trp63tm1Fmc/Trp63+
(involves: 129S4/SvJae * C57BL/6)
|
increased histiocytic sarcoma incidence
|
J:98958
|
increased lung adenoma incidence
|
J:98958
|
Trp63tm1Fmc/Trp63+ Trp73tm1Fmc/Trp73+
(involves: 129S4/SvJae * C57BL/6)
|
increased chronic myelocytic leukemia incidence
|
J:98958
|
increased lung adenocarcinoma incidence
|
J:98958
|
increased lung adenoma incidence
|
J:98958
|
increased mammary adenocarcinoma incidence
|
J:98958
|
increased salivary gland adenoma incidence
|
J:98958
|
increased T cell derived lymphoma incidence
|
J:98958
|
Trp73tm1Fmc/Trp73+
(involves: 129S4/SvJae * C57BL/6)
|
increased lung adenocarcinoma incidence
|
J:98958
|
increased lung adenoma incidence
|
J:98958
|
increased T cell derived lymphoma incidence
|
J:98958
|
Trp73tm1Fmc/Trp73tm1Fmc
(involves: 129S4/SvJae * C57BL/6)
|
increased lung adenocarcinoma incidence
|
J:98958
|
Trp73tm1Mak/Trp73+
(involves: 129P2/OlaHsd * C57BL/6J)
|
increased lung adenocarcinoma incidence
|
J:142848
|
increased lymphoma incidence
|
J:142848
|
increased T cell derived lymphoma incidence
|
J:142848
|
Trp73tm1Mak/Trp73tm1Mak
(involves: 129P2/OlaHsd * C57BL/6J)
|
increased lung adenocarcinoma incidence
|
J:142848
|
increased lymphoma incidence
|
J:142848
|
increased T cell derived lymphoma incidence
|
J:142848
|
Ts(16C-tel)1Cje/0
(involves: C57BL/6J * Rb(11.16)2H * Rb(16.17)32Lub)
|
increased follicular lymphoma incidence
|
J:174270
|
increased lymphoma incidence
|
J:174270
|
Ts(1716)65Dn/0
(involves: C3H/HeJ * C57BL/6J * DBA/2J)
|
increased follicular lymphoma incidence
|
J:174270
|
increased lymphoma incidence
|
J:174270
|
Tsc1tm1.1Djk/Tsc1+
(either: 129S4/SvJae-Tsc1tm1Djk or (involves: 129S4/SvJae * BALB/cJ) or (involves: 129S4/SvJae * C57BL/6J))
|
increased hepatic hemangioma incidence
|
J:75243
|
increased renal carcinoma incidence
|
J:75243
|
increased renal cystadenoma incidence
|
J:75243
|
Tsc1tm1Chdl/Tsc1+
(involves: 129P2/OlaHsd * C57BL/6JOlaHsd)
|
increased hepatic hemangioma incidence
|
J:99796
|
increased renal carcinoma incidence
|
J:99796
|
increased renal cystadenoma incidence
|
J:99796
|
Tsc1tm1Chdl/Tsc1+
(involves: 129P2/OlaHsd * Balb/cOlaHsd * C57BL/6JOlaHsd)
|
increased hepatic hemangioma incidence
|
J:99796
|
increased renal carcinoma incidence
|
J:99796
|
increased renal cystadenoma incidence
|
J:99796
|
Tsc1tm1Chdl/Tsc1+
(involves: 129P2/OlaHsd * C3H/HeNHsd * C57BL/6JOlaHsd)
|
increased hepatic hemangioma incidence
|
J:99796
|
increased renal cystadenoma incidence
|
J:99796
|
Tsc1tm1Hin/Tsc1+
(involves: 129S4/SvJae * C57BL/6J)
|
increased hepatic hemangioma incidence
|
J:70463
|
increased leiomyosarcoma incidence
|
J:70463
|
increased renal carcinoma incidence
|
J:70463
|
increased renal cystadenoma incidence
|
J:70463
|
increased uterus leiomyoma incidence
|
J:70463
|
Tsc2tm1.1Kido/Tsc2+
(involves: 129S4/SvJae * C57BL/6)
|
increased kidney tumor incidence
|
J:135811
|
Tsc2tm1.1Mjg/Tsc2tm1.1Mjg Pgrtm2(cre)Lyd/Pgr+
(involves: 129S1/Sv * 129X1/SvJ)
|
increased lung tumor incidence
|
J:221228
|
increased uterus leiomyoma incidence
|
J:221228
|
Tsc2tm1Djk/Tsc2+
(either: (involves: 129S4/SvJae * BALB/cJ) or (involves: 129S4/SvJae * Black Swiss) or (involves: 129S4/SvJae * C57BL/6J))
|
increased hepatic hemangioma incidence
|
J:57631
|
increased lung adenoma incidence
|
J:57631
|
increased renal carcinoma incidence
|
J:57631
|
increased renal cystadenoma incidence
|
J:57631
|
Tsc2tm1Tno/Tsc2+
(involves: 129S4/SvJae * C57BL/6J)
|
increased hepatic hemangioma incidence
|
J:52464
|
increased renal carcinoma incidence
|
J:52464
|
Tsc2tm2.2Djk/Tsc2+
(involves: 129S4/SvJae * C57BL/6)
|
increased renal cystadenoma incidence
|
J:149326
|
TsilTg(Myc)12ALvn/Tsil+
(involves: C57BL/6 * SJL/J)
|
increased lymphoma incidence
|
J:33857
|
Tspan33tm1Stsa/Tspan33tm1Stsa
(involves: 129S1/Sv * 129X1/SvJ)
|
increased liver tumor incidence
|
J:143158
|
Tusc2tm1Avi/Tusc2+
(involves: 129S1/Sv * C57BL/6J)
|
increased leukemia incidence
|
J:119985
|
increased lymphoma incidence
|
J:119985
|
Tusc2tm1Avi/Tusc2tm1Avi
(involves: 129S1/Sv * C57BL/6J)
|
increased lymphoma incidence
|
J:119985
|
TxnipHyplip1/Txnip+
(involves: CAST/Ei * HcB19/Dem)
|
increased hepatocellular carcinoma incidence
|
J:112292
|
TxnipHyplip1/TxnipHyplip1
(HcB19/Dem-TxnipHyplip1)
|
increased hepatocellular carcinoma incidence
|
J:112292
|
TxnipHyplip1/TxnipHyplip1
(involves: CAST/Ei * HcB19/Dem)
|
increased hepatocellular carcinoma incidence
|
J:112292
|
Uacatm1Kiy/Uacatm1Kiy
(B6.129P2-Uacatm1Kiy)
|
increased hepatocellular carcinoma incidence
|
J:157049
|
Ube2otm1.1(KOMP)Mbp/Ube2otm1.1(KOMP)Mbp Ptentm1Ppp/Ptentm1Ppp
(involves: 129S1/Sv * C57BL/6 * C57BL/6N * FVB/N)
|
increased lymphoma incidence
|
J:239679
|
Ube2otm1.1(KOMP)Mbp/Ube2otm1.1(KOMP)Mbp Tg(IghMyc)22Bri/0
(involves: C57BL * C57BL/6N * FVB/N * SJL)
|
increased B cell derived lymphoma incidence
|
J:239679
|
Uimc1Gt(RRN158)Byg/Uimc1Gt(RRN158)Byg
(involves: 129P2/OlaHsd * C57BL/6)
|
increased B cell derived lymphoma incidence
|
J:188388
|
Uimc1tm1.2Amj/Uimc1tm1.2Amj
(involves: BALB/cJ * C57BL/6)
|
increased B cell derived lymphoma incidence
|
J:191827
|
increased lymphoma incidence
|
J:191827
|
increased T cell derived lymphoma incidence
|
J:191827
|
Ungtm1Tld/Ungtm1Tld
(Not Specified)
|
increased B cell derived lymphoma incidence
|
J:85353
|
Urahplt2/Urahplt2
(C57BL/6-Urahplt2)
|
increased hepatocellular carcinoma incidence
|
J:164423
|
Usp24Gt(XB614)Byg/Usp24+
(involves: 129P2/OlaHsd * C57BL/6)
|
increased liver tumor incidence
|
J:303991
|
increased lung tumor incidence
|
J:303991
|
Usp44tm1.2Pjgl/Usp44tm1.2Pjgl
(involves: 129S4/SvJae * 129S7/SvEvBrd)
|
increased hepatoma incidence
|
J:193965
|
increased lung adenoma incidence
|
J:193965
|
increased lymphoma incidence
|
J:193965
|
Vhltm1.1Jae/Vhl+
(involves: 129S4/SvJae * BALB/c)
|
increased hepatic hemangioma incidence
|
J:67505
|
Vhltm1.1Lss/Vhl+
(involves: BALB/c)
|
increased hepatic hemangioma incidence
|
J:85513
|
Vhltm1Lss/Vhltm1.1Lss
(involves: 129X1/SvJ * C57BL/6)
|
increased hepatic hemangioma incidence
|
J:85513
|
Vhltm1Lss/Vhltm1.1Lss Tg(ACTB-cre)1Tes/0
(involves: 129X1/SvJ * C3H * C57BL/6)
|
increased hepatic hemangioma incidence
|
J:85513
|
Vhltm1Lss/Vhltm1Lss Tg(Pdx1-cre)89.1Dam/0
(involves: 129X1/SvJ * C57BL/6 * CBA)
|
increased pancreas adenoma incidence
|
J:148174
|
Wif1tm1Dmth/Wif1tm1Dmth
(involves: 129 * C57BL/6)
|
increased osteosarcoma incidence
|
J:149607
|
Wwc1tm1Arsc/Wwc1tm1Arsc Wwc2tm1.1Arte/Wwc2tm1.1Arte Speer6-ps1Tg(Alb-cre)21Mgn/Speer6-ps1+
(involves: 129 * C57BL/6 * C57BL/6J * DBA)
|
increased liver tumor incidence
|
J:305034
|
WwoxGt(XG218)Byg/WwoxGt(XG218)Byg
(involves: 129P2/OlaHsd)
|
increased B cell derived lymphoma incidence
|
J:132078
|
Wwoxtm1Ria/Wwox+
(involves: 129X1/SvJ * C57BL/6)
|
increased lung tumor incidence
|
J:120064
|
Wwoxtm1Ria/Wwoxtm1Ria
(involves: 129X1/SvJ * C57BL/6)
|
increased osteosarcoma incidence
|
J:120064
|
Wwoxtm2.1Ria/Wwoxtm2.1Ria
(involves: 129S1/Sv * 129X1/SvJ * C57BL/6J * FVB/N)
|
increased skeletal tumor incidence
|
J:198845
|
Xpatm1Tnka/Xpatm1Tnka
(involves: C57BL/6 * CBA)
|
increased lung adenocarcinoma incidence
|
J:62877
|
increased lung adenoma incidence
|
J:62877
|
increased skin squamous cell carcinoma incidence
|
J:28709
|
Xpatm1Tnka/Xpatm1Tnka
(C3.Cg-Xpatm1Tnka)
|
increased liver adenoma incidence
|
J:76206
|
increased liver tumor incidence
|
J:76206
|
Xpatm1Tnka/Xpatm1Tnka Tg(KRT14-Kitl)1Takk/?
(involves: C57BL/6 * CBA * SJL)
|
increased skin tumor incidence
|
J:100608
|
Xpctm1Ecf/Xpctm1Ecf
(involves: 129 * C57BL/6)
|
increased lung adenocarcinoma incidence
|
J:101421
|
increased lung adenoma incidence
|
J:101421
|
increased lung tumor incidence
|
J:101421
|
Xpnpep1tm1a(KOMP)Wtsi/Xpnpep1tm1a(KOMP)Wtsi
(C57BL/6N-Xpnpep1tm1a(KOMP)Wtsi/Wtsi)
|
increased trigeminal neuroma incidence
|
J:239583
|
Xrcc1tm1Pmc/Xrcc1tm1Pmc Trp53tm1Tyj/Trp53+ Tg(Nes-cre)1Kln/0
(involves: 129S1/Sv * 129S2/SvPas * C57BL/6 * SJL)
|
increased medulloblastoma incidence
|
J:152528
|
Xrcc1tm1Pmc/Xrcc1tm1Pmc Trp53tm1Tyj/Trp53tm1Tyj Tg(Nes-cre)1Kln/0
(involves: 129S1/Sv * 129S2/SvPas * C57BL/6 * SJL)
|
increased medulloblastoma incidence
|
J:152528
|
Xrcc6tm1Fwa/Xrcc6tm1Fwa
(involves: 129S6/SvEvTac * C57BL/6J)
|
increased T cell derived lymphoma incidence
|
J:44361
|
Zeb1tm1Yhi/Zeb1tm1Yhi
(either: (involves: 129 * C3H * C57BL/6) or (involves: 129 * C57BL/6 * ICR))
|
increased T cell derived lymphoma incidence
|
J:139194
|
Zfand2btm1Otin/Zfand2btm1Otin
(involves: 129S7/SvEvBrd * C57BL/6)
|
increased chronic myelocytic leukemia incidence
|
J:233169
|
Zfhx3tm1.1Jtd/Zfhx3tm1.1Jtd Tg(Pbsn-cre)4Prb/0
(involves: 129S6/SvEvTac * C57BL/6 * C57BL/6J * SJL)
|
increased prostate intraepithelial neoplasia incidence
|
J:189563
|
Zfp14tm1Xch/Zfp14+
(involves: C57BL/6)
|
increased B cell derived lymphoma incidence
|
J:331393
|
Zfp14tm1Xch/Zfp14tm1Xch
(involves: C57BL/6)
|
increased B cell derived lymphoma incidence
|
J:331393
|
Zfp36l1tm1.1Tnr/Zfp36l1tm1.1Tnr Zfp36l2tm1.1Tnr/Zfp36l2tm1.1Tnr Tg(CD2-icre)4Kio/0
(involves: C57BL/6 * C57BL/10 * CBA/Ca * SJL)
|
increased leukemia incidence
|
J:162388
|
increased T cell derived lymphoma incidence
|
J:162388
|
Zfp871tm1a(EUCOMM)Wtsi/Zfp871+
(C57BL/6N-Zfp871tm1a(EUCOMM)Wtsi/BayMmucd)
|
increased B cell derived lymphoma incidence
|
J:317166
|